-- ============================================
-- QBANK DATA IMPORT
-- Run this AFTER 007_qbank_questions.sql
-- ============================================

INSERT INTO questions (question_id, concept_id, batch, system, stem, options, correct_answer, explanation, cognitive_error, source, status)
VALUES
  ('B1_C01', 'b1-01-diabetic-ketoacidosis-dka-initial-management', 'Batch1', 'Endocrinology', 'A 28-year-old woman with type 1 diabetes mellitus presents to the emergency department with nausea, vomiting, and abdominal pain for 12 hours. She 
ran out of insulin 2 days ago. On examination, she is lethargic but arousable. Temperature is 37.1°C (98.8°F), blood pressure is 92/58 mm Hg, pulse is 
118/min, and respirations are 26/min with deep, labored breathing. Mucous membranes are dry, and skin turgor is decreased. 
Laboratory studies show: 
• 
Serum glucose: 486 mg/dL 
• 
Serum sodium: 131 mEq/L 
• 
Serum potassium: 5.4 mEq/L 
• 
Serum bicarbonate: 10 mEq/L 
• 
BUN: 38 mg/dL 
• 
Creatinine: 1.6 mg/dL 
• 
Arterial pH: 7.18 
• 
Serum ketones: positive

Which of the following is the most appropriate initial step in management?', '[{"label":"A","text":"Intravenous regular insulin bolus followed by continuous infusion"},{"label":"B","text":"Intravenous normal saline bolus"},{"label":"C","text":"Intravenous sodium bicarbonate"},{"label":"D","text":"Subcutaneous rapid-acting insulin"},{"label":"E","text":"Intravenous potassium chloride"}]'::jsonb, 'B', 'This patient presents with classic DKA: hyperglycemia (>250 mg/dL), anion gap metabolic acidosis (pH <7.30, bicarbonate <18), and ketonemia. The critical initial management decision is fluid resuscitation before insulin. Why fluids first? • DKA causes profound volume depletion (average deficit 5–7 L) due to osmotic diuresis • Hypotension and tachycardia indicate hemodynamic compromise requiring immediate volume expansion • Insulin administration before adequate fluid resuscitation can precipitate cardiovascular collapse and hypokalemia • Initial NS bolus (15–20 mL/kg/hr or 1–1.5 L in first hour) restores perfusion Why not insulin first (A, D)? • Insulin drives potassium intracellularly; giving insulin before confirming adequate potassium (>3.3 mEq/L) and before fluid resuscitation risks fatal arrhythmia • This patient''s potassium of 5.4 mEq/L is falsely elevated due to acidosis — total body potassium is depleted Why not bicarbonate (C)? • Bicarbonate is reserved for pH <6.9 or severe hyperkalemia with ECG changes • Routine bicarbonate worsens intracellular acidosis and delays ketone clearance Why not potassium first (E)? • Potassium is 5.4 mEq/L (>5.2); potassium replacement begins once K+ falls below 5.2 mEq/L during treatment Clinical pearl: The sequence in DKA is: Fluids → Potassium assessment → Insulin. This order reduces mortality.', NULL, 'internal', 'active'),
  ('B1_C02', 'b1-02-thyroid-storm-recognition-and-immediate-treatment', 'Batch1', 'Endocrinology', 'A 42-year-old woman is brought to the emergency department by her family for confusion and agitation. She has a history of Graves disease but 
stopped taking her methimazole 3 weeks ago. Yesterday she developed fever, diarrhea, and palpitations. Today she became disoriented and combative. 
On examination, temperature is 39.8°C (103.6°F), blood pressure is 168/70 mm Hg, pulse is 152/min and irregularly irregular, and respirations are 24/min. 
She is diaphoretic with a fine tremor, lid lag, and diffuse thyroid enlargement. 
Laboratory studies show: 
• 
TSH: <0.01 mIU/L 
• 
Free T4: 6.8 ng/dL (normal 0.8–1.8) 
• 
Free T3: 892 pg/dL (normal 230–420) 
ECG shows atrial fibrillation with rapid ventricular response.

In addition to supportive care and cooling measures, which of the following is the most appropriate FIRST pharmacologic intervention?', '[{"label":"A","text":"Propylthiouracil"},{"label":"B","text":"Propranolol"},{"label":"C","text":"Lugol iodine solution"},{"label":"D","text":"Hydrocortisone"},{"label":"E","text":"Radioactive iodine ablation"}]'::jsonb, 'B', 'This patient has thyroid storm (Burch-Wartofsky score would be >45), a life-threatening exacerbation of hyperthyroidism characterized by: • Fever (>39°C) • CNS dysfunction (confusion, agitation) • Cardiovascular compromise (tachycardia, atrial fibrillation, widened pulse pressure) • GI symptoms (diarrhea) • Precipitating event (medication discontinuation) Treatment sequence matters: 1. Beta-blocker FIRST (Propranolol) • Controls life-threatening sympathetic hyperactivity • Propranolol specifically also inhibits peripheral T4→T3 conversion • Addresses immediate mortality risk from arrhythmia and cardiovascular collapse • Must be given before iodine to prevent iodine from fueling further hormone synthesis 2. Thionamide (PTU preferred in storm) • Blocks new hormone synthesis • PTU also inhibits peripheral T4→T3 conversion • Given after beta-blockade is initiated 3. Iodine (Lugol''s or SSKI) — given 1 hour AFTER thionamide • Blocks hormone release (Wolff-Chaikoff effect) • Must wait until thionamide has blocked synthesis; otherwise iodine provides substrate for more hormone production 4. Glucocorticoids • Block peripheral T4→T3 conversion • Treat potential concurrent adrenal insufficiency • Given as adjunct, not first-line Why not (A) PTU first? • While essential, it does not address immediate cardiovascular crisis • Beta-blockade provides faster symptomatic control Why not (C) Iodine first? • Giving iodine before thionamide can worsen thyrotoxicosis (Jod-Basedow phenomenon) Why not (E)? • Radioactive iodine is contraindicated in thyroid storm — would release preformed hormone', NULL, 'internal', 'active'),
  ('B1_C03', 'b1-03-primary-adrenal-insufficiency-addison-disease-diagnosis', 'Batch1', 'Endocrinology', 'A 34-year-old woman comes to the clinic with a 4-month history of progressive fatigue, 7-kg (15-lb) unintentional weight loss, and intermittent nausea. 
She also reports light-headedness when standing. She has no significant medical history and takes no medications. 

On examination, blood pressure is 94/62 mm Hg supine and 78/50 mm Hg standing with pulse increasing from 72 to 98/min. Hyperpigmentation is 
noted on the palmar creases, buccal mucosa, and a recent surgical scar. 
Laboratory studies show: 
• 
Serum sodium: 128 mEq/L 
• 
Serum potassium: 5.8 mEq/L 
• 
Fasting glucose: 64 mg/dL 
• 
Morning cortisol: 2.1 µg/dL (normal 5–25) 
• 
ACTH: 892 pg/mL (normal 10–60)

Which of the following is the most appropriate next step to confirm the diagnosis?', '[{"label":"A","text":"24-hour urine free cortisol"},{"label":"B","text":"Low-dose dexamethasone suppression test"},{"label":"C","text":"Cosyntropin stimulation test"},{"label":"D","text":"CT of the adrenal glands"},{"label":"E","text":"Adrenal vein sampling"}]'::jsonb, 'C', 'This patient presents with classic features of primary adrenal insufficiency (Addison disease): Clinical features: • Fatigue, weight loss, nausea (chronic glucocorticoid deficiency) • Orthostatic hypotension (mineralocorticoid deficiency → salt wasting) • Hyperpigmentation in sun-exposed and pressure areas (elevated ACTH stimulates melanocortin receptors) Laboratory findings supporting primary adrenal insufficiency: • Hyponatremia (mineralocorticoid deficiency) • Hyperkalemia (aldosterone deficiency) • Hypoglycemia (cortisol deficiency) • Low morning cortisol (<5 µg/dL is highly suggestive) • Elevated ACTH (confirms primary, not secondary) Confirmatory test: The cosyntropin (ACTH) stimulation test is the gold standard: • 250 µg synthetic ACTH given IV/IM • Cortisol measured at 30 and 60 minutes • Normal response: cortisol ≥18–20 µg/dL • Failure to rise confirms adrenal insufficiency Why not other options? (A) 24-hour urine free cortisol — Used to diagnose Cushing syndrome (cortisol excess), not deficiency (B) Dexamethasone suppression test — Also for Cushing syndrome workup (D) CT of adrenal glands — May be done after biochemical confirmation to identify etiology (autoimmune, hemorrhage, infection, metastasis) but is not the confirmatory diagnostic test (E) Adrenal vein sampling — Used in primary hyperaldosteronism workup to lateralize adenoma After confirmation: Most common cause in developed countries is autoimmune adrenalitis (check 21-hydroxylase antibodies). Start glucocorticoid (hydrocortisone) and mineralocorticoid (fludrocortisone) replacement.', NULL, 'internal', 'active'),
  ('B1_C04', 'b1-04-hyperosmolar-hyperglycemic-state-hhs-vs-dka-differentiation-', 'Batch1', 'Endocrinology', 'A 72-year-old man with type 2 diabetes mellitus is brought to the emergency department from a nursing home with altered mental status. Staff report 
he has had decreased oral intake and increasing lethargy over the past week following a urinary tract infection treated with antibiotics. 
On examination, he is obtunded and responds only to painful stimuli. Temperature is 37.4°C (99.3°F), blood pressure is 88/52 mm Hg, pulse is 112/min, 
and respirations are 18/min. Mucous membranes are severely dry, and skin tenting is present. 
Laboratory studies show: 
• 
Serum glucose: 928 mg/dL 
• 
Serum sodium: 149 mEq/L (corrected: 162 mEq/L) 
• 
Serum potassium: 4.8 mEq/L 
• 
Serum bicarbonate: 21 mEq/L 
• 
BUN: 68 mg/dL 
• 
Creatinine: 2.4 mg/dL 
• 
Arterial pH: 7.32 
• 
Serum osmolality: 384 mOsm/kg 
• 
Serum ketones: trace 
• 
Urine: positive for bacteria and WBCs

Which of the following is the most appropriate initial treatment?', '[{"label":"A","text":"Intravenous regular insulin bolus"},{"label":"B","text":"Intravenous 0.45% saline at 250 mL/hr"},{"label":"C","text":"Intravenous 0.9% saline at 1 L/hr"},{"label":"D","text":"Intravenous 5% dextrose with 0.45% saline"},{"label":"E","text":"Subcutaneous long-acting insulin"}]'::jsonb, 'C', 'This patient has Hyperosmolar Hyperglycemic State (HHS), distinguished from DKA by: Feature HHS DKA Glucose >600 mg/dL (often >1000) >250 mg/dL Osmolality >320 mOsm/kg Variable pH >7.30 <7.30 Bicarbonate >18 mEq/L <18 mEq/L Feature HHS DKA Ketones Absent/trace Moderate-large Mental status Often severely altered Variable Key management principles: 1. Aggressive fluid resuscitation is the FIRST priority • HHS patients have more profound volume depletion than DKA (average 8–10 L deficit vs 5–7 L) • Start with isotonic saline (0.9% NS) regardless of sodium level • Initial rate: 1–1.5 L in first hour • This patient is hypotensive — isotonic fluid is essential to restore intravascular volume 2. Switch to hypotonic saline (0.45%) AFTER: • Hemodynamic stability is achieved • Corrected sodium is evaluated (if elevated, use 0.45% NS; if low/normal, continue 0.9% NS) Why not (A) insulin bolus? • Fluid resuscitation alone will lower glucose significantly in HHS • Insulin is started at lower doses (0.025–0.05 units/kg/hr) and only after initial fluids • Rapid glucose correction risks cerebral edema Why not (B) 0.45% saline? • Hypotonic saline is inappropriate initial therapy in hypotensive patients • Need isotonic fluid first to restore perfusion Why not (D) D5 with 0.45% NS? • Dextrose-containing fluids are added later when glucose reaches 250–300 mg/dL • Not appropriate initially with glucose of 928 mg/dL Mortality in HHS (10–20%) exceeds DKA (1–5%) — often due to delayed recognition, underlying precipitant (infection, MI), and thromboembolic complications.', NULL, 'internal', 'active'),
  ('B1_C05', 'b1-05-pheochromocytoma-preoperative-management', 'Batch1', 'Endocrinology', 'A 38-year-old woman is evaluated for episodes of severe headache, palpitations, and diaphoresis occurring several times per week for the past 3 months. 
During these episodes, she feels intense anxiety and her face becomes flushed. Her blood pressure between episodes is 142/92 mm Hg. Family history is 
notable for a brother who had thyroid cancer. 

Evaluation reveals elevated 24-hour urine catecholamines and metanephrines. CT of the abdomen shows a 4.2-cm right adrenal mass with high 
attenuation.

Surgical resection is planned. Which of the following is the most appropriate preoperative management?', '[{"label":"A","text":"Initiate propranolol followed by phenoxybenzamine"},{"label":"B","text":"Initiate phenoxybenzamine followed by propranolol"},{"label":"C","text":"Initiate propranolol alone"},{"label":"D","text":"Initiate labetalol alone"},{"label":"E","text":"Proceed directly to surgery without pharmacologic preparation"}]'::jsonb, 'B', 'This patient has classic pheochromocytoma — episodic catecholamine release causing the triad of: • Headache • Palpitations • Diaphoresis (+ hypertension) The family history of thyroid cancer raises concern for MEN2 syndrome (medullary thyroid cancer + pheochromocytoma ± hyperparathyroidism). Preoperative alpha-blockade is MANDATORY before surgery: Why alpha-blockade FIRST (phenoxybenzamine)? • Blocks α1 receptors → vasodilation → controls hypertension • Allows intravascular volume expansion (catecholamine-induced vasoconstriction causes chronic volume contraction) • Prevents intraoperative hypertensive crisis during tumor manipulation • Started 10–14 days before surgery; liberal salt/fluid intake encouraged Why beta-blockade SECOND? • Beta-blockade controls reflex tachycardia that occurs after alpha-blockade • NEVER give beta-blockers before alpha-blockade — this causes unopposed alpha stimulation → severe hypertensive crisis • Typically added 2–3 days after alpha-blockade is established Why not (A)? • Propranolol (beta-blocker) before alpha-blockade is dangerous • Allows unopposed alpha-adrenergic vasoconstriction → hypertensive emergency Why not (C) propranolol alone? • Same rationale — no alpha coverage leads to crisis Why not (D) labetalol alone? • Labetalol has both alpha and beta effects, but beta effects predominate • Not reliable for adequate alpha-blockade in pheochromocytoma Why not (E)? • Surgery without preoperative blockade has historically high mortality from intraoperative hypertensive crisis, arrhythmias, and cardiovascular collapse Metyrosine (inhibits catecholamine synthesis) is sometimes added in refractory cases.', NULL, 'internal', 'active'),
  ('B1_C06', 'b1-06-myxedema-coma-emergency-recognition-and-treatment', 'Batch1', 'Endocrinology', 'A 68-year-old woman is brought to the emergency department by her daughter who found her minimally responsive at home. The daughter reports her 
mother has seemed increasingly confused and lethargic over the past 2 weeks. The patient has a history of hypothyroidism but has not been taking her 
levothyroxine for "several months." 
On examination, the patient is obtunded. Temperature is 34.2°C (93.6°F), blood pressure is 88/58 mm Hg, pulse is 48/min, and respirations are 8/min. She 
has periorbital edema, macroglossia, dry coarse skin, and delayed relaxation of deep tendon reflexes. 
Laboratory studies show: 
• 
TSH: 89 mIU/L (normal 0.5–4.5) 
• 
Free T4: <0.2 ng/dL (normal 0.8–1.8) 
• 
Serum sodium: 118 mEq/L 
• 
Serum glucose: 52 mg/dL 
• 
Serum cortisol: 8 µg/dL 
In addition to supportive care including warming and airway management, which of the following is the most appropriate pharmacologic

treatment?', '[{"label":"A","text":"Oral levothyroxine"},{"label":"B","text":"Intravenous levothyroxine alone"},{"label":"C","text":"Intravenous levothyroxine plus intravenous hydrocortisone"},{"label":"D","text":"Intravenous liothyronine (T3) alone"},{"label":"E","text":"Radioactive iodine"}]'::jsonb, 'C', 'This patient has myxedema coma, a life-threatening decompensation of severe hypothyroidism characterized by: • Altered mental status (cardinal feature) • Hypothermia • Bradycardia • Hypotension • Hypoventilation • Hyponatremia (impaired free water excretion) • Hypoglycemia Treatment must address two critical issues: 1. Thyroid hormone replacement (IV levothyroxine) • Oral absorption is unreliable in critically ill patients • Loading dose: 200–400 µg IV, then 50–100 µg/day • Some protocols add IV T3 (liothyronine) for faster onset 2. Glucocorticoid coverage (IV hydrocortisone) — CRITICAL • Severe hypothyroidism impairs adrenal function • Additionally, thyroid hormone replacement increases cortisol metabolism • Starting levothyroxine without glucocorticoids can precipitate adrenal crisis • Give hydrocortisone 100 mg IV, then 50–100 mg q8h until adrenal function confirmed Why must steroids be given with thyroid hormone? • Hypothyroidism reduces cortisol clearance, masking underlying adrenal insufficiency • Giving T4 alone accelerates cortisol metabolism → relative adrenal insufficiency → cardiovascular collapse Why not (A)? • Oral administration is inappropriate in obtunded patient with GI hypomotility Why not (B)? • Missing the crucial glucocorticoid coverage Why not (D)? • T3 alone without T4 provides no sustained hormone levels • T3 may be added as adjunct to T4, not as sole therapy Precipitants to identify: infection (most common), cold exposure, sedatives, surgery, trauma Mortality remains 30–60% even with treatment — emphasizes the emergency nature.', NULL, 'internal', 'active'),
  ('B1_C07', 'b1-07-siadh-vs-cerebral-salt-wasting-volume-status-differentiation', 'Batch1', 'Endocrinology, Nephrology', 'A 52-year-old man is hospitalized following surgical clipping of a ruptured intracranial aneurysm 5 days ago. He initially did well postoperatively but now 
has mild confusion. 
Vital signs show blood pressure 108/68 mm Hg (baseline 132/84), pulse 98/min, and temperature 37.0°C. Physical examination reveals dry mucous 
membranes and flat neck veins. Skin turgor is mildly decreased. 

Laboratory studies show: 
• 
Serum sodium: 124 mEq/L 
• 
Serum osmolality: 258 mOsm/kg 
• 
Urine sodium: 85 mEq/L 
• 
Urine osmolality: 420 mOsm/kg 
• 
BUN: 28 mg/dL 
• 
Creatinine: 1.1 mg/dL 
• 
Uric acid: 2.1 mg/dL

Which of the following is the most appropriate treatment?', '[{"label":"A","text":"Fluid restriction to 1 L/day"},{"label":"B","text":"Intravenous 0.9% normal saline"},{"label":"C","text":"Demeclocycline"},{"label":"D","text":"Oral salt tablets with fluid restriction"},{"label":"E","text":"Conivaptan"}]'::jsonb, 'B', 'This patient has hyponatremia in the setting of neurosurgery — the differential includes SIADH and cerebral salt wasting (CSW). Both share: • Hypotonic hyponatremia • Inappropriately concentrated urine (osmolality >100) • Elevated urine sodium (>40 mEq/L) • Low serum uric acid The KEY differentiator is VOLUME STATUS: Feature SIADH CSW Volume status Euvolemic Hypovolemic BP/HR Normal ↓BP, ↑HR Physical exam No edema, no dehydration Dry mucosa, poor turgor, flat JVP BUN/Cr Normal or low Elevated (hemoconcentration) Urine output Normal/decreased Increased This patient has CSW: • Decreased BP from baseline • Tachycardia • Dry mucous membranes • Flat neck veins • Elevated BUN (28) with normal creatinine suggests volume depletion Treatment differs completely: CSW (hypovolemic) → Volume replacement with isotonic saline • Replace sodium and water losses • Restores intravascular volume • Correct hyponatremia gradually (<8–10 mEq/L per 24 hours to prevent osmotic demyelination) SIADH (euvolemic) → Fluid restriction • Excess free water is the problem • NS would worsen hyponatremia in SIADH (kidneys excrete sodium, retain water) Why not (A) fluid restriction? • This would be appropriate for SIADH but dangerous in hypovolemic CSW • Would worsen volume depletion and potentially cause hypotension/shock Why not (C) or (E)? • Demeclocycline and vaptans are used for chronic SIADH, not CSW • Vaptans cause aquaresis (free water loss) — harmful in already volume-depleted patient Clinical pearl: Post-neurosurgical hyponatremia requires careful volume assessment. Getting this wrong can be fatal — fluid restriction in CSW worsens dehydration; fluids in SIADH worsen hyponatremia.', NULL, 'internal', 'active'),
  ('B1_C08', 'b1-08-subclinical-hypothyroidism-treatment-decision', 'Batch1', 'Endocrinology', 'A 58-year-old woman comes to the clinic for routine follow-up. She feels well and has no specific complaints. She has a history of hypertension 
controlled with lisinopril. She denies fatigue, constipation, cold intolerance, or weight changes. 
Physical examination shows blood pressure 128/78 mm Hg, pulse 72/min, and BMI 26 kg/m². Thyroid is normal in size without nodules. Deep tendon 
reflexes are normal. 
Screening laboratory studies show: 
• 
TSH: 8.2 mIU/L (normal 0.5–4.5) 
• 
Free T4: 1.1 ng/dL (normal 0.8–1.8) 
Repeat testing 6 weeks later confirms: 
• 
TSH: 7.8 mIU/L 
• 
Free T4: 1.0 ng/dL 
• 
Anti-TPO antibodies: positive

Which of the following is the most appropriate management?', '[{"label":"A","text":"Initiate levothyroxine"},{"label":"B","text":"Observation with repeat TSH in 6–12 months"},{"label":"C","text":"Radioactive iodine uptake scan"},{"label":"D","text":"Thyroid ultrasound"},{"label":"E","text":"Trial of liothyronine (T3)"}]'::jsonb, 'A', 'This patient has subclinical hypothyroidism: elevated TSH with normal free T4. The decision to treat depends on several factors: Indications to TREAT subclinical hypothyroidism: 1. TSH >10 mIU/L — treat regardless of symptoms 2. TSH 5–10 mIU/L with: • Symptoms of hypothyroidism • Positive TPO antibodies (predicts progression to overt hypothyroidism) • Goiter • Pregnancy or planning pregnancy • Dyslipidemia • Significant cardiovascular disease • Age <65–70 years This patient should be treated because: • Persistent elevation (confirmed on repeat testing) • TSH 7.8 mIU/L (approaching 10) • Positive anti-TPO antibodies — key factor; indicates autoimmune thyroiditis with ~4.3% annual progression rate to overt hypothyroidism • Age 58 (younger patients benefit more from treatment) • Cardiovascular risk factors (hypertension) Treatment: Low-dose levothyroxine (25–50 µg daily), titrate to normalize TSH Why not (B) observation alone? • Would be appropriate if: • TSH only mildly elevated (5–7) AND • No TPO antibodies AND • No symptoms or risk factors • Positive antibodies change the calculation — progression likely Why not (C) or (D)? • RAI uptake scan is for hyperthyroidism workup • Ultrasound indicated if nodule suspected; not needed for straightforward subclinical hypothyroidism Why not (E)? • T3 monotherapy is not standard treatment for hypothyroidism • Levothyroxine (T4) is the standard of care In elderly patients (>70–80 years): More conservative approach; TSH targets may be higher, as overtreatment risks atrial fibrillation and bone loss.', NULL, 'internal', 'active'),
  ('B1_C09', 'b1-09-acute-coronary-syndrome-stemi-door-to-balloon-time', 'Batch1', 'Cardiology', 'A 62-year-old man presents to a rural emergency department with 45 minutes of severe substernal chest pressure radiating to his left arm, associated 
with diaphoresis and nausea. He has a history of hypertension and smoking. 
On examination, he appears anxious and diaphoretic. Blood pressure is 148/92 mm Hg, pulse is 96/min, respirations are 20/min. Lungs are clear, and 
there is no jugular venous distension. 
ECG shows 4-mm ST-segment elevation in leads V1–V4 with reciprocal ST depression in leads II, III, and aVF. 
The nearest PCI-capable facility is 95 minutes away by ambulance. The current facility does not have cardiac catheterization capabilities.

Which of the following is the most appropriate immediate management?', '[{"label":"A","text":"Administer fibrinolytic therapy now"},{"label":"B","text":"Transfer immediately for primary PCI"},{"label":"C","text":"Administer aspirin and heparin only, then transfer"},{"label":"D","text":"Obtain serial troponins before deciding on treatment"},{"label":"E","text":"Perform stress testing before intervention"}]'::jsonb, 'A', 'This patient has an anterior STEMI (ST elevation V1–V4 with reciprocal changes). Immediate reperfusion is critical — "time is myocardium." Decision framework for reperfusion strategy: Primary PCI is preferred if: • Door-to-balloon time <90 minutes at PCI-capable hospital • Door-to-balloon time <120 minutes if transfer required (including transfer time) Fibrinolysis is indicated when: • PCI not available within 120 minutes of first medical contact • No contraindications to fibrinolytics • Symptom onset <12 hours (ideally <3 hours for maximum benefit) This case: • Transfer time alone is 95 minutes • Add door-to-door time, door-to-balloon time at receiving facility → likely >120 minutes total • Patient has clear STEMI with symptoms for only 45 minutes • No stated contraindications to fibrinolytics Fibrinolysis should be administered within 30 minutes of arrival ("door-to-needle") Adjunctive therapy with either strategy: • Aspirin 325 mg (chewed) • P2Y12 inhibitor (clopidogrel if fibrinolysis; ticagrelor/prasugrel if PCI) • Anticoagulation (heparin) • Consider transfer for rescue PCI after fibrinolysis Why not (B)? • Would exceed the 120-minute window • Delays reperfusion → larger infarct → higher mortality Why not (C)? • Incomplete therapy — aspirin and heparin alone don''t provide reperfusion Why not (D) or (E)? • STEMI is a clinical and ECG diagnosis • Troponins take time and should not delay reperfusion • Stress testing is contraindicated in acute MI Key time targets: • Door-to-needle: ≤30 minutes • Door-to-balloon: ≤90 minutes (same hospital) or ≤120 minutes (transfer)', NULL, 'internal', 'active'),
  ('B1_C10', 'b1-10-heart-failure-with-reduced-ejection-fraction-mortality-reduc', 'Batch1', 'Cardiology', 'A 64-year-old man with ischemic cardiomyopathy returns for follow-up. His last echocardiogram showed left ventricular ejection fraction of 30%. He 
reports New York Heart Association class II symptoms — dyspnea with moderate exertion but comfortable at rest. 
Current medications: 
• 
Lisinopril 20 mg daily 
• 
Carvedilol 25 mg twice daily 
• 
Furosemide 40 mg daily 
• 
Atorvastatin 40 mg daily 
Vital signs: blood pressure 118/72 mm Hg, pulse 64/min. Physical examination shows no peripheral edema, jugular venous pressure is normal, and lungs 
are clear. 
Laboratory studies: 

• 
Serum potassium: 4.2 mEq/L 
• 
Serum creatinine: 1.1 mg/dL 
• 
eGFR: 72 mL/min/1.73m²

Which of the following additional medications would provide a mortality benefit?', '[{"label":"A","text":"Digoxin"},{"label":"B","text":"Hydralazine"},{"label":"C","text":"Spironolactone"},{"label":"D","text":"Amlodipine"},{"label":"E","text":"Isosorbide dinitrate"}]'::jsonb, 'C', 'This patient has HFrEF (EF ≤40%) on suboptimal GDMT. The "four pillars" of mortality-reducing therapy in HFrEF are: Drug Class Example Mortality Benefit ACE-I/ARB/ARNI Lisinopril, Sacubitril-valsartan ✓ Yes Beta-blocker Carvedilol, Metoprolol succinate, Bisoprolol ✓ Yes MRA Spironolactone, Eplerenone ✓ Yes SGLT2 inhibitor Dapagliflozin, Empagliflozin ✓ Yes This patient is missing an MRA (mineralocorticoid receptor antagonist) Evidence for spironolactone (RALES trial): • 30% reduction in mortality in NYHA III–IV HF • Also reduces hospitalizations • Indicated for EF ≤35% (some extend to ≤40%) with NYHA II–IV symptoms Before starting, verify: • K+ <5.0 mEq/L ✓ (this patient: 4.2) • eGFR >30 mL/min ✓ (this patient: 72) • No history of hyperkalemia Why not other options? (A) Digoxin: • Reduces HF hospitalizations • Does NOT reduce mortality • Used for symptom control or rate control in atrial fibrillation (B) Hydralazine and (E) Isosorbide dinitrate: • Combination (Hydralazine-ISDN) provides mortality benefit specifically in African American patients with HFrEF • Not first-line for all patients; added if ACE-I/ARB not tolerated or in addition to GDMT in African Americans (D) Amlodipine: • Safe in HF (unlike other calcium channel blockers) • Does NOT reduce mortality • Used only if additional BP or angina control needed Next optimization steps for this patient: 1. Add spironolactone 12.5–25 mg daily 2. Consider switching ACE-I to ARNI (sacubitril-valsartan) — superior mortality benefit 3. Add SGLT2 inhibitor 4. Assess for ICD indication (EF ≤35% on GDMT for ≥3 months)', NULL, 'internal', 'active'),
  ('B1_C11', 'b1-11-pulmonary-embolism-risk-stratification-and-disposition', 'Batch1', 'Pulmonology, Hematology', 'A 45-year-old woman presents to the emergency department with sudden-onset dyspnea and right-sided pleuritic chest pain that began 6 hours ago. 
She returned from a 14-hour international flight 3 days ago. She has no significant medical history and takes oral contraceptives. 
On examination, she is alert and anxious. Temperature is 37.2°C (99.0°F), blood pressure is 132/78 mm Hg, pulse is 102/min, respirations are 22/min, and 
oxygen saturation is 94% on room air. Lungs are clear, and there is no lower extremity edema or calf tenderness. 
CT pulmonary angiography shows a segmental pulmonary embolus in the right lower lobe. Echocardiogram shows normal right ventricular size and 
function. Troponin I is 0.02 ng/mL (normal <0.04). BNP is 45 pg/mL (normal <100).

Which of the following is the most appropriate management?', '[{"label":"A","text":"Admit to ICU for thrombolysis"},{"label":"B","text":"Admit to telemetry for IV heparin and monitoring"},{"label":"C","text":"Discharge with rivaroxaban and outpatient follow-up"},{"label":"D","text":"Admit for observation and IVC filter placement"},{"label":"E","text":"Discharge with aspirin only"}]'::jsonb, 'C', 'This patient has an acute pulmonary embolism with features suggesting low risk for adverse outcomes: Risk stratification for PE: High-risk (massive) PE: • Hemodynamic instability (SBP <90, shock) • Requires ICU, consider thrombolysis Intermediate-risk (submassive) PE: • Hemodynamically stable BUT • RV dysfunction on echo OR elevated troponin/BNP • Requires admission for monitoring Low-risk PE: • Hemodynamically stable AND • No RV dysfunction AND • Normal biomarkers AND • Low clinical risk score (sPESI = 0 or PESI class I–II) This patient is LOW RISK: • Hemodynamically stable ✓ • Normal RV function on echo ✓ • Normal troponin ✓ • Normal BNP ✓ • Simplified PESI (sPESI) score: likely 0 (no hypotension, no hypoxia <90%, no cancer, no chronic cardiopulmonary disease, no altered mental status, age <80) Low-risk PE can be managed as outpatient with: • Direct oral anticoagulant (DOAC): rivaroxaban, apixaban, or edoxaban • Duration: Provoked PE (flight + OCPs) → 3 months minimum • Close follow-up within 1 week Why not (A)? • Thrombolysis reserved for massive PE with hemodynamic instability • This patient is stable with no RV strain Why not (B)? • Unnecessary hospitalization for low-risk PE • Increases costs, VTE risk from immobility, nosocomial risks Why not (D)? • IVC filter only if anticoagulation contraindicated • This patient can be anticoagulated Why not (E)? • Aspirin is not treatment for PE • Requires anticoagulation DOAC advantages: No bridging required, fixed dosing, no INR monitoring (for rivaroxaban/apixaban)', NULL, 'internal', 'active'),
  ('B1_C12', 'b1-12-copd-exacerbation-when-to-add-antibiotics', 'Batch1', 'Pulmonology', 'A 68-year-old man with COPD (FEV1 45% predicted) presents with 3 days of worsening dyspnea, increased sputum production, and change in sputum 
from white to yellow-green. He uses tiotropium and albuterol inhalers at home. He has had two COPD exacerbations requiring hospitalization in the past 
year. 
On examination, temperature is 37.6°C (99.7°F), blood pressure is 138/82 mm Hg, pulse is 94/min, respirations are 24/min, and oxygen saturation is 89% 
on room air. He has diffuse expiratory wheezes and is using accessory muscles. There are no signs of consolidation. 
Chest X-ray shows hyperinflation without infiltrate.

Which of the following is the most appropriate treatment regimen?', '[{"label":"A","text":"Increased frequency of albuterol only"},{"label":"B","text":"Oral prednisone plus increased bronchodilators"},{"label":"C","text":"Oral prednisone plus azithromycin plus increased bronchodilators"},{"label":"D","text":"Intravenous antibiotics plus bronchodilators without steroids"},{"label":"E","text":"Inhaled corticosteroids only"}]'::jsonb, 'C', 'This patient has an acute exacerbation of COPD (AECOPD) meeting criteria for antibiotic therapy. Anthonisen criteria for AECOPD severity: 1. Increased dyspnea 2. Increased sputum volume 3. Increased sputum purulence (change in color) Antibiotic indications: • All 3 cardinal symptoms present (Type 1 — severe) → Antibiotics indicated • 2 of 3 symptoms IF one is purulence → Antibiotics indicated • Mechanical ventilation required → Antibiotics indicated • Mild exacerbation (1 symptom) → No antibiotics This patient has ALL 3: • ✓ Increased dyspnea • ✓ Increased sputum volume • ✓ Purulent sputum (yellow-green) Standard AECOPD treatment: Component Details Bronchodilators SABA (albuterol) ± SAMA (ipratropium), nebulized if severe Systemic corticosteroids Prednisone 40 mg × 5 days Antibiotics (if indicated) Azithromycin, doxycycline, or respiratory fluoroquinolone Oxygen Target SpO2 88–92% Why not (A)? • Missing corticosteroids and antibiotics; inadequate for this severity Why not (B)? • Missing antibiotics despite meeting criteria (Type 1 exacerbation) Why not (D)? • IV antibiotics not necessary for uncomplicated AECOPD without pneumonia • Missing systemic steroids (proven to reduce treatment failure and hospital stay) Why not (E)? • Inhaled steroids have no role in acute exacerbation management • Systemic steroids required Antibiotic choice: Cover typical pathogens (H. influenzae, M. catarrhalis, S. pneumoniae) • Azithromycin or doxycycline for most • Fluoroquinolone if recent antibiotic use or Pseudomonas risk', NULL, 'internal', 'active'),
  ('B1_C13', 'b1-13-community-acquired-pneumonia-outpatient-vs-inpatient-decisio', 'Batch1', 'Pulmonology, Infectious Disease', 'A 72-year-old man presents with 4 days of productive cough with rust-colored sputum, fever, and pleuritic chest pain. He has well-controlled 
hypertension and type 2 diabetes. 
On examination, temperature is 38.6°C (101.5°F), blood pressure is 102/64 mm Hg, pulse is 108/min, respirations are 26/min, and oxygen saturation is 
91% on room air. He is oriented to person, place, and time. Right lower lung field has bronchial breath sounds and dullness to percussion. 
Laboratory studies show BUN 24 mg/dL (normal 7–20) and WBC 18,400/µL. 
Chest X-ray shows right lower lobe consolidation.

Which of the following is the most appropriate disposition?', '[{"label":"A","text":"Discharge with oral amoxicillin"},{"label":"B","text":"Discharge with oral azithromycin plus amoxicillin"},{"label":"C","text":"Admit to medical ward for IV antibiotics"},{"label":"D","text":"Admit to ICU for IV antibiotics and monitoring"},{"label":"E","text":"Observe in ED for 6 hours, then discharge"}]'::jsonb, 'C', 'This patient has community-acquired pneumonia (CAP) requiring severity assessment for disposition. CURB-65 score (1 point each): • Confusion → No (0) • Uremia (BUN >19 mg/dL or >7 mmol/L) → Yes (1) • Respiratory rate ≥30 → No, but close at 26 (0) • Blood pressure (SBP <90 or DBP ≤60) → DBP 64, borderline (0 or 1) • Age ≥65 → Yes (1) Score: 2–3 points CURB-65 interpretation: Score Mortality Risk Disposition 0–1 Low (1.5%) Outpatient 2 Intermediate (9.2%) Consider admission 3–5 High (22%) Admit; ≥4 consider ICU Additional concerning features: • Hypoxemia (SpO2 91%) • Elderly with comorbidities (DM) • Borderline hypotension • Elevated WBC suggesting significant infection This patient warrants hospital admission but does not meet ICU criteria. ICU admission criteria (any one major or ≥3 minor): • Major: Septic shock requiring vasopressors, mechanical ventilation • Minor: RR ≥30, PaO2/FiO2 ≤250, multilobar infiltrates, confusion, BUN ≥20, WBC <4000, platelets <100,000, hypothermia, hypotension requiring fluids Inpatient treatment (non-ICU): • Respiratory fluoroquinolone (levofloxacin or moxifloxacin) alone, OR • Beta-lactam (ceftriaxone, ampicillin-sulbactam) PLUS macrolide (azithromycin) Why not (A) or (B)? • Outpatient therapy inappropriate given severity score and hypoxemia Why not (D)? • Does not meet major ICU criteria (hemodynamically stable, not in respiratory failure) Why not (E)? • Brief observation insufficient; requires admission', NULL, 'internal', 'active'),
  ('B1_C14', 'b1-14-upper-gi-bleed-timing-of-endoscopy', 'Batch1', 'Gastroenterology', 'A 58-year-old man presents to the emergency department after vomiting approximately 500 mL of bright red blood 2 hours ago. He has a history of 
alcohol use disorder and takes ibuprofen regularly for back pain. He denies abdominal pain. 
On examination, he is anxious but alert. Temperature is 36.8°C (98.2°F), blood pressure is 98/62 mm Hg (108/70 after 1L NS), pulse is 112/min (98 after 
fluids), respirations are 18/min. Abdomen is soft, nontender. Rectal examination shows melena. 
Laboratory studies: 
• 
Hemoglobin: 8.4 g/dL (baseline 14 g/dL) 
• 
Platelets: 142,000/µL 
• 
INR: 1.2 
• 
BUN: 42 mg/dL 
• 
Creatinine: 1.0 mg/dL

After initial resuscitation and IV PPI, which of the following is the most appropriate timing for esophagogastroduodenoscopy (EGD)?', '[{"label":"A","text":"Immediately (within 1 hour)"},{"label":"B","text":"Urgent (within 12 hours)"},{"label":"C","text":"Within 24 hours"},{"label":"D","text":"Within 48–72 hours after stabilization"},{"label":"E","text":"Elective outpatient EGD in 2 weeks"}]'::jsonb, 'C', 'This patient has acute upper GI bleeding (hematemesis with melena) requiring risk stratification for EGD timing. Risk assessment (Glasgow-Blatchford Score — GBS): • BUN 42 → 4 points • Hemoglobin 8.4 (male) → 3 points • SBP 98 → 2 points • Pulse ≥100 → 1 point • Melena → 1 point • Total: ~11 points → High risk EGD timing guidelines: Clinical Scenario Timing Hemodynamic instability unresponsive to resuscitation, ongoing hemorrhage Emergent (within 12 hours, some say <6 hours) High-risk but hemodynamically stabilized Urgent (within 24 hours) ← This patient Low-risk (GBS 0–1) May be appropriate for outpatient This patient: • High-risk features (significant hemoglobin drop, melena, elevated BUN) • BUT responded to fluid resuscitation (BP and HR improved) • Appropriate for EGD within 24 hours (not emergency <12 hours) Why within 24 hours, not immediately? • Studies show no mortality benefit of <6 hour EGD vs <24 hour EGD in hemodynamically stable patients • Allows adequate resuscitation, correction of coagulopathy if needed • Improved visualization with controlled endoscopy Immediate/emergent EGD (<12 hours) indicated if: • Ongoing hemodynamic instability despite resuscitation • Signs of continued active bleeding • High suspicion for variceal bleed with instability Pre-endoscopy management: • IV PPI (pantoprazole 80 mg bolus then infusion) • Transfuse if Hgb <7 g/dL (or <8–9 in CAD) • Correct coagulopathy (INR 1.2 is acceptable) • NPO, prokinetic (erythromycin) may improve visualization Why not (A)? • Patient stabilized; no evidence emergent EGD improves outcomes in this scenario Why not (D) or (E)? • Delayed endoscopy increases risk of rebleeding and missed high-risk lesions', NULL, 'internal', 'active'),
  ('B1_C15', 'b1-15-spontaneous-bacterial-peritonitis-diagnosis-and-treatment', 'Batch1', 'Gastroenterology, Infectious Disease', 'A 56-year-old man with alcoholic cirrhosis and ascites presents with 2 days of worsening abdominal pain, fever, and confusion. He had a prior episode of 
spontaneous bacterial peritonitis (SBP) 8 months ago but stopped taking prophylactic antibiotics. 
On examination, temperature is 38.4°C (101.1°F), blood pressure is 94/58 mm Hg, pulse is 110/min. He is disoriented. Abdomen is distended with diffuse 
tenderness and positive fluid wave. There is no rebound tenderness. 
Diagnostic paracentesis is performed: 

• 
Ascitic fluid WBC: 680 cells/µL 
• 
Ascitic fluid PMN (neutrophils): 420 cells/µL 
• 
Ascitic fluid protein: 0.8 g/dL 
• 
Ascitic fluid culture: pending 
• 
Ascitic fluid glucose: 85 mg/dL 
• 
Serum-ascites albumin gradient (SAAG): 1.8 g/dL

Which of the following is the most appropriate next step?', '[{"label":"A","text":"Await culture results before starting antibiotics"},{"label":"B","text":"Start IV cefotaxime and albumin infusion"},{"label":"C","text":"Start oral ciprofloxacin"},{"label":"D","text":"Emergent surgical exploration"},{"label":"E","text":"Repeat paracentesis in 48 hours"}]'::jsonb, 'B', 'This patient has spontaneous bacterial peritonitis (SBP), diagnosed clinically and confirmed by paracentesis. Diagnostic criteria for SBP: • Ascitic fluid PMN count ≥250 cells/µL ← This patient has 420 • Culture may be negative in up to 40% ("culture-negative neutrocytic ascites") DO NOT wait for culture results — SBP is a clinical diagnosis requiring immediate treatment Treatment of SBP: Component Details Antibiotics IV 3rd-generation cephalosporin (cefotaxime 2g q8h) × 5 days Albumin 1.5 g/kg on day 1, 1 g/kg on day 3 Alternative antibiotics Ceftriaxone, fluoroquinolone (if no recent FQ use) Why albumin? • Reduces mortality and hepatorenal syndrome risk • Study showed mortality reduction from 29% to 10% when albumin added to antibiotics • Indicated especially if: Cr >1 mg/dL, BUN >30 mg/dL, or bilirubin >4 mg/dL This patient should receive albumin because: • Hypotension (SBP 94) • Altered mental status (hepatic encephalopathy or sepsis) • Prior SBP episode (high-risk) Why not (A)? • Cultures take 24–48+ hours; SBP mortality increases with treatment delay • PMN ≥250 is sufficient to diagnose and treat Why not (C)? • Oral fluoroquinolone inadequate for active SBP with sepsis • Reserved for prophylaxis, not treatment • Additionally, this patient was on FQ prophylaxis → may have resistant organisms Why not (D)? • SBP is treated medically, not surgically • Secondary bacterial peritonitis (from perforation) would show: glucose <50, LDH elevation, protein >1 g/dL, multiple organisms, polymicrobial Why not (E)? • Treatment should start immediately • Repeat paracentesis at 48 hours is done to confirm response (>25% decrease in PMN) Secondary prophylaxis: After recovery, lifelong norfloxacin or TMP-SMX (this patient needs to restart)', NULL, 'internal', 'active'),
  ('B1_C16', 'b1-16-acute-pancreatitis-severity-assessment-and-fluid-resuscitati', 'Batch1', 'Gastroenterology', 'A 44-year-old woman presents with severe epigastric pain radiating to the back for 12 hours, associated with nausea and vomiting. She drinks 4–5 
glasses of wine daily. She has had similar but milder episodes before. 
On examination, temperature is 37.8°C (100°F), blood pressure is 104/68 mm Hg, pulse is 108/min. She has epigastric tenderness with guarding but no 
rebound. Bowel sounds are hypoactive. 
Laboratory studies: 
• 
Lipase: 1,842 U/L (normal <160) 
• 
WBC: 16,200/µL 
• 
Hematocrit: 48% 
• 
BUN: 32 mg/dL 
• 
Creatinine: 1.4 mg/dL 
• 
Glucose: 186 mg/dL 
• 
AST: 58 U/L 
• 
Calcium: 7.8 mg/dL 
• 
LDH: 420 U/L

Which of the following is the most appropriate initial management?', '[{"label":"A","text":"Immediate CT of the abdomen"},{"label":"B","text":"Aggressive IV crystalloid resuscitation (250–500 mL/hr)"},{"label":"C","text":"IV antibiotics to prevent infected necrosis"},{"label":"D","text":"Urgent ERCP"},{"label":"E","text":"TPN initiation"}]'::jsonb, 'B', 'This patient has acute pancreatitis (epigastric pain + lipase >3× upper limit of normal). Severity assessment using Ranson criteria at admission: • Age >55 → No (44) • WBC >16,000 → Yes ✓ • Glucose >200 → No (186) • AST >250 → No • LDH >350 → Yes ✓ Additional concerning features: • Elevated BUN (32) → predictor of severity • Elevated hematocrit (48%) → hemoconcentration indicating third-spacing • Hypocalcemia (7.8) → marker of severe pancreatitis • Tachycardia with borderline hypotension → early hypovolemia This is likely moderately severe to severe pancreatitis requiring aggressive management. Initial management priorities: 1. Aggressive IV fluid resuscitation — MOST IMPORTANT • Goal-directed: 250–500 mL/hr of LR (preferred) or NS • Target: urine output >0.5 mL/kg/hr, decreasing BUN, normalizing vitals • First 12–24 hours are critical; fluid needs are highest early • Prevents pancreatic necrosis by maintaining perfusion 2. Pain control (IV opioids) 3. NPO initially (consider early enteral feeding if tolerated) 4. Monitor for organ failure (respiratory, renal, cardiovascular) Why not (A)? • CT is not indicated initially unless: • Diagnosis uncertain • No improvement after 48–72 hours (concern for necrosis/complications) • Early CT can underestimate necrosis; inflammation takes time to develop Why not (C)? • Prophylactic antibiotics do NOT prevent infected necrosis • Antibiotics only indicated for documented infection (infected necrosis, cholangitis) Why not (D)? • ERCP indicated for gallstone pancreatitis with concurrent cholangitis or persistent biliary obstruction • This appears to be alcohol-related; no indication for ERCP Why not (E)? • TPN avoided; enteral nutrition preferred (maintains gut barrier) • Early oral/enteral feeding (within 24–48 hours) if tolerated improves outcomes', NULL, 'internal', 'active'),
  ('B1_C17', 'b1-17-acute-kidney-injury-prerenal-vs-intrinsic-differentiation', 'Batch1', 'Nephrology', 'A 78-year-old woman is admitted with community-acquired pneumonia. She has hypertension treated with lisinopril and hydrochlorothiazide. Due to 
poor oral intake and fever, she has been volume depleted. On hospital day 2, you note her creatinine has risen from 1.1 mg/dL on admission to 2.4 
mg/dL. 
Physical examination shows blood pressure 102/68 mm Hg (baseline 138/82), pulse 96/min, dry mucous membranes, and decreased skin turgor. Urine 
output has been 15 mL/hr over the past 6 hours. 
Urine studies: 
• 
Urine sodium: 8 mEq/L 
• 
Urine creatinine: 112 mg/dL 
• 
Serum creatinine: 2.4 mg/dL 
• 
Fractional excretion of sodium (FENa): 0.3% 
• 
Urine osmolality: 650 mOsm/kg 
• 
Urine microscopy: Few hyaline casts, no cells or cellular casts

Which of the following is the most likely diagnosis?', '[{"label":"A","text":"Acute tubular necrosis"},{"label":"B","text":"Acute interstitial nephritis"},{"label":"C","text":"Prerenal azotemia"},{"label":"D","text":"Postrenal obstruction"},{"label":"E","text":"Contrast-induced nephropathy"}]'::jsonb, 'C', 'This patient has acute kidney injury (AKI) in the setting of volume depletion. The urine studies help differentiate prerenal from intrinsic causes. Urine indices comparison: Parameter Prerenal ATN (Intrinsic) Urine sodium <20 mEq/L >40 mEq/L FENa <1% >2% Urine osmolality >500 mOsm/kg <350 mOsm/kg BUN:Cr ratio >20:1 <15:1 Urine sediment Bland, hyaline casts Muddy brown granular casts This patient''s findings: • Urine sodium 8 mEq/L → Low (<20) ✓ • FENa 0.3% → <1% ✓ • Urine osmolality 650 → Concentrated (>500) ✓ • Bland sediment with hyaline casts ✓ All consistent with PRERENAL AZOTEMIA Pathophysiology: The kidneys are appropriately retaining sodium and water in response to decreased perfusion. Tubular function is intact. Clinical context supports prerenal: • Volume depletion (poor intake, fever, dry mucosa) • Hypotension below baseline • On diuretics and ACE inhibitor (reduced GFR autoregulation) Management: • IV fluid resuscitation • Hold diuretics and ACE inhibitor temporarily • Expect creatinine to improve within 24–48 hours Why not (A) ATN? • FENa would be >2% • Urine would be dilute (osmolality <350) • Would see muddy brown granular casts Why not (B) AIN? • Usually drug-induced (NSAIDs, antibiotics, PPIs) • Would see WBC casts, eosinophiluria • Often presents with fever, rash, eosinophilia (but not always) Why not (D)? • Postrenal requires obstruction (bilateral or single functioning kidney) • No symptoms suggesting obstruction, no hydronephrosis mentioned Why not (E)? • No contrast exposure mentioned Caveat: FENa can be <1% in ATN if caused by contrast, myoglobin, or early sepsis. Use FEUrea (<35% prerenal) if on diuretics.', NULL, 'internal', 'active'),
  ('B1_C18', 'b1-18-hyperkalemia-emergency-management-sequence', 'Batch1', 'Nephrology, Cardiology', 'A 62-year-old man with end-stage renal disease on hemodialysis missed his last two sessions due to transportation issues. He presents with generalized 
weakness and palpitations. 
On examination, blood pressure is 168/98 mm Hg, pulse is 52/min and irregular. He has 2+ lower extremity edema bilaterally. 
ECG shows peaked T waves, prolonged PR interval, and widening of the QRS complex. 
Laboratory studies: 
• 
Serum potassium: 7.8 mEq/L 
• 
Serum bicarbonate: 16 mEq/L 
• 
Serum creatinine: 8.9 mg/dL

Which of the following is the most appropriate FIRST step in management?', '[{"label":"A","text":"Insulin plus dextrose"},{"label":"B","text":"IV calcium gluconate"},{"label":"C","text":"Sodium polystyrene sulfonate (Kayexalate)"},{"label":"D","text":"Emergent hemodialysis"},{"label":"E","text":"IV sodium bicarbonate"}]'::jsonb, 'B', 'This patient has severe hyperkalemia (K+ 7.8) with ECG changes — a life-threatening emergency. The ECG progression of hyperkalemia: 1. Peaked T waves (early) 2. Prolonged PR interval 3. Widened QRS 4. Sine wave pattern 5. VFib/asystole This patient has advanced ECG changes (peaked T, prolonged PR, wide QRS) → imminent risk of fatal arrhythmia Treatment sequence for severe hyperkalemia: Step Treatment Mechanism Onset 1. FIRST IV Calcium gluconate Stabilizes cardiac membrane 1–3 min 2. Insulin + glucose Shifts K+ into cells 15–30 min 3. Sodium bicarbonate Shifts K+ into cells (if acidotic) 30–60 min 3. Beta-agonist (albuterol) Shifts K+ into cells 15–30 min 4. Definitive removal Dialysis, Kayexalate, patiromer Hours Why calcium FIRST? • Does NOT lower potassium • Directly antagonizes the cardiac membrane effects of hyperkalemia • Provides immediate protection against arrhythmia • Buys time for other treatments to work Why not (A) insulin/glucose first? • Insulin lowers potassium but takes 15–30 minutes • With ECG changes, patient may develop fatal arrhythmia before insulin works • Calcium stabilizes the heart within minutes Why not (C) Kayexalate? • Removes potassium from body but takes hours to work • Not appropriate for acute emergency • Role is in removal after stabilization Why not (D) dialysis first? • Definitive treatment but takes time to arrange • Patient may arrest while waiting • Start dialysis after initial stabilization Why not (E) bicarbonate first? • Less effective than insulin for potassium shift • Useful adjunct if metabolic acidosis present • Not first-line Complete management sequence for this patient: 1. IV calcium gluconate 1–2 g → monitor ECG for narrowing QRS 2. Insulin 10 units IV + D50 25 g (or D10 drip) 3. Emergent hemodialysis', NULL, 'internal', 'active'),
  ('B1_C19', 'b1-19-neutropenic-fever-empiric-antibiotic-selection', 'Batch1', 'Infectious Disease, Hematology/Oncology', 'A 58-year-old woman with acute myeloid leukemia completed her third cycle of chemotherapy 10 days ago. She presents with fever (38.9°C/102°F) and 
mild fatigue. She denies cough, diarrhea, urinary symptoms, or skin changes. She has a tunneled central venous catheter in place. 
On examination, she appears tired but comfortable. Blood pressure is 118/72 mm Hg, pulse is 102/min. Examination of the catheter site shows no 
erythema or discharge. Lungs are clear. Abdomen is soft, nontender. 
Laboratory studies: 
• 
WBC: 400/µL with ANC 80/µL 
• 
Hemoglobin: 9.2 g/dL 
• 
Platelets: 34,000/µL 
Chest X-ray shows no infiltrates.

Which of the following is the most appropriate initial antibiotic therapy?', '[{"label":"A","text":"Vancomycin monotherapy"},{"label":"B","text":"Cefepime monotherapy"},{"label":"C","text":"Ceftriaxone plus metronidazole"},{"label":"D","text":"Ciprofloxacin plus amoxicillin-clavulanate"},{"label":"E","text":"Wait for blood culture results before starting antibiotics"}]'::jsonb, 'B', 'This patient has febrile neutropenia — a medical emergency: • Fever: Single temperature ≥38.3°C (101°F) OR ≥38.0°C (100.4°F) sustained for ≥1 hour • Neutropenia: ANC <500/µL OR ANC <1000/µL expected to decline to <500 • This patient: ANC 80/µL with fever 38.9°C Key principle: Start empiric antibiotics IMMEDIATELY. Do not wait for culture results or localizing signs. Initial empiric therapy options (IDSA guidelines): Regimen Examples Anti-pseudomonal beta-lactam monotherapy Cefepime, piperacillin-tazobactam, meropenem, imipenem Dual therapy (if indicated) Add vancomycin or aminoglycoside for specific indications Cefepime is appropriate because: • Broad-spectrum anti-pseudomonal coverage • Covers most gram-negative pathogens (including Pseudomonas) • Adequate gram-positive coverage for initial empiric therapy • Monotherapy is standard initial approach When to ADD vancomycin to initial regimen: • Hemodynamic instability/sepsis • Skin/soft tissue infection • Catheter-related infection suspected (erythema, tunnel tenderness) • Known MRSA colonization • Gram-positive cocci on blood culture • Severe mucositis • Pneumonia • Fluoroquinolone prophylaxis (increased risk of gram-positive infection) This patient has NONE of these indications — stable vital signs, no catheter site infection, no mucositis, no pneumonia → vancomycin not needed initially. Why not (A)? • Vancomycin alone has no gram-negative coverage — unacceptable Why not (C)? • Ceftriaxone lacks anti-pseudomonal activity • Metronidazole adds anaerobic coverage but not gram-negative/Pseudomonas Why not (D)? • Oral fluoroquinolone regimen may be appropriate for low-risk outpatients • This patient has AML, profound neutropenia (ANC 80), central catheter → HIGH RISK • Requires IV therapy and admission Why not (E)? • NEVER delay antibiotics in febrile neutropenia • Mortality increases with each hour of delayed antibiotic therapy', NULL, 'internal', 'active'),
  ('B1_C20', 'b1-20-infective-endocarditis-duke-criteria-and-empiric-therapy', 'Batch1', 'Infectious Disease, Cardiology', 'A 34-year-old man who uses IV heroin presents with 2 weeks of fever, night sweats, and malaise. He also reports progressive dyspnea and a new cough 
productive of blood-tinged sputum. 
On examination, temperature is 38.8°C (101.8°F), blood pressure is 108/62 mm Hg, pulse is 110/min, respirations are 22/min. There is a 3/6 holosystolic 
murmur at the left lower sternal border that increases with inspiration. Examination reveals splinter hemorrhages and tender nodules on the fingertips. 
Lungs have scattered crackles bilaterally. 
Laboratory studies show WBC 18,400/µL and hemoglobin 10.2 g/dL. Chest X-ray shows multiple bilateral peripheral nodular infiltrates, some with 
cavitation. 
Blood cultures are drawn and sent.

Which of the following is the most appropriate empiric antibiotic regimen while awaiting culture results?', '[{"label":"A","text":"Vancomycin plus gentamicin"},{"label":"B","text":"Ceftriaxone plus gentamicin"},{"label":"C","text":"Penicillin G monotherapy"},{"label":"D","text":"Vancomycin monotherapy"},{"label":"E","text":"Ciprofloxacin plus rifampin"}]'::jsonb, 'A', 'This patient has clinical features consistent with infective endocarditis (IE) with likely tricuspid valve involvement (right-sided IE). Modified Duke Criteria assessment: Major criteria: 1. Blood cultures pending (likely to be positive if IE) 2. Echocardiographic evidence of vegetation (not yet done, but murmur + IVDU highly suggestive) Minor criteria: 1. ✓ Predisposing condition (IVDU) 2. ✓ Fever 3. ✓ Vascular phenomena: septic pulmonary emboli (cavitary lung nodules + hemoptysis) 4. ✓ Immunologic phenomena: Osler nodes (tender fingertip nodules) Clinical picture: • IVDU → Right-sided (tricuspid) IE most common • Tricuspid regurgitation murmur (holosystolic at LLSB, increases with inspiration) • Septic pulmonary emboli → multiple cavitary lung nodules • Most likely organism: Staphylococcus aureus (especially MRSA in IVDU) Empiric treatment for native valve IE in IVDU: Context Empiric Regimen IVDU, native valve Vancomycin (MRSA coverage) + gentamicin Non-IVDU, native valve Ceftriaxone + vancomycin (or nafcillin if low MRSA risk) Prosthetic valve Vancomycin + gentamicin + rifampin Why vancomycin + gentamicin? • Vancomycin: MRSA coverage essential in IVDU population (high prevalence) • Gentamicin: Synergistic killing, enhances bactericidal activity against staphylococci • Adjust/narrow once cultures speciate Why not (B)? • Ceftriaxone lacks MRSA coverage • Would be appropriate for streptococcal IE but not empiric for IVDU Why not (C)? • Penicillin G for penicillin-susceptible streptococci only • Inadequate for empiric therapy Why not (D)? • Vancomycin monotherapy adequate for some cases but gentamicin adds synergy for serious S. aureus infection Why not (E)? • Not a standard IE regimen • Rifampin is added for prosthetic valve IE, not native valve Next steps: Obtain echocardiogram (TTE first, may need TEE), follow blood cultures, narrow antibiotics when sensitivities available', NULL, 'internal', 'active'),
  ('B1_C21', 'b1-21-heparin-induced-thrombocytopenia-diagnosis-and-management', 'Batch1', 'Hematology', 'A 64-year-old woman is postoperative day 7 after hip replacement surgery. She has been receiving subcutaneous unfractionated heparin for DVT 
prophylaxis since admission. The nurse reports that her platelet count has decreased significantly. 
Review of laboratory values: 
• 
Preoperative platelets: 248,000/µL 
• 
POD 2: 234,000/µL 
• 
POD 5: 168,000/µL 
• 
POD 7 (today): 89,000/µL 
She has no bleeding symptoms but reports new pain and swelling in her left calf. On examination, the left calf is 3 cm larger in circumference than the 
right with tenderness and warmth.

Which of the following is the most appropriate immediate management?', '[{"label":"A","text":"Continue heparin and transfuse platelets"},{"label":"B","text":"Discontinue heparin and start warfarin"},{"label":"C","text":"Discontinue heparin and start argatroban"},{"label":"D","text":"Discontinue heparin and observe platelet count"},{"label":"E","text":"Switch to low-molecular-weight heparin"}]'::jsonb, 'C', 'This patient has heparin-induced thrombocytopenia (HIT), a prothrombotic disorder paradoxically caused by heparin. 4Ts Score for HIT: Criterion This Patient Points Thrombocytopenia (50% fall or nadir 20–100K) 89K (64% fall from baseline) 2 Timing (5–10 days after heparin start) Day 7 of heparin 2 Thrombosis or other sequelae New DVT suspected (calf swelling) 2 OTher causes for thrombocytopenia None apparent (postop, no sepsis) 2 Score: 8 (High probability) Key features of HIT: • Onset 5–10 days after heparin exposure (or sooner if prior exposure) • Platelet drop >50% from baseline (or to <150,000) • Paradoxical thrombosis (arterial or venous) — NOT bleeding • Antibodies against platelet factor 4-heparin complex Management principles: 1. STOP ALL HEPARIN — including heparin flushes, LMWH, heparin-coated catheters 2. Start non-heparin anticoagulant immediately — patients are hypercoagulable • Argatroban (direct thrombin inhibitor) — preferred in renal impairment • Bivalirudin — for PCI • Fondaparinux — sometimes used but technically a heparinoid 3. Do NOT give warfarin until platelets recover — warfarin causes protein C drop, increasing thrombosis risk 4. Do NOT transfuse platelets — "fuel for the fire"; increases thrombosis risk 5. Send HIT antibody testing (PF4/heparin ELISA, serotonin release assay) Why not (A)? • Continuing heparin worsens HIT; platelets may trigger more thrombosis Why not (B)? • Warfarin alone is contraindicated in acute HIT • Must wait until platelets >150,000 AND on therapeutic non-heparin anticoagulant • Warfarin monotherapy causes warfarin-induced skin necrosis/limb gangrene Why not (D)? • Observation inadequate — 50% of HIT patients develop thrombosis if untreated Why not (E)? • LMWH cross-reacts with HIT antibodies in ~90% of cases • Contraindicated in HIT', NULL, 'internal', 'active'),
  ('B1_C22', 'b1-22-tumor-lysis-syndrome-prevention-and-management', 'Batch1', 'Hematology/Oncology, Nephrology', 'A 22-year-old man is newly diagnosed with Burkitt lymphoma with extensive abdominal lymphadenopathy. CT shows multiple bulky retroperitoneal 
lymph nodes with the largest measuring 12 cm. Laboratory studies show WBC 32,000/µL, LDH 2,450 U/L (normal <250), uric acid 9.8 mg/dL, potassium 
4.6 mEq/L, phosphorus 5.2 mg/dL, and creatinine 1.2 mg/dL. 
Chemotherapy is planned to begin tomorrow.

Which of the following is the most appropriate prophylactic management?', '[{"label":"A","text":"Rasburicase, aggressive IV hydration, and close monitoring"},{"label":"B","text":"Allopurinol and IV hydration only"},{"label":"C","text":"Sodium bicarbonate to alkalinize urine"},{"label":"D","text":"Observation with treatment if TLS develops"},{"label":"E","text":"Delay chemotherapy until uric acid normalizes"}]'::jsonb, 'A', 'This patient is at HIGH RISK for tumor lysis syndrome (TLS) and requires aggressive prophylaxis. TLS risk factors present: • Burkitt lymphoma (one of highest TLS risk malignancies) • Bulky disease (12 cm lymph node mass) • Elevated LDH (marker of tumor burden/cell turnover) • Elevated baseline uric acid (9.8 mg/dL) • High WBC TLS involves release of intracellular contents causing: • ↑ Potassium → arrhythmias • ↑ Phosphorus → binds calcium → hypocalcemia → tetany, arrhythmias • ↑ Uric acid → crystallizes in renal tubules → AKI • ↑ LDH (marker) Risk stratification and prophylaxis: Risk Level Examples Prophylaxis High Burkitt, lymphoblastic lymphoma, AML with WBC >100K, bulky disease, elevated LDH/uric acid Rasburicase + aggressive hydration Intermediate Most hematologic malignancies Allopurinol + hydration Low Solid tumors, indolent lymphomas Hydration ± allopurinol Why rasburicase for high-risk? • Recombinant urate oxidase • Rapidly converts uric acid to allantoin (soluble, easily excreted) • Works within hours (vs. days for allopurinol) • Prevents uric acid nephropathy • Critical when uric acid already elevated or very high tumor burden Why not (B) allopurinol alone? • Allopurinol only prevents NEW uric acid formation (blocks xanthine oxidase) • Does not break down existing uric acid • Takes days to lower uric acid • Inadequate for high-risk patients with elevated baseline uric acid Why not (C)? • Urine alkalinization was historically used but now discouraged • Increases calcium phosphate precipitation (more dangerous than uric acid crystals) • Not recommended by current guidelines Why not (D)? • Treating TLS after it develops is much harder than preventing it • Dialysis often required; significant mortality Why not (E)? • Delaying chemotherapy for aggressive lymphoma worsens outcomes • Rasburicase allows safe initiation of chemotherapy Additional measures: • IV hydration 2–3 L/m²/day • Monitor electrolytes q6–8 hours • Avoid potassium in IV fluids • Dialysis if AKI or refractory hyperkalemia/hyperphosphatemia Rasburicase contraindication: G6PD deficiency (causes hemolysis)', NULL, 'internal', 'active'),
  ('B1_C23', 'b1-23-sickle-cell-disease-acute-chest-syndrome-management', 'Batch1', 'Hematology, Pulmonology', 'A 24-year-old man with sickle cell disease presents with fever, cough, and chest pain for 2 days. He was admitted 4 days ago for a vaso-occlusive pain 
crisis affecting his lower back and legs and has been receiving IV morphine and fluids. 
On examination, temperature is 38.7°C (101.7°F), blood pressure is 102/68 mm Hg, pulse is 118/min, respirations are 28/min, and oxygen saturation is 
88% on room air. He appears in moderate distress. Lung examination reveals decreased breath sounds and crackles at the left base. He has mild scleral 
icterus. 
Laboratory studies: 
• 
Hemoglobin: 6.8 g/dL (baseline 8.5 g/dL) 
• 
WBC: 18,200/µL 
• 
Reticulocyte count: 1.2% (low for hemolysis) 
• 
LDH: 680 U/L 
Chest X-ray shows a new left lower lobe infiltrate not present on admission.

Which of the following is the most appropriate immediate management?', '[{"label":"A","text":"Simple blood transfusion to hemoglobin 10 g/dL"},{"label":"B","text":"Exchange transfusion"},{"label":"C","text":"Supplemental oxygen and incentive spirometry only"},{"label":"D","text":"Bronchoscopy with bronchoalveolar lavage"},{"label":"E","text":"Increase morphine dose for pain control"}]'::jsonb, 'B', 'This patient has acute chest syndrome (ACS), the leading cause of death in sickle cell disease. Diagnosis of ACS: • New pulmonary infiltrate on imaging • PLUS at least ONE of: • Fever • Chest pain • Respiratory symptoms (cough, dyspnea) • Hypoxia This patient has ALL features: New infiltrate + fever + chest pain + cough + hypoxia (88%) ACS often develops during hospitalization for pain crisis — this presentation is classic. Severity assessment: Feature Mild/Moderate Severe Oxygen requirement Low-flow High-flow, worsening Respiratory distress Mild Moderate-severe Multilobar involvement No Yes, or rapidly progressing Hemoglobin drop Mild Significant (>2 g/dL) This patient has SEVERE ACS: • Significant hypoxia (88% on room air) • Hemoglobin dropped 1.7 g/dL from baseline • Tachypnea (RR 28), tachycardia • Low reticulocyte count suggests bone marrow suppression (parvovirus? infarction?) Management of severe ACS: Priority Intervention 1 Exchange transfusion (reduces HbS% to <30%) 2 Supplemental oxygen (target SpO2 >95%) 3 Antibiotics (cover atypical + typical pathogens) 4 Bronchodilators if wheezing 5 Incentive spirometry (prevents atelectasis) 6 Pain control (avoid over-sedation) Why exchange transfusion over simple transfusion? • More rapidly decreases HbS percentage • Prevents hyperviscosity (simple transfusion raises hemoglobin but doesn''t reduce HbS as effectively) • Indicated for severe ACS, stroke, multiorgan failure When is simple transfusion acceptable? • Mild ACS with modest hemoglobin drop • Target Hgb 10 g/dL (not higher to avoid hyperviscosity) Why not (C)? • Supplemental oxygen and incentive spirometry are supportive but inadequate alone for severe ACS • Needed, but transfusion is the priority Why not (D)? • Bronchoscopy may be considered if unusual pathogen suspected but not first-line • Empiric antibiotics appropriate Why not (E)? • Excessive opioids cause hypoventilation/atelectasis → worsens ACS • Pain control important but should use multimodal approach', NULL, 'internal', 'active'),
  ('B1_C24', 'b1-24-giant-cell-arteritis-when-to-start-steroids', 'Batch1', 'Rheumatology, Ophthalmology', 'A 72-year-old woman presents with severe new-onset headache for the past 2 weeks, located primarily over her right temple. She also reports jaw pain 
when chewing that resolves with rest, and she noticed blurred vision in her right eye yesterday that resolved after a few minutes. She has had fatigue, 
low-grade fevers, and unintentional 5-kg weight loss over the past 2 months. She also notes shoulder stiffness. 
On examination, temperature is 37.8°C (100°F), and there is tenderness over the right temporal artery, which feels thickened and has diminished 
pulsation. Fundoscopic examination of the right eye shows pallor of the optic disc. 
Laboratory studies show ESR 98 mm/hr and CRP 68 mg/L.

Which of the following is the most appropriate next step in management?', '[{"label":"A","text":"Schedule temporal artery biopsy before starting treatment"},{"label":"B","text":"Start high-dose oral prednisone immediately"},{"label":"C","text":"Order temporal artery ultrasound before treatment"},{"label":"D","text":"Start low-dose aspirin and monitor symptoms"},{"label":"E","text":"Refer to ophthalmology for evaluation first"}]'::jsonb, 'B', 'This patient has giant cell arteritis (GCA) with impending vision loss — a medical emergency. Clinical features of GCA: • Age >50 (usually >70) • New headache (temporal) • Scalp/temporal artery tenderness • Jaw claudication (most specific symptom) • Visual symptoms (amaurosis fugax, diplopia) • Constitutional symptoms (fever, weight loss, fatigue) • Associated polymyalgia rheumatica (shoulder/hip stiffness) Laboratory findings: • ESR markedly elevated (>50, often >100) • Elevated CRP • Possible normocytic anemia, thrombocytosis This patient has HIGH-RISK features: • Amaurosis fugax (transient visual loss) — WARNING of impending permanent blindness • Optic disc pallor — suggests early ischemic optic neuropathy CRITICAL PRINCIPLE: START STEROIDS IMMEDIATELY — DO NOT DELAY FOR BIOPSY Why? • Untreated GCA causes permanent bilateral blindness in 15–20% of patients • Once vision is lost, it rarely recovers • Steroids prevent progression to permanent blindness • Temporal artery biopsy remains positive for 1–2 weeks after starting steroids Treatment: Presentation Steroid Regimen GCA without visual symptoms Prednisone 40–60 mg/day GCA with visual symptoms Prednisone 60–80 mg/day OR IV methylprednisolone 1g/day × 3 days This patient should receive high-dose prednisone immediately. Why not (A) or (C)? • Do NOT wait for biopsy or imaging before treatment • Biopsy can be done within 1–2 weeks while on steroids • Every hour of delay increases blindness risk Why not (D)? • Aspirin may reduce ischemic complications but does not treat GCA • Steroids are disease-modifying Why not (E)? • Ophthalmology consultation is appropriate but should not delay steroid initiation • Start steroids, then refer Additional management: • Temporal artery biopsy (still indicated; remains positive 1–2 weeks after steroids) • Consider tocilizumab for steroid-sparing • PCP prophylaxis and bone protection if prolonged steroid course', NULL, 'internal', 'active'),
  ('B1_C25', 'b1-25-gout-vs-septic-arthritis-diagnostic-differentiation', 'Batch1', 'Rheumatology, Infectious Disease, Orthopedics', 'A 58-year-old man with a history of gout (last flare 3 years ago) and type 2 diabetes presents with severe pain, swelling, and redness of his right knee for 
2 days. He denies recent trauma. He reports fever and chills since this morning. 
On examination, temperature is 38.6°C (101.5°F), blood pressure is 128/78 mm Hg, pulse is 102/min. The right knee is erythematous, warm, and swollen 
with a moderate effusion. He cannot bear weight and has severe pain with any range of motion. 
Laboratory studies show WBC 16,400/µL, ESR 78 mm/hr, and serum uric acid 8.9 mg/dL.

Which of the following is the most appropriate next step?', '[{"label":"A","text":"Start colchicine and NSAIDs for presumed gout flare"},{"label":"B","text":"Start empiric IV antibiotics for presumed septic arthritis"},{"label":"C","text":"Arthrocentesis of the right knee"},{"label":"D","text":"Order MRI of the knee before intervention"},{"label":"E","text":"Start allopurinol to lower uric acid"}]'::jsonb, 'C', 'This patient presents with acute monoarticular arthritis with features suggesting BOTH gout (history, elevated uric acid) AND septic arthritis (fever, diabetes, systemic symptoms). CRITICAL RULE: Any acute monoarticular arthritis with systemic symptoms requires arthrocentesis to rule out septic arthritis. Why arthrocentesis is mandatory: • Septic arthritis and gout can be clinically indistinguishable • Septic arthritis destroys cartilage within 24–48 hours if untreated • Gout history and elevated uric acid do NOT exclude infection • Coexistent gout and septic arthritis can occur • Only synovial fluid analysis can differentiate Synovial fluid analysis: Parameter Septic Arthritis Gout Normal WBC >50,000 (often >100,000) 2,000–50,000 <200 PMN% >90% >50% <25% Crystals None Needle-shaped, negative birefringent None Gram stain May be positive Negative Negative Culture Positive (60–80%) Negative Negative This patient has RED FLAGS for septic arthritis: • Fever (38.6°C) • Systemic symptoms (chills) • Diabetes (immunocompromised) • Unable to bear weight • Leukocytosis with elevated ESR Why not (A)? • Cannot presume gout without ruling out infection • Treating gout alone while missing septic arthritis → joint destruction, sepsis, death Why not (B)? • Do NOT start antibiotics before obtaining synovial fluid (decreases culture yield) • Arthrocentesis first, then antibiotics if septic arthritis suspected Why not (D)? • MRI may show synovitis/effusion but cannot differentiate gout from infection • Joint aspiration is the diagnostic procedure Why not (E)? • Allopurinol should never be started during an acute gout flare (can worsen/prolong attack) • This patient needs diagnosis first Procedure of joint aspiration in suspected septic arthritis: 1. Aspirate joint (even if on anticoagulation — risk of missing septic arthritis > bleeding risk) 2. Send for: cell count, Gram stain, culture, crystal analysis 3. If septic arthritis confirmed: IV antibiotics + orthopedic consultation for possible surgical drainage', NULL, 'internal', 'active'),
  ('B1_C26', 'b1-26-acute-appendicitis-imaging-and-management-decision', 'Batch1', 'Gastrointestinal', 'A 24-year-old man presents with 18 hours of abdominal pain that began around his umbilicus and has now localized to his right lower quadrant. He has 
had nausea and two episodes of vomiting. He has no appetite. 
On examination, temperature is 38.2°C (100.8°F), blood pressure is 124/78 mm Hg, pulse is 92/min. Abdomen shows tenderness at McBurney''s point with 
voluntary guarding. Rovsing sign is positive. There is no rebound tenderness. 
Laboratory studies show WBC 14,200/µL with 82% neutrophils and CRP 4.8 mg/dL.

Which of the following is the most appropriate next step in management?', '[{"label":"A","text":"CT abdomen/pelvis with IV contrast"},{"label":"B","text":"Immediate surgical consultation for laparoscopic appendectomy"},{"label":"C","text":"Abdominal ultrasound"},{"label":"D","text":"Observation and serial abdominal examinations"},{"label":"E","text":"IV antibiotics and discharge with outpatient follow-up"}]'::jsonb, 'B', 'This patient has a high pretest probability of acute appendicitis based on clinical presentation. Classic appendicitis presentation: • Periumbilical pain → migrating to RLQ (visceral → parietal peritoneum) • Anorexia (almost universal) • Nausea/vomiting (usually after pain onset) • Low-grade fever • RLQ tenderness (McBurney''s point) • Positive Rovsing sign (RLQ pain with LLQ palpation) • Leukocytosis with left shift Alvarado Score (MANTRELS): • Migration of pain: 1 • Anorexia: 1 • Nausea/vomiting: 1 • Tenderness in RLQ: 2 • Rebound tenderness: 1 • Elevated temperature: 1 • Leukocytosis: 2 • Shift to left: 1 This patient scores 7–8: HIGH probability When is imaging needed? Clinical Scenario Imaging Approach Classic presentation in young/thin male Often proceed directly to surgery Intermediate probability (Alvarado 5–6) CT abdomen/pelvis Women of childbearing age CT (preferred) or ultrasound first Pregnant women Ultrasound first, then MRI if inconclusive Pediatric Ultrasound first This patient (young male, classic presentation, high Alvarado) can proceed to surgery without imaging, though CT is often obtained in practice to exclude other diagnoses and plan surgery. Acceptable approaches: • Option B (direct to surgery) — appropriate given high clinical probability • CT if any diagnostic uncertainty — would show dilated appendix (>6 mm), periappendiceal fat stranding, appendicolith Why not (A) as NEXT step? • CT is reasonable but not strictly required with this classic presentation • In high-probability cases, imaging delays definitive treatment • Many surgeons will operate based on clinical diagnosis alone Why not (C)? • Ultrasound less sensitive in adults (operator-dependent, body habitus) • CT preferred in adult males when imaging needed Why not (D)? • Observation inappropriate with high clinical probability and systemic signs • Risk of perforation increases with delay Why not (E)? • Antibiotics alone with discharge is not appropriate management • While "antibiotic-first" strategy exists for uncomplicated appendicitis, requires careful patient selection and inpatient monitoring Surgery: Laparoscopic appendectomy is preferred — lower wound infection rate, faster recovery.', NULL, 'internal', 'active'),
  ('B1_C27', 'b1-27-bowel-obstruction-small-bowel-vs-large-bowel-differentiation', 'Batch1', 'Gastrointestinal', 'A 68-year-old man presents with 2 days of progressive abdominal distension, crampy abdominal pain, and vomiting. He has not had a bowel movement 
or passed flatus for 36 hours. His surgical history includes open appendectomy 30 years ago and cholecystectomy 10 years ago. 
On examination, temperature is 37.2°C (99°F), blood pressure is 118/72 mm Hg, pulse is 94/min. Abdomen is distended with high-pitched bowel sounds 
and mild diffuse tenderness without peritoneal signs. There is a well-healed RLQ scar. 
Abdominal X-ray shows multiple dilated loops of small bowel (up to 5 cm) with air-fluid levels in a stepladder pattern. No colonic gas is seen. No free air. 
Laboratory studies show WBC 11,200/µL, BUN 28 mg/dL, and lactate 1.4 mmol/L.

Which of the following is the most appropriate initial management?', '[{"label":"A","text":"Emergent exploratory laparotomy"},{"label":"B","text":"Colonoscopy for decompression"},{"label":"C","text":"Nasogastric tube decompression, IV fluids, and NPO"},{"label":"D","text":"Water-soluble contrast enema"},{"label":"E","text":"Oral polyethylene glycol bowel preparation"}]'::jsonb, 'C', 'This patient has small bowel obstruction (SBO), most likely due to adhesions from prior abdominal surgery. Differentiating SBO from LBO: Feature SBO LBO Pain Crampy, periumbilical Crampy, lower abdominal Vomiting Early, prominent Late, may be feculent Distension Moderate Marked Obstipation Later Earlier X-ray Dilated small bowel, air-fluid levels Dilated colon, "cut-off" sign Common causes Adhesions (most common), hernia Colon cancer, diverticulitis, volvulus This patient has SBO: • Previous abdominal surgeries → adhesions (#1 cause of SBO) • Dilated small bowel with air-fluid levels on X-ray • No colonic gas (complete or near-complete obstruction) • Vomiting prominent Management of uncomplicated/partial SBO: Step Intervention 1 NPO (bowel rest) 2 Nasogastric tube (decompression, relieves vomiting) 3 IV fluid resuscitation (third-spacing causes dehydration) 4 Foley catheter (monitor urine output) 5 Serial abdominal exams 6 Correct electrolytes This conservative "drip and suck" approach resolves 65–80% of adhesive SBO without surgery. When is surgery indicated (emergently)? • Peritoneal signs (rebound, guarding) — bowel compromise • Fever, tachycardia, leukocytosis (significant) — strangulation • Elevated lactate — ischemia • Closed-loop obstruction • Failure to improve with conservative management (24–72 hours) • Complete obstruction that doesn''t resolve This patient lacks emergent surgical indications: • No peritoneal signs • Mild tachycardia, minimal leukocytosis • Normal lactate Why not (A)? • No signs of strangulation or peritonitis • Surgery reserved for complicated SBO or failed conservative management Why not (B)? • Colonoscopy is for LBO (e.g., sigmoid volvulus decompression) • Not useful for SBO Why not (D)? • Water-soluble contrast (Gastrografin) can be used but is given orally/via NGT in SBO (not enema) • Therapeutic and diagnostic — appearance of contrast in colon within 24 hours predicts resolution Why not (E)? • Oral prep contraindicated in bowel obstruction', NULL, 'internal', 'active'),
  ('B1_C28', 'b1-28-abdominal-aortic-aneurysm-screening-and-rupture-recognition', 'Batch1', 'Vascular', 'A 72-year-old man is brought to the emergency department with sudden-onset severe lower back and abdominal pain that began 45 minutes ago. He 
has a history of hypertension, hyperlipidemia, and 50-pack-year smoking history. He quit smoking 5 years ago. 
On examination, he is pale, diaphoretic, and appears to be in severe distress. Blood pressure is 78/52 mm Hg, pulse is 124/min and weak. Abdomen is 
distended with a pulsatile mass palpable in the periumbilical region. Femoral pulses are weak bilaterally. 
Laboratory studies show hemoglobin 9.2 g/dL.

Which of the following is the most appropriate next step?', '[{"label":"A","text":"CT angiography of the abdomen"},{"label":"B","text":"Immediate surgical repair"},{"label":"C","text":"Abdominal ultrasound at bedside"},{"label":"D","text":"IV fluids to stabilize blood pressure before imaging"},{"label":"E","text":"Obtain type and crossmatch, then await hemodynamic stability"}]'::jsonb, 'B', 'This patient has ruptured abdominal aortic aneurysm (rAAA) — a surgical emergency with mortality approaching 50% even with treatment, and >80% without. Classic triad of ruptured AAA: 1. Sudden severe abdominal or back pain 2. Hypotension 3. Pulsatile abdominal mass This patient has all three features — the diagnosis is clinical. Management of hemodynamically UNSTABLE rAAA: Priority Action 1 Immediate transfer to OR for surgical repair 2 Permissive hypotension (target SBP ~70–80, avoid aggressive fluid resuscitation) 3 Type and crossmatch, activate massive transfusion protocol 4 Do NOT delay for imaging if diagnosis is clear Why immediate surgery without imaging? • In unstable patients with classic triad, imaging delays definitive treatment • Every minute without repair increases mortality • Diagnosis is clinical; imaging may cause death in unstable patients When is imaging appropriate? • Hemodynamically STABLE patients with suspected AAA → CT angiography • Screens for extent of aneurysm, involvement of renal/iliac arteries • Plans surgical or endovascular approach Why permissive hypotension? • Aggressive IV fluids can: • Dislodge tamponading clot • Dilute clotting factors • Increase hemorrhage • Maintain "just enough" pressure for end-organ perfusion Why not (A)? • CT delays surgery in unstable patient • Appropriate only if hemodynamically stable Why not (C)? • Bedside ultrasound can confirm AAA but should not delay OR • In this case, clinical diagnosis is clear Why not (D)? • Avoid aggressive fluid resuscitation — permissive hypotension preferred • Proceed directly to OR Why not (E)? • Type and crossmatch should be drawn but don''t wait for stability — this patient may never stabilize without surgery Repair options: • Open surgical repair (traditional) • Endovascular aneurysm repair (EVAR) — increasingly used even for rupture in selected patients Screening recommendation (USPSTF): • One-time abdominal ultrasound for men aged 65–75 who have ever smoked', NULL, 'internal', 'active'),
  ('B1_C29', 'b1-29-pediatric-dehydration-assessment-and-fluid-replacement', 'Batch1', 'Nephrology, Gastroenterology', 'An 18-month-old boy is brought to the emergency department with 3 days of watery diarrhea (8–10 episodes daily) and vomiting. His mother reports he 
has been increasingly lethargic and has had decreased urine output for the past 24 hours. 
On examination, temperature is 37.8°C (100°F), heart rate is 156/min, respirations are 32/min, and blood pressure is 85/50 mm Hg. Weight is 10 kg 
(baseline 11 kg). He is lethargic but responds to stimuli. Eyes are sunken with absent tears. Mucous membranes are dry. Capillary refill is 4 seconds. Skin 
turgor is decreased with tenting.

Which of the following is the most appropriate initial fluid management?', '[{"label":"A","text":"Oral rehydration solution 50 mL/kg over 4 hours"},{"label":"B","text":"IV 0.9% normal saline 200 mL/kg bolus"},{"label":"C","text":"IV 0.9% normal saline 20 mL/kg bolus, reassess, repeat as needed"},{"label":"D","text":"IV D5 0.45% normal saline at maintenance rate"},{"label":"E","text":"IV 3% hypertonic saline"}]'::jsonb, 'C', 'This child has severe dehydration requiring IV fluid resuscitation. Dehydration severity assessment: Feature Mild (3–5%) Moderate (6–9%) Severe (≥10%) Mental status Alert Irritable/lethargic Lethargic/obtunded Thirst Slight Moderate Drinks poorly Heart rate Normal Increased Markedly increased Blood pressure Normal Normal/orthostatic Hypotension Tears Present Decreased Absent Eyes Normal Slightly sunken Deeply sunken Mucous membranes Moist Dry Parched Capillary refill <2 sec 2–3 sec >3 sec Skin turgor Normal Decreased Tenting Urine output Decreased Oliguria Anuria This child has SEVERE dehydration (≥10%): • 9% weight loss (11 kg → 10 kg) • Lethargic • Absent tears • Sunken eyes • Capillary refill 4 seconds • Tenting • Hypotension for age • Tachycardia Fluid management by severity: Severity Management Mild ORS 50 mL/kg over 4 hours Moderate ORS 100 mL/kg over 4 hours (consider IV if can''t tolerate PO) Severe IV bolus 20 mL/kg NS (isotonic), reassess, repeat up to 3 boluses Why NS 20 mL/kg bolus? • Isotonic fluid expands intravascular volume • 20 mL/kg is safe initial dose • Reassess after each bolus (HR, BP, capillary refill, mental status) • May need 2–3 boluses for severe dehydration • After stabilization → calculate deficit + maintenance Why not (A)? • Oral rehydration inappropriate for severe dehydration with lethargy • Risk of aspiration, inadequate absorption Why not (B)? • 200 mL/kg at once is excessive and dangerous • Can cause fluid overload, pulmonary edema Why not (D)? • Hypotonic maintenance fluid inappropriate for resuscitation • Does not adequately expand intravascular volume • D5 0.45% NS used for maintenance after resuscitation Why not (E)? • Hypertonic saline for symptomatic hyponatremia only • Not indicated for routine dehydration After stabilization: • Calculate deficit (10% of body weight = 1000 mL) • Replace deficit over 24–48 hours plus maintenance • Replace ongoing losses', NULL, 'internal', 'active'),
  ('B1_C30', 'b1-30-kawasaki-disease-diagnosis-and-treatment', 'Batch1', '', 'A 3-year-old boy is brought to the clinic with 6 days of high fever (up to 40°C/104°F) that has not responded to acetaminophen. His mother reports he 
has been increasingly irritable. Over the past few days, she noticed redness in both eyes without discharge, cracked red lips, and a rash on his trunk. 
On examination, temperature is 39.5°C (103.1°F), heart rate is 132/min. He is irritable but consolable. He has bilateral conjunctival injection without 
exudate. Lips are erythematous and cracked; tongue appears red with prominent papillae ("strawberry tongue"). There is a polymorphous maculopapular 
rash on his trunk. Bilateral cervical lymph nodes are palpable (largest 1.8 cm). Hands are edematous with erythema of the palms. 
Laboratory studies show WBC 18,400/µL, hemoglobin 10.8 g/dL, platelets 486,000/µL, ESR 82 mm/hr, CRP 12 mg/dL, and albumin 2.8 g/dL.

Which of the following is the most appropriate treatment?', '[{"label":"A","text":"IV antibiotics for presumed scarlet fever"},{"label":"B","text":"High-dose aspirin and supportive care only"},{"label":"C","text":"IV immunoglobulin (IVIG) plus high-dose aspirin"},{"label":"D","text":"Oral corticosteroids"},{"label":"E","text":"Reassurance and follow-up in 2–3 days"}]'::jsonb, 'C', 'This patient meets criteria for Kawasaki disease (KD), a medium-vessel vasculitis affecting children, primarily dangerous for its cardiac complications (coronary artery aneurysms). Diagnostic criteria (classic KD): Fever ≥5 days PLUS ≥4 of 5: 1. Bilateral conjunctival injection (non-exudative) ✓ 2. Oral mucosal changes (strawberry tongue, cracked lips) ✓ 3. Polymorphous rash ✓ 4. Extremity changes (edema, erythema, later desquamation) ✓ 5. Cervical lymphadenopathy (≥1.5 cm, usually unilateral) ✓ This patient: 6 days of fever + 5/5 criteria = CLASSIC KAWASAKI DISEASE Laboratory findings supporting KD: • Leukocytosis • Anemia (normocytic) • Thrombocytosis (peaks in week 2–3) • Elevated ESR/CRP • Hypoalbuminemia • Elevated transaminases • Sterile pyuria may be present Treatment — CRITICAL to start within 10 days of fever onset: Component Details Purpose IVIG 2 g/kg single infusion Reduces coronary aneurysm risk from 25% → <5% Aspirin (high-dose) 80–100 mg/kg/day divided q6h Anti-inflammatory Aspirin (low-dose) 3–5 mg/kg/day after fever resolves Antiplatelet for 6–8 weeks Why IVIG + aspirin? • IVIG dramatically reduces coronary artery aneurysm development • Treatment within 10 days of fever onset is most effective • Aspirin alone is inadequate Why not (A)? • KD is not bacterial; antibiotics ineffective • Can resemble scarlet fever but conjunctivitis is not a feature of scarlet fever • Scarlet fever has sandpaper rash, not polymorphous Why not (B)? • Aspirin alone does not prevent coronary aneurysms • IVIG is essential Why not (D)? • Corticosteroids reserved for IVIG-refractory KD • Not first-line **', NULL, 'internal', 'active'),
  ('B2_Q01', 'afib-ablation-candidate', 'Batch2', 'Cardiology', 'A 58-year-old man with paroxysmal atrial fibrillation presents for follow-up. Despite optimal doses of metoprolol and flecainide, he continues to have symptomatic episodes 2-3 times monthly with palpitations and fatigue that significantly affect his quality of life. Echocardiogram shows normal LV function and left atrial size of 4.2 cm. His CHA₂DS₂-VASc score is 1.

What is the most appropriate next step in management?', '[{"label":"A","text":"Add amiodarone to current regimen"},{"label":"B","text":"Refer for catheter ablation"},{"label":"C","text":"Switch to sotalol monotherapy"},{"label":"D","text":"Increase metoprolol dose"},{"label":"E","text":"Recommend rate control strategy only"}]'::jsonb, 'B', 'Catheter ablation is appropriate for patients with symptomatic AFib refractory to at least one antiarrhythmic drug (AAD) or in patients who prefer ablation over long-term AAD therapy. This patient has failed flecainide and continues to have quality-of-life-limiting symptoms. His preserved LV function and moderately sized left atrium make him a good ablation candidate. Amiodarone (A) could be tried but has significant long-term toxicity. Rate control alone (E) is inappropriate given his symptomatic episodes despite adequate rate control.', NULL, 'internal', 'active'),
  ('B2_Q02', 'betablocker-initiation-timing-hf', 'Batch2', 'Cardiology', 'A 67-year-old woman with newly diagnosed HFrEF (EF 30%) is admitted for acute decompensated heart failure with dyspnea at rest and bilateral lower extremity edema. She is started on IV furosemide with good urine output. On hospital day 2, she still has 2+ peripheral edema, JVP of 12 cm, and bibasilar crackles. Her blood pressure is 118/72 mmHg and heart rate is 92 bpm.

Regarding beta-blocker therapy, what is the most appropriate approach?', '[{"label":"A","text":"Start low-dose carvedilol now to reduce mortality"},{"label":"B","text":"Wait until euvolemic before initiating beta-blocker"},{"label":"C","text":"Beta-blockers are contraindicated in HFrEF"},{"label":"D","text":"Start metoprolol tartrate for rate control"},{"label":"E","text":"Defer beta-blocker indefinitely due to acute presentation"}]'::jsonb, 'B', 'Beta-blockers are essential GDMT for HFrEF and reduce mortality, but initiation during acute decompensation with persistent congestion can worsen symptoms and hemodynamics. The patient has ongoing volume overload (elevated JVP, edema, crackles). Beta-blockers should be started only after achieving euvolemia, typically before discharge or at early outpatient follow-up. Starting now (A) risks worsening congestion. Metoprolol tartrate (D) is not an evidence-based HF beta-blocker (use succinate). Beta-blockers are not contraindicated (C) and should not be deferred indefinitely (E).', NULL, 'internal', 'active'),
  ('B2_Q03', 'digoxin-role-hf-afib', 'Batch2', 'Cardiology', 'A 72-year-old man with HFrEF (EF 25%) and permanent atrial fibrillation has a resting heart rate of 102 bpm despite maximum tolerated dose of carvedilol 25 mg twice daily. He cannot tolerate higher doses due to symptomatic hypotension (BP 98/62 mmHg). He is on appropriate GDMT including sacubitril/valsartan, spironolactone, and dapagliflozin.

What is the most appropriate addition for rate control?', '[{"label":"A","text":"Diltiazem"},{"label":"B","text":"Verapamil"},{"label":"C","text":"Digoxin"},{"label":"D","text":"Amiodarone"},{"label":"E","text":"Ivabradine"}]'::jsonb, 'C', 'Digoxin is appropriate for rate control in HFrEF patients with AFib when beta-blockers alone are insufficient or limited by hypotension. It provides rate control without negative inotropy or hypotension. Non-dihydropyridine calcium channel blockers (A, B) are contraindicated in HFrEF due to negative inotropic effects. Amiodarone (D) is for rhythm control, not rate control. Ivabradine (E) is ineffective in AFib because it works on the SA node, which is overridden by atrial fibrillation.', NULL, 'internal', 'active'),
  ('B2_Q04', 'statin-intolerance-alternatives', 'Batch2', 'Cardiology', 'A 62-year-old man with CAD and prior MI requires high-intensity statin therapy. He develops severe bilateral thigh myalgias 3 weeks after starting atorvastatin 80 mg. CK is mildly elevated at 380 U/L (normal <200). The statin is stopped and symptoms resolve after 2 weeks. He previously had similar myalgias on rosuvastatin 20 mg.

What is the most appropriate next step?', '[{"label":"A","text":"Rechallenge with atorvastatin 80 mg"},{"label":"B","text":"Trial of rosuvastatin 5 mg every other day"},{"label":"C","text":"Start ezetimibe monotherapy"},{"label":"D","text":"No lipid-lowering therapy needed given intolerance"},{"label":"E","text":"Start fenofibrate"}]'::jsonb, 'B', 'For patients with statin intolerance, a trial of an alternative statin at lower dose or with alternate-day dosing is the first step. Rosuvastatin has a long half-life making every-other-day dosing feasible. If this fails, ezetimibe (C) or PCSK9 inhibitors can be added or substituted. Rechallenging with the same high dose (A) will likely reproduce symptoms. Abandoning lipid therapy (D) is inappropriate given his high ASCVD risk. Fenofibrate (E) does not have the same cardiovascular benefit as statins.', NULL, 'internal', 'active'),
  ('B2_Q05', 'hypertrophic-cardiomyopathy-avoidance', 'Batch2', 'Cardiology', 'A 24-year-old college athlete is diagnosed with hypertrophic cardiomyopathy after a pre-participation screening echocardiogram showed asymmetric septal hypertrophy of 18 mm. He is asymptomatic with no syncope or family history of sudden cardiac death. He asks about continuing to play competitive basketball.

Which of the following recommendations is most appropriate?', '[{"label":"A","text":"Continue competitive sports if stress test is normal"},{"label":"B","text":"Disqualification from competitive sports is recommended"},{"label":"C","text":"Sports participation allowed with prophylactic ICD"},{"label":"D","text":"Competitive sports allowed if on beta-blocker therapy"},{"label":"E","text":"Restriction only applies to contact sports"}]'::jsonb, 'B', 'HCM is the leading cause of sudden cardiac death in young athletes. Current guidelines recommend disqualification from competitive sports regardless of symptoms, risk stratification, or treatment. Exercise causes dynamic obstruction, arrhythmias, and ischemia in HCM. Low-intensity recreational activity may be considered after shared decision-making, but competitive athletics are contraindicated. An ICD (C) prevents death but does not make competitive sports safe. Beta- blockers (D) do not eliminate the risk.', NULL, 'internal', 'active'),
  ('B2_Q06', 'icd-primary-prevention-ef', 'Batch2', 'Cardiology', 'A 58-year-old man with ischemic cardiomyopathy had a STEMI 3 weeks ago treated with PCI. Current EF is 28%. He is now on optimal GDMT including sacubitril/valsartan, carvedilol, spironolactone, and empagliflozin with good blood pressure and symptom control.

What is the most appropriate recommendation regarding ICD placement?', '[{"label":"A","text":"Implant ICD now given EF <30%"},{"label":"B","text":"Reassess EF in 3 months; ICD if EF remains ≤35%"},{"label":"C","text":"ICD only if he has documented ventricular arrhythmia"},{"label":"D","text":"ICD contraindicated in ischemic cardiomyopathy"},{"label":"E","text":"Implant ICD only if EF <20%"}]'::jsonb, 'B', 'Primary prevention ICD is indicated if EF remains ≤35% despite at least 3 months of optimal GDMT. However, ICD should NOT be implanted within 40 days of MI or within 90 days of revascularization, as EF may improve with GDMT and revascularization. This patient is only 3 weeks post-MI. Reassessment at 3 months will determine if he still meets criteria. Waiting for documented arrhythmia (C) describes secondary prevention, not primary prevention.', NULL, 'internal', 'active'),
  ('B2_Q07', 'anticoagulation-bridging-decision', 'Batch2', 'Cardiology', 'A 68-year-old woman with a mechanical mitral valve on warfarin (INR goal 2.5-3.5) requires elective hip replacement surgery. Her INR is 3.0. The surgeon plans to hold warfarin 5 days preoperatively.

What is the appropriate anticoagulation management perioperatively?', '[{"label":"A","text":"Hold warfarin only; no bridging needed"},{"label":"B","text":"Bridge with therapeutic enoxaparin, stop 24h before surgery"},{"label":"C","text":"Bridge with therapeutic unfractionated heparin, stop 4-6h before surgery"},{"label":"D","text":"Continue warfarin through surgery with close INR monitoring"},{"label":"E","text":"Switch to apixaban for the perioperative period"}]'::jsonb, 'B', 'Patients with mechanical heart valves (especially mitral position) have high thromboembolic risk and require bridging anticoagulation when warfarin is held. Therapeutic-dose LMWH or UFH should be used. LMWH is stopped 24 hours before surgery; UFH is stopped 4-6 hours before. No bridging (A) is inappropriate for mechanical valves. Continuing warfarin (D) creates unacceptable surgical bleeding risk. DOACs (E) are contraindicated with mechanical valves.', NULL, 'internal', 'active'),
  ('B2_Q08', 'resistant-hypertension-workup', 'Batch2', 'Cardiology', 'A 54-year-old man has blood pressure of 158/96 mmHg despite amlodipine 10 mg, lisinopril 40 mg, and chlorthalidone 25 mg daily. He reports taking his medications consistently. His BMI is 32 kg/m². Basic metabolic panel shows potassium 3.2 mEq/L and creatinine 1.0 mg/dL. Urinalysis is negative for protein.

Which secondary cause should be evaluated first based on his presentation?', '[{"label":"A","text":"Pheochromocytoma"},{"label":"B","text":"Primary hyperaldosteronism"},{"label":"C","text":"Renal artery stenosis"},{"label":"D","text":"Cushing syndrome"},{"label":"E","text":"Coarctation of the aorta"}]'::jsonb, 'B', 'This patient has resistant hypertension (BP uncontrolled on 3 drugs including a diuretic). The hypokalemia (K 3.2) despite not being on a potassium-wasting diuretic at high dose strongly suggests primary hyperaldosteronism, which is present in 10-20% of resistant hypertension. Screening is with aldosterone-to-renin ratio. Renal artery stenosis (C) would be suggested by rising creatinine on ACE inhibitor, which is not present. Pheochromocytoma (A) typically presents with episodic symptoms.', NULL, 'internal', 'active'),
  ('B2_Q09', 'ics-withdrawal-copd-safety', 'Batch2', 'Pulmonology', 'A 66-year-old man with COPD (FEV1 55% predicted) has been on fluticasone/salmeterol for 3 years. He has had no exacerbations in the past 2 years. Recent CBC shows blood eosinophils of 80 cells/μL. He asks about simplifying his regimen due to concern about pneumonia risk from ICS.

What is the most appropriate recommendation?', '[{"label":"A","text":"Continue current ICS/LABA regimen indefinitely"},{"label":"B","text":"Withdraw ICS; continue LABA monotherapy"},{"label":"C","text":"Withdraw ICS; switch to LAMA/LABA combination"},{"label":"D","text":"Add LAMA to current ICS/LABA regimen"},{"label":"E","text":"ICS withdrawal is never safe in COPD"}]'::jsonb, 'C', 'ICS withdrawal is safe and appropriate in COPD patients with low eosinophil counts (<300 cells/μL) and infrequent exacerbations (<2/year). This patient meets both criteria (eosinophils 80, no exacerbations in 2 years). ICS increases pneumonia risk in COPD without providing benefit in this population. Withdrawing to LAMA/LABA maintains bronchodilation while eliminating ICS risks. LABA monotherapy (B) is less effective than dual bronchodilation. ICS withdrawal is evidence-based when appropriate (E is incorrect).', NULL, 'internal', 'active'),
  ('B2_Q10', 'pulmonary-nodule-followup', 'Batch2', 'Pulmonology', 'A 58-year-old woman with a 25-pack-year smoking history has an incidental 7 mm solid pulmonary nodule found on CT chest performed for rib pain after a fall. She has no respiratory symptoms. The nodule has smooth margins. She has no prior imaging for comparison.

What is the most appropriate next step?', '[{"label":"A","text":"PET-CT for metabolic characterization"},{"label":"B","text":"CT-guided biopsy"},{"label":"C","text":"Repeat CT in 6-12 months per Fleischner criteria"},{"label":"D","text":"Surgical resection given smoking history"},{"label":"E","text":"No follow-up needed for nodules <8 mm"}]'::jsonb, 'C', 'Per Fleischner Society guidelines for solid pulmonary nodules, a 6-8 mm nodule in a high-risk patient (>25 pack-year smoking) warrants CT surveillance at 6-12 months, then consider additional imaging at 18-24 months. PET-CT (A) has limited utility for nodules <8-10 mm due to poor sensitivity. Biopsy (B) and surgery (D) are premature without evidence of growth. Nodules <6 mm in high-risk patients may be followed; this nodule requires surveillance (E is incorrect).', NULL, 'internal', 'active'),
  ('B2_Q11', 'bronchiectasis-airway-clearance', 'Batch2', 'Pulmonology', 'A 52-year-old woman with non-CF bronchiectasis has chronic productive cough with 30-50 mL of purulent sputum daily. She has had 3 exacerbations requiring antibiotics in the past year. Sputum cultures persistently grow Pseudomonas aeruginosa. She is currently on inhaled hypertonic saline.

Which additional therapy is most likely to reduce exacerbation frequency?', '[{"label":"A","text":"Long-term oral azithromycin"},{"label":"B","text":"Inhaled corticosteroids"},{"label":"C","text":"Daily oral fluoroquinolone"},{"label":"D","text":"Continuous oral amoxicillin"},{"label":"E","text":"Systemic corticosteroids"}]'::jsonb, 'A', 'In bronchiectasis with frequent exacerbations (≥3/year), long-term macrolide therapy (azithromycin) reduces exacerbation frequency through anti-inflammatory and immunomodulatory effects, not just antimicrobial action. Airway clearance techniques and mucolytics are foundational. ICS (B) is not standard for bronchiectasis. Continuous fluoroquinolones (C) or amoxicillin (D) promote resistance without proven exacerbation reduction. Inhaled antibiotics (tobramycin) may be considered for Pseudomonas but weren''t listed.', NULL, 'internal', 'active'),
  ('B2_Q12', 'ild-antifibrotic-indication', 'Batch2', 'Pulmonology', 'A 68-year-old man with idiopathic pulmonary fibrosis (IPF) diagnosed by HRCT showing UIP pattern has progressive dyspnea. His FVC is 72% predicted, down from 80% one year ago. He asks about treatment options to slow disease progression.

What is the most appropriate pharmacotherapy?', '[{"label":"A","text":"Prednisone 40 mg daily"},{"label":"B","text":"Azathioprine plus prednisone"},{"label":"C","text":"Pirfenidone or nintedanib"},{"label":"D","text":"Mycophenolate mofetil"},{"label":"E","text":"N-acetylcysteine monotherapy"}]'::jsonb, 'C', 'Antifibrotic agents (pirfenidone or nintedanib) are the only pharmacotherapies proven to slow FVC decline in IPF. Importantly, systemic corticosteroids (A) and immunosuppression (B, D) are NOT beneficial and may increase mortality in IPF (PANTHER-IPF trial showed harm with prednisone/azathioprine/NAC). N-acetylcysteine monotherapy (E) showed no benefit. These patients should be referred for lung transplant evaluation.', NULL, 'internal', 'active'),
  ('B2_Q13', 'nippv-contraindications', 'Batch2', 'Pulmonology', 'A 71-year-old man with severe COPD presents with acute hypercapnic respiratory failure (pH 7.28, pCO2 68 mmHg). He is drowsy but arousable and follows commands. He is hemodynamically stable. The team considers non-invasive positive pressure ventilation (NIPPV).

Which of the following would be a contraindication to NIPPV in this patient?', '[{"label":"A","text":"Drowsiness with ability to follow commands"},{"label":"B","text":"pH < 7.30"},{"label":"C","text":"Copious respiratory secretions with inability to clear"},{"label":"D","text":"pCO2 > 60 mmHg"},{"label":"E","text":"Respiratory rate of 28/min"}]'::jsonb, 'C', 'NIPPV is contraindicated when the patient cannot protect their airway, including those with copious secretions they cannot clear. This creates aspiration risk and prevents effective ventilation. Drowsiness alone (A) is not a contraindication if the patient can cooperate and protect their airway. Acidosis (B) and hypercapnia (D) are indications for, not against, NIPPV. Other contraindications include: facial trauma/surgery, hemodynamic instability, cardiac arrest, and GI bleeding with emesis risk.', NULL, 'internal', 'active'),
  ('B2_Q14', 'pulmonary-hypertension-group-1-rx', 'Batch2', 'Pulmonology', 'A 45-year-old woman with progressive dyspnea undergoes right heart catheterization showing mPAP 42 mmHg, PCWP 10 mmHg, and PVR 6 Wood units. Echocardiogram shows normal LV function. V/Q scan and workup for connective tissue disease are negative. She is diagnosed with idiopathic pulmonary arterial hypertension.

Which therapy class is appropriate for this patient?', '[{"label":"A","text":"Calcium channel blockers as first-line for all PAH"},{"label":"B","text":"Endothelin receptor antagonist (bosentan)"},{"label":"C","text":"Loop diuretics as primary therapy"},{"label":"D","text":"Beta-blockers for rate control"},{"label":"E","text":"Sildenafil is contraindicated in PAH"}]'::jsonb, 'B', 'This patient has Group 1 PAH (precapillary PH with normal PCWP). Specific PAH therapies include endothelin receptor antagonists (bosentan, ambrisentan), PDE5 inhibitors (sildenafil, tadalafil), and prostacyclins. These are NOT indicated for Group 2 PH (left heart disease). Calcium channel blockers (A) are only for the minority with positive vasoreactivity testing. Diuretics (C) are supportive, not primary therapy. Beta-blockers (D) are generally avoided. Sildenafil (E) IS indicated for PAH.', NULL, 'internal', 'active'),
  ('B2_Q15', 'barrett-surveillance-interval', 'Batch2', 'Gastroenterology', 'A 56-year-old man with chronic GERD undergoes EGD showing 4 cm of salmon-colored mucosa extending from the GE junction. Biopsies confirm intestinal metaplasia without dysplasia. He is on omeprazole 20 mg daily.

What is the appropriate surveillance interval for repeat EGD?', '[{"label":"A","text":"Repeat EGD in 6 months"},{"label":"B","text":"Repeat EGD in 1 year"},{"label":"C","text":"Repeat EGD in 3-5 years"},{"label":"D","text":"No further surveillance needed if no dysplasia"},{"label":"E","text":"EGD only if symptoms worsen"}]'::jsonb, 'C', 'Barrett''s esophagus without dysplasia requires surveillance EGD every 3-5 years to detect progression to dysplasia or adenocarcinoma. More frequent surveillance (6-12 months) is reserved for low-grade dysplasia. High-grade dysplasia requires intervention (ablation or resection). Surveillance should not be abandoned (D) given malignancy risk. The patient should also be on optimized PPI therapy (consider increasing to 40 mg or BID dosing).', NULL, 'internal', 'active'),
  ('B2_Q16', 'ppi-long-term-risks', 'Batch2', 'Gastroenterology', 'A 72-year-old woman has been on omeprazole 40 mg daily for 8 years for GERD symptoms. She now presents with fatigue. Labs show hemoglobin 10.2 g/dL with MCV 108 fL, vitamin B12 level of 180 pg/mL (normal >200), and magnesium 1.4 mEq/L (normal 1.7-2.2).

Which findings are most likely related to her long-term PPI use?', '[{"label":"A","text":"Vitamin B12 deficiency only"},{"label":"B","text":"Hypomagnesemia only"},{"label":"C","text":"Both vitamin B12 deficiency and hypomagnesemia"},{"label":"D","text":"Neither finding is PPI-related"},{"label":"E","text":"These findings indicate PPI overdose toxicity"}]'::jsonb, 'C', 'Long-term PPI use is associated with vitamin B12 deficiency (reduced acid impairs B12 absorption from food) and hypomagnesemia (mechanism unclear, may involve intestinal TRPM6 channels). Other risks include C. difficile infection, community-acquired pneumonia, and hip fractures. The appropriate response is to use the lowest effective PPI dose, supplement B12 and magnesium as needed, and reassess ongoing PPI necessity. These are not "toxicity" but rather chronic effects.', NULL, 'internal', 'active'),
  ('B2_Q17', 'nafld-nash-progression-risk', 'Batch2', 'Gastroenterology', 'A 52-year-old woman with obesity (BMI 34) and type 2 diabetes has elevated ALT of 68 U/L. Ultrasound shows hepatic steatosis. FibroScan reveals liver stiffness of 9.8 kPa, suggesting significant fibrosis (F2-F3). Hepatitis B and C serologies are negative.

Which intervention has the strongest evidence for improving liver histology?', '[{"label":"A","text":"Ursodeoxycholic acid"},{"label":"B","text":"Vitamin E 800 IU daily"},{"label":"C","text":"Weight loss of 7-10% of body weight"},{"label":"D","text":"Metformin intensification"},{"label":"E","text":"Milk thistle supplementation"}]'::jsonb, 'C', 'Weight loss of 7-10% body weight is the most effective intervention for improving NASH histology, including steatosis, inflammation, and fibrosis. This patient with significant fibrosis (F2-F3) is at high risk for progression to cirrhosis. Vitamin E (B) may help inflammation in non-diabetic NASH but has less effect on fibrosis. Metformin (D) does not improve liver histology despite glucose benefits. GLP-1 agonists and SGLT2 inhibitors show promise. Ursodeoxycholic acid (A) and milk thistle (E) lack evidence.', NULL, 'internal', 'active'),
  ('B2_Q18', 'refeeding-syndrome-prevention', 'Batch2', 'Gastroenterology', 'A 32-year-old woman with anorexia nervosa (BMI 14.5) is admitted after syncopal episode. She reports minimal oral intake for 3 weeks. Labs show phosphorus 2.8 mg/dL (normal 2.5-4.5), potassium 3.4 mEq/L, and magnesium 1.8 mEq/L. The team plans to initiate nutritional support.

What is the most appropriate initial approach to nutrition?', '[{"label":"A","text":"Start full caloric requirements immediately to reverse malnutrition"},{"label":"B","text":"Start at 10-15 kcal/kg/day with phosphorus, potassium, and thiamine supplementation"},{"label":"C","text":"TPN is required for severe malnutrition"},{"label":"D","text":"High-protein diet to rebuild muscle mass"},{"label":"E","text":"Wait for electrolytes to normalize before feeding"}]'::jsonb, 'B', 'Refeeding syndrome is a life-threatening complication of rapid nutritional repletion in malnourished patients. It causes profound hypophosphatemia, hypokalemia, and hypomagnesemia as insulin surge drives electrolytes intracellularly. Prevention requires starting low-calorie feeds (10-15 kcal/kg/day), advancing slowly, supplementing phosphorus/potassium/magnesium prophylactically, and giving thiamine before glucose. Full caloric feeding (A) precipitates the syndrome. Waiting (E) delays necessary nutrition.', NULL, 'internal', 'active'),
  ('B2_Q19', 'lactulose-titration-goal', 'Batch2', 'Gastroenterology', 'A 63-year-old man with cirrhosis and prior hepatic encephalopathy episodes is on lactulose 30 mL three times daily. He presents confused with asterixis. His wife reports he has had 6 loose bowel movements daily for the past week and reduced oral intake due to nausea.

What is the most appropriate adjustment to his lactulose regimen?', '[{"label":"A","text":"Increase lactulose to 45 mL three times daily"},{"label":"B","text":"Decrease lactulose and reassess fluid/electrolyte status"},{"label":"C","text":"Stop lactulose; it is ineffective if he is still encephalopathic"},{"label":"D","text":"Continue same dose; 6 bowel movements is appropriate"},{"label":"E","text":"Switch to rifaximin monotherapy"}]'::jsonb, 'B', 'Lactulose should be titrated to 2-3 soft bowel movements per day. Excessive lactulose causing >4-5 BMs leads to dehydration and electrolyte disturbances that can paradoxically worsen or precipitate encephalopathy. This patient''s 6 BMs daily with reduced intake suggests lactulose-induced dehydration as a precipitant of his current encephalopathy. The appropriate response is to reduce lactulose, correct volume/electrolytes, and reassess. Rifaximin (E) is adjunctive, not replacement, therapy.', NULL, 'internal', 'active'),
  ('B2_Q20', 'sbp-treatment-failure-secondary', 'Batch2', 'Gastroenterology', 'A 58-year-old man with decompensated cirrhosis and ascites was diagnosed with spontaneous bacterial peritonitis (PMN 850/mm³, monomicrobial E. coli) 72 hours ago and started on ceftriaxone. Repeat paracentesis shows PMN 920/mm³. He has new diffuse abdominal tenderness and rebound.

What is the most appropriate next step?', '[{"label":"A","text":"Continue ceftriaxone for full 5-day course"},{"label":"B","text":"Add metronidazole for anaerobic coverage"},{"label":"C","text":"Obtain CT abdomen to evaluate for secondary peritonitis"},{"label":"D","text":"Switch to meropenem for resistant organisms"},{"label":"E","text":"Repeat paracentesis in 48 hours"}]'::jsonb, 'C', 'Failure to improve on appropriate SBP therapy (defined as <25% decrease in PMN count at 48-72 hours) should raise concern for secondary peritonitis from a surgical source (bowel perforation, abscess, cholecystitis). The development of new peritoneal signs (rebound tenderness) further supports this. CT abdomen is essential to identify a surgically treatable source. Polymicrobial cultures or high protein ascites also suggest secondary peritonitis. Simply changing antibiotics (B, D) without imaging misses potentially life-threatening pathology.', NULL, 'internal', 'active'),
  ('B2_Q21', 'fena-unreliable-diuretics', 'Batch2', 'Nephrology', 'A 74-year-old woman on chronic furosemide therapy for HFrEF presents with creatinine rise from 1.2 to 2.4 mg/dL. She has orthostatic hypotension and poor skin turgor. Urinalysis shows bland sediment. FENa is calculated at 2.8%.

How should this FENa result be interpreted?', '[{"label":"A","text":"FENa >2% confirms intrinsic renal injury (ATN)"},{"label":"B","text":"FENa is unreliable; calculate FEUrea instead"},{"label":"C","text":"FENa >1% rules out prerenal azotemia"},{"label":"D","text":"The elevated FENa indicates post-renal obstruction"},{"label":"E","text":"Diuretics do not affect FENa calculation"}]'::jsonb, 'B', 'FENa is unreliable in patients on diuretics because diuretics cause obligate sodium wasting, elevating FENa even in prerenal states. This patient has clinical signs of volume depletion (orthostasis, poor turgor) suggesting prerenal AKI, but her FENa is falsely elevated by furosemide. FEUrea (fractional excretion of urea) is unaffected by diuretics; FEUrea <35% suggests prerenal azotemia. Using FENa alone here would lead to misdiagnosis and inappropriate withholding of volume resuscitation.', NULL, 'internal', 'active'),
  ('B2_Q22', 'nsaid-aki-triple-whammy', 'Batch2', 'Nephrology', 'A 68-year-old man with hypertension on lisinopril 20 mg and hydrochlorothiazide 25 mg daily presents for knee pain. He is considering taking ibuprofen 600 mg three times daily for osteoarthritis. His baseline creatinine is 1.4 mg/dL.

What is the most appropriate advice regarding NSAID use?', '[{"label":"A","text":"Ibuprofen is safe at this dose for short-term use"},{"label":"B","text":"Avoid NSAIDs; high risk for acute kidney injury"},{"label":"C","text":"NSAIDs are safe if taken with food"},{"label":"D","text":"Switch hydrochlorothiazide to furosemide before starting NSAID"},{"label":"E","text":"NSAIDs are nephrotoxic only in patients with CKD stage 4-5"}]'::jsonb, 'B', 'The combination of NSAID + ACE inhibitor/ARB + diuretic is called the "triple whammy" and carries significantly elevated risk of AKI. NSAIDs block prostaglandin-mediated afferent arteriolar vasodilation, ACEi/ARBs block efferent arteriolar constriction, and diuretics reduce intravascular volume. Together, they can precipitate severe prerenal AKI. This patient should avoid NSAIDs; alternatives include acetaminophen, topical NSAIDs, or considering temporary NSAID use with holding ACEi during that period (with close monitoring).', NULL, 'internal', 'active'),
  ('B2_Q23', 'post-obstructive-diuresis', 'Batch2', 'Nephrology', 'A 72-year-old man with BPH presents with urinary retention and creatinine of 6.8 mg/dL. Foley catheter is placed with immediate drainage of 1400 mL of urine. Over the next 6 hours, he produces 2800 mL of urine. His blood pressure is 108/68 mmHg, down from 142/86 mmHg on admission.

What is the most appropriate fluid management?', '[{"label":"A","text":"Strict fluid restriction to reduce urine output"},{"label":"B","text":"Replace urine output 1:1 with IV normal saline"},{"label":"C","text":"Replace approximately 50% of urine output with IV fluids"},{"label":"D","text":"No IV fluids needed; this diuresis is physiologic"},{"label":"E","text":"Furosemide to control excessive urine output"}]'::jsonb, 'C', 'Post-obstructive diuresis is common after relief of urinary obstruction and results from accumulated urea acting as an osmotic diuretic plus impaired tubular concentrating ability. While some diuresis is physiologic (clearing retained solutes), excessive replacement (1:1) perpetuates the diuresis. Replacing approximately 50% of urine output prevents hypovolemia while allowing the diuresis to naturally resolve. This patient''s hypotension indicates he needs volume replacement. Strict restriction (A) risks hypovolemia and hemodynamic collapse.', NULL, 'internal', 'active'),
  ('B2_Q24', 'iodinated-contrast-ckd-metformin', 'Batch2', 'Nephrology', 'A 64-year-old man with type 2 diabetes on metformin 1000 mg twice daily and CKD stage 3b (eGFR 38 mL/min) requires CT angiography with IV contrast to evaluate peripheral vascular disease. His creatinine is 1.8 mg/dL.

What is the appropriate management of metformin?', '[{"label":"A","text":"Continue metformin without interruption"},{"label":"B","text":"Hold metformin for 24 hours before and 48 hours after contrast"},{"label":"C","text":"Hold metformin starting the day of the procedure and for 48 hours after, then check creatinine"},{"label":"D","text":"Metformin is contraindicated in patients receiving IV contrast"},{"label":"E","text":"Switch to insulin permanently before contrast studies"}]'::jsonb, 'C', 'Metformin itself is not nephrotoxic, but if contrast causes AKI, metformin accumulation can cause lactic acidosis. Current guidelines recommend holding metformin starting the day of the procedure in patients with eGFR <45 (or <60 if receiving intra-arterial contrast). Metformin should be held for 48 hours post-contrast, and renal function should be checked before resuming. Pre-procedure hydration should also be provided. Permanent discontinuation (E) is unnecessary if renal function remains stable.', NULL, 'internal', 'active'),
  ('B2_Q25', 'hemodialysis-vs-peritoneal-selection', 'Batch2', 'Nephrology', 'A 58-year-old woman with ESKD from diabetic nephropathy requires dialysis initiation. She works full-time as a teacher, values independence, and wants to minimize time at medical facilities. She has no significant cardiac disease. Her partner is willing to assist with treatments.

Which dialysis modality best fits her preferences?', '[{"label":"A","text":"In-center hemodialysis 3 times per week"},{"label":"B","text":"Peritoneal dialysis"},{"label":"C","text":"Hemodialysis is medically superior and should be chosen"},{"label":"D","text":"Dialysis modality should be chosen by nephrologist, not patient"},{"label":"E","text":"She should defer dialysis as long as possible"}]'::jsonb, 'B', 'Peritoneal dialysis (PD) offers advantages for patients who prioritize independence, flexible scheduling, and minimizing facility visits. PD is performed at home (often overnight), allows continued employment, and preserves residual renal function better than HD initially. This patient''s preferences, home support, and lack of contraindications (severe cardiac disease, abdominal surgery) make her an excellent PD candidate. Modality selection should be shared decision-making, not physician-imposed (D). Neither modality has clear survival advantage for most patients.', NULL, 'internal', 'active'),
  ('B2_Q26', 'steroid-taper-adrenal-suppression', 'Batch2', 'Endocrinology', 'A 54-year-old woman with polymyalgia rheumatica has been on prednisone 20 mg daily for 4 months with good symptom control. Her rheumatologist wants to discontinue steroids. She asks about the safest way to stop the medication.

What is the most appropriate approach to discontinuation?', '[{"label":"A","text":"Stop prednisone abruptly; adrenal suppression is rare"},{"label":"B","text":"Taper prednisone gradually over weeks to months"},{"label":"C","text":"Switch to hydrocortisone for one week then stop"},{"label":"D","text":"Taper only needed if dose was >40 mg daily"},{"label":"E","text":"Check morning cortisol; if normal, stop immediately"}]'::jsonb, 'B', 'Corticosteroid use for >3 weeks suppresses the hypothalamic-pituitary-adrenal (HPA) axis and adrenal cortisol production. Abrupt discontinuation can cause adrenal crisis (hypotension, shock, death). Gradual tapering allows HPA axis recovery. Typical approach: reduce by 5-10 mg every 1-2 weeks until reaching physiologic dose (5-7.5 mg prednisone), then slower taper. Patients should also receive stress-dose steroids if surgery or serious illness occurs during and shortly after the taper.', NULL, 'internal', 'active'),
  ('B2_Q27', 'sick-euthyroid-no-treatment', 'Batch2', 'Endocrinology', 'A 62-year-old man is in the ICU with septic shock from pneumonia. Thyroid function tests show: TSH 0.8 mIU/L (normal 0.5-4.5), free T4 0.9 ng/dL (normal 0.8-1.8), and total T3 42 ng/dL (low; normal 80-180). He has no history of thyroid disease.

What is the most appropriate management of these thyroid abnormalities?', '[{"label":"A","text":"Start levothyroxine for low T3"},{"label":"B","text":"Start liothyronine (T3) replacement"},{"label":"C","text":"No treatment; recheck thyroid function after recovery"},{"label":"D","text":"Order thyroid ultrasound to evaluate for thyroiditis"},{"label":"E","text":"Start combination T4/T3 therapy"}]'::jsonb, 'C', 'This is sick euthyroid syndrome (nonthyroidal illness syndrome), characterized by low T3 with normal or low-normal TSH and T4 in critically ill patients. It represents an adaptive response to illness, not true thyroid dysfunction. T3 is reduced due to decreased peripheral conversion from T4. Treatment with thyroid hormone has not shown benefit and may be harmful. Thyroid function typically normalizes with recovery from the underlying illness. Retesting after recovery confirms resolution.', NULL, 'internal', 'active'),
  ('B2_Q28', 'dm-insulin-sick-day-rules', 'Batch2', 'Endocrinology', 'A 45-year-old woman with type 1 diabetes on basal-bolus insulin calls because she has gastroenteritis with vomiting and has not been able to eat for 24 hours. Her blood glucose is 186 mg/dL. She asks if she should skip her insulin doses.

What is the most appropriate advice?', '[{"label":"A","text":"Hold all insulin until able to eat normally"},{"label":"B","text":"Continue basal insulin; hold bolus insulin; monitor glucose frequently"},{"label":"C","text":"Take only 50% of usual basal insulin"},{"label":"D","text":"Continue all usual insulin doses regardless of intake"},{"label":"E","text":"Stop insulin and present to ED immediately"}]'::jsonb, 'B', 'Sick day rules for type 1 diabetes: continue basal insulin even when not eating, as basal insulin prevents DKA (the body still needs insulin to prevent ketogenesis). Bolus/mealtime insulin can be held or reduced if not eating. Blood glucose should be monitored every 2-4 hours, ketones should be checked, and hydration maintained. Stopping all insulin (A) risks DKA. Counter-regulatory hormones during illness often raise glucose despite reduced intake. She should seek care if unable to keep down fluids or if ketones are elevated.', NULL, 'internal', 'active'),
  ('B2_Q29', 'hyperthyroid-pregnancy-ptu-switch', 'Batch2', 'Endocrinology', 'A 28-year-old woman at 8 weeks gestation has Graves'' disease diagnosed before pregnancy. She is currently on methimazole 10 mg daily with controlled thyroid function (TSH 0.8 mIU/L, free T4 1.2 ng/dL). She asks about continuing her medication during pregnancy.

What is the most appropriate antithyroid drug management?', '[{"label":"A","text":"Continue methimazole throughout pregnancy"},{"label":"B","text":"Switch to propylthiouracil (PTU) now; consider switching back to methimazole after first trimester"},{"label":"C","text":"Stop all antithyroid drugs; use beta-blockers only"},{"label":"D","text":"Proceed with thyroidectomy during pregnancy"},{"label":"E","text":"Radioactive iodine ablation is safe in early pregnancy"}]'::jsonb, 'B', 'Methimazole is associated with teratogenicity in the first trimester (aplasia cutis, choanal atresia, esophageal atresia). PTU is preferred during the first trimester despite its hepatotoxicity risk. After the first trimester (when organogenesis is complete), switching back to methimazole is recommended due to PTU''s hepatotoxicity risk. Stopping antithyroid drugs (C) risks uncontrolled hyperthyroidism, which is harmful to fetus (growth restriction, preterm delivery). Radioactive iodine (E) is absolutely contraindicated in pregnancy.', NULL, 'internal', 'active'),
  ('B2_Q30', 'anticoagulation-cancer-lmwh-doac', 'Batch2', 'Hematology', 'A 58-year-old woman with metastatic pancreatic cancer is diagnosed with acute DVT of the left femoral vein. She has normal renal function and no GI bleeding history. She asks about anticoagulation options.

What is the most appropriate anticoagulation choice?', '[{"label":"A","text":"Warfarin with INR goal 2-3"},{"label":"B","text":"Low-molecular-weight heparin (enoxaparin) or edoxaban/rivaroxaban"},{"label":"C","text":"Unfractionated heparin indefinitely"},{"label":"D","text":"Fondaparinux as first-line for cancer VTE"},{"label":"E","text":"Inferior vena cava filter instead of anticoagulation"}]'::jsonb, 'B', 'For cancer-associated VTE, LMWH or select DOACs (edoxaban, rivaroxaban) are preferred over warfarin based on lower recurrence rates. The HOKUSAI VTE-Cancer and SELECT-D trials showed DOACs are non-inferior to LMWH. However, DOACs carry higher GI bleeding risk in GI/GU malignancies, so LMWH remains preferred in those patients. Warfarin (A) is less effective in cancer patients due to drug interactions and variable INR. IVC filters (E) are reserved for anticoagulation contraindications, not first-line.', NULL, 'internal', 'active'),
  ('B2_Q31', 'iron-deficiency-iv-indication', 'Batch2', 'Hematology', 'A 42-year-old woman with heavy menstrual bleeding has iron deficiency anemia (hemoglobin 9.2 g/dL, ferritin 8 ng/mL, iron saturation 10%). She was started on oral ferrous sulfate 325 mg three times daily 8 weeks ago but reports severe constipation and abdominal cramping. Repeat hemoglobin is 9.4 g/dL.

What is the most appropriate next step?', '[{"label":"A","text":"Continue oral iron; adequate response takes 3-6 months"},{"label":"B","text":"Switch to a different oral iron formulation"},{"label":"C","text":"Administer intravenous iron infusion"},{"label":"D","text":"Oral iron is the only appropriate treatment for iron deficiency"},{"label":"E","text":"Blood transfusion for anemia"}]'::jsonb, 'C', 'IV iron is indicated when oral iron is not tolerated (as in this patient with severe GI side effects), when oral iron is ineffective (malabsorption, ongoing losses exceeding oral replacement capacity), or when rapid repletion is needed. This patient has documented intolerance and minimal response after 8 weeks. IV iron formulations (iron sucrose, ferric carboxymaltose, ferumoxytol) bypass GI absorption and rapidly replenish stores. Transfusion (E) is reserved for symptomatic anemia or hemodynamic instability, not for this stable patient.', NULL, 'internal', 'active'),
  ('B2_Q32', 'transfusion-threshold-restrictive', 'Batch2', 'Hematology', 'A 72-year-old man with COPD undergoes elective hip replacement. Post-operatively, his hemoglobin is 7.4 g/dL. He is hemodynamically stable with no chest pain, dyspnea, or signs of active bleeding.

What is the most appropriate transfusion approach?', '[{"label":"A","text":"Transfuse to goal hemoglobin >10 g/dL"},{"label":"B","text":"Transfuse one unit of PRBCs; reassess"},{"label":"C","text":"No transfusion needed if asymptomatic"},{"label":"D","text":"Transfuse only if hemoglobin <6 g/dL"},{"label":"E","text":"Liberal transfusion strategy improves surgical outcomes"}]'::jsonb, 'B', 'Restrictive transfusion strategy (transfuse at Hgb <7 g/dL) is appropriate for most stable hospitalized patients and is associated with equivalent or better outcomes compared to liberal strategies. This patient''s hemoglobin of 7.4 g/dL is at the threshold; transfusing one unit and reassessing is reasonable given his age and comorbidities (COPD). The TRICC and TRACS trials support restrictive thresholds. Liberal threshold (<9-10 g/dL) is reserved for ACS or symptomatic anemia. Waiting until <6 g/dL (D) is unnecessarily restrictive.', NULL, 'internal', 'active'),
  ('B2_Q33', 'antiplatelet-gi-bleed-resume', 'Batch2', 'Hematology', 'A 66-year-old man with recent drug-eluting stent placement 3 months ago (on aspirin and clopidogrel) presents with melena. EGD reveals a duodenal ulcer with clean base that is treated with PPI. He is hemodynamically stable with hemoglobin of 10.2 g/dL. The GI team achieves hemostasis.

What is the appropriate management of antiplatelet therapy?', '[{"label":"A","text":"Discontinue all antiplatelets for 4 weeks"},{"label":"B","text":"Discontinue clopidogrel; continue aspirin once hemostasis confirmed"},{"label":"C","text":"Resume dual antiplatelet therapy within 24-48 hours if hemostasis achieved"},{"label":"D","text":"Permanently discontinue all antiplatelet therapy given bleeding history"},{"label":"E","text":"Bridge with heparin while antiplatelets are held"}]'::jsonb, 'C', 'In patients with recent coronary stent on DAPT, prolonged antiplatelet interruption carries high risk of stent thrombosis, which has 30-40% mortality. Once endoscopic hemostasis is achieved and the patient is stable, DAPT should be resumed early (within 24-48 hours in high-risk cardiac patients). The ulcer had a clean base (low rebleeding risk). Continued PPI therapy reduces recurrent bleeding. Permanently stopping antiplatelets (D) or prolonged interruption (A) risks catastrophic stent thrombosis, which outweighs bleeding risk.', NULL, 'internal', 'active'),
  ('B2_Q34', 'pcc-vs-ffp-reversal', 'Batch2', 'Hematology', 'A 78-year-old man on warfarin for AFib (INR 4.2) presents after a fall with acute subdural hematoma and declining mental status. His blood pressure is 168/94 mmHg. Emergent reversal of anticoagulation is required.

What is the most appropriate reversal strategy?', '[{"label":"A","text":"Fresh frozen plasma 4 units + vitamin K 10 mg IV"},{"label":"B","text":"Vitamin K 10 mg IV alone"},{"label":"C","text":"4-factor prothrombin complex concentrate (PCC) + vitamin K 10 mg IV"},{"label":"D","text":"Activated charcoal to absorb warfarin"},{"label":"E","text":"Hold warfarin and recheck INR in 24 hours"}]'::jsonb, 'C', 'For life-threatening bleeding on warfarin (intracranial hemorrhage), 4-factor PCC is preferred over FFP for reversal. PCC advantages: faster reversal (minutes vs hours), smaller volume (avoids fluid overload), complete factor replacement, no thawing required. Vitamin K should be given concurrently for sustained reversal (PCC effect wanes as factors are consumed). FFP alone (A) is slower and may not fully correct INR. Vitamin K alone (B) takes 12-24 hours for effect, too slow for ICH. This is a medical emergency; observation (E) is inappropriate.', NULL, 'internal', 'active'),
  ('B2_Q35', 'asymptomatic-bacteriuria-no-treat', 'Batch2', 'Infectious Disease', 'A 72-year-old woman with type 2 diabetes is admitted for elective knee replacement. Preoperative urinalysis shows >100,000 CFU/mL E. coli. She has no urinary symptoms, fever, or costovertebral angle tenderness. The orthopedic team asks if she needs antibiotic treatment before surgery.

What is the most appropriate management?', '[{"label":"A","text":"Treat with ciprofloxacin for 7 days before surgery"},{"label":"B","text":"Treat with nitrofurantoin for 5 days before surgery"},{"label":"C","text":"No antibiotic treatment indicated; proceed with surgery"},{"label":"D","text":"Cancel surgery until urine is sterile"},{"label":"E","text":"Obtain urine culture to guide antibiotic selection"}]'::jsonb, 'C', 'Asymptomatic bacteriuria should NOT be treated except in two specific situations: pregnancy and prior to urologic procedures involving mucosal trauma. Orthopedic surgery does not require treatment of asymptomatic bacteriuria. Treatment does not reduce surgical site infections and promotes antibiotic resistance. The patient has no symptoms of UTI (dysuria, frequency, urgency, fever), so this is true asymptomatic bacteriuria. Diabetic status does not change this recommendation.', NULL, 'internal', 'active'),
  ('B2_Q36', 'empiric-mrsa-coverage-criteria', 'Batch2', 'Infectious Disease', 'A 58-year-old man presents with pneumonia requiring ICU admission. He was hospitalized 6 weeks ago for a COPD exacerbation. He is not on hemodialysis and has no known MRSA history. Chest X-ray shows multilobar infiltrates. He is hypotensive requiring vasopressors.

Should empiric MRSA coverage (vancomycin) be included in his antibiotic regimen?', '[{"label":"A","text":"No; MRSA coverage not needed for community-acquired pneumonia"},{"label":"B","text":"Yes; recent hospitalization is a risk factor for MRSA"},{"label":"C","text":"Only if sputum Gram stain shows gram-positive cocci"},{"label":"D","text":"MRSA coverage is only needed for skin infections"},{"label":"E","text":"Wait for culture results before adding MRSA coverage"}]'::jsonb, 'B', 'Risk factors for MRSA pneumonia that warrant empiric vancomycin/linezolid include: prior MRSA infection or colonization, recent hospitalization (within 90 days), hemodialysis, IV drug use, and severe/necrotizing presentation. This patient''s recent hospitalization 6 weeks ago qualifies him for empiric MRSA coverage. Waiting for culture results (E) is inappropriate given his severe presentation. MRSA coverage should be de-escalated if cultures return negative at 48-72 hours.', NULL, 'internal', 'active'),
  ('B2_Q37', 'antibiotic-deescalation-culture', 'Batch2', 'Infectious Disease', 'A 64-year-old man was started on vancomycin and piperacillin-tazobactam for healthcare-associated pneumonia. Blood cultures grow methicillin-sensitive Staphylococcus aureus (MSSA). He has defervesced and is clinically improving at 72 hours.

What is the most appropriate antibiotic adjustment?', '[{"label":"A","text":"Continue vancomycin and piperacillin-tazobactam for full course"},{"label":"B","text":"Stop vancomycin; continue piperacillin-tazobactam"},{"label":"C","text":"Stop both; switch to nafcillin or cefazolin"},{"label":"D","text":"Stop piperacillin-tazobactam; continue vancomycin"},{"label":"E","text":"Add gentamicin for synergy"}]'::jsonb, 'C', 'Antibiotic de-escalation based on culture and sensitivity data is essential stewardship. MSSA bacteremia should be treated with a beta-lactam (nafcillin, oxacillin, or cefazolin), which has superior efficacy compared to vancomycin for MSSA. Continuing vancomycin (D) provides inferior MSSA coverage. Continuing broad-spectrum empiric therapy (A) promotes resistance and adverse effects. The patient is clinically improving, supporting de-escalation. Note: MSSA bacteremia typically requires 4-6 weeks of treatment with evaluation for endocarditis.', NULL, 'internal', 'active'),
  ('B2_Q38', 'latent-tb-treatment-indications', 'Batch2', 'Infectious Disease', 'A 34-year-old healthcare worker from the Philippines has a positive interferon-gamma release assay (IGRA) during routine screening. Chest X-ray is normal. She has no symptoms of cough, fever, night sweats, or weight loss. She has no history of TB treatment. She is not immunocompromised.

What is the most appropriate management?', '[{"label":"A","text":"No treatment needed if asymptomatic with normal chest X-ray"},{"label":"B","text":"Treat for latent TB infection"},{"label":"C","text":"Repeat IGRA in 3 months to confirm"},{"label":"D","text":"Treat only if she develops active TB symptoms"},{"label":"E","text":"Isoniazid prophylaxis only for immunocompromised patients"}]'::jsonb, 'B', 'This patient has latent TB infection (LTBI): positive IGRA with no symptoms or radiographic evidence of active disease. Healthcare workers have ongoing TB exposure risk, and LTBI treatment reduces her 5-10% lifetime risk of reactivation to <1%. Treatment options include 4 months of rifampin, 3 months of isoniazid-rifapentine, or 6-9 months of isoniazid. Foreign-born individuals from high-prevalence countries and healthcare workers are high-risk groups for whom LTBI treatment is recommended. Waiting for active disease (D) is inappropriate prevention.', NULL, 'internal', 'active'),
  ('B2_Q39', 'aed-selection-comorbidity', 'Batch2', 'Neurology', 'A 28-year-old woman with newly diagnosed focal epilepsy requires anti-seizure medication. She is planning pregnancy within the next year. She has no other medical conditions.

Which anti-seizure medication should be avoided due to teratogenicity concerns?', '[{"label":"A","text":"Levetiracetam"},{"label":"B","text":"Lamotrigine"},{"label":"C","text":"Valproate"},{"label":"D","text":"Lacosamide"},{"label":"E","text":"Oxcarbazepine"}]'::jsonb, 'C', 'Valproate is the most teratogenic anti-seizure medication and should be avoided in women of childbearing potential. It causes neural tube defects, craniofacial abnormalities, and neurodevelopmental impairment at rates significantly higher than other ASMs. Levetiracetam (A) and lamotrigine (B) have the best safety data in pregnancy and are preferred for women planning conception. All women on ASMs planning pregnancy should take high-dose folic acid (4 mg daily). Valproate also has significant weight gain and polycystic ovary syndrome associations.', NULL, 'internal', 'active'),
  ('B2_Q40', 'lumbar-puncture-imaging-first', 'Batch2', 'Neurology', 'A 52-year-old man presents with fever, severe headache, and neck stiffness. He is alert and oriented with no focal neurologic deficits. Fundoscopic exam is normal without papilledema. He is immunocompetent with no HIV risk factors.

What is the most appropriate next step before lumbar puncture?', '[{"label":"A","text":"CT head is required before LP in all patients with suspected meningitis"},{"label":"B","text":"Proceed directly to LP; CT head not needed"},{"label":"C","text":"MRI brain before LP"},{"label":"D","text":"CT head required because of his age >50"},{"label":"E","text":"Blood cultures and antibiotics; defer LP"}]'::jsonb, 'B', 'CT before LP is only required if the patient has risk factors for herniation or space-occupying lesion: focal neurologic deficits, papilledema, altered mental status, immunocompromised state (HIV, transplant), or history of CNS disease. This patient has none of these features: he is alert, oriented, non-immunocompromised, without focal findings or papilledema. LP can proceed immediately. Age alone (D) is not an indication for pre-LP imaging. Delaying LP for imaging can delay diagnosis and treatment of bacterial meningitis.', NULL, 'internal', 'active'),
  ('B2_Q41', 'ssri-discontinuation-syndrome', 'Batch2', 'Psychiatry', 'A 38-year-old woman on paroxetine 40 mg daily for 2 years abruptly stops her medication because she "feels better." Five days later, she presents with dizziness, nausea, "electric shock" sensations, irritability, and vivid dreams. Her vital signs are normal.

What is the most likely diagnosis?', '[{"label":"A","text":"Recurrence of major depressive disorder"},{"label":"B","text":"Serotonin syndrome"},{"label":"C","text":"SSRI discontinuation syndrome"},{"label":"D","text":"Generalized anxiety disorder"},{"label":"E","text":"Panic disorder"}]'::jsonb, 'C', 'SSRI discontinuation syndrome occurs when SSRIs (especially those with short half-lives like paroxetine and venlafaxine) are abruptly stopped. Symptoms include "FINISH": Flu-like symptoms, Insomnia, Nausea, Imbalance/dizziness, Sensory disturbances (electric shock/"brain zaps"), and Hyperarousal. Symptoms typically begin 2-4 days after stopping and resolve within 1-2 weeks or upon reinstatement. This is not serotonin syndrome (B), which presents with hyperthermia, rigidity, and autonomic instability from serotonin excess. Treatment: restart medication and taper gradually.', NULL, 'internal', 'active'),
  ('B2_Q42', 'antidepressant-switch-washout', 'Batch2', 'Psychiatry', 'A 45-year-old woman with treatment-resistant depression on fluoxetine 60 mg is transitioning to phenelzine (an MAOI) after failing multiple medication trials. The psychiatrist plans to stop fluoxetine.

What is the minimum required washout period before starting phenelzine?', '[{"label":"A","text":"No washout needed; start immediately"},{"label":"B","text":"2 weeks"},{"label":"C","text":"3 weeks"},{"label":"D","text":"5 weeks"},{"label":"E","text":"8 weeks"}]'::jsonb, 'D', 'Switching from an SSRI to an MAOI requires a washout period to prevent serotonin syndrome. For most SSRIs, 2 weeks (5 half-lives) is sufficient. However, fluoxetine has a long half-life (4-6 days) and an active metabolite (norfluoxetine) with a half-life of 4-16 days, requiring at least 5 weeks washout. Similarly, when switching FROM an MAOI TO any serotonergic agent, a 2-week washout is required. This patient cannot start phenelzine for at least 5 weeks after stopping fluoxetine.', NULL, 'internal', 'active'),
  ('B2_Q43', 'benzodiazepine-elderly-avoid', 'Batch2', 'Psychiatry', 'An 82-year-old woman with mild dementia is admitted to the hospital for hip fracture repair. Post-operatively, she is agitated and having difficulty sleeping. Her daughter asks if she can receive "something to help her relax and sleep," mentioning her mother took lorazepam in the past.

Why should benzodiazepines be avoided in this patient?', '[{"label":"A","text":"Benzodiazepines are contraindicated after surgery"},{"label":"B","text":"Risk of falls, cognitive impairment, and paradoxical agitation in elderly"},{"label":"C","text":"Benzodiazepines are ineffective for insomnia"},{"label":"D","text":"Lorazepam is only available in IV formulation"},{"label":"E","text":"Benzodiazepines cause serotonin syndrome in elderly"}]'::jsonb, 'B', 'Benzodiazepines are included on the Beers Criteria of potentially inappropriate medications in older adults. In the elderly, they increase risk of: falls and hip fractures, cognitive impairment, confusion and delirium (especially in those with baseline dementia), paradoxical agitation/disinhibition, over-sedation, and respiratory depression. This patient with dementia and recent hip fracture is at particularly high risk. Alternatives for insomnia include sleep hygiene, melatonin, or low-dose trazodone. Non-pharmacologic delirium prevention is preferred.', NULL, 'internal', 'active'),
  ('B3_ms-acute-relapse-vs-pseudo-relapse', 'ms-acute-relapse-vs-pseudo-relapse', 'Batch3', 'Neurology', 'A 34-year-old woman with relapsing-remitting multiple sclerosis on natalizumab presents with worsening right leg weakness over 2 days. She reports low-grade fever and dysuria for the past 4 days. Her last relapse was 8 months ago. Examination shows 4/5 strength in the right lower extremity (baseline was 4+/5) and an MRI from 3 months ago showed stable lesion burden.

What is the most appropriate next step in management?', '[{"label":"A","text":"Administer IV methylprednisolone 1g daily for 3–5 days"},{"label":"B","text":"Obtain urinalysis and urine culture before initiating steroids"},{"label":"C","text":"Obtain MRI brain and spine with gadolinium"},{"label":"D","text":"Switch disease-modifying therapy due to breakthrough disease"},{"label":"E","text":"Reassure and observe with outpatient follow-up in 1 week"}]'::jsonb, 'B', 'This presentation is classic for pseudo-relapse—worsening of pre-existing neurologic deficits triggered by physiological stressor (here, UTI). Key distinguishing features: • Pseudo-relapse: Occurs with infection, fever, heat, or stress; symptoms are recurrence/worsening of OLD deficits; resolves when trigger treated; no new MRI lesions • True relapse: New or substantially worsened symptoms lasting >24 hours; typically new lesions on MRI; no identifiable trigger The dysuria and fever strongly suggest UTI as the culprit. Treatment of the underlying infection typically resolves neurologic worsening within 24–48 hours. Administering steroids before ruling out infection is inappropriate— steroids can worsen infection and won''t address the underlying cause. Why other options are wrong: • A: Premature—steroids should not be given until infection is excluded; treating UTI may resolve symptoms entirely • C: MRI is reasonable if infection workup is negative and symptoms persist, but not the immediate next step • D: No evidence of breakthrough disease—this appears triggered by infection, not DMT failure • E: Untreated UTI in MS patient risks worsening pseudo-relapse and systemic complications High-Yield Takeaway: Always rule out infection (especially UTI), fever, and metabolic derangements before diagnosing MS relapse— pseudo-relapse resolves with trigger treatment and does not require steroids.', NULL, 'internal', 'active'),
  ('B3_seizure-breakthrough-on-aed-workup', 'seizure-breakthrough-on-aed-workup', 'Batch3', 'Neurology', 'A 28-year-old man with well-controlled focal epilepsy on levetiracetam 1500mg twice daily presents after a witnessed seizure this morning—his first in 2 years. He denies missed doses and his pill count confirms adherence. He started a new job last week with irregular sleep and reports taking over-the-counter diphenhydramine for insomnia. Vitals and neurologic exam are normal. Levetiracetam level is 18 mcg/mL (therapeutic: 12–46 mcg/mL).

What is the most appropriate next step?', '[{"label":"A","text":"Increase levetiracetam to 2000mg twice daily"},{"label":"B","text":"Add a second antiepileptic drug"},{"label":"C","text":"Obtain EEG and MRI brain"},{"label":"D","text":"Counsel on sleep hygiene and discontinue diphenhydramine"},{"label":"E","text":"Check CBC and comprehensive metabolic panel"}]'::jsonb, 'D', 'Breakthrough seizures in adherent patients with therapeutic drug levels require identification of modifiable triggers before escalating therapy. This patient has two clear precipitants: 1. Sleep deprivation — Most common seizure trigger; lowers seizure threshold significantly 2. Diphenhydramine — Antihistamines lower seizure threshold and should be avoided in epilepsy The approach to breakthrough seizure in compliant patient: 1. Verify adherence (done—pill count confirms) 2. Check drug level (done—therapeutic) 3. Identify triggers (sleep deprivation, new medications, alcohol, illness, stress) 4. Address triggers before adjusting AED regimen Why other options are wrong: • A: Level is therapeutic; increasing dose adds side effects without addressing the cause • B: Premature—trigger modification should be attempted first; adding AEDs increases polypharmacy burden • C: EEG/MRI indicated if concern for new lesion or change in semiology; routine imaging not needed for single breakthrough with clear trigger • E: Metabolic workup reasonable but less likely to yield actionable findings than addressing obvious triggers High-Yield Takeaway: Breakthrough seizure + therapeutic AED level + clear trigger = address the trigger first. Common culprits: sleep deprivation, alcohol, medication interactions (fluoroquinolones, tramadol, bupropion, antihistamines), and illness.', NULL, 'internal', 'active'),
  ('B3_migraine-prophylaxis-agent-selection', 'migraine-prophylaxis-agent-selection', 'Batch3', 'Neurology', 'A 42-year-old woman with migraines (8–10 headache days/month) and BMI 34 requests preventive therapy. She also has hypertension controlled on lisinopril and reports depressed mood for which she declines antidepressant medication. She is concerned about weight gain. Prior trial of topiramate was stopped due to significant word- finding difficulty.

Which prophylactic agent is most appropriate for this patient?', '[{"label":"A","text":"Propranolol"},{"label":"B","text":"Amitriptyline"},{"label":"C","text":"Valproate"},{"label":"D","text":"Venlafaxine"},{"label":"E","text":"Onabotulinumtoxin A"}]'::jsonb, 'A', 'Migraine prophylaxis selection requires matching agent to comorbidities: Agent Benefits Avoid if Beta-blockers HTN, anxiety, tremor Asthma, depression (relative), bradycardia Topiramate Obesity (weight loss) Kidney stones, cognitive concerns Amitriptyline Insomnia, depression, tension-type overlap Obesity, cardiac conduction issues Valproate Bipolar, epilepsy Obesity, childbearing potential Venlafaxine Depression, anxiety HTN (can raise BP) CGRP inhibitors Failed ≥2 preventives Cost/access This patient: • Hypertension → beta-blocker provides dual benefit • Obesity → avoid valproate and amitriptyline (weight gain) • Topiramate intolerance → already failed • Declines antidepressants → rules out amitriptyline, venlafaxine • Does not meet criteria for onabotulinumtoxin A (requires ≥15 headache days/month for chronic migraine) Propranolol addresses HTN and provides first-line migraine prophylaxis without weight gain. Why other options are wrong: • B: Causes weight gain; patient declined antidepressants • C: Significant weight gain; teratogenic (relevant for reproductive-age woman) • D: Patient declined antidepressants; can worsen hypertension • E: Only FDA-approved for chronic migraine (≥15 days/month); she has 8–10 days High-Yield Takeaway: Match migraine prophylaxis to comorbidities: beta-blocker for HTN; topiramate for obesity; amitriptyline for insomnia/depression; valproate for epilepsy (avoid in women of childbearing age); CGRP inhibitors after failing 2+ preventives.', NULL, 'internal', 'active'),
  ('B3_tia-dual-antiplatelet-duration', 'tia-dual-antiplatelet-duration', 'Batch3', 'Neurology', 'A 67-year-old man presented 3 days ago with transient left arm weakness lasting 30 minutes. MRI showed a small acute infarct in the right corona radiata. ABCD2 score was 5. He was started on aspirin 81mg plus clopidogrel 75mg. Carotid imaging shows <50% stenosis bilaterally. Echocardiogram and telemetry show no cardioembolic source. He now asks how long he needs to take both medications.

What is the appropriate duration of dual antiplatelet therapy for this patient?', '[{"label":"A","text":"21 days, then aspirin monotherapy"},{"label":"B","text":"90 days, then aspirin monotherapy"},{"label":"C","text":"12 months, then reassess"},{"label":"D","text":"Indefinitely, given high-risk features"},{"label":"E","text":"Discontinue clopidogrel now; aspirin alone is sufficient"}]'::jsonb, 'A', 'The POINT and CHANCE trials established dual antiplatelet therapy (DAPT) for high-risk TIA/minor stroke: Indications for DAPT: • High-risk TIA (ABCD2 ≥4) OR minor ischemic stroke (NIHSS ≤3) • Non-cardioembolic mechanism • Initiated within 24 hours of symptom onset Duration: • 21 days of aspirin + clopidogrel (CHANCE protocol, preferred) • Alternative: 21–30 days (some guidelines extend to 30) • NOT 90 days — POINT trial showed increased bleeding without additional benefit beyond 21–30 days • After DAPT: Continue aspirin monotherapy indefinitely This patient has minor stroke (DWI+ TIA = minor stroke by definition), ABCD2 of 5 (high-risk), and non- cardioembolic etiology—perfect candidate for 21-day DAPT. Why other options are wrong: • B: 90 days showed excess bleeding in POINT trial without additional stroke reduction; 21 days is current standard • C: No indication for 12-month DAPT in stroke (unlike coronary stenting) • D: Indefinite DAPT increases bleeding; long-term management is aspirin monotherapy • E: Stopping clopidogrel at day 3 loses the early high-risk window benefit High-Yield Takeaway: High-risk TIA or minor stroke → 21 days of aspirin + clopidogrel (start within 24 hours) → then aspirin monotherapy lifelong. Do not extend DAPT beyond 21–30 days due to bleeding risk.', NULL, 'internal', 'active'),
  ('B3_parkinsons-motor-fluctuation-management', 'parkinsons-motor-fluctuation-management', 'Batch3', 'Neurology', 'A 71-year-old man with Parkinson disease for 9 years on carbidopa-levodopa 25/100mg four times daily reports that his medications "wear off" about 1 hour before each dose. He also experiences involuntary writhing movements of his trunk and limbs during peak effect. His wife confirms the dyskinesias occur 1–2 hours after each dose.

Which adjustment best addresses both his wearing-off and peak-dose dyskinesia?', '[{"label":"A","text":"Increase each carbidopa-levodopa dose"},{"label":"B","text":"Add entacapone to each levodopa dose"},{"label":"C","text":"Give smaller, more frequent doses of carbidopa-levodopa"},{"label":"D","text":"Add amantadine"},{"label":"E","text":"Add pramipexole"}]'::jsonb, 'C', 'This patient demonstrates two common motor complications: 1. Wearing-off — Motor benefit wanes before next dose (predictable end-of-dose deterioration) 2. Peak-dose dyskinesia — Involuntary choreiform movements at time of peak levodopa levels The management strategy depends on which fluctuation predominates: Problem Strategy Wearing-off alone Add COMT inhibitor (entacapone), increase dose, add dopamine agonist, or shorten dosing interval Peak-dose dyskinesia alone Reduce individual doses, add amantadine Both wearing-off AND dyskinesia Smaller, more frequent doses (smooths plasma levels); add amantadine for dyskinesia Smaller, more frequent dosing reduces peak levels (↓ dyskinesia) while maintaining more consistent coverage (↓ wearing-off). This addresses both issues simultaneously. Why other options are wrong: • A: Higher doses worsen peak-dose dyskinesia • B: Entacapone prolongs levodopa effect (helps wearing-off) but increases peak levels → worsens dyskinesia • D: Amantadine specifically treats dyskinesia but doesn''t address wearing-off; reasonable add-on but not first adjustment • E: Dopamine agonists help wearing-off but can worsen dyskinesia; higher risk of impulse control disorders in elderly High-Yield Takeaway: Wearing-off + peak-dose dyskinesia → smaller, more frequent levodopa doses to smooth plasma levels. Amantadine is the specific add-on for refractory dyskinesia.', NULL, 'internal', 'active'),
  ('B3_neuropathy-workup-stepwise', 'neuropathy-workup-stepwise', 'Batch3', 'Neurology', 'A 58-year-old man presents with 6 months of progressive numbness and burning in both feet. He has no diabetes (HbA1c 5.4%), drinks 1–2 beers weekly, and takes no medications. Examination reveals decreased pinprick and vibration sense to the mid-shin bilaterally with absent ankle reflexes. Initial labs show normal glucose, B12, TSH, and CBC.

What is the most appropriate next step in evaluation?', '[{"label":"A","text":"Nerve conduction studies and electromyography"},{"label":"B","text":"Serum protein electrophoresis and immunofixation"},{"label":"C","text":"Lumbar puncture with CSF analysis"},{"label":"D","text":"Genetic testing for Charcot-Marie-Tooth disease"},{"label":"E","text":"Trial of gabapentin for symptomatic relief"}]'::jsonb, 'B', 'When initial workup for peripheral neuropathy is unrevealing, systematic evaluation for treatable causes is essential. Tiered approach to cryptogenic neuropathy: Tier 1 (Initial): Glucose/HbA1c, B12, TSH, CBC, CMP — rules out the "big 3" (diabetes, B12 deficiency, hypothyroidism) — done and normal Tier 2 (Extended): • SPEP/immunofixation — screens for monoclonal gammopathy (MGUS, myeloma, amyloidosis, POEMS) • HIV, hepatitis B/C serologies • ANA, ESR (vasculitis, connective tissue disease) • Methylmalonic acid (functional B12 deficiency) Tier 3 (Specialized): NCS/EMG (characterizes neuropathy type), genetic testing, nerve biopsy, paraneoplastic antibodies Monoclonal gammopathy causes ~10% of initially idiopathic neuropathies and is treatable. SPEP with immunofixation (not just SPEP alone) is essential because immunofixation detects small monoclonal proteins missed by SPEP. Why other options are wrong: • A: NCS/EMG characterizes neuropathy pattern but doesn''t identify cause; appropriate after serologic workup • C: LP indicated if inflammatory/infectious etiology suspected (AIDP, CIDP); not routine for distal sensory neuropathy • D: CMT typically presents younger with foot deformities and family history; genetic testing is tier 3 • E: Symptomatic treatment before diagnosis may mask progression and delay identifying treatable cause High-Yield Takeaway: Idiopathic neuropathy with negative initial labs → check SPEP with immunofixation (monoclonal gammopathy is common and treatable), HIV, hepatitis serologies, and ANA before proceeding to electrodiagnostics.', NULL, 'internal', 'active'),
  ('B3_myasthenia-crisis-vs-cholinergic-crisis', 'myasthenia-crisis-vs-cholinergic-crisis', 'Batch3', 'Neurology', 'A 62-year-old woman with myasthenia gravis on pyridostigmine 90mg every 4 hours presents with worsening dyspnea and generalized weakness over 2 days. She increased her pyridostigmine dose 3 days ago due to perceived symptom worsening. Vitals: HR 58, BP 110/70, RR 24, SpO2 91% on room air. Exam shows bilateral ptosis, proximal weakness, diffuse fasciculations, diaphoresis, and excessive salivation. Negative inspiratory force is -18 cmH2O.

What is the most appropriate immediate management?', '[{"label":"A","text":"Administer additional pyridostigmine"},{"label":"B","text":"Administer atropine and prepare for intubation"},{"label":"C","text":"Hold pyridostigmine and prepare for intubation"},{"label":"D","text":"Administer edrophonium as a diagnostic test"},{"label":"E","text":"Start IV immunoglobulin immediately"}]'::jsonb, 'C', 'This patient has cholinergic crisis—excess acetylcholinesterase inhibitor causing both nicotinic and muscarinic toxicity: Feature Myasthenic Crisis Cholinergic Crisis Cause Undertreated MG Excess anticholinesterase Weakness Present Present Fasciculations Absent Present SLUDGE symptoms Absent Present (salivation, lacrimation, urination, diarrhea, GI upset, emesis) Bradycardia Absent Present Pupils Normal Miotic Response to edrophonium Improves Worsens Key findings indicating cholinergic crisis: • Recent pyridostigmine increase • Fasciculations (nicotinic excess) • SLUDGE: salivation, diaphoresis (muscarinic excess) • Bradycardia Management: 1. Stop anticholinesterase medications immediately 2. Airway protection — NIF < -20 to -25 indicates impending respiratory failure 3. Supportive care; atropine only if severe bradycardia or secretions compromising airway Why other options are wrong: • A: Would worsen cholinergic crisis catastrophically • B: Atropine addresses muscarinic symptoms but doesn''t reverse nicotinic weakness; holding pyridostigmine is the priority • D: Edrophonium would worsen cholinergic crisis; contraindicated when cholinergic crisis suspected • E: IVIG treats myasthenic crisis, not cholinergic crisis; stopping the offending medication is first priority High-Yield Takeaway: Fasciculations + SLUDGE symptoms + bradycardia in MG patient on anticholinesterases = cholinergic crisis → stop pyridostigmine immediately and prepare for airway management.', NULL, 'internal', 'active'),
  ('B3_idiopathic-intracranial-hypertension-escalation', 'idiopathic-intracranial-hypertension-escalation', 'Batch3', 'Neurology', 'A 32-year-old woman with BMI 38 and idiopathic intracranial hypertension has been on maximum-dose acetazolamide (2g/day) for 4 months with dietary counseling. She reports persistent daily headaches. Ophthalmology exam shows stable moderate papilledema with visual field testing demonstrating enlarged blind spots and early peripheral field constriction—worse than 2 months ago. LP shows opening pressure of 38 cmH2O.

What is the most appropriate next step in management?', '[{"label":"A","text":"Add topiramate for adjunctive ICP lowering"},{"label":"B","text":"Continue current management and recheck in 2 months"},{"label":"C","text":"Refer for optic nerve sheath fenestration or CSF shunting"},{"label":"D","text":"Refer for bariatric surgery evaluation"},{"label":"E","text":"Perform serial therapeutic lumbar punctures"}]'::jsonb, 'C', 'IIH management follows a stepwise approach with vision preservation as the primary goal: Step 1 — Conservative: • Weight loss (5–10% body weight can resolve IIH) • Acetazolamide (first-line medical therapy, up to 4g/day) Step 2 — Escalation indications: • Progressive visual field loss despite maximum medical therapy • Severe or rapidly progressive papilledema • Intractable headache with visual deterioration Step 3 — Surgical options: • Optic nerve sheath fenestration (ONSF) — Primarily for visual symptoms; less effective for headache • CSF diversion (VP or LP shunt) — For both visual and headache symptoms • Venous sinus stenting — If venous sinus stenosis present This patient has: • Maximum-dose acetazolamide (4 months) • Progressive visual field loss (primary concern) • Persistent elevated ICP Progressive visual field deterioration on maximum medical therapy = surgical intervention required. Why other options are wrong: • A: Topiramate provides modest additional benefit but won''t reverse progressive visual loss; delay risks permanent vision damage • B: Vision is worsening—cannot wait; permanent optic nerve damage is irreversible • D: Bariatric surgery is effective long-term but takes months for results; cannot wait with progressive visual loss • E: Serial LPs provide temporary relief but are not definitive; impractical for chronic management and don''t prevent ongoing damage High-Yield Takeaway: IIH with progressive visual field loss despite maximum acetazolamide → surgical intervention (ONSF or shunt) is indicated to prevent permanent vision loss. Do not delay for weight loss or additional medical trials. OB/GYN', NULL, 'internal', 'active'),
  ('B3_pprom-preterm-expectant-vs-deliver', 'pprom-preterm-expectant-vs-deliver', 'Batch3', 'OB/GYN', 'A 29-year-old G2P1 at 31 weeks gestation presents with rupture of membranes confirmed by pooling, ferning, and positive AmniSure. She is afebrile with reassuring fetal heart tracing and no contractions. GBS status is unknown. She received her first dose of betamethasone 6 hours ago.

What is the most appropriate management plan?', '[{"label":"A","text":"Proceed with delivery given confirmed rupture of membranes"},{"label":"B","text":"Expectant management with antibiotics until 34 weeks or complications develop"},{"label":"C","text":"Expectant management until 37 weeks"},{"label":"D","text":"Administer tocolytics for 48 hours, then induce at 32 weeks"},{"label":"E","text":"Perform amniocentesis to assess fetal lung maturity before deciding"}]'::jsonb, 'B', 'PPROM (preterm prelabor rupture of membranes) management depends on gestational age: GA Management <23 weeks Counsel on options (expectant vs termination); high morbidity 23–34 weeks Expectant management with latency antibiotics until 34 weeks or complications 34–37 weeks Current evidence supports delivery at 34 weeks (some centers extend to 36-37) ≥37 weeks Deliver Components of expectant management at 31 weeks: 1. Corticosteroids — Complete course (2 doses, 24h apart) 2. Latency antibiotics — Ampicillin + azithromycin (7-day course) to prolong latency and reduce chorioamnionitis 3. GBS prophylaxis — If unknown status, treat as positive during labor 4. Magnesium sulfate — For neuroprotection if delivery anticipated <32 weeks 5. Monitoring — Serial maternal vitals, fetal heart rate monitoring, signs of infection/labor Indications to deliver despite prematurity: • Chorioamnionitis (fever, uterine tenderness, fetal tachycardia, maternal leukocytosis) • Non-reassuring fetal status • Placental abruption • Cord prolapse • Advanced labor Why other options are wrong: • A: At 31 weeks, prematurity risk exceeds infection risk in stable patients; expectant management improves outcomes • C: Most guidelines recommend delivery by 34 weeks (some 36–37); extending to 37 weeks increases infection risk without clear benefit • D: Tocolytics only indicated for 48 hours to complete steroids/magnesium; not for prolonged latency • E: Amniocentesis for FLM no longer recommended; gestational age guides decisions High-Yield Takeaway: PPROM 23–34 weeks + stable = expectant management with latency antibiotics and corticosteroids until 34 weeks or complications. Deliver immediately if signs of infection, non-reassuring fetal status, or abruption.', NULL, 'internal', 'active'),
  ('B3_gdm-insulin-initiation-timing', 'gdm-insulin-initiation-timing', 'Batch3', 'OB/GYN', 'A 33-year-old G1P0 at 30 weeks with gestational diabetes has been on dietary modification for 2 weeks. Her fasting glucose logs show values of 98, 102, 95, 105, and 99 mg/dL over the past week. Two-hour postprandial values are consistently 115–125 mg/dL. She has gained 2 pounds since diagnosis. Fetal growth ultrasound is scheduled for 32 weeks.

What is the most appropriate next step in management?', '[{"label":"A","text":"Continue diet therapy; recheck in 2 weeks"},{"label":"B","text":"Add metformin for fasting hyperglycemia"},{"label":"C","text":"Initiate nighttime NPH insulin"},{"label":"D","text":"Initiate rapid-acting insulin with meals"},{"label":"E","text":"Increase dietary carbohydrate restriction"}]'::jsonb, 'C', 'GDM glucose targets (Fifth International Workshop): • Fasting: <95 mg/dL (some use <90) • 1-hour postprandial: <140 mg/dL • 2-hour postprandial: <120 mg/dL This patient''s values: • Fasting: 95–105 → Consistently elevated (4/5 values exceed 95) • Postprandial: 115–125 → At or slightly above 2-hour target When to escalate from diet to pharmacotherapy: • Fasting or postprandial targets not achieved after 1–2 weeks of diet/exercise • Majority of values out of range Choosing the agent: • Fasting hyperglycemia → Hepatic glucose production overnight → Nighttime NPH insulin (or long-acting insulin) • Postprandial hyperglycemia → Inadequate insulin response to meals → Rapid-acting insulin with meals or metformin • Both → Combination therapy This patient''s primary issue is fasting glucose, so nighttime NPH addresses the pathophysiology (suppresses overnight hepatic gluconeogenesis). Why other options are wrong: • A: Two weeks is adequate diet trial; persistent fasting elevation requires escalation • B: Metformin primarily lowers fasting glucose by reducing hepatic glucose output; however, insulin is first- line in GDM due to more predictable pharmacokinetics and established safety profile • D: Postprandial values are borderline/at target; prandial insulin addresses postprandial, not fasting glucose • E: Further carbohydrate restriction unlikely to address fasting glucose; may be inadequate nutrition High-Yield Takeaway: GDM with elevated fasting glucose despite diet → start nighttime NPH insulin. Elevated postprandial glucose → add prandial rapid-acting insulin or consider metformin (second-line).', NULL, 'internal', 'active'),
  ('B3_iugr-surveillance-frequency', 'iugr-surveillance-frequency', 'Batch3', 'OB/GYN', 'A 34-year-old G2P1 at 28 weeks has an ultrasound showing estimated fetal weight at the 5th percentile with normal amniotic fluid. Umbilical artery Doppler shows elevated S/D ratio but positive end-diastolic flow. Fetal anatomy and middle cerebral artery Doppler are normal. She has chronic hypertension on labetalol.

What is the most appropriate surveillance plan?', '[{"label":"A","text":"Weekly biophysical profile; deliver at 34 weeks"},{"label":"B","text":"Twice-weekly NST and weekly umbilical artery Doppler; deliver by 37 weeks"},{"label":"C","text":"Daily fetal kick counts; deliver at 39 weeks"},{"label":"D","text":"Continuous inpatient monitoring until delivery"},{"label":"E","text":"Repeat growth ultrasound in 4 weeks; routine prenatal care"}]'::jsonb, 'B', 'IUGR (FGR) management depends on severity, Doppler findings, and gestational age: Classification by umbilical artery (UA) Doppler: UA Doppler Severity Surveillance Delivery Timing Normal Mild FGR Weekly NST; growth q3-4 weeks 38–39 weeks Elevated S/D, positive EDF Moderate Twice-weekly NST; weekly Dopplers 37 weeks Absent EDF (AEDF) Severe Daily NST or admission; steroids if <34wk 33–34 weeks Reversed EDF (REDF) Critical Inpatient; often deliver after steroids 30–32 weeks This fetus has: • EFW 5th percentile = FGR • Elevated S/D ratio but positive end-diastolic flow = moderate severity • 28 weeks = time to optimize with steroids before potential delivery Surveillance: Twice-weekly NST and weekly umbilical artery Doppler to detect progression to AEDF/REDF Delivery: By 37 weeks if stable; earlier if Dopplers worsen Why other options are wrong: • A: Weekly BPP alone is insufficient; UA Doppler progression guides management. Delivery at 34 weeks is premature for this stage • C: Too conservative; misses FGR severity. Kick counts alone inadequate for moderate FGR • D: Inpatient monitoring reserved for AEDF/REDF; not indicated for elevated S/D with positive EDF • E: Growth in 4 weeks is appropriate, but surveillance is insufficient given abnormal Doppler High-Yield Takeaway: FGR with elevated UA S/D ratio but positive EDF → twice-weekly NST + weekly Dopplers; deliver by 37 weeks. Absent or reversed EDF requires more intensive monitoring and earlier delivery.', NULL, 'internal', 'active'),
  ('B3_cervical-insufficiency-cerclage-criteria', 'cervical-insufficiency-cerclage-criteria', 'Batch3', 'OB/GYN', 'A 30-year-old G3P0020 at 18 weeks presents for routine ultrasound. Her obstetric history includes two second- trimester losses at 19 and 21 weeks—both presented with painless cervical dilation. Current transvaginal ultrasound shows cervical length of 2.8 cm with closed internal os. She has had no contractions, bleeding, or ROM.

What is the most appropriate management?', '[{"label":"A","text":"Immediate cerclage placement based on obstetric history"},{"label":"B","text":"Serial cervical length monitoring; cerclage if length <25mm"},{"label":"C","text":"Vaginal progesterone supplementation only"},{"label":"D","text":"Reassurance; cervical length is normal"},{"label":"E","text":"Cerclage now plus vaginal progesterone"}]'::jsonb, 'B', 'Cerclage indications fall into three categories: Type Criteria Timing History-indicated ≥3 prior second-trimester losses OR prior preterm birth with cervical insufficiency 12–14 weeks (before cervical changes) Ultrasound-indicated Prior spontaneous PTB <34wk + current short cervix (<25mm) before 24wk When cervix shortens Rescue (physical exam– indicated) Dilated cervix with visible membranes Emergency This patient: • 2 prior second-trimester losses (classic cervical insufficiency history) • Does NOT meet history-indicated threshold (requires ≥3 losses or 1 loss with documented insufficiency) • Current cervix is 2.8 cm = normal length Management for patient with 1–2 prior losses suggestive of insufficiency but not meeting history-indicated criteria: • Serial transvaginal cervical length surveillance q2 weeks starting at 16 weeks • Ultrasound-indicated cerclage if cervix shortens to <25mm before 24 weeks • Vaginal progesterone if short cervix develops (can be used with or instead of cerclage) Why other options are wrong: • A: History-indicated cerclage requires ≥3 losses; this patient has 2 • C: Progesterone alone is reasonable for short cervix but cervix is currently normal; surveillance is priority • D: Given her history, she requires serial monitoring even with normal current length • E: No indication for cerclage with current cervical length of 28mm High-Yield Takeaway: History-indicated cerclage: ≥3 prior second-trimester losses. For 1–2 losses: serial cervical length monitoring with ultrasound-indicated cerclage if cervix shortens to <25mm before 24 weeks.', NULL, 'internal', 'active'),
  ('B3_hyperemesis-vs-molar-pregnancy', 'hyperemesis-vs-molar-pregnancy', 'Batch3', 'OB/GYN', 'A 28-year-old G1P0 at 10 weeks presents with severe nausea and vomiting for 3 weeks. She has lost 8% of pre- pregnancy weight and has 3+ ketonuria. Vitals: HR 108, BP 138/88. Labs show TSH 0.1 mIU/L, free T4 1.8 ng/dL (slightly elevated). She has not yet had an ultrasound.

What is the most appropriate next step?', '[{"label":"A","text":"Start methimazole for gestational hyperthyroidism"},{"label":"B","text":"Obtain pelvic ultrasound before further management"},{"label":"C","text":"Initiate IV fluids and antiemetics; discharge when tolerating oral intake"},{"label":"D","text":"Check serum hCG level to guide imaging decision"},{"label":"E","text":"Obtain TSH receptor antibodies to differentiate Graves disease"}]'::jsonb, 'B', 'Hyperemesis gravidarum with hyperthyroidism in the first trimester requires ruling out gestational trophoblastic disease (GTD), particularly complete molar pregnancy: Features suggesting molar pregnancy: • Hyperemesis — More severe than typical pregnancy (very high hCG) • Gestational hyperthyroidism — hCG cross-reacts with TSH receptor • Hypertension — Preeclampsia before 20 weeks (classic for molar pregnancy) • Uterine size > dates • Vaginal bleeding This patient has a concerning triad: 1. Severe hyperemesis (8% weight loss) 2. Hyperthyroidism (suppressed TSH, elevated T4) 3. Hypertension at 10 weeks — Should NOT occur in normal pregnancy this early Management priority: Pelvic ultrasound to evaluate for: • Viable intrauterine pregnancy • Molar pregnancy ("snowstorm" pattern, no fetal pole) • Size-dates discrepancy Gestational hyperthyroidism (from normal pregnancy) typically doesn''t require treatment—it resolves as hCG declines. But molar pregnancy requires suction evacuation and surveillance. Why other options are wrong: • A: Gestational hyperthyroidism doesn''t require antithyroid drugs; more importantly, must rule out molar pregnancy first • C: Supportive care is appropriate for hyperemesis but doesn''t address the concerning hypertension/hyperthyroidism combination • D: While very high hCG suggests molar pregnancy, ultrasound is the definitive diagnostic test • E: TSH receptor antibodies distinguish Graves from gestational hyperthyroidism, but the immediate concern is ruling out GTD High-Yield Takeaway: Hyperemesis + hyperthyroidism + early hypertension (before 20 weeks) = suspect molar pregnancy → obtain pelvic ultrasound immediately.', NULL, 'internal', 'active'),
  ('B3_abnormal-pap-colposcopy-timing', 'abnormal-pap-colposcopy-timing', 'Batch3', 'OB/GYN', 'A 32-year-old woman has a Pap smear showing atypical squamous cells of undetermined significance (ASC-US) with positive high-risk HPV co-testing. She had a normal Pap with negative HPV 3 years ago. She has no history of abnormal Paps or cervical procedures.

What is the most appropriate next step?', '[{"label":"A","text":"Repeat co-testing in 1 year"},{"label":"B","text":"Colposcopy"},{"label":"C","text":"Repeat cytology alone in 6 months"},{"label":"D","text":"HPV genotyping for types 16/18"},{"label":"E","text":"Repeat co-testing in 3 years"}]'::jsonb, 'B', 'Management of abnormal cervical cytology depends on the Pap result AND HPV status: Cytology HPV Status Management ASC-US HPV positive Colposcopy ASC-US HPV negative Repeat co-testing in 3 years ASC-US HPV unknown Reflex HPV testing or repeat cytology in 1 year LSIL Any Colposcopy (regardless of HPV) ASC-H Any Colposcopy HSIL Any Colposcopy (consider immediate LEEP) This patient: • ASC-US + HPV positive = Colposcopy indicated The combination of abnormal cytology and high-risk HPV significantly increases the risk of underlying CIN2+ compared to either finding alone. HPV 16/18 genotyping is used in some algorithms when Pap is normal with positive HPV, not for ASC-US/HPV+. Why other options are wrong: • A: One-year follow-up is for lower-risk scenarios (e.g., ASC-US with HPV unknown) • C: Cytology alone at 6 months was the old algorithm before HPV co-testing • D: Genotyping for 16/18 is used when cytology is negative but HPV is positive (to decide between 1-year repeat vs colposcopy) • E: Three-year repeat is for ASC-US with negative HPV (very low risk) High-Yield Takeaway: ASC-US + HPV positive = colposcopy. ASC-US + HPV negative = repeat co-testing in 3 years. LSIL or higher = colposcopy regardless of HPV status.', NULL, 'internal', 'active'),
  ('B3_endometriosis-medical-vs-surgical', 'endometriosis-medical-vs-surgical', 'Batch3', 'OB/GYN', 'A 29-year-old nulligravid woman presents with 2 years of progressive dysmenorrhea, deep dyspareunia, and dyschezia during menses. She is not currently trying to conceive but hopes to have children within 2–3 years. Pelvic exam reveals a fixed, retroverted uterus with nodularity in the posterior cul-de-sac. Transvaginal ultrasound shows a 3 cm left ovarian endometrioma.

What is the most appropriate management approach?', '[{"label":"A","text":"Combined oral contraceptives for symptom suppression"},{"label":"B","text":"GnRH agonist therapy for 6 months"},{"label":"C","text":"Diagnostic laparoscopy with excision of endometriosis"},{"label":"D","text":"Expectant management until she is ready to conceive"},{"label":"E","text":"Refer for in vitro fertilization"}]'::jsonb, 'C', 'Endometriosis management depends on symptom severity, fertility goals, and disease extent: Medical therapy indications: • Suspected endometriosis without endometrioma or deep infiltrating disease • Pain management when fertility not immediately desired • Post-surgical suppression Surgical therapy indications: • Endometrioma >3 cm — May impact ovarian reserve; cystectomy improves fertility and symptoms • Deep infiltrating endometriosis — Nodularity in cul-de-sac, rectovaginal involvement • Failed medical management • Definitive diagnosis needed • Fertility optimization — Surgery improves spontaneous conception rates in mild-moderate disease This patient: • Moderate-severe symptoms • Endometrioma (3 cm) • Deep infiltrating disease (cul-de-sac nodularity, dyschezia) • Desires future fertility Surgical excision is preferred because: 1. Endometrioma and deep disease respond poorly to medical therapy alone 2. Surgery improves fertility outcomes before conception attempts 3. Medical therapy only suppresses, doesn''t treat; symptoms recur after stopping Why other options are wrong: • A: COCs may help pain but don''t treat endometrioma or deep disease; delay definitive treatment • B: GnRH agonists cause hypoestrogenic side effects, don''t shrink endometriomas significantly, and symptoms recur after stopping • D: Disease progression may worsen fertility; proactive treatment indicated • E: IVF is for conception, not treatment of symptomatic endometriosis; she''s not trying to conceive yet High-Yield Takeaway: Endometrioma ≥3 cm or deep infiltrating endometriosis (especially with future fertility goals) → surgical excision. Medical therapy is for symptom suppression in mild disease or post-surgical maintenance.', NULL, 'internal', 'active'),
  ('B3_pcos-ovulation-induction-sequence', 'pcos-ovulation-induction-sequence', 'Batch3', 'OB/GYN', 'A 31-year-old woman with PCOS and BMI 27 presents with 14 months of infertility. She has 3–4 menses per year. Her partner''s semen analysis is normal. HSG shows patent tubes. She has tried lifestyle modifications for 6 months without achieving spontaneous ovulation.

What is the first-line pharmacologic agent for ovulation induction?', '[{"label":"A","text":"Clomiphene citrate"},{"label":"B","text":"Letrozole"},{"label":"C","text":"Metformin"},{"label":"D","text":"Gonadotropins (FSH injections)"},{"label":"E","text":"Combined oral contraceptives to regulate cycles first"}]'::jsonb, 'B', 'Ovulation induction in PCOS follows a stepwise approach: Line Agent Notes First Letrozole Superior live birth and ovulation rates vs clomiphene in PCOS (PPCOS II trial); lower multiple gestation risk Second Clomiphene Alternative first-line; anti-estrogen at hypothalamus → ↑ GnRH/FSH Third Gonadotropins For clomiphene/letrozole failures; higher multiple gestation and OHSS risk Third Laparoscopic ovarian drilling Alternative to gonadotropins Line Agent Notes Third IVF For failed ovulation induction or other factors Letrozole vs Clomiphene: • Letrozole: Aromatase inhibitor → ↓ estrogen → ↑ FSH; thinner endometrial lining is NOT an issue (unlike clomiphene); fewer multiples • Clomiphene: Anti-estrogen → blocks negative feedback → ↑ GnRH/FSH; can cause hostile cervical mucus and thin endometrium The landmark PPCOS II trial (2014) established letrozole as superior to clomiphene for PCOS ovulation induction: • Higher ovulation rate • Higher live birth rate (27.5% vs 19.1%) • Lower multiple gestation rate Why other options are wrong: • A: Clomiphene is an acceptable alternative but no longer first-line per current evidence • C: Metformin improves ovulation rates but is inferior to letrozole/clomiphene for conception; adjunctive role • D: Gonadotropins are second/third-line due to higher risk profile • E: OCPs regulate cycles but prevent pregnancy; not indicated when actively trying to conceive High-Yield Takeaway: First-line ovulation induction for PCOS = letrozole (PPCOS II trial). Clomiphene is second-line. Gonadotropins for refractory cases. Pediatrics', NULL, 'internal', 'active'),
  ('B3_febrile-seizure-recurrence-counseling', 'febrile-seizure-recurrence-counseling', 'Batch3', 'Pediatrics', 'A 20-month-old girl is brought to the ED after a 2-minute generalized tonic-clonic seizure during a febrile illness (T 39.2°C). She returned to baseline within 20 minutes. This is her second simple febrile seizure—her first occurred at 13 months. Neurologic exam is normal. Family history is notable for the patient''s mother having febrile seizures as a child.

What is the most appropriate counseling regarding seizure prophylaxis?', '[{"label":"A","text":"Start daily levetiracetam to prevent recurrence"},{"label":"B","text":"Prescribe rectal diazepam for use during future febrile illnesses"},{"label":"C","text":"Reassure that prophylaxis is not indicated for simple febrile seizures"},{"label":"D","text":"Start daily phenobarbital given recurrent seizures"},{"label":"E","text":"Obtain EEG before deciding on prophylaxis"}]'::jsonb, 'C', 'Simple febrile seizures are benign and do NOT require prophylactic antiepileptic medication, even with recurrence. Simple febrile seizure criteria: • Age 6 months to 5 years • Generalized seizure • Duration <15 minutes • Single seizure in 24 hours • Normal neurologic exam afterward • No prior afebrile seizures Key points for counseling: • Recurrence risk: ~30% after first seizure; higher with younger age, lower temperature at seizure, family history, short duration of fever before seizure • Epilepsy risk: NOT increased by simple febrile seizures (~1%, same as general population) • Prophylaxis: NOT recommended—AEDs have significant side effects (sedation, behavioral changes, hepatotoxicity) that outweigh benefit for a benign condition • Antipyretics: Do NOT prevent febrile seizures (fever is a marker, not the cause) Options for high-anxiety families (not standard of care): • Intermittent rectal or nasal diazepam at fever onset—reduces recurrence but has sedation risks; reserved for parental anxiety, not medical necessity Why other options are wrong: • A: Daily AEDs not indicated for simple febrile seizures regardless of recurrence • B: Intermittent diazepam is an option for parental anxiety but NOT standard recommendation; doesn''t change long-term outcome • D: Phenobarbital has significant cognitive/behavioral side effects; risks far outweigh benefits • E: EEG not indicated for simple febrile seizures; findings don''t change management and may cause unnecessary concern High-Yield Takeaway: Simple febrile seizures (even recurrent) do not require prophylaxis—reassure parents of benign prognosis. Daily AEDs and intermittent antipyretics do NOT prevent recurrence and carry risks exceeding benefits.', NULL, 'internal', 'active'),
  ('B3_failure-to-thrive-organic-vs-nonorganic', 'failure-to-thrive-organic-vs-nonorganic', 'Batch3', 'Pediatrics', 'A 10-month-old boy is evaluated for poor weight gain. His weight has dropped from the 25th percentile at 4 months to the 3rd percentile now, while length and head circumference remain at the 25th percentile. He was breastfed exclusively until 6 months, then started solids. Mother reports he is a "picky eater" and mealtimes are stressful. He has no vomiting, diarrhea, or respiratory symptoms. He reaches appropriately for food and has normal activity level. Physical exam is unremarkable except for decreased subcutaneous fat.

What is the most likely etiology of this patient''s failure to thrive?', '[{"label":"A","text":"Celiac disease"},{"label":"B","text":"Cystic fibrosis"},{"label":"C","text":"Inadequate caloric intake"},{"label":"D","text":"Growth hormone deficiency"},{"label":"E","text":"Congenital heart disease"}]'::jsonb, 'C', 'Failure to thrive (FTT) evaluation hinges on distinguishing organic from nonorganic (psychosocial/nutritional) causes: Pattern recognition: Feature Organic FTT Nonorganic FTT Weight, length, HC All affected (or length/HC first) Weight affected first, length/HC preserved Symptoms Vomiting, diarrhea, respiratory, dysmorphism Usually absent Feeding behavior May have oral aversion, dysphagia Chaotic mealtimes, food refusal Activity May be decreased Normal Catch-up with adequate calories May not catch up Rapid catch-up This patient: • Weight declined while length/HC preserved → classic for inadequate intake • No GI symptoms (argues against celiac, CF) • Normal activity and development • Stressful mealtimes, "picky eater" → feeding behavior issues • Transition from breastfeeding to solids at 6 months correlates with weight decline Management of suspected inadequate intake: 1. Detailed feeding history (volume, frequency, preparation of formula, introduction of solids) 2. Observed feeding session 3. Caloric prescription and close follow-up 4. If rapid catch-up with adequate calories → confirms diagnosis Why other options are wrong: • A: Celiac causes diarrhea, abdominal distension; typically presents after gluten introduction with malabsorption symptoms • B: CF causes malabsorption with steatorrhea, respiratory symptoms; this child has neither • D: GH deficiency affects length primarily, with relatively preserved weight; opposite pattern • E: CHD causes poor feeding with diaphoresis, tachypnea, hepatomegaly; exam is unremarkable High-Yield Takeaway: FTT with weight loss but preserved length/head circumference and no organic symptoms = inadequate caloric intake until proven otherwise. Detailed feeding history and observed feeding are diagnostic.', NULL, 'internal', 'active'),
  ('B3_developmental-delay-tiered-workup', 'developmental-delay-tiered-workup', 'Batch3', 'Pediatrics', 'An 18-month-old boy is evaluated for developmental concerns. He is not yet walking independently (pulls to stand), has no words (babbles), and does not point to request or show objects. He has no dysmorphic features. He was born at term with uncomplicated delivery. Hearing screen at birth was passed. There is no family history of developmental disorders. Physical exam including head circumference is normal.

What is the most appropriate initial diagnostic test?', '[{"label":"A","text":"Brain MRI"},{"label":"B","text":"Chromosomal microarray"},{"label":"C","text":"Fragile X testing"},{"label":"D","text":"Metabolic panel including lactate, ammonia, and urine organic acids"},{"label":"E","text":"Electroencephalogram"}]'::jsonb, 'B', 'Global developmental delay (GDD) evaluation follows a tiered approach based on diagnostic yield: Definition of GDD: Significant delay (<2 SD) in ≥2 developmental domains in child <5 years Tiered workup: Tier Test Yield When to Order 1 Chromosomal microarray (CMA) 15–20% First-line for unexplained GDD 1 Fragile X (males) 2–3% First-line for males with GDD 2 Brain MRI 30% abnormal, but rarely changes management if CMA/FX negative Abnormal neuro exam, microcephaly, regression, seizures 2 Metabolic studies <1% in non-syndromic GDD Regression, episodic symptoms, consanguinity, organomegaly 3 Whole exome sequencing Variable After CMA/FX negative This patient: • Global developmental delay (motor, language, social) • No dysmorphic features, normal exam • No regression or episodic symptoms Chromosomal microarray is first-line because: • Highest diagnostic yield (~15–20%) for unexplained GDD • Detects copy number variants (deletions, duplications) missed by karyotype • Non-invasive (blood test) • Results guide prognosis and recurrence risk counseling Why other options are wrong: • A: MRI often abnormal but rarely diagnostic in non-syndromic GDD without focal findings; pursue after genetic testing • C: Fragile X testing appropriate for males but CMA should be sent simultaneously as it has higher overall yield • D: Metabolic workup has very low yield (<1%) without red flags (regression, consanguinity, organomegaly, acidosis) • E: EEG indicated for seizures or regression (Landau-Kleffner); not routine for GDD High-Yield Takeaway: Unexplained global developmental delay → chromosomal microarray first (15–20% yield). Add Fragile X testing for males. MRI and metabolic studies are second-tier for those with additional red flags.', NULL, 'internal', 'active'),
  ('B3_jia-dmard-initiation', 'jia-dmard-initiation', 'Batch3', 'Pediatrics', 'A 7-year-old girl with oligoarticular juvenile idiopathic arthritis affecting her left knee has been treated with naproxen and intra-articular corticosteroid injection 8 weeks ago. Despite initial improvement, she now has recurrent swelling and stiffness in the same knee with limited range of motion. Ophthalmologic exam is normal.

What is the most appropriate next step in management?', '[{"label":"A","text":"Repeat intra-articular corticosteroid injection"},{"label":"B","text":"Switch to a different NSAID"},{"label":"C","text":"Initiate methotrexate"},{"label":"D","text":"Initiate etanercept (TNF inhibitor)"},{"label":"E","text":"Refer for synovectomy"}]'::jsonb, 'C', 'JIA treatment follows a stepwise approach based on disease subtype and response: Oligoarticular JIA (≤4 joints): Step Therapy 1 NSAIDs + intra-articular corticosteroid (first-line) 2 DMARD (methotrexate) if inadequate response to above 3 Biologic (TNF inhibitor) if DMARD failure Indications to escalate to methotrexate: • Inadequate response to 2 months of NSAIDs • Recurrence after intra-articular injection • Functional limitation • High-risk features (uveitis risk, extended oligoarticular disease) This patient: • Failed NSAID + intra-articular steroid • Recurrent synovitis at 8 weeks (beyond typical 4–6 week response window) • Functional impairment (limited ROM) Methotrexate is the first DMARD used in JIA because: • Extensive efficacy and safety data in children • Weekly dosing (oral or subcutaneous) • Also protects against uveitis (important in oligoarticular JIA) Why other options are wrong: • A: Repeated injections into same joint without systemic therapy risks cartilage damage and is temporizing • B: NSAID switching rarely effective if first NSAID failed; doesn''t address disease-modifying need • D: Biologics are reserved for DMARD failures; must trial methotrexate first per guidelines • E: Synovectomy is rarely indicated in modern era of effective medical therapy High-Yield Takeaway: JIA with inadequate response to NSAIDs + intra-articular steroids → initiate methotrexate. Biologics (TNF inhibitors) are second-line after DMARD failure.', NULL, 'internal', 'active'),
  ('B3_adolescent-scoliosis-brace-vs-observe', 'adolescent-scoliosis-brace-vs-observe', 'Batch3', 'Pediatrics', 'A 12-year-old girl is evaluated for scoliosis noted on school screening. She has no back pain. She had menarche 6 months ago. Spine radiograph shows a 28-degree right thoracic curve. Risser sign is 1.

What is the most appropriate management?', '[{"label":"A","text":"Observation with repeat imaging in 6–12 months"},{"label":"B","text":"Full-time bracing (23 hours/day)"},{"label":"C","text":"Physical therapy and core strengthening"},{"label":"D","text":"Referral for surgical consultation"},{"label":"E","text":"Nighttime-only bracing"}]'::jsonb, 'B', 'Adolescent idiopathic scoliosis (AIS) management depends on curve magnitude and skeletal maturity: Skeletal maturity indicators: • Risser sign: 0–1 = immature (significant growth remaining); 4–5 = mature • Menarche: Growth typically continues 2 years post-menarche • Triradiate cartilage: Open = immature Management algorithm: Curve Risser 0–2 (Immature) Risser 3+ (Mature) <25° Observe q4-6 months Observe annually 25–40° Brace (18–23 hr/day) Observe >40–50° Surgical evaluation Observe or surgery if progressing This patient: • 28° curve (within bracing range 25–40°) • Risser 1 (immature, significant growth remaining) • 6 months post-menarche (1.5 years of growth remaining) Bracing efficacy (BrAIST trial): • Full-time bracing (average 18+ hours/day) significantly reduces progression to surgical threshold • Number needed to treat = 3 Why other options are wrong: • A: Observation alone inappropriate for skeletally immature patient with curve in bracing range—high progression risk • C: Physical therapy does not prevent curve progression; may improve symptoms but not curvature • D: Surgical threshold typically >45–50°; this curve doesn''t meet criteria • E: Nighttime-only bracing less effective; full-time recommended for curves approaching 30° High-Yield Takeaway: AIS + Cobb angle 25–40° + Risser 0–2 (immature) = full-time bracing. Observation for curves <25° or skeletally mature patients. Surgery for curves >45–50°.', NULL, 'internal', 'active'),
  ('B3_pediatric-uti-vcug-indications', 'pediatric-uti-vcug-indications', 'Batch3', 'Pediatrics', 'A 3-year-old girl presents with her first febrile UTI. Urine culture grows >100,000 CFU/mL of E. coli. She is treated with oral antibiotics with clinical improvement. Renal bladder ultrasound shows normal kidneys bilaterally with no hydronephrosis or bladder abnormalities.

What is the most appropriate next step regarding imaging?', '[{"label":"A","text":"Voiding cystourethrogram (VCUG) to evaluate for vesicoureteral reflux"},{"label":"B","text":"DMSA renal scan to assess for scarring"},{"label":"C","text":"No additional imaging indicated"},{"label":"D","text":"Repeat renal ultrasound in 6 months"},{"label":"E","text":"CT urogram for detailed anatomical evaluation"}]'::jsonb, 'C', 'Pediatric UTI imaging strategy has evolved to reduce unnecessary invasive testing (AAP 2011, reaffirmed): After first febrile UTI (age 2–24 months): • Renal bladder ultrasound (RBUS): Recommended for ALL children with first febrile UTI • VCUG: NOT routine for first febrile UTI if RBUS is normal VCUG indications after first UTI: • Abnormal RBUS (hydronephrosis, scarring, other anomalies) • Recurrent febrile UTI • Atypical UTI course (poor response to appropriate antibiotics, unusual organism) • Family history of high-grade VUR • Clinical concern for posterior urethral valves (males with poor stream) This patient: • First febrile UTI • Normal RBUS • Good clinical response • No atypical features VUR is common (30–40% of children with UTI) but: • Most cases are low-grade and resolve spontaneously • Antibiotic prophylaxis for low-grade VUR has questionable benefit • VCUG is invasive (catheterization, radiation) The "top-down" approach: RBUS screens for significant anomalies; VCUG reserved for those with abnormalities or recurrence. Why other options are wrong: • A: VCUG not indicated with normal ultrasound after first UTI—exposes child to catheterization and radiation without clear benefit • B: DMSA indicated if concern for scarring (recurrent UTI, atypical course); not routine after first UTI with normal ultrasound • D: Repeat ultrasound not needed if initial study was normal and child responded well • E: CT exposes child to significant radiation; never first-line in pediatrics High-Yield Takeaway: First febrile UTI + normal renal ultrasound = no VCUG needed. VCUG indicated for abnormal ultrasound, recurrent UTI, or atypical course. Surgery', NULL, 'internal', 'active'),
  ('B3_post-cholecystectomy-bile-leak-management', 'post-cholecystectomy-bile-leak-management', 'Batch3', 'Surgery', 'A 48-year-old woman is post-operative day 3 after laparoscopic cholecystectomy for acute cholecystitis. She develops worsening right upper quadrant pain, fever to 38.4°C, and nausea. Her drain (placed intraoperatively due to inflamed gallbladder bed) output has increased to 200 mL of bilious fluid over 24 hours. Labs show WBC 14,000 and total bilirubin 2.8 mg/dL.

What is the most appropriate next step in management?', '[{"label":"A","text":"Return to operating room for exploratory laparotomy"},{"label":"B","text":"ERCP with sphincterotomy and possible stent placement"},{"label":"C","text":"CT abdomen with IV contrast"},{"label":"D","text":"Remove drain and observe"},{"label":"E","text":"HIDA scan to confirm bile leak"}]'::jsonb, 'B', 'Post-cholecystectomy bile leak is a recognized complication occurring in 0.3–0.5% of cases. Management depends on leak source and severity: Bile leak sources: • Cystic duct stump — Most common; usually low-grade • Duct of Luschka — Small duct from liver bed • Common bile duct injury — Most severe; requires surgical repair Management algorithm: Scenario Management Controlled leak with drain in place ERCP with sphincterotomy ± stent (first-line) Uncontrolled leak / biloma without drain CT-guided drainage + ERCP Major CBD injury (transection/ligation) Surgical repair (hepaticojejunostomy) Why ERCP is first-line for most bile leaks: 1. Sphincterotomy reduces sphincter of Oddi pressure, redirecting bile flow to duodenum 2. Stent placement further reduces pressure gradient across the leak 3. 90% of cystic duct/duct of Luschka leaks resolve with ERCP alone 4. Also diagnostic—cholangiogram identifies leak site and any CBD injury This patient: • Controlled leak (drain in place with bilious output) • Low-grade leak (200 mL/day) • No signs of peritonitis Why other options are wrong: • A: Surgery reserved for major CBD injury or failed ERCP; too aggressive for controlled low-grade leak • C: CT may be helpful if drain not in place (to identify biloma) but won''t change management here—ERCP is both diagnostic and therapeutic • D: Removing drain would lead to biloma formation; drain is protective • E: HIDA confirms bile leak but doesn''t treat it; ERCP is both diagnostic and therapeutic High-Yield Takeaway: Post-cholecystectomy bile leak (controlled) → ERCP with sphincterotomy ± stent (>90% success rate). Maintain drain in place. Surgery only for major CBD injury or ERCP failure.', NULL, 'internal', 'active'),
  ('B3_anastomotic-leak-early-vs-late', 'anastomotic-leak-early-vs-late', 'Batch3', 'Surgery', 'A 62-year-old man underwent low anterior resection for rectal cancer 12 days ago. He was progressing well until today when he developed fever (38.6°C), tachycardia, and diffuse abdominal tenderness with guarding. CT abdomen/pelvis shows extraluminal air and fluid collection adjacent to the colorectal anastomosis with free fluid in the pelvis.

What is the most appropriate management?', '[{"label":"A","text":"Broad-spectrum antibiotics and observation"},{"label":"B","text":"CT-guided percutaneous drainage"},{"label":"C","text":"Operative intervention with likely fecal diversion"},{"label":"D","text":"Endoscopic stent placement across the anastomosis"},{"label":"E","text":"Total parenteral nutrition and bowel rest for 2 weeks"}]'::jsonb, 'C', 'Anastomotic leak management depends on timing, patient stability, and leak characteristics: Leak classification: Timing Characteristics Management Early (<7 days) Often technical failure; fresh tissues allow primary repair Reoperation: revision of anastomosis or diversion Timing Characteristics Management Late (7–14 days) Tissues friable; primary repair usually not possible Diversion (stoma) ± drainage; avoid anastomotic revision Contained leak No peritonitis, walled-off collection Percutaneous drainage + antibiotics Uncontained leak Peritonitis, sepsis, free spillage Operative intervention This patient: • Post-operative day 12 (late leak) • Peritonitis (diffuse tenderness, guarding) • Free fluid in pelvis (uncontained) • CT shows extraluminal air at anastomosis Surgical approach for late uncontained leak: 1. Exploratory laparotomy 2. Washout of peritoneal cavity 3. Fecal diversion (end colostomy, Hartmann procedure, or proximal diverting loop ileostomy) 4. ± Drain placement 5. Leave anastomosis alone (tissues too friable for repair) Why other options are wrong: • A: Peritonitis requires source control; antibiotics alone inadequate • B: Percutaneous drainage appropriate for contained collections without peritonitis; this leak is uncontained with peritonitis • D: Endoscopic stenting used for small, contained leaks; cannot address peritonitis • E: NPO and TPN supportive but doesn''t address sepsis/peritonitis requiring source control High-Yield Takeaway: Anastomotic leak with peritonitis = operative intervention with fecal diversion. Late leaks (>7 days) preclude primary repair—divert proximally and allow to heal.', NULL, 'internal', 'active'),
  ('B3_incisional-hernia-mesh-timing', 'incisional-hernia-mesh-timing', 'Batch3', 'Surgery', 'A 55-year-old man presents with a 6-cm reducible incisional hernia at his midline laparotomy scar from colectomy 2 years ago. The surgery was for perforated diverticulitis with gross fecal contamination. His BMI is 32. He is otherwise healthy with no current infection.

What is the most appropriate repair approach?', '[{"label":"A","text":"Primary suture repair without mesh"},{"label":"B","text":"Repair with synthetic mesh (polypropylene)"},{"label":"C","text":"Repair with biologic mesh"},{"label":"D","text":"Watchful waiting given contamination history"},{"label":"E","text":"Preoperative weight loss then synthetic mesh repair"}]'::jsonb, 'B', 'Incisional hernia repair considerations: Primary suture vs mesh: • Primary suture: Recurrence rate 30–50% • Mesh repair: Recurrence rate 10–15% • Recommendation: Mesh repair for all incisional hernias >2 cm Mesh selection based on wound classification: Wound Class Contamination Mesh Type Clean (Class I) None Synthetic mesh (polypropylene) Clean-contaminated (Class II) GI opened without spillage Synthetic (caution) or biologic Contaminated (Class III) Gross spillage, fresh trauma Biologic preferred Dirty (Class IV) Purulence, fecal contamination Biologic or delayed repair Key point: The wound classification at the TIME OF HERNIA REPAIR determines mesh choice, not the classification at original surgery. This patient: • Current presentation: Clean (Class I) — no infection, no contamination • History of contaminated surgery is irrelevant to current repair • 6-cm hernia → requires mesh (too large for primary repair) • Clean field → synthetic mesh appropriate Synthetic mesh is preferred in clean fields due to: • Lower cost • Better long-term durability • Equivalent infection rates to biologic in clean fields Why other options are wrong: • A: Primary repair has unacceptable recurrence rate for 6-cm hernia • C: Biologic mesh reserved for contaminated/infected fields; more expensive, less durable • D: Watchful waiting risks incarceration, enlargement; repair recommended for symptomatic hernias • E: While weight loss may reduce recurrence, no absolute BMI cutoff for repair; surgery shouldn''t be indefinitely delayed High-Yield Takeaway: Incisional hernia mesh selection depends on contamination at time of REPAIR, not original surgery. Clean field → synthetic mesh. Contaminated/infected → biologic mesh.', NULL, 'internal', 'active'),
  ('B3_postoperative-ileus-vs-sbo', 'postoperative-ileus-vs-sbo', 'Batch3', 'Surgery', 'A 67-year-old woman underwent open sigmoid colectomy for colon cancer 5 days ago. She had return of bowel function (flatus) on post-operative day 3 and was tolerating a regular diet until this morning when she developed nausea, vomiting, and abdominal distension. She reports intermittent crampy abdominal pain. Exam shows distended abdomen with high-pitched bowel sounds. She passed flatus this morning.

What is the most likely diagnosis?', '[{"label":"A","text":"Prolonged postoperative ileus"},{"label":"B","text":"Anastomotic leak"},{"label":"C","text":"Early postoperative small bowel obstruction"},{"label":"D","text":"Ogilvie syndrome (colonic pseudo-obstruction)"},{"label":"E","text":"Clostridium difficile colitis"}]'::jsonb, 'C', 'Distinguishing ileus from early postoperative SBO is crucial: Feature Postoperative Ileus Early SBO Timing POD 0–3; no prior return of function After initial return of function Pain Mild, constant discomfort Crampy, intermittent Bowel sounds Absent or hypoactive High-pitched, hyperactive Passage of flatus Absent May be present (partial) Course Gradually improves Worsens without intervention This patient: • Initial return of function (flatus POD 3, tolerating diet) — ileus had resolved • New symptoms after resolution — concerning for mechanical obstruction • Crampy pain — suggests peristalsis against obstruction • High-pitched bowel sounds — classic for SBO • Continued flatus — partial obstruction Early postoperative SBO (within 30 days): • Occurs in ~1% of abdominal surgeries • Causes: adhesions (most common), internal hernia, kinking at anastomosis • Management: NGT decompression, CT to evaluate; most resolve non-operatively initially Why other options are wrong: • A: Ileus doesn''t present with crampy pain and hyperactive bowel sounds; typically no return of function • B: Anastomotic leak presents with fever, peritonitis, tachycardia; not typically obstructive symptoms • D: Ogilvie syndrome affects colon (massive colonic dilation); presents with distension but not crampy pain or high-pitched sounds • E: C. diff presents with watery diarrhea, fever, leukocytosis; not obstruction pattern High-Yield Takeaway: Crampy pain + high-pitched bowel sounds + symptoms AFTER initial return of bowel function = early postoperative SBO, not prolonged ileus. Ileus has absent/hypoactive sounds and no prior return of function.', NULL, 'internal', 'active'),
  ('B3_thyroidectomy-hypocalcemia-management', 'thyroidectomy-hypocalcemia-management', 'Batch3', 'Surgery', 'A 45-year-old woman is post-operative day 1 after total thyroidectomy for papillary thyroid carcinoma. She reports perioral tingling and finger numbness. Labs show calcium 7.6 mg/dL and intact PTH 8 pg/mL (normal 15–65). She has no prior calcium supplementation.

What is the most appropriate management?', '[{"label":"A","text":"Oral calcium carbonate 500mg three times daily"},{"label":"B","text":"Oral calcium carbonate plus calcitriol"},{"label":"C","text":"IV calcium gluconate bolus followed by oral calcium"},{"label":"D","text":"Observation with repeat calcium in 6 hours"},{"label":"E","text":"Magnesium replacement before calcium supplementation"}]'::jsonb, 'B', 'Post-thyroidectomy hypocalcemia results from parathyroid injury (transient stunning or inadvertent removal): Severity assessment: • Mild: Asymptomatic or perioral paresthesias; Ca 7.5–8.0 mg/dL • Moderate: Symptomatic paresthesias; Ca 7.0–7.5 mg/dL • Severe: Carpopedal spasm, tetany, arrhythmia; Ca <7.0 mg/dL Management by severity: Severity Management Symptomatic (any level) Oral calcium + calcitriol Severe (Ca <7.0 or severe symptoms) IV calcium gluconate → oral calcium + calcitriol Asymptomatic Oral calcium alone may suffice Why calcitriol (1,25-OH vitamin D)? • PTH normally stimulates 1α-hydroxylase to convert 25-OH vitamin D → active 1,25-OH vitamin D • With low PTH, this conversion is impaired • Calcitriol provides the active form, allowing calcium absorption • Without calcitriol, oral calcium alone is poorly absorbed This patient: • Symptomatic (paresthesias) • Low PTH (8 pg/mL) — confirms hypoparathyroidism • Moderate hypocalcemia (7.6 mg/dL) Why other options are wrong: • A: Calcium alone insufficient when PTH is low—needs calcitriol for adequate absorption • C: IV calcium reserved for severe/life-threatening symptoms (tetany, seizure, arrhythmia); this patient has mild symptoms • D: Patient is symptomatic—requires treatment, not observation • E: Magnesium should be checked but hypomagnesemia is not the likely cause post-thyroidectomy; parathyroid injury is High-Yield Takeaway: Post-thyroidectomy hypocalcemia with low PTH = oral calcium PLUS calcitriol (active vitamin D). Calcitriol compensates for impaired 1α-hydroxylation due to PTH deficiency.', NULL, 'internal', 'active'),
  ('B3_breast-conserving-vs-mastectomy-criteria', 'breast-conserving-vs-mastectomy-criteria', 'Batch3', 'Surgery', 'A 52-year-old woman has a newly diagnosed 2.5-cm invasive ductal carcinoma in the upper outer quadrant of her right breast. MRI shows a second suspicious 1.5-cm lesion in the lower inner quadrant of the same breast, confirmed as invasive carcinoma on biopsy. The lesions are 7 cm apart. She has C-cup breasts and strongly desires breast conservation if oncologically appropriate.

What is the most appropriate surgical recommendation?', '[{"label":"A","text":"Lumpectomy of both lesions with radiation"},{"label":"B","text":"Neoadjuvant chemotherapy followed by reassessment"},{"label":"C","text":"Mastectomy"},{"label":"D","text":"Oncoplastic lumpectomy with bilateral reduction mammoplasty"},{"label":"E","text":"Lumpectomy of larger lesion only"}]'::jsonb, 'C', 'Breast-conserving surgery (BCS) vs mastectomy decision depends on several factors: Contraindications to breast-conserving surgery: Factor Rationale Multicentric disease Tumors in different quadrants (>5 cm apart) Large tumor-to-breast ratio Cannot achieve negative margins with acceptable cosmesis Inability to achieve negative margins After reasonable re-excisions Prior breast radiation Cannot reirradiate Inflammatory breast cancer Requires mastectomy Diffuse suspicious microcalcifications Suggests extensive DCIS Pregnancy (relative) Radiation contraindicated; can delay if late pregnancy This patient: • Two invasive carcinomas in different quadrants (upper outer + lower inner) • 7 cm apart = multicentric disease • Multicentric disease = contraindication to BCS Why multicentric disease requires mastectomy: • BCS requires single surgical field with radiation to tumor bed • Multiple widely separated tumors cannot be encompassed by standard BCS + radiation • Higher local recurrence rates with BCS for multicentric disease Why other options are wrong: • A: Multiple lumpectomies for multicentric disease associated with high local recurrence; not standard of care • B: Neoadjuvant chemotherapy may shrink tumors but doesn''t change multicentric anatomy; still requires mastectomy • D: Oncoplastic techniques don''t overcome multicentricity; still separate tumor beds • E: Leaving untreated cancer is not appropriate High-Yield Takeaway: Multicentric breast cancer (tumors in different quadrants >5 cm apart) is a contraindication to breast-conserving surgery → mastectomy required. Multifocal (same quadrant) may still permit BCS.', NULL, 'internal', 'active'),
  ('B3_acute-limb-ischemia-revascularization-timing', 'acute-limb-ischemia-revascularization-timing', 'Batch3', 'Surgery', 'A 68-year-old man with atrial fibrillation (non-adherent with anticoagulation) presents with acute onset of severe left leg pain and numbness 4 hours ago. Exam shows a cold, pale leg with no palpable pulses below the femoral artery. The foot is mottled. He has minimal motor function (cannot wiggle toes) and absent sensation below the ankle.

What is the most appropriate management?', '[{"label":"A","text":"Systemic anticoagulation and vascular surgery consultation within 24 hours"},{"label":"B","text":"Immediate thrombolysis via catheter-directed approach"},{"label":"C","text":"Emergent surgical embolectomy"},{"label":"D","text":"CT angiography to localize obstruction before treatment"},{"label":"E","text":"Amputation given the severity of ischemia"}]'::jsonb, 'C', 'Acute limb ischemia (ALI) classification guides management urgency: Rutherford Classification: Class Motor Sensory Doppler Viability Management I Intact Intact Audible Viable Anticoagulation; elective revascularization IIA Intact Mild loss Inaudible Marginally threatened Urgent revascularization (within hours) IIB Mild-moderate loss More than toes Inaudible Immediately threatened Emergent revascularization III Profound paralysis Anesthetic None Irreversible Amputation This patient: • 4-hour duration • Motor loss (cannot wiggle toes) • Sensory loss to ankle • Mottled foot = Rutherford IIB (immediately threatened limb) Treatment for Class IIB: • Emergent revascularization — surgical embolectomy preferred for embolic etiology (AFib source) • Time is muscle — delays lead to irreversible damage and progression to Class III • Heparin anticoagulation should be given immediately while preparing for OR Embolectomy vs thrombolysis: • Embolectomy: Preferred for IIB, embolic source, <14 days duration; faster • Thrombolysis: Better for thrombotic occlusion of native vessel/graft; Class I–IIA; requires 12–24 hours to work Why other options are wrong: • A: Class IIB requires emergent intervention, not next-day consultation • B: Thrombolysis too slow for immediately threatened limb; risk of irreversible damage during infusion • D: Imaging delays revascularization; clinical exam sufficient to diagnose ALI and proceed • E: Limb is still potentially salvageable (motor function present, <6 hours); amputation only for Class III High-Yield Takeaway: Acute limb ischemia with motor deficit (Rutherford IIB) = emergent surgical revascularization. Thrombolysis is too slow for immediately threatened limbs. Class III (profound paralysis, anesthesia, rigor) = amputation. Psychiatry', NULL, 'internal', 'active'),
  ('B3_treatment-resistant-depression-augmentation', 'treatment-resistant-depression-augmentation', 'Batch3', 'Psychiatry', 'A 48-year-old woman with major depressive disorder has failed adequate trials of sertraline (200mg x 10 weeks) and venlafaxine (225mg x 8 weeks) with minimal improvement. She has no history of mania, psychosis, or substance use. She asks about options beyond switching to another antidepressant.

Which augmentation strategy has the strongest evidence for treatment-resistant depression?', '[{"label":"A","text":"Add lithium"},{"label":"B","text":"Add buspirone"},{"label":"C","text":"Add modafinil"},{"label":"D","text":"Add atypical antipsychotic (aripiprazole)"},{"label":"E","text":"Add thyroid hormone (T3)"}]'::jsonb, 'D', 'Treatment-resistant depression (TRD) is defined as failure of ≥2 adequate antidepressant trials. Options include: Evidence-based augmentation strategies: Agent Evidence Level Notes Atypical antipsychotics Strongest (FDA-approved) Aripiprazole, quetiapine, olanzapine/fluoxetine Lithium Strong (older studies) Requires monitoring; smaller effect in modern trials Thyroid hormone (T3) Moderate 25–50 mcg; better for T3 than T4 Bupropion Moderate Combination rather than augmentation Buspirone Weak-moderate Less robust data Atypical antipsychotics are currently first-line for TRD augmentation because: • FDA-approved: Aripiprazole (Abilify), quetiapine XR (Seroquel XR), olanzapine/fluoxetine (Symbyax), brexpiprazole (Rexulti) • Consistent efficacy in large RCTs • Aripiprazole has favorable metabolic profile among atypicals Lithium augmentation: • Well-established in older literature • Modern meta-analyses show smaller effect sizes than initially reported • Requires level monitoring, renal/thyroid function checks • Reserved for patients who also need mood stabilization or have suicidality (lithium reduces suicide risk) Why other options are wrong: • A: Lithium has evidence but is no longer first-line given monitoring burden and smaller modern effect sizes • B: Buspirone augmentation has weaker evidence than atypicals • C: Modafinil may help fatigue/concentration but limited antidepressant augmentation data • E: T3 augmentation has moderate evidence but atypicals have stronger, more consistent data High-Yield Takeaway: Treatment-resistant depression augmentation: first-line = atypical antipsychotic (aripiprazole or quetiapine). Lithium and T3 are alternatives with moderate evidence.', NULL, 'internal', 'active'),
  ('B3_antipsychotic-switch-vs-clozapine', 'antipsychotic-switch-vs-clozapine', 'Batch3', 'Psychiatry', 'A 32-year-old man with schizophrenia has persistent auditory hallucinations and disorganized thinking despite adequate trials of risperidone (6mg x 8 weeks), olanzapine (20mg x 10 weeks), and aripiprazole (30mg x 8 weeks) with confirmed adherence. He has no history of seizures. His symptoms significantly impair his daily functioning.

What is the most appropriate next step in management?', '[{"label":"A","text":"Add a second antipsychotic to current regimen"},{"label":"B","text":"Initiate clozapine"},{"label":"C","text":"Trial another atypical antipsychotic (ziprasidone)"},{"label":"D","text":"Add valproate for mood stabilization"},{"label":"E","text":"Initiate long-acting injectable antipsychotic"}]'::jsonb, 'B', 'Treatment-resistant schizophrenia (TRS) is defined as failure of ≥2 adequate antipsychotic trials (including at least one atypical). Clozapine is the ONLY antipsychotic with proven efficacy for TRS: Feature Clozapine Indication Treatment-resistant schizophrenia (failed ≥2 antipsychotics) Efficacy 30–60% response rate in TRS (no other agent approaches this) Unique benefits Reduces suicidality in schizophrenia (FDA indication); may reduce violence Monitoring requirement Weekly → biweekly → monthly ANC due to agranulocytosis risk (1%) Other side effects Metabolic syndrome, seizures (dose-related), myocarditis, constipation/ileus This patient: • Failed 3 adequate antipsychotic trials with documented adherence • Meets definition of TRS • No seizure history (would require extra caution but not contraindication) Key point: There is no evidence that switching between non-clozapine antipsychotics improves outcomes after 2 failures. Clozapine has unique efficacy that other antipsychotics lack. Why other options are wrong: • A: Antipsychotic polypharmacy lacks evidence; adds side effects without proven benefit • C: Fourth trial of non-clozapine antipsychotic delays effective treatment; low likelihood of response • D: Valproate augmentation has minimal evidence in schizophrenia without mood component • E: LAI improves adherence but this patient has confirmed adherence; efficacy still limited by TRS High-Yield Takeaway: Treatment-resistant schizophrenia (failed ≥2 antipsychotic trials) → clozapine is the only evidence-based option. Do not delay with additional non-clozapine trials. Requires ANC monitoring for agranulocytosis.', NULL, 'internal', 'active'),
  ('B3_bipolar-depression-agent-choice', 'bipolar-depression-agent-choice', 'Batch3', 'Psychiatry', 'A 38-year-old woman with bipolar I disorder presents with a 3-week depressive episode characterized by hypersomnia, low energy, anhedonia, and passive suicidal ideation. Her last manic episode was 2 years ago on no medications; she has been stable on lithium (level 0.8 mEq/L) since then. She has no history of rapid cycling.

What is the most appropriate pharmacologic addition for her depressive episode?', '[{"label":"A","text":"Sertraline"},{"label":"B","text":"Quetiapine"},{"label":"C","text":"Lamotrigine"},{"label":"D","text":"Aripiprazole"},{"label":"E","text":"Bupropion"}]'::jsonb, 'B', 'Bipolar depression treatment differs fundamentally from unipolar depression: FDA-approved for bipolar depression: 1. Quetiapine (monotherapy) 2. Lurasidone (monotherapy or adjunct to lithium/valproate) 3. Olanzapine-fluoxetine combination (Symbyax) 4. Cariprazine (monotherapy) Treatment hierarchy for bipolar depression: Agent Role Notes Quetiapine First-line Strong evidence; sedating (good for insomnia); metabolic effects Lurasidone First-line Strong evidence; less sedating; take with food Lamotrigine Preventive/adjunct Better at preventing than treating acute depression; slow titration required Antidepressants Controversial Risk of switch to mania; avoid monotherapy; may consider with mood stabilizer This patient: • Acute bipolar depressive episode • Already on lithium (mood stabilizer in place) • Needs acute treatment for depression Quetiapine (or lurasidone) added to lithium is evidence-based for acute bipolar depression. Why other options are wrong: • A: SSRIs risk manic switch; controversial even as adjunct; not first-line • C: Lamotrigine requires 6-week titration (risk of SJS with rapid increase); better for maintenance than acute treatment • D: Aripiprazole is FDA-approved for bipolar mania and maintenance, not depression • E: Bupropion has lowest switch risk among antidepressants but is not FDA-approved and lacks strong evidence for bipolar depression High-Yield Takeaway: Acute bipolar depression → quetiapine or lurasidone (FDA-approved). Lamotrigine is for maintenance/prevention. Avoid antidepressant monotherapy due to switch risk.', NULL, 'internal', 'active'),
  ('B3_benzodiazepine-taper-protocol', 'benzodiazepine-taper-protocol', 'Batch3', 'Psychiatry', 'A 62-year-old woman has been taking alprazolam 1mg three times daily for generalized anxiety disorder for 8 years, prescribed by her previous physician. She wants to discontinue due to cognitive concerns. She has no history of seizures or complicated withdrawal.

What is the most appropriate tapering approach?', '[{"label":"A","text":"Discontinue alprazolam and start buspirone for anxiety coverage"},{"label":"B","text":"Reduce alprazolam dose by 25% every 2 weeks until discontinued"},{"label":"C","text":"Convert to equivalent dose of long-acting benzodiazepine, then taper gradually over months"},{"label":"D","text":"Reduce alprazolam by 50% immediately, then taper the remainder over 4 weeks"},{"label":"E","text":"Refer to inpatient detoxification for medically supervised withdrawal"}]'::jsonb, 'C', 'Benzodiazepine discontinuation requires careful tapering to prevent withdrawal seizures and severe symptoms: Risk factors for complicated withdrawal: • Long duration of use (this patient: 8 years — high risk) • High doses • Short-acting agents (alprazolam — high risk) • History of seizures or complicated withdrawal • Concurrent alcohol use Tapering protocol for long-term, short-acting benzodiazepine: Step Action 1 Convert to long-acting benzodiazepine (diazepam or clonazepam) 2 Gradual taper over weeks to months (longer duration = slower taper) Step Action 3 Typical reduction: 10–25% every 1–2 weeks initially; slower near the end 4 Total taper: 6–12 months for long-term users Why convert to long-acting agent? • Short-acting agents (alprazolam, lorazepam) cause interdose withdrawal and wide plasma fluctuations • Long-acting agents (diazepam, clonazepam) provide stable plasma levels, smoother taper • Conversion: Alprazolam 1mg ≈ Diazepam 10–20mg ≈ Clonazepam 0.5mg Why other options are wrong: • A: Abrupt discontinuation after 8 years risks severe withdrawal including seizures; buspirone doesn''t prevent BZD withdrawal • B: Tapering alprazolam directly is difficult due to short half-life and interdose fluctuations • D: 50% immediate reduction too aggressive; risks withdrawal symptoms • E: Outpatient taper is safe for uncomplicated cases; inpatient reserved for high-dose, complicated history, or poor social support High-Yield Takeaway: Long-term benzodiazepine discontinuation: convert short-acting (alprazolam) to long-acting (diazepam/clonazepam), then taper gradually over months. Abrupt discontinuation risks seizures.', NULL, 'internal', 'active'),
  ('B3_antidepressant-pregnancy-continuation', 'antidepressant-pregnancy-continuation', 'Batch3', 'Psychiatry', 'A 29-year-old woman at 8 weeks gestation has a history of severe recurrent major depressive disorder with two prior hospitalizations for suicidal ideation. She has been stable on sertraline 150mg daily for 3 years. She asks whether she should stop her medication to protect her baby.

What is the most appropriate recommendation?', '[{"label":"A","text":"Discontinue sertraline; depression can be managed with psychotherapy during pregnancy"},{"label":"B","text":"Continue sertraline at current dose with close monitoring"},{"label":"C","text":"Switch to bupropion, which has the lowest teratogenic risk"},{"label":"D","text":"Taper sertraline and discontinue by second trimester"},{"label":"E","text":"Discontinue sertraline and start fluoxetine, which has more safety data"}]'::jsonb, 'B', 'Antidepressant use in pregnancy requires weighing fetal risks against maternal relapse risk: SSRI risks in pregnancy: • First trimester: Small absolute increase in cardiac defects (paroxetine > others); overall risk remains low (~1%) • Third trimester: Neonatal adaptation syndrome (30%) — jitteriness, respiratory distress; transient, not life- threatening • No increased risk of major malformations with sertraline or fluoxetine Maternal depression risks (untreated): • Relapse rate: 60–70% if antidepressant discontinued during pregnancy • Poor prenatal care, substance use, poor nutrition • Preterm birth, low birth weight • Postpartum depression • Suicide Risk-benefit analysis: Scenario Recommendation Mild depression, single episode Consider taper; psychotherapy Severe/recurrent depression, prior hospitalization Continue antidepressant Currently stable for years Continuation preferred; high relapse risk with discontinuation This patient: • Severe recurrent MDD with hospitalizations • Stable on sertraline (favorable safety profile) • High relapse risk if discontinued The benefit of continued treatment clearly outweighs the small, uncertain fetal risks. Why other options are wrong: • A: Psychotherapy alone inadequate for severe recurrent MDD; high relapse risk • C: No evidence bupropion is safer; switching stable medication introduces unnecessary risk • D: Tapering in stable patient with severe history risks relapse • E: Fluoxetine and sertraline have similar safety data; no benefit to switching stable medication High-Yield Takeaway: Severe/recurrent depression stable on SSRI → continue antidepressant throughout pregnancy. Untreated maternal depression poses greater risk than SSRIs (especially sertraline, fluoxetine). Discontinuation leads to 60–70% relapse.', NULL, 'internal', 'active'),
  ('B3_lithium-toxicity-subacute-management', 'lithium-toxicity-subacute-management', 'Batch3', 'Psychiatry', 'A 58-year-old man with bipolar disorder on lithium for 15 years presents with 1 week of progressive tremor, unsteady gait, and confusion. His family reports he''s been vomiting from a "stomach bug" for 5 days and has been taking extra ibuprofen for back pain. He appears lethargic with coarse tremor and ataxia. Labs: lithium level 2.8 mEq/L (therapeutic 0.6–1.2), creatinine 2.1 mg/dL (baseline 1.0), and potassium 5.1 mEq/L.

What is the most appropriate management?', '[{"label":"A","text":"IV normal saline hydration alone"},{"label":"B","text":"Hold lithium and observe; repeat level in 12 hours"},{"label":"C","text":"Hemodialysis"},{"label":"D","text":"Activated charcoal"},{"label":"E","text":"IV sodium bicarbonate for alkaline diuresis"}]'::jsonb, 'C', 'Lithium toxicity classification and management: Types of lithium toxicity: Type Mechanism Level vs Symptoms Management Acute (overdose) Ingestion High level, mild symptoms initially GI decontamination; IVF; HD if severe Chronic Decreased clearance Moderate level, SEVERE symptoms HD often needed Acute-on-chronic Both Variable Based on symptoms This patient has CHRONIC lithium toxicity: • Gradual symptom onset (1 week) • Precipitants: Volume depletion (vomiting) + NSAIDs (ibuprofen inhibits renal lithium clearance) • Level 2.8 with severe CNS symptoms (confusion, ataxia) • AKI (Cr 2.1) Key principle: In chronic toxicity, lithium has equilibrated into tissues (especially brain). Even "moderate" levels (2– 2.5) can cause severe toxicity because CNS levels are high. Hemodialysis indications: • Level >4.0 (any toxicity type) • Level >2.5 with significant symptoms • Any level with severe neurologic symptoms (altered mental status, seizures, coma) • Renal impairment limiting clearance • Unable to tolerate fluids Why other options are wrong: • A: IVF helps in mild toxicity but insufficient for severe neurologic symptoms with AKI • B: Observation too conservative; CNS symptoms require intervention • D: Activated charcoal doesn''t bind lithium; not helpful • E: Lithium is not amenable to alkaline diuresis (unlike salicylates) High-Yield Takeaway: Chronic lithium toxicity with neurologic symptoms (confusion, ataxia, tremor) → hemodialysis, even at moderate levels (2.5–3.5). Chronic toxicity causes severe symptoms at lower levels than acute toxicity due to CNS lithium accumulation.', NULL, 'internal', 'active'),
  ('B3_eating-disorder-inpatient-criteria', 'eating-disorder-inpatient-criteria', 'Batch3', 'Psychiatry', 'A 19-year-old woman with anorexia nervosa is brought by her parents for worsening restriction. She reports eating ~400 calories daily for the past month. BMI is 15.2 kg/m². Vitals: HR 42, BP 78/50, temperature 35.6°C. Labs: potassium 2.9 mEq/L, glucose 58 mg/dL, phosphorus 2.2 mg/dL. ECG shows sinus bradycardia with prolonged QTc (480 ms).

What is the most appropriate disposition?', '[{"label":"A","text":"Intensive outpatient program with daily monitoring"},{"label":"B","text":"Psychiatric hospitalization for supervised refeeding"},{"label":"C","text":"Medical hospitalization for cardiac and metabolic stabilization"},{"label":"D","text":"Residential eating disorder treatment facility"},{"label":"E","text":"Outpatient follow-up with dietitian within 1 week"}]'::jsonb, 'C', 'Anorexia nervosa hospitalization requires understanding medical vs psychiatric criteria: Medical hospitalization criteria (any ONE): Category Threshold Heart rate <50 bpm (this patient: 42) Blood pressure <80/50 or orthostatic (this patient: 78/50) Potassium <3.0 mEq/L (this patient: 2.9) Glucose <60 mg/dL (this patient: 58) Phosphorus <2.5 mg/dL (this patient: 2.2) QTc >450–460 ms (this patient: 480) Temperature <36°C (this patient: 35.6) BMI <14–15 kg/m² (varies by guideline) This patient has MULTIPLE medical hospitalization criteria: • HR 42 ✓ • BP 78/50 ✓ • K+ 2.9 ✓ • Glucose 58 ✓ • Phos 2.2 ✓ • QTc 480 ms ✓ • Temp 35.6°C ✓ Medical vs psychiatric hospitalization: • Medical floor: Cardiac monitoring, electrolyte repletion, supervised refeeding with refeeding syndrome precautions • Psychiatric unit: After medical stabilization; for patients who are medically stable but refuse treatment or have severe psychiatric comorbidity Why other options are wrong: • A: Intensive outpatient cannot manage medical instability • B: Psychiatric hospitalization is appropriate AFTER medical stabilization; this patient needs cardiac monitoring • D: Residential programs are for stable patients requiring long-term behavioral treatment • E: Medical instability precludes outpatient management High-Yield Takeaway: Anorexia nervosa with bradycardia (<50), hypotension, electrolyte abnormalities, or ECG changes = medical hospitalization first. Psychiatric hospitalization follows medical stabilization. BATCH 3 — QUESTION GENERATION COMPLETE Summary: • Neurology: 8 questions • OB/GYN: 8 questions • Pediatrics: 6 questions • Surgery: 7 questions • Psychiatry: 7 questions Total: 36 questions', NULL, 'internal', 'active'),
  ('B4_hfpef-diuretic-resistance-switch', 'hfpef-diuretic-resistance-switch', 'Batch4', 'Cardiology', 'A 74-year-old woman with hypertension, type 2 diabetes, and heart failure with preserved ejection fraction (EF 58%) presents with progressive lower extremity edema and dyspnea on exertion over the past 3 weeks. She has been adherent to her furosemide 80 mg twice daily but reports minimal urine output despite the medication. Her weight has increased 4 kg since her last visit. Vital signs show BP 148/88 mmHg, HR 72 bpm. Labs reveal sodium 134 mEq/L, potassium 3.6 mEq/L, creatinine 1.4 mg/dL (baseline 1.2), and BNP 680 pg/mL. Physical exam confirms 3+ pitting edema bilaterally and bibasilar crackles.

What is the most appropriate next step in management?', '[{"label":"A","text":"Increase furosemide to 120 mg twice daily"},{"label":"B","text":"Add metolazone 2.5 mg daily"},{"label":"C","text":"Switch furosemide to bumetanide"},{"label":"D","text":"Add spironolactone 25 mg daily"},{"label":"E","text":"Initiate continuous furosemide infusion"}]'::jsonb, 'B', 'This patient demonstrates loop diuretic resistance, a common phenomenon in HFpEF where chronic loop diuretic use leads to distal nephron hypertrophy and compensatory sodium reabsorption. The clinical clues—adequate loop diuretic dosing, poor response, and volume overload—indicate the need for sequential nephron blockade. Adding a thiazide-type diuretic (metolazone) to the existing loop diuretic blocks sodium reabsorption at the distal convoluted tubule, overcoming the resistance mechanism. This synergistic approach is more effective than simply increasing the loop diuretic dose, which often yields diminishing returns. Why Other Options Are Wrong: • A (Increase furosemide): In true diuretic resistance, dose escalation has a ceiling effect due to distal nephron adaptation; sequential blockade is preferred. • C (Switch to bumetanide): Switching loop diuretics may help with absorption issues but does not address distal nephron compensation. • D (Add spironolactone): While beneficial long-term in HFpEF, spironolactone is a weak diuretic and will not produce the acute diuresis needed here. • E (Continuous infusion): Reserved for hospitalized patients with severe acute decompensation; this outpatient has chronic resistance, not acute failure. High-Yield Takeaway: When a patient on adequate loop diuretic dosing shows persistent volume overload, add a thiazide (metolazone) for sequential nephron blockade rather than escalating the loop diuretic dose.', NULL, 'internal', 'active'),
  ('B4_afib-rate-vs-rhythm-chf-reversal', 'afib-rate-vs-rhythm-chf-reversal', 'Batch4', 'Cardiology', 'A 58-year-old man with a 2-year history of persistent atrial fibrillation managed with metoprolol and apixaban presents with 6 weeks of progressive exertional dyspnea and orthopnea. He denies chest pain or palpitations. Echocardiogram reveals a new finding of left ventricular ejection fraction of 38% (previously 55% one year ago), moderate mitral regurgitation, and left atrial enlargement. His ventricular rate is well-controlled at 78 bpm. NT-proBNP is elevated at 2,400 pg/mL. He has no history of coronary artery disease, and recent coronary angiography was unremarkable.

What is the most appropriate change to his atrial fibrillation management?', '[{"label":"A","text":"Continue current rate control with metoprolol"},{"label":"B","text":"Add digoxin for enhanced rate control"},{"label":"C","text":"Refer for catheter ablation with goal of rhythm control"},{"label":"D","text":"Initiate amiodarone for pharmacologic cardioversion"},{"label":"E","text":"Increase metoprolol dose to achieve resting rate below 60 bpm"}]'::jsonb, 'C', 'This patient has tachycardia-mediated cardiomyopathy (or AFib-related cardiomyopathy), where persistent atrial fibrillation has led to new-onset heart failure with reduced ejection fraction. Despite "adequate" rate control by traditional metrics, the loss of atrial kick and irregularity of AFib contributes to ventricular dysfunction. In this setting, the discovery of new HFrEF fundamentally changes the treatment paradigm from rate control to rhythm control. Catheter ablation for AFib in patients with HFrEF has been shown to improve ejection fraction, reduce hospitalizations, and decrease mortality compared to continued rate control. This represents a reversal of the initial strategy based on the new clinical context. Why Other Options Are Wrong: • A (Continue rate control): The development of HFrEF in the setting of AFib indicates rate control alone is insufficient and may be contributing to cardiomyopathy. • B (Add digoxin): Adding another rate-control agent does not address the underlying issue; rhythm control is now indicated. • D (Amiodarone): While amiodarone can achieve rhythm control, catheter ablation has superior outcomes in AFib with HFrEF and avoids long- term drug toxicity. • E (Stricter rate control): Aggressive rate control with goal HR <60 is not supported and does not restore atrial contribution to cardiac output. High-Yield Takeaway: New-onset heart failure with reduced EF in a patient with atrial fibrillation should prompt a shift from rate control to rhythm control, preferably via catheter ablation.', NULL, 'internal', 'active'),
  ('B4_pericarditis-nsaid-failure-colchicine-timing', 'pericarditis-nsaid-failure-colchicine-timing', 'Batch4', 'Cardiology', 'A 32-year-old man was diagnosed with acute viral pericarditis 10 days ago and started on ibuprofen 600 mg three times daily. He initially improved but returns with recurrent sharp pleuritic chest pain that worsens with inspiration and lying flat. Temperature is 37.8°C, and a pericardial friction rub is present. ECG shows diffuse ST elevations with PR depression. Echocardiogram reveals a trivial pericardial effusion without tamponade physiology. He has been adherent to ibuprofen and denies NSAID intolerance.

What is the most appropriate next step in management?', '[{"label":"A","text":"Increase ibuprofen to 800 mg three times daily"},{"label":"B","text":"Add colchicine 0.5 mg twice daily"},{"label":"C","text":"Switch to prednisone 0.5 mg/kg daily"},{"label":"D","text":"Add colchicine and prednisone simultaneously"},{"label":"E","text":"Obtain pericardiocentesis for diagnostic evaluation"}]'::jsonb, 'B', 'This patient has NSAID-refractory acute pericarditis, defined as persistent or recurrent symptoms despite adequate NSAID therapy. The appropriate escalation is to add colchicine to the existing NSAID regimen, not to switch therapies. Colchicine works synergistically with NSAIDs by inhibiting microtubule assembly in inflammatory cells and has been shown in the COPE and ICAP trials to reduce recurrence rates significantly. Corticosteroids should be avoided as first-line add-on therapy because they are associated with increased recurrence rates and should be reserved for patients who fail NSAID-colchicine combination or have contraindications to both. Why Other Options Are Wrong: • A (Increase ibuprofen): He is already on therapeutic dosing; the issue is mechanism of resistance, not dose inadequacy. • C (Switch to prednisone): Corticosteroids increase recurrence risk and are reserved for NSAID/colchicine failure or contraindications. • D (Add both): Adding steroids prematurely increases recurrence risk; colchicine alone should be tried first. • E (Pericardiocentesis): Only indicated for large effusions, tamponade, or suspected purulent/malignant pericarditis; a trivial effusion does not warrant drainage. High-Yield Takeaway: When acute pericarditis fails to respond to NSAIDs alone, add colchicine rather than switching to or adding corticosteroids, which increase recurrence risk. PULMONOLOGY', NULL, 'internal', 'active'),
  ('B4_copd-exacerbation-antibiotic-threshold', 'copd-exacerbation-antibiotic-threshold', 'Batch4', 'Pulmonology', 'A 67-year-old man with GOLD stage III COPD presents with 4 days of increased dyspnea and cough. He reports his sputum volume has increased but remains white-gray in color, similar to his baseline. He denies fever, chills, or chest pain. Vital signs show temperature 37.1°C, RR 22/min, SpO2 89% on room air (baseline 92%). Lung exam reveals diffuse expiratory wheezes without focal consolidation. Chest X-ray shows hyperinflation without infiltrate. He uses tiotropium and a fluticasone/salmeterol inhaler daily.

What is the most appropriate antibiotic management?', '[{"label":"A","text":"Azithromycin 500 mg daily for 3 days"},{"label":"B","text":"Amoxicillin-clavulanate 875 mg twice daily for 5 days"},{"label":"C","text":"Levofloxacin 750 mg daily for 5 days"},{"label":"D","text":"Doxycycline 100 mg twice daily for 7 days"},{"label":"E","text":"No antibiotics indicated at this time"}]'::jsonb, 'E', 'This patient has a COPD exacerbation with only one Anthonisen criterion (increased dyspnea) without purulent sputum or significantly increased sputum volume beyond baseline. According to the Anthonisen classification, antibiotics are indicated for Type I exacerbations (all three cardinal symptoms: increased dyspnea, increased sputum volume, and sputum purulence) or Type II exacerbations if purulence is one of the two symptoms present. Sputum purulence is the strongest predictor of bacterial infection and antibiotic benefit. This patient has non-purulent sputum, making antibiotic therapy unlikely to provide benefit and exposing him to unnecessary side effects and resistance development. Management should focus on bronchodilators and systemic corticosteroids. Why Other Options Are Wrong: • A, B, C, D (Various antibiotics): All represent antibiotic therapy, which is not indicated without sputum purulence as a key criterion for bacterial involvement. High-Yield Takeaway: In COPD exacerbations, sputum purulence is the critical Anthonisen criterion driving antibiotic use; increased dyspnea and non-purulent sputum alone do not warrant antibiotics.', NULL, 'internal', 'active'),
  ('B4_pe-subsegmental-no-anticoagulation', 'pe-subsegmental-no-anticoagulation', 'Batch4', 'Pulmonology', 'A 45-year-old woman with no significant past medical history undergoes CT pulmonary angiography for evaluation of pleuritic chest pain following a 6- hour car ride. The scan reveals a single subsegmental pulmonary embolism in the right lower lobe without evidence of right heart strain. She has no tachycardia, hypoxia, or hemodynamic instability. D-dimer is mildly elevated at 0.8 μg/mL. Lower extremity duplex ultrasound shows no deep vein thrombosis. She has a history of heavy menstrual bleeding and is otherwise healthy.

What is the most appropriate management?', '[{"label":"A","text":"Therapeutic anticoagulation with rivaroxaban for 3 months"},{"label":"B","text":"Therapeutic anticoagulation with low-molecular-weight heparin for 3 months"},{"label":"C","text":"Inferior vena cava filter placement"},{"label":"D","text":"Clinical surveillance without anticoagulation"},{"label":"E","text":"Repeat CT pulmonary angiography in 48-72 hours"}]'::jsonb, 'D', 'Isolated subsegmental pulmonary embolism (SSPE) in a low-risk patient without proximal DVT represents a clinical scenario where the risk-benefit ratio of anticoagulation is uncertain. Per current guidelines, clinical surveillance without anticoagulation is a reasonable option for patients with SSPE who have low risk of recurrence (no ongoing risk factors), no proximal DVT on bilateral leg imaging, low cardiopulmonary reserve is not compromised, and no symptoms requiring treatment. This patient''s minor provocation (short car ride), absence of DVT, hemodynamic stability, and bleeding risk (menorrhagia) favor observation. The false-positive rate of CT for subsegmental clots is non-trivial, and anticoagulating all SSPEs leads to unnecessary bleeding complications. Why Other Options Are Wrong: • A, B (Therapeutic anticoagulation): Not mandatory for isolated SSPE in low-risk patients without DVT; bleeding risk may outweigh benefit. • C (IVC filter): Only indicated when anticoagulation is required but contraindicated; observation is the alternative here, not filtration. • E (Repeat CT): Unnecessary radiation exposure; clinical monitoring is sufficient for stable isolated SSPE. High-Yield Takeaway: Isolated subsegmental PE without proximal DVT in a low-risk, hemodynamically stable patient can be managed with clinical surveillance rather than anticoagulation.', NULL, 'internal', 'active'),
  ('B4_asthma-step-down-failure-reassess', 'asthma-step-down-failure-reassess', 'Batch4', 'Pulmonology', 'A 28-year-old woman with well-controlled asthma on medium-dose inhaled corticosteroid plus long-acting beta-agonist (ICS-LABA) had her therapy stepped down to low-dose ICS alone 6 weeks ago after 3 months of complete symptom control. She now presents with nighttime awakenings twice weekly and uses her rescue albuterol 4 times per week. She denies respiratory infection, new environmental exposures, or medication non-adherence. Peak flow is 75% of her personal best.

What is the most appropriate next step in management?', '[{"label":"A","text":"Restart medium-dose ICS-LABA and continue indefinitely"},{"label":"B","text":"Restart medium-dose ICS-LABA and reassess step-down eligibility in 3 months"},{"label":"C","text":"Increase to high-dose ICS monotherapy"},{"label":"D","text":"Add oral montelukast to current low-dose ICS"},{"label":"E","text":"Prescribe a short course of oral prednisone"}]'::jsonb, 'B', 'This patient''s symptoms represent failure of step-down therapy rather than a true exacerbation. The appropriate response is to return to the previously effective regimen (medium-dose ICS-LABA) and reassess step-down eligibility after re-establishing control for at least 3 months. Failed step-down does not mean permanent therapy escalation—it means the patient was not ready for de-escalation at that time. After regaining control, another step-down attempt may be successful, particularly if modifiable factors (allergen exposure, technique, adherence) are optimized. The goal remains the lowest effective therapy. Why Other Options Are Wrong: • A (Continue indefinitely): Premature; step-down should be re-attempted after control is re-established. • C (High-dose ICS monotherapy): Less effective than ICS-LABA and represents over-escalation for a step-down failure. • D (Add montelukast): Less effective add-on than LABA and does not address the demonstrated need for LABA. • E (Oral prednisone): Reserved for true exacerbations; this is loss of control, not acute exacerbation. High-Yield Takeaway: Failed asthma step-down requires returning to the prior effective regimen and re-attempting step-down after 3 months of regained control, not permanent escalation. GASTROENTEROLOGY', NULL, 'internal', 'active'),
  ('B4_hcc-surveillance-escape-afp-negative', 'hcc-surveillance-escape-afp-negative', 'Batch4', 'Gastroenterology', 'A 62-year-old man with compensated cirrhosis secondary to hepatitis C (SVR achieved 4 years ago) undergoes routine HCC surveillance. Ultrasound performed by an experienced technician shows a 1.5-cm hypoechoic lesion in the right hepatic lobe not seen on prior imaging 6 months ago. AFP level is 8 ng/mL (normal <10). He is asymptomatic with Child-Pugh class A cirrhosis. Prior surveillance ultrasounds were unremarkable.

What is the most appropriate next step?', '[{"label":"A","text":"Repeat ultrasound in 3 months"},{"label":"B","text":"Obtain multiphasic CT or MRI of the liver"},{"label":"C","text":"Obtain AFP-L3 and des-gamma-carboxyprothrombin levels"},{"label":"D","text":"Proceed directly to percutaneous biopsy"},{"label":"E","text":"Continue routine surveillance with ultrasound in 6 months"}]'::jsonb, 'B', 'This patient has a new liver lesion detected on surveillance ultrasound in the setting of cirrhosis, which raises concern for hepatocellular carcinoma regardless of AFP level. AFP has limited sensitivity (~60%) for HCC detection, meaning 40% of HCCs are AFP-negative. A normal AFP should never be used to rule out malignancy or defer further workup when imaging is abnormal. The appropriate next step is multiphasic contrast-enhanced CT or MRI to characterize the lesion. These modalities can diagnose HCC non-invasively if the lesion demonstrates characteristic arterial enhancement with washout in the portal venous or delayed phases. Why Other Options Are Wrong: • A (Repeat ultrasound in 3 months): Delays diagnosis of a potentially malignant lesion; cross-sectional imaging is indicated now. • C (Additional biomarkers): AFP-L3 and DCP are adjunctive and do not replace imaging for lesion characterization. • D (Percutaneous biopsy): Not first-line; HCC can often be diagnosed non-invasively with characteristic imaging features. • E (Continue 6-month surveillance): Ignores the new lesion requiring evaluation; inappropriate delay. High-Yield Takeaway: A new liver lesion on surveillance ultrasound in cirrhosis requires multiphasic CT or MRI regardless of AFP level; normal AFP does not exclude HCC.', NULL, 'internal', 'active'),
  ('B4_cdiff-fidaxomicin-over-vancomycin', 'cdiff-fidaxomicin-over-vancomycin', 'Batch4', 'Gastroenterology', 'A 71-year-old woman with a history of Clostridioides difficile infection (CDI) 4 months ago (treated with oral vancomycin with resolution) presents with 5 days of watery diarrhea, abdominal cramping, and low-grade fever. She completed a course of ciprofloxacin for a urinary tract infection 2 weeks ago. Stool PCR for C. difficile toxin is positive. She has 6-8 loose stools daily, WBC is 11,200/μL, and creatinine is 1.0 mg/dL. She is hemodynamically stable and tolerating oral intake.

What is the most appropriate treatment?', '[{"label":"A","text":"Oral vancomycin 125 mg four times daily for 10 days"},{"label":"B","text":"Oral fidaxomicin 200 mg twice daily for 10 days"},{"label":"C","text":"Oral vancomycin tapered and pulsed regimen over 6 weeks"},{"label":"D","text":"Fecal microbiota transplantation"},{"label":"E","text":"Oral metronidazole 500 mg three times daily for 10 days"}]'::jsonb, 'B', 'This patient has a first recurrence of CDI, which fundamentally changes the treatment approach. For first recurrence, fidaxomicin is preferred over standard-course vancomycin because it has demonstrated lower rates of subsequent recurrence. Fidaxomicin has a narrower spectrum with minimal disruption of the gut microbiome and achieves high fecal concentrations with sustained post-antibiotic effect against C. difficile spores. The IDSA/SHEA guidelines recommend fidaxomicin as the preferred agent for first recurrence, with a vancomycin taper/pulse regimen as an alternative. Standard 10-day vancomycin is no longer recommended for recurrent disease. Why Other Options Are Wrong: • A (Standard vancomycin): Not recommended for first recurrence due to higher recurrence rates compared to fidaxomicin. • C (Vancomycin taper/pulse): Acceptable alternative but fidaxomicin is preferred due to simpler regimen and efficacy data. • D (FMT): Reserved for multiple recurrences (typically ≥2 recurrences or ≥3 total episodes); premature for first recurrence. • E (Metronidazole): Not recommended for any recurrence or non-initial episodes due to inferior efficacy. High-Yield Takeaway: For first recurrence of C. difficile infection, fidaxomicin is the preferred treatment over standard vancomycin due to lower subsequent recurrence rates.', NULL, 'internal', 'active'),
  ('B4_pud-hp-negative-still-treat', 'pud-hp-negative-still-treat', 'Batch4', 'Gastroenterology', 'A 54-year-old man undergoes EGD for epigastric pain revealing a 1.2-cm duodenal ulcer without active bleeding. He denies NSAID or aspirin use and drinks alcohol socially. Biopsies are obtained, and he is started on a proton pump inhibitor. Histopathology returns negative for Helicobacter pylori on hematoxylin and eosin stain and special stains. He was taking omeprazole for 3 weeks prior to the EGD prescribed by another provider. Stool antigen for H. pylori is also negative (obtained while on PPI). Serology for H. pylori IgG is positive.

What is the most appropriate next step in management?', '[{"label":"A","text":"Continue PPI monotherapy with no further H. pylori workup"},{"label":"B","text":"Treat for H. pylori infection with triple therapy"},{"label":"C","text":"Repeat EGD with biopsy after 4 weeks off PPI"},{"label":"D","text":"Obtain urea breath test after 4 weeks off PPI"},{"label":"E","text":"Consider the patient H. pylori negative and evaluate for Zollinger-Ellison syndrome"}]'::jsonb, 'B', 'This patient has duodenal ulcer disease with discordant H. pylori testing—negative histology and stool antigen but positive serology. The critical detail is that he was on a PPI for 3 weeks prior to testing. PPIs significantly reduce H. pylori bacterial load and urease activity, leading to false-negative results on urease-based tests (stool antigen, urea breath test) and histology. Serology detects antibodies from prior exposure and is unaffected by PPI use. In the setting of active duodenal ulcer disease (which has >90% association with H. pylori historically), positive serology combined with negative tests confounded by PPI use should be interpreted as likely H. pylori infection. Treatment is warranted without delaying for repeat testing. Why Other Options Are Wrong: • A (PPI monotherapy): Misses the opportunity to eradicate H. pylori and cure the ulcer disease definitively. • C (Repeat EGD): Unnecessarily invasive; clinical evidence supports treatment. • D (Urea breath test off PPI): Reasonable but delays treatment; clinical suspicion is sufficient. • E (Evaluate for ZES): Zollinger-Ellison is rare; H. pylori is the most likely cause and should be treated first. High-Yield Takeaway: Negative H. pylori testing on histology and stool antigen in a patient on PPI therapy does not exclude infection; positive serology with duodenal ulcer warrants empiric treatment.', NULL, 'internal', 'active'),
  ('B4_acute-pancreatitis-early-feeding-timing', 'acute-pancreatitis-early-feeding-timing', 'Batch4', 'Gastroenterology', 'A 41-year-old woman is admitted with acute pancreatitis secondary to gallstones. On hospital day 2, she has mild epigastric tenderness, lipase of 890 U/L (down from 2,400 U/L on admission), and no nausea or vomiting. She reports feeling hungry. She has been receiving IV fluids and IV morphine for pain control. CT performed on admission showed interstitial edematous pancreatitis without necrosis. She remains afebrile with stable vital signs.

What is the most appropriate nutritional management?', '[{"label":"A","text":"Continue NPO status until lipase normalizes"},{"label":"B","text":"Initiate nasojejunal tube feeding"},{"label":"C","text":"Start a clear liquid diet and advance as tolerated"},{"label":"D","text":"Delay oral intake until abdominal pain completely resolves"},{"label":"E","text":"Begin total parenteral nutrition"}]'::jsonb, 'C', 'Current evidence supports early oral feeding (within 24-48 hours) in acute pancreatitis when patients can tolerate it, regardless of lipase levels or mild residual pain. The traditional teaching of prolonged NPO status ("pancreatic rest") until complete pain resolution and lipase normalization has been disproven. Early enteral feeding maintains gut barrier function, reduces infectious complications, decreases length of stay, and may reduce mortality. This patient is hungry, has no nausea/vomiting, has mild uncomplicated (interstitial) pancreatitis, and has improving clinical status—all favorable indicators for initiating oral intake. A low-fat solid diet is acceptable; routine use of clear liquid progression is not mandatory. Why Other Options Are Wrong: • A (NPO until lipase normalizes): Outdated practice; lipase normalization is not required before feeding. • B (Nasojejunal feeding): Reserved for patients who cannot tolerate oral intake; unnecessary here. • D (Wait for complete pain resolution): Unnecessary delay; mild pain is not a contraindication to oral feeding. • E (TPN): Only indicated when enteral feeding is not possible for prolonged periods; not appropriate here. High-Yield Takeaway: In acute pancreatitis, initiate oral feeding within 24-48 hours when tolerated; do not wait for complete pain resolution or lipase normalization. NEPHROLOGY', NULL, 'internal', 'active'),
  ('B4_aki-on-ckd-hold-ace-permanently', 'aki-on-ckd-hold-ace-permanently', 'Batch4', 'Nephrology', 'A 68-year-old man with CKD stage 3b (baseline creatinine 2.1 mg/dL), heart failure with reduced ejection fraction, and type 2 diabetes is hospitalized for acute kidney injury in the setting of volume depletion from gastroenteritis. His lisinopril was held on admission. Creatinine peaked at 3.8 mg/dL and has now recovered to 2.3 mg/dL after IV fluid resuscitation. His blood pressure is 128/78 mmHg. He is preparing for discharge. Prior to this hospitalization, his creatinine had been stable on lisinopril for 3 years with good BP control and no hyperkalemia.

What is the most appropriate management of his lisinopril at discharge?', '[{"label":"A","text":"Permanently discontinue lisinopril due to AKI"},{"label":"B","text":"Switch to an ARB which has better renal safety"},{"label":"C","text":"Restart lisinopril at the prior dose once creatinine returns to baseline"},{"label":"D","text":"Restart lisinopril at a reduced dose with creatinine monitoring in 1 week"},{"label":"E","text":"Delay lisinopril restart for 3 months to allow renal recovery"}]'::jsonb, 'D', 'ACE inhibitors provide significant long-term cardiorenal protection in patients with HFrEF and diabetic nephropathy. Temporary discontinuation during AKI is appropriate, but permanent discontinuation based solely on a hemodynamic/pre-renal AKI episode is not indicated. The AKI in this case was clearly precipitated by volume depletion, not intrinsic ACE inhibitor nephrotoxicity. Once the reversible trigger has resolved and creatinine is trending toward baseline, the ACE inhibitor should be restarted—often at a reduced dose initially—with close monitoring. The mortality and heart failure hospitalization benefits of ACE inhibitors in HFrEF outweigh the risks in patients with stable CKD. Why Other Options Are Wrong: • A (Permanently discontinue): Removes a medication with proven mortality benefit; not indicated for hemodynamic AKI. • B (Switch to ARB): ARBs have similar hemodynamic effects on GFR; no safety advantage over ACE inhibitors in this scenario. • C (Restart at full dose): More cautious approach with reduced dose and monitoring is prudent post-AKI. • E (Delay 3 months): Unnecessarily prolongs the time without cardioprotective therapy. High-Yield Takeaway: ACE inhibitors held during pre-renal AKI should be restarted (often at reduced dose with monitoring) once the precipitant resolves; permanent discontinuation forfeits cardiorenal benefits.', NULL, 'internal', 'active'),
  ('B4_nephrotic-anticoagulation-threshold', 'nephrotic-anticoagulation-threshold', 'Batch4', 'Nephrology', 'A 52-year-old man with recently diagnosed membranous nephropathy is being managed with immunosuppressive therapy. Labs show serum albumin of 1.8 g/dL, urine protein-to-creatinine ratio of 11 g/g, and creatinine of 1.1 mg/dL. He has no personal or family history of thromboembolism. He is not immobilized and has no other prothrombotic conditions. Renal biopsy confirmed primary membranous nephropathy with PLA2R antibody positivity.

What is the most appropriate recommendation regarding anticoagulation?', '[{"label":"A","text":"No anticoagulation needed unless thrombosis occurs"},{"label":"B","text":"Low-dose aspirin 81 mg daily for prophylaxis"},{"label":"C","text":"Prophylactic anticoagulation with apixaban or warfarin"},{"label":"D","text":"Anticoagulation only if antithrombin III level is low"},{"label":"E","text":"Compression stockings and early ambulation only"}]'::jsonb, 'C', 'Membranous nephropathy carries the highest thrombotic risk among nephrotic syndrome etiologies, with venous thromboembolism occurring in 20- 30% of patients. The degree of hypoalbuminemia correlates with thrombotic risk, and albumin <2.5-2.8 g/dL is commonly used as a threshold for prophylactic anticoagulation, particularly in membranous nephropathy. This patient''s albumin of 1.8 g/dL places him in a high-risk category. The mechanism involves urinary loss of antithrombin III, protein C, and protein S, along with increased hepatic synthesis of procoagulant factors. Prophylactic anticoagulation is recommended despite no prior VTE. Why Other Options Are Wrong: • A (Wait for thrombosis): Reactive approach misses the window for prevention; primary prophylaxis is warranted at this albumin level. • B (Aspirin): Antiplatelet therapy does not prevent venous thromboembolism, which is the primary concern. • D (Based on antithrombin III): Albumin level is a more practical and validated risk stratification tool. • E (Mechanical prophylaxis): Insufficient for the high thrombotic risk in severe nephrotic syndrome. High-Yield Takeaway: In membranous nephropathy with serum albumin <2.5 g/dL, initiate prophylactic anticoagulation due to high venous thromboembolism risk. ENDOCRINOLOGY', NULL, 'internal', 'active'),
  ('B4_dka-insulin-before-potassium-exception', 'dka-insulin-before-potassium-exception', 'Batch4', 'Endocrinology', 'A 24-year-old man with type 1 diabetes presents with altered mental status, Kussmaul respirations, and severe abdominal pain. Labs reveal glucose 580 mg/dL, pH 6.92, bicarbonate 4 mEq/L, anion gap 32, and potassium 2.9 mEq/L. He is hypotensive with BP 78/50 mmHg and tachycardic at 128 bpm. IV fluid resuscitation is initiated. Initial potassium replacement is started, but his pH continues to drop, and he is becoming increasingly obtunded.

What is the most appropriate next step?', '[{"label":"A","text":"Continue aggressive potassium replacement before starting insulin"},{"label":"B","text":"Start insulin infusion at 0.1 units/kg/hour immediately"},{"label":"C","text":"Administer sodium bicarbonate bolus"},{"label":"D","text":"Wait until potassium reaches 3.3 mEq/L before starting insulin"},{"label":"E","text":"Intubate for airway protection before any other intervention"}]'::jsonb, 'B', 'The traditional teaching is to withhold insulin until potassium is ≥3.3 mEq/L because insulin drives potassium intracellularly and can precipitate fatal arrhythmias. However, in severe life-threatening acidosis (pH <7.0) with hemodynamic instability and altered mental status, the immediate threat is the acidosis itself. In this scenario, insulin should be started without delay while aggressively replacing potassium simultaneously. The rationale is that untreated severe acidosis will lead to death before hypokalemia can be corrected. Continuous cardiac monitoring and very aggressive potassium replacement (often via central access with rates up to 40 mEq/hour in ICU settings) accompany insulin initiation. Why Other Options Are Wrong: • A (Continue K+ replacement before insulin): Delays insulin in life-threatening acidosis; both should occur simultaneously. • C (Sodium bicarbonate): Not routinely recommended even in severe DKA; insulin and fluids correct acidosis. • D (Wait for K+ 3.3): Standard approach but overridden by life-threatening acidosis where delay is more dangerous. • E (Intubate first): May be needed but is not the immediate next step; metabolic management takes priority unless imminent respiratory arrest. High-Yield Takeaway: In DKA with life-threatening acidosis (pH <7.0), start insulin immediately despite K+ <3.3 mEq/L while aggressively replacing potassium simultaneously.', NULL, 'internal', 'active'),
  ('B4_subclinical-hypothyroid-pregnancy-treat', 'subclinical-hypothyroid-pregnancy-treat', 'Batch4', 'Endocrinology', 'A 29-year-old woman at 8 weeks gestation presents for her first prenatal visit. She has no history of thyroid disease. Routine thyroid screening shows TSH of 4.8 mIU/L (pregnancy-specific reference range: 0.1-2.5 mIU/L for first trimester), free T4 of 1.1 ng/dL (normal), and TPO antibodies are negative. She is asymptomatic and has no goiter on exam. Her pregnancy is otherwise uncomplicated.

What is the most appropriate management?', '[{"label":"A","text":"No treatment needed as free T4 is normal"},{"label":"B","text":"Repeat thyroid function tests in the second trimester"},{"label":"C","text":"Initiate levothyroxine therapy"},{"label":"D","text":"Recheck TSH after iodine supplementation"},{"label":"E","text":"Observe and treat only if TSH exceeds 10 mIU/L"}]'::jsonb, 'C', 'Pregnancy fundamentally changes the TSH threshold for treatment of hypothyroidism. In the first trimester, fetal neurodevelopment depends entirely on maternal thyroid hormone, and the upper limit of normal for TSH is reduced (typically 2.5-4.0 mIU/L depending on the assay and population). This patient has subclinical hypothyroidism by pregnancy-specific criteria (elevated TSH with normal free T4). The American Thyroid Association recommends treatment with levothyroxine for pregnant women with TSH above the trimester-specific reference range. Even without TPO antibodies, treatment is indicated given the elevated TSH in early pregnancy when thyroid hormone is critical for fetal brain development. Why Other Options Are Wrong: • A (No treatment, normal T4): Ignores pregnancy-specific TSH thresholds; subclinical hypothyroidism in pregnancy warrants treatment. • B (Repeat in second trimester): Delays treatment during the critical period of fetal neurodevelopment. • D (Iodine supplementation): While prenatal vitamins include iodine, this does not address elevated TSH. • E (Wait for TSH >10): Non-pregnant threshold; not applicable during pregnancy. High-Yield Takeaway: In pregnancy, TSH above the trimester-specific reference range (typically >2.5-4.0 mIU/L in first trimester) warrants levothyroxine, even if free T4 is normal.', NULL, 'internal', 'active'),
  ('B4_adrenal-incidentaloma-no-workup-size', 'adrenal-incidentaloma-no-workup-size', 'Batch4', 'Endocrinology', 'A 58-year-old woman undergoes CT abdomen for evaluation of kidney stones. Incidentally, a 0.9-cm homogeneous adrenal nodule is discovered with Hounsfield units of 8 (consistent with lipid-rich adenoma). She is normotensive, has no cushingoid features, and has no symptoms of hyperaldosteronism or catecholamine excess. She has no personal or family history of malignancy.

What is the most appropriate next step?', '[{"label":"A","text":"24-hour urine catecholamines and metanephrines"},{"label":"B","text":"1-mg overnight dexamethasone suppression test"},{"label":"C","text":"Plasma aldosterone-to-renin ratio"},{"label":"D","text":"Complete hormonal workup including all of the above"},{"label":"E","text":"No further workup indicated"}]'::jsonb, 'E', 'Adrenal incidentalomas <1 cm with benign imaging characteristics (low Hounsfield units indicating lipid-rich content, homogeneous appearance, smooth borders) have extremely low malignant potential and low rates of hormonal hypersecretion. Current guidelines suggest that nodules <1 cm with imaging features consistent with adenoma do not require routine biochemical workup or follow-up imaging. The risk of clinically significant disease is negligible, and the cost and patient anxiety of testing outweigh potential benefits. This contrasts with lesions ≥1 cm, which typically warrant biochemical evaluation regardless of imaging appearance. Why Other Options Are Wrong: • A, B, C, D (Various hormonal tests): Not indicated for <1 cm lipid-rich adenomas; biochemical workup is reserved for larger lesions or those with concerning imaging features. High-Yield Takeaway: Adrenal incidentalomas <1 cm with benign imaging features (lipid-rich, homogeneous) require no further hormonal workup or surveillance. HEMATOLOGY/ONCOLOGY', NULL, 'internal', 'active'),
  ('B4_hit-argatroban-vs-fondaparinux', 'hit-argatroban-vs-fondaparinux', 'Batch4', 'Hematology/Oncology', 'A 72-year-old man hospitalized after hip fracture surgery develops acute thrombocytopenia on postoperative day 7. Platelet count dropped from 180,000/μL to 58,000/μL. He has no bleeding but develops unilateral leg swelling. Duplex ultrasound confirms new deep vein thrombosis in the operated limb. Heparin is discontinued, and HIT antibody testing is sent. His creatinine is 3.2 mg/dL (baseline 1.4 mg/dL), indicating acute kidney injury likely secondary to contrast from imaging studies.

What is the most appropriate anticoagulant?', '[{"label":"A","text":"Fondaparinux 7.5 mg subcutaneous daily"},{"label":"B","text":"Argatroban continuous IV infusion"},{"label":"C","text":"Bivalirudin continuous IV infusion"},{"label":"D","text":"Rivaroxaban 15 mg twice daily"},{"label":"E","text":"Warfarin with INR target 2-3"}]'::jsonb, 'B', 'This patient has probable heparin-induced thrombocytopenia (HIT) with thrombosis (HITT) requiring immediate alternative anticoagulation. The choice of agent depends critically on renal function. Fondaparinux, while effective in HIT, is renally eliminated and contraindicated or requires dose adjustment in significant renal impairment (CrCl <30 mL/min). This patient''s acute kidney injury makes fondaparinux a poor choice. Argatroban is a direct thrombin inhibitor that is hepatically metabolized and is the preferred agent in HIT with renal dysfunction. Bivalirudin is also hepatically cleared but is typically reserved for patients undergoing PCI. Why Other Options Are Wrong: • A (Fondaparinux): Renally cleared; inappropriate in acute kidney injury with creatinine 3.2 mg/dL. • C (Bivalirudin): Hepatically metabolized but primarily used for PCI, not general HIT management. • D (Rivaroxaban): Direct oral anticoagulants are not recommended for initial treatment of HIT; used for transition after platelet recovery. • E (Warfarin): Contraindicated in acute HIT due to risk of warfarin-induced skin necrosis and venous limb gangrene; only used after platelet recovery. High-Yield Takeaway: In heparin-induced thrombocytopenia with renal impairment, argatroban (hepatically metabolized) is preferred over fondaparinux (renally eliminated).', NULL, 'internal', 'active'),
  ('B4_warfarin-supratherapeutic-no-vitamin-k', 'warfarin-supratherapeutic-no-vitamin-k', 'Batch4', 'Hematology/Oncology', 'A 68-year-old woman on warfarin for atrial fibrillation presents for routine INR monitoring. She is asymptomatic with no signs of bleeding—no bruising, hematuria, melena, or epistaxis. Her INR is 5.8 (target 2-3). She took an extra warfarin dose by mistake 3 days ago. Physical examination is unremarkable. Complete blood count shows hemoglobin of 12.4 g/dL (baseline 12.6 g/dL). She is at low risk for falls and has no history of major bleeding.

What is the most appropriate management?', '[{"label":"A","text":"Administer vitamin K 2.5 mg orally"},{"label":"B","text":"Administer vitamin K 10 mg IV"},{"label":"C","text":"Hold warfarin and recheck INR in 24-48 hours"},{"label":"D","text":"Hold warfarin and administer fresh frozen plasma"},{"label":"E","text":"Continue warfarin at current dose and recheck INR in 1 week"}]'::jsonb, 'C', 'For asymptomatic supratherapeutic INR between 4.5-10 without bleeding, the recommended management is to hold warfarin and monitor. Vitamin K is not routinely indicated unless INR is >10 or the patient is bleeding or at high bleeding risk. This patient''s INR of 5.8 with no bleeding, stable hemoglobin, and clear explanation (accidental extra dose) can be managed conservatively. The half-life of warfarin means INR will drift down over 24-48 hours simply by holding doses. Administering vitamin K in this scenario risks overcorrection and subsequent subtherapeutic anticoagulation, which can increase thromboembolic risk. Why Other Options Are Wrong: • A (Oral vitamin K 2.5 mg): Not indicated for INR 5-10 without bleeding; may cause overcorrection. • B (IV vitamin K 10 mg): Reserved for serious/life-threatening bleeding with full reversal needs. • D (FFP): Only indicated with active bleeding requiring immediate reversal. • E (Continue warfarin): Incorrect; must hold warfarin with significantly elevated INR. High-Yield Takeaway: For INR 4.5-10 without bleeding, hold warfarin and monitor; vitamin K is not routinely needed unless INR >10 or bleeding present. RHEUMATOLOGY', NULL, 'internal', 'active'),
  ('B4_gout-flare-continue-allopurinol', 'gout-flare-continue-allopurinol', 'Batch4', 'Rheumatology', 'A 56-year-old man with gout has been on allopurinol 300 mg daily for 6 weeks, started after his second gout flare. He now presents with acute onset of severe pain, redness, and swelling of his left first metatarsophalangeal joint. He was not prescribed prophylaxis at the time of allopurinol initiation. Uric acid level 2 weeks ago was 5.2 mg/dL (down from 9.8 mg/dL). Joint aspiration confirms negatively birefringent needle-shaped crystals.

What is the most appropriate management of his allopurinol during this acute flare?', '[{"label":"A","text":"Discontinue allopurinol until the flare resolves"},{"label":"B","text":"Reduce allopurinol dose to 100 mg daily during the flare"},{"label":"C","text":"Continue allopurinol at current dose"},{"label":"D","text":"Increase allopurinol to 400 mg daily to lower uric acid further"},{"label":"E","text":"Switch to febuxostat for better uric acid control"}]'::jsonb, 'C', 'When a gout flare occurs in a patient already on urate-lowering therapy (ULT), the ULT should be continued at the same dose, not stopped or adjusted. Historically, there was concern that continuing allopurinol would prolong flares, but evidence shows that discontinuing ULT during a flare leads to uric acid fluctuations that may worsen or prolong the attack. The flare should be treated with appropriate anti-inflammatory therapy (NSAIDs, colchicine, or corticosteroids), while allopurinol is maintained. Flares during ULT initiation are expected and reflect crystal mobilization as deposits dissolve—this is why prophylactic anti-inflammatory coverage should have been prescribed at initiation. Why Other Options Are Wrong: • A (Discontinue allopurinol): Causes uric acid fluctuation that may worsen or prolong the flare. • B (Reduce dose): Same problem as discontinuation; dose changes during flares are not recommended. • D (Increase dose): Dose adjustments should not occur during acute flares. • E (Switch to febuxostat): No indication to switch during acute flare; continue current ULT. High-Yield Takeaway: Do not stop or adjust urate-lowering therapy during an acute gout flare; continue the current regimen and treat the flare with anti-inflammatory medications.', NULL, 'internal', 'active'),
  ('B4_lupus-nephritis-biopsy-timing', 'lupus-nephritis-biopsy-timing', 'Batch4', 'Rheumatology', 'A 28-year-old woman with known systemic lupus erythematosus (SLE) presents with 2 weeks of facial swelling and foamy urine. She is currently on hydroxychloroquine only. Labs reveal creatinine 1.6 mg/dL (baseline 0.8 mg/dL), urine protein-to-creatinine ratio of 4.2 g/g, and urine microscopy shows numerous RBC casts. C3 and C4 are low, and anti-dsDNA antibody titers have risen four-fold. She is hemodynamically stable but increasingly edematous. Nephrology consultation for renal biopsy has a 10-day wait due to scheduling constraints.

What is the most appropriate management while awaiting biopsy?', '[{"label":"A","text":"Wait for biopsy results before initiating any immunosuppressive therapy"},{"label":"B","text":"Start high-dose prednisone now and await biopsy for further decisions"},{"label":"C","text":"Start hydroxychloroquine dose increase only"},{"label":"D","text":"Initiate both high-dose corticosteroids and mycophenolate empirically"},{"label":"E","text":"Proceed with cyclophosphamide induction empirically"}]'::jsonb, 'B', 'This patient has active lupus nephritis based on nephrotic-range proteinuria, rising creatinine, active urine sediment (RBC casts), and serologic activity (low complements, rising anti-dsDNA). Renal biopsy remains essential for classification and guiding long-term therapy, but when biopsy is delayed and there is clear evidence of active nephritis, initiating high-dose corticosteroids empirically is appropriate. Steroids provide immediate anti-inflammatory effect and can be safely started while awaiting histologic classification. The addition of specific steroid-sparing agents (mycophenolate vs. cyclophosphamide) typically depends on biopsy results (Class III/IV vs. V), so these should await histology unless there is rapidly progressive disease. Why Other Options Are Wrong: • A (Wait for biopsy): Delays necessary treatment; active nephritis can progress rapidly. • C (Increase hydroxychloroquine): Inadequate for active nephritis; immunosuppression needed. • D (Add mycophenolate empirically): Reasonable but typically guided by biopsy class; starting steroids alone is standard. • E (Cyclophosphamide): Aggressive choice typically reserved for severe proliferative nephritis confirmed on biopsy. High-Yield Takeaway: When lupus nephritis is clinically evident but biopsy is delayed, initiate high-dose corticosteroids empirically; additional immunosuppression is guided by biopsy results. INFECTIOUS DISEASE', NULL, 'internal', 'active'),
  ('B4_latent-tb-rifampin-over-inh', 'latent-tb-rifampin-over-inh', 'Batch4', 'Infectious Disease', 'A 62-year-old man from an endemic region is found to have a positive interferon-gamma release assay during routine screening prior to starting adalimumab for rheumatoid arthritis. Chest X-ray is normal. He has no symptoms of active tuberculosis. He has a history of isoniazid-related hepatotoxicity during a prior incomplete treatment attempt 10 years ago (ALT rose to 8 times the upper limit of normal). His current liver function tests are normal.

What is the most appropriate treatment for latent tuberculosis infection?', '[{"label":"A","text":"Isoniazid 300 mg daily for 9 months with hepatic monitoring"},{"label":"B","text":"Isoniazid 300 mg plus rifapentine weekly for 12 weeks"},{"label":"C","text":"Rifampin 600 mg daily for 4 months"},{"label":"D","text":"No treatment needed given prior hepatotoxicity"},{"label":"E","text":"Delay TNF-inhibitor therapy indefinitely"}]'::jsonb, 'C', 'This patient requires latent TB infection (LTBI) treatment prior to TNF-inhibitor therapy due to high reactivation risk. However, he has a documented history of significant isoniazid-induced hepatotoxicity, which precludes re-challenge with isoniazid-containing regimens. Rifampin monotherapy for 4 months is an effective alternative with a better hepatic safety profile than isoniazid. It is particularly appropriate in patients with prior isoniazid intolerance, those at risk for hepatotoxicity, or when adherence to longer regimens is a concern. The 4-month duration also improves completion rates compared to 9-month isoniazid. Why Other Options Are Wrong: • A (Isoniazid 9 months): Contraindicated given prior severe hepatotoxicity; re-challenge is not appropriate. • B (INH + rifapentine 3HP): Contains isoniazid; contraindicated in this patient. • D (No treatment): Unacceptable; TNF-inhibitor therapy dramatically increases TB reactivation risk. • E (Delay TNF-inhibitor indefinitely): Not necessary; rifampin allows safe treatment of LTBI. High-Yield Takeaway: For latent TB in patients with isoniazid intolerance or hepatotoxicity, rifampin monotherapy for 4 months is the preferred alternative regimen. NEUROLOGY & PSYCHIATRY', NULL, 'internal', 'active'),
  ('B4_ms-relapse-steroid-refractory-plex', 'ms-relapse-steroid-refractory-plex', 'Batch4', 'Neurology & Psychiatry', 'A 34-year-old woman with relapsing-remitting multiple sclerosis presents with acute right-sided weakness and difficulty walking, progressing over 3 days. MRI brain shows a new enhancing lesion in the left periventricular white matter. She receives high-dose IV methylprednisolone (1g daily) for 5 days but shows no improvement 10 days after completing the course. She cannot ambulate without assistance, and repeat MRI shows persistent enhancement. She has not responded to oral prednisone taper initiated after IV steroids.

What is the most appropriate next step in management?', '[{"label":"A","text":"Repeat 5-day course of IV methylprednisolone"},{"label":"B","text":"Initiate plasma exchange (plasmapheresis)"},{"label":"C","text":"Start natalizumab immediately"},{"label":"D","text":"Transition to cyclophosphamide pulse therapy"},{"label":"E","text":"Observe for spontaneous improvement over the next 4 weeks"}]'::jsonb, 'B', 'This patient has a steroid-refractory MS relapse, defined as lack of meaningful clinical improvement after high-dose IV corticosteroids. Plasma exchange (plasmapheresis or PLEX) is the established second-line treatment for severe, disabling MS relapses that fail to respond to corticosteroids. PLEX removes circulating autoantibodies and inflammatory mediators and has been shown to produce improvement in approximately 40-50% of steroid-refractory patients. It is typically administered as 5-7 exchanges over 10-14 days. This is distinct from disease-modifying therapy escalation, which addresses relapse prevention rather than acute relapse treatment. Why Other Options Are Wrong: • A (Repeat IV steroids): Repeating a failed therapy is unlikely to provide benefit; escalation to PLEX is indicated. • C (Natalizumab): A disease-modifying therapy for relapse prevention, not acute relapse treatment. • D (Cyclophosphamide): Not standard for acute relapse treatment; reserved for highly active or refractory disease prevention. • E (Observe): Inappropriate for a disabling relapse with persistent deficits; active intervention warranted. High-Yield Takeaway: Steroid-refractory MS relapse with significant disability warrants plasma exchange as the next step, not repeat steroids or disease-modifying therapy initiation.', NULL, 'internal', 'active'),
  ('B4_depression-ssri-augmentation-timing', 'depression-ssri-augmentation-timing', 'Batch4', 'Neurology & Psychiatry', 'A 45-year-old woman with major depressive disorder has been on sertraline 200 mg daily (maximum dose) for 10 weeks. She reports some improvement—her sleep is better, and she no longer has passive suicidal ideation—but continues to have low energy, anhedonia, and poor concentration that impair her work function. PHQ-9 score has decreased from 22 to 14. She tolerates the medication well with no significant side effects.

What is the most appropriate next step in management?', '[{"label":"A","text":"Continue sertraline monotherapy and reassess in 4 more weeks"},{"label":"B","text":"Switch to a different SSRI"},{"label":"C","text":"Augment with aripiprazole"},{"label":"D","text":"Switch to venlafaxine"},{"label":"E","text":"Discontinue sertraline and start psychotherapy alone"}]'::jsonb, 'C', 'This patient has a partial response to adequate SSRI therapy (maximum dose, adequate duration of 10 weeks). A partial response is defined as some improvement but with persistent clinically significant symptoms. In this scenario, augmentation is preferred over switching because the patient has shown benefit from the current medication. Switching would abandon gains and restart the clock on response. Atypical antipsychotics (aripiprazole, quetiapine, brexpiprazole) and other augmenting agents (bupropion, lithium, thyroid hormone) can enhance response to SSRIs. Aripiprazole has strong evidence for augmentation in partial responders. Why Other Options Are Wrong: • A (Continue and reassess): Already at maximum dose for adequate duration with only partial response; augmentation is indicated. • B (Switch to different SSRI): Switching is appropriate for non-responders or intolerance, not partial responders who have shown benefit. • D (Switch to venlafaxine): Switching classes loses current gains; augmentation preserves partial response. • E (Discontinue and use psychotherapy alone): Would abandon pharmacologic gains; psychotherapy can be added but medication should continue. High-Yield Takeaway: For partial SSRI response (some improvement but residual symptoms), augment with a second agent rather than switching medications.', NULL, 'internal', 'active'),
  ('B4_nms-vs-serotonin-syndrome-overlap', 'nms-vs-serotonin-syndrome-overlap', 'Batch4', 'Neurology & Psychiatry', 'A 42-year-old man with schizophrenia and comorbid depression is brought to the emergency department with altered mental status, temperature of 39.8°C, diaphoresis, and generalized tremor. He was recently started on haloperidol 2 weeks ago for psychotic exacerbation and fluoxetine 3 days ago for worsening depression. On examination, he has marked muscle rigidity (lead-pipe type), hyperreflexia, bilateral ankle clonus, and dilated pupils. Vital signs show HR 118 bpm, BP 162/98 mmHg. Labs show WBC 14,000/μL and CK 2,400 U/L.

Which clinical feature most reliably distinguishes between the two most likely diagnoses?', '[{"label":"A","text":"Elevated temperature"},{"label":"B","text":"Presence of tremor"},{"label":"C","text":"Elevated creatine kinase"},{"label":"D","text":"Hyperreflexia with clonus"},{"label":"E","text":"Muscle rigidity"}]'::jsonb, 'D', 'This patient has features overlapping between neuroleptic malignant syndrome (NMS) from haloperidol and serotonin syndrome from fluoxetine. Both can cause hyperthermia, altered mental status, autonomic instability, and elevated CK. The distinguishing feature is the neurologic examination: NMS causes lead-pipe rigidity with bradyreflexia or normal reflexes (extrapyramidal/dopaminergic), while serotonin syndrome causes hyperreflexia, clonus, and myoclonus (serotonergic neuromuscular excitation). This patient''s hyperreflexia and ankle clonus point toward serotonin syndrome or a mixed picture, despite the rigidity suggesting NMS. The presence of clonus is classically associated with serotonin syndrome and is unusual in pure NMS. Why Other Options Are Wrong: • A (Elevated temperature): Present in both conditions; not distinguishing. • B (Tremor): Can occur in both; not reliable discriminator. • C (Elevated CK): Present in both (higher in NMS but overlaps significantly). • E (Muscle rigidity): Classic for NMS but can occur in severe serotonin syndrome; clonus is more specific. High-Yield Takeaway: Hyperreflexia and clonus suggest serotonin syndrome, while lead-pipe rigidity with normal/decreased reflexes suggests NMS; this distinction is critical when a patient is on both antipsychotics and serotonergic medications. OB/GYN', NULL, 'internal', 'active'),
  ('B4_iugr-early-vs-late-onset-delivery', 'iugr-early-vs-late-onset-delivery', 'Batch4', 'Ob/Gyn', 'A 32-year-old G2P1 woman at 28 weeks gestation is found to have an estimated fetal weight below the 3rd percentile with elevated umbilical artery Doppler pulsatility index (>95th percentile) but positive end-diastolic flow. Amniotic fluid index is 6 cm (low-normal). Detailed anatomic survey and genetic testing were normal. She has chronic hypertension controlled on labetalol. Biophysical profile is 8/8. Middle cerebral artery Doppler shows brain- sparing effect.

What is the most appropriate delivery timing if fetal status remains stable?', '[{"label":"A","text":"Deliver immediately due to IUGR severity"},{"label":"B","text":"Deliver at 34 weeks after antenatal corticosteroids"},{"label":"C","text":"Deliver at 37 weeks"},{"label":"D","text":"Deliver at 39 weeks"},{"label":"E","text":"Allow spontaneous labor regardless of gestational age"}]'::jsonb, 'B', 'This is early-onset fetal growth restriction (FGR), defined by onset before 32 weeks with abnormal umbilical artery Doppler. Early-onset FGR has different pathophysiology and management than late-onset FGR (>32 weeks). The presence of abnormal umbilical artery Doppler with brain-sparing (MCA redistribution) indicates placental insufficiency. For early-onset FGR with abnormal Doppler but preserved end-diastolic flow and reassuring biophysical profile, delivery is typically recommended around 34-37 weeks after antenatal corticosteroids, with closer timing (34 weeks) for more severe Doppler abnormalities or additional risk factors. This patient''s combination of early onset, EFW <3rd percentile, and abnormal UA Doppler with brain-sparing warrants delivery around 34 weeks rather than waiting until term. Why Other Options Are Wrong: • A (Deliver immediately): Premature at 28 weeks with stable fetal status; expectant management with monitoring is appropriate. • C (37 weeks): May be appropriate for late-onset FGR but too late for early-onset with abnormal Doppler. • D (39 weeks): Too late given the severity of early-onset FGR with Doppler abnormalities. • E (Spontaneous labor): Ignores the need for planned delivery based on severity of FGR. High-Yield Takeaway: Early-onset FGR (<32 weeks) with abnormal umbilical artery Doppler warrants earlier delivery (around 34 weeks with stable fetus) compared to late-onset FGR, which can be managed closer to term.', NULL, 'internal', 'active'),
  ('B4_gdm-glyburide-failure-switch-insulin', 'gdm-glyburide-failure-switch-insulin', 'Batch4', 'Ob/Gyn', 'A 34-year-old G1P0 woman at 30 weeks gestation was diagnosed with gestational diabetes at 26 weeks. After diet and exercise failed to achieve glycemic targets, glyburide 5 mg twice daily was initiated 3 weeks ago and titrated to 10 mg twice daily. Her fasting glucose remains 115-125 mg/dL (goal <95), and postprandial values are 160-180 mg/dL (goal <120 at 2 hours). She is adherent to medication and dietary recommendations. Fetal growth is at the 75th percentile.

What is the most appropriate next step in management?', '[{"label":"A","text":"Increase glyburide to 15 mg twice daily"},{"label":"B","text":"Add metformin to glyburide"},{"label":"C","text":"Switch to insulin therapy"},{"label":"D","text":"Continue current regimen as values are near target"},{"label":"E","text":"Recommend increased exercise and stricter diet"}]'::jsonb, 'C', 'This patient has failed glyburide therapy for gestational diabetes. Oral agent failure is defined as inability to achieve glycemic targets despite maximum or near-maximum dosing with adequate adherence. Glyburide''s maximum effective dose in pregnancy is typically 10-20 mg daily, and this patient is at 20 mg daily with persistently elevated fasting and postprandial glucoses. The appropriate next step is transition to insulin, which remains the gold standard for GDM and has the most predictable dose-response relationship. Fetal macrosomia risk increases with hyperglycemia, making timely control essential. Why Other Options Are Wrong: • A (Increase glyburide): At or near maximum dose; further increase has diminishing returns and increased hypoglycemia risk. • B (Add metformin): Adding a second oral agent is not standard; insulin is preferred for oral agent failure. • D (Continue current regimen): Values are significantly above target; continued hyperglycemia increases fetal risk. • E (More diet/exercise): Already on medication indicating lifestyle alone insufficient; insulin is needed. High-Yield Takeaway: Failure to achieve glycemic targets on maximum oral agent therapy in gestational diabetes mandates transition to insulin, not addition of another oral agent.', NULL, 'internal', 'active'),
  ('B4_pprom-latency-antibiotics-duration', 'pprom-latency-antibiotics-duration', 'Batch4', 'Ob/Gyn', 'A 29-year-old G2P1 woman at 31 weeks gestation presents with spontaneous rupture of membranes confirmed by nitrazine and ferning tests. She is afebrile, non-contracting, and fetal heart tracing is category I. Group B streptococcus status is unknown. She receives antenatal corticosteroids for fetal lung maturity. Latency antibiotics are initiated per protocol.

What is the appropriate duration of latency antibiotic therapy?', '[{"label":"A","text":"48 hours only"},{"label":"B","text":"Until delivery occurs"},{"label":"C","text":"7 days regardless of delivery timing"},{"label":"D","text":"10 days with oral agent completion at home"},{"label":"E","text":"Until GBS culture results return"}]'::jsonb, 'C', 'In preterm premature rupture of membranes (PPROM), latency antibiotics are administered to prolong pregnancy and reduce infectious complications. The standard regimen is 7 days total: typically 48 hours of IV ampicillin and erythromycin (or azithromycin) followed by 5 days of oral amoxicillin and erythromycin (or azithromycin alone for 5 days after IV). This regimen has been shown to prolong latency, reduce chorioamnionitis, and improve neonatal outcomes. The duration is 7 days total, not until delivery or based on culture results. GBS prophylaxis during labor is a separate consideration. Why Other Options Are Wrong: • A (48 hours): Only the IV component; oral antibiotics should continue to complete 7-day course. • B (Until delivery): Exceeds evidence-based duration; 7 days is the proven regimen. • D (10 days): Longer than standard regimen; no additional benefit demonstrated. • E (Until GBS results): GBS prophylaxis during labor is separate from latency antibiotics. High-Yield Takeaway: Latency antibiotics in PPROM are administered for 7 days total (not until delivery) to prolong pregnancy and reduce infection.', NULL, 'internal', 'active'),
  ('B4_ectopic-mtx-failure-criteria', 'ectopic-mtx-failure-criteria', 'Batch4', 'Ob/Gyn', 'A 26-year-old woman with a 6-week ectopic pregnancy (β-hCG 2,800 mIU/mL, adnexal mass 2.5 cm, no fetal cardiac activity, hemodynamically stable) received single-dose methotrexate (50 mg/m²) 7 days ago. Day 4 β-hCG was 3,100 mIU/mL and day 7 β-hCG is 2,950 mIU/mL (5% decline from day 4). She has mild abdominal discomfort but no rebound or guarding. Hemoglobin is stable at 11.8 g/dL.

What is the most appropriate next step in management?', '[{"label":"A","text":"Administer second dose of methotrexate"},{"label":"B","text":"Proceed to surgical management"},{"label":"C","text":"Check β-hCG in 1 week and continue observation"},{"label":"D","text":"Repeat methotrexate only if β-hCG rises above 3,500 mIU/mL"},{"label":"E","text":"Discharge with close outpatient follow-up"}]'::jsonb, 'C', 'Methotrexate treatment success is assessed by comparing day 4 and day 7 β-hCG levels. A decline of ≥15% from day 4 to day 7 indicates adequate response. This patient had only a 5% decline (3,100 to 2,950), which is technically insufficient by the 15% threshold. However, any decline (even if <15%) warrants continued observation with weekly β-hCG monitoring rather than immediate second dose or surgery, as many patients with slow initial decline will ultimately respond. A second dose is indicated if β-hCG rises or plateaus (fails to decline) between day 4 and day 7, not simply for declining <15%. Given that her levels are decreasing and she remains hemodynamically stable with mild symptoms, continued observation with weekly β-hCG is appropriate. Why Other Options Are Wrong: • A (Second MTX dose): Indicated for β-hCG rise or plateau, not slow decline; premature intervention. • B (Surgery): Reserved for true MTX failure, hemodynamic instability, or ruptured ectopic; not indicated here. • D (Wait for 3,500): No specific threshold for second dose; trend matters more than absolute value. • E (Discharge with follow-up): Appropriate but the key management is continued β-hCG monitoring, not just follow-up. High-Yield Takeaway: Methotrexate for ectopic pregnancy is considered failing if β-hCG plateaus or rises between days 4-7; a slow decline warrants observation, not immediate second dose. PEDIATRICS', NULL, 'internal', 'active'),
  ('B4_kawasaki-ivig-refractory-escalation', 'kawasaki-ivig-refractory-escalation', 'Batch4', 'Pediatrics', 'A 4-year-old boy was diagnosed with Kawasaki disease and received IVIG (2 g/kg) plus aspirin 5 days ago. His fever resolved for 48 hours but has returned, with temperature now 39.4°C. He has persistent conjunctival injection, cracked lips, and a new desquamating rash on his fingertips. Echocardiogram shows mild coronary artery dilation (z-score 2.8) without aneurysm. Labs show CRP 8.5 mg/dL (elevated) and platelet count 650,000/μL.

What is the most appropriate next step in management?', '[{"label":"A","text":"Repeat IVIG 2 g/kg infusion"},{"label":"B","text":"Initiate high-dose IV methylprednisolone"},{"label":"C","text":"Add infliximab to current regimen"},{"label":"D","text":"Continue aspirin only and observe"},{"label":"E","text":"Repeat IVIG plus add IV methylprednisolone"}]'::jsonb, 'A', 'This patient has IVIG-refractory Kawasaki disease, defined as persistent or recrudescent fever ≥36 hours after completing initial IVIG. Approximately 10- 20% of patients are IVIG-refractory. The standard first-line treatment for IVIG-refractory disease is a second dose of IVIG (2 g/kg). Addition of corticosteroids to retreatment may be considered, particularly for patients with risk factors for coronary artery aneurysms, but the primary intervention is repeat IVIG. Infliximab or other biologics are typically reserved for patients who fail second-line therapy or have high-risk features. Why Other Options Are Wrong: • B (Steroids alone): Steroids alone are not first-line for IVIG-refractory disease; second IVIG dose is standard. • C (Infliximab): Typically reserved for failure of second IVIG dose or high-risk cases. • D (Observe): Inadequate; persistent fever increases coronary aneurysm risk. • E (IVIG + steroids): Adding steroids is reasonable in high-risk patients but second IVIG alone is the standard first step; this option may overcomplicate initial retreatment. High-Yield Takeaway: IVIG-refractory Kawasaki disease (persistent fever ≥36 hours after initial IVIG) is first managed with a second dose of IVIG; escalation to steroids or infliximab follows if refractory persists.', NULL, 'internal', 'active'),
  ('B4_pyloric-stenosis-correct-alkalosis-first', 'pyloric-stenosis-correct-alkalosis-first', 'Batch4', 'Pediatrics', 'A 5-week-old male infant presents with 5 days of progressively forceful, non-bilious vomiting occurring after every feed. He appears dehydrated with a sunken fontanelle and dry mucous membranes. Abdominal examination reveals a palpable "olive" in the epigastrium. Labs show sodium 132 mEq/L, potassium 2.8 mEq/L, chloride 88 mEq/L, bicarbonate 34 mEq/L, and pH 7.52. Abdominal ultrasound confirms pyloric stenosis.

What is the most appropriate next step in management?', '[{"label":"A","text":"Emergent pyloromyotomy within 2 hours"},{"label":"B","text":"IV fluid resuscitation with correction of electrolyte abnormalities, then surgery"},{"label":"C","text":"Nasogastric tube decompression and trial of prokinetic agents"},{"label":"D","text":"Atropine therapy to relax the pylorus"},{"label":"E","text":"Immediate surgical consultation for pyloromyotomy today"}]'::jsonb, 'B', 'Pyloric stenosis causes hypochloremic, hypokalemic metabolic alkalosis due to loss of gastric hydrochloric acid through vomiting. While pyloromyotomy is the definitive treatment, it is not a surgical emergency. Operating on a significantly alkalotic infant increases anesthetic risk, particularly post-operative apnea, because metabolic alkalosis causes compensatory hypoventilation that may not recover quickly after anesthesia. The priority is to resuscitate with IV normal saline (with potassium supplementation once urinating) to correct dehydration and electrolyte abnormalities. Surgery is performed once the infant is adequately resuscitated, typically within 24-48 hours. Why Other Options Are Wrong: • A (Emergent surgery in 2 hours): Dangerous without correcting metabolic derangements; increases anesthetic complications. • C (NG tube and prokinetics): Does not address pyloric stenosis; surgical correction is required. • D (Atropine): Rarely used historical medical management with poor efficacy; not standard of care. • E (Surgery today): May be appropriate once resuscitated but premature before metabolic correction. High-Yield Takeaway: Pyloric stenosis requires metabolic correction (alkalosis, hypokalemia, dehydration) before pyloromyotomy; surgery is not emergent and carries increased risk in uncorrected alkalotic infants.', NULL, 'internal', 'active'),
  ('B4_bronchiolitis-hypertonic-saline-inpatient-only', 'bronchiolitis-hypertonic-saline-inpatient-only', 'Batch4', 'Pediatrics', 'A 7-month-old infant presents with 3 days of rhinorrhea, cough, and wheezing. She has mild tachypnea and scattered wheezes with adequate oxygen saturation of 94% on room air. She is feeding well, taking about 70% of her usual intake. RSV rapid antigen test is positive. The parents ask about nebulized treatments they read about online that can "clear the mucus."

What is the most appropriate recommendation regarding nebulized hypertonic saline?', '[{"label":"A","text":"Prescribe nebulized 3% hypertonic saline for home use"},{"label":"B","text":"Administer nebulized hypertonic saline in the emergency department and discharge"},{"label":"C","text":"Admit for nebulized hypertonic saline therapy"},{"label":"D","text":"Nebulized hypertonic saline is not indicated for this patient"},{"label":"E","text":"Use nebulized normal saline as a safer alternative"}]'::jsonb, 'D', 'This infant has mild bronchiolitis with adequate oxygen saturation and feeding. AAP guidelines recommend supportive care (hydration, nasal suctioning, oxygen if needed) as the mainstay of bronchiolitis management. Nebulized hypertonic saline is not recommended for infants treated in the emergency department or outpatient setting. While some evidence suggests modest benefit in reducing length of stay for hospitalized patients (likely through improved mucociliary clearance), this benefit does not apply to outpatients. In the ED or outpatient setting, hypertonic saline has not been shown to prevent hospitalization or improve outcomes and adds cost and bronchospasm risk. Why Other Options Are Wrong: • A (Prescribe for home): Not indicated; no outpatient benefit demonstrated. • B (Give in ED and discharge): ED administration has not shown benefit in preventing hospitalization. • C (Admit for therapy): This infant does not meet admission criteria; admitting solely for hypertonic saline is inappropriate. • E (Normal saline): Also not routinely recommended; no proven benefit over supportive care. High-Yield Takeaway: Nebulized hypertonic saline may have modest benefit in hospitalized bronchiolitis patients but is not indicated in the emergency department or outpatient settings.', NULL, 'internal', 'active'),
  ('B4_febrile-seizure-complex-features-workup', 'febrile-seizure-complex-features-workup', 'Batch4', 'Pediatrics', 'An 18-month-old girl with no prior seizure history is brought in after having a generalized tonic-clonic seizure at home lasting approximately 20 minutes. She has had fever for 2 days with rhinorrhea and cough. On arrival, she is postictal and then has a second brief generalized seizure. Temperature is 39.5°C. After the seizure stops, she gradually becomes more alert but has left-sided weakness noted on exam. She is up to date on vaccinations including Hib and pneumococcal conjugate.

What is the most appropriate diagnostic evaluation?', '[{"label":"A","text":"Reassurance and discharge with return precautions"},{"label":"B","text":"EEG only"},{"label":"C","text":"Lumbar puncture and neuroimaging"},{"label":"D","text":"Lumbar puncture only"},{"label":"E","text":"Neuroimaging only"}]'::jsonb, 'C', 'This child has a complex febrile seizure with multiple concerning features: duration >15 minutes, multiple seizures within 24 hours, and focal postictal findings (Todd''s paralysis). Complex febrile seizures, particularly with focal features, warrant additional evaluation to exclude serious underlying pathology. Lumbar puncture should be performed to evaluate for meningitis/encephalitis given the age, prolonged seizure, and focal findings. Neuroimaging (CT or MRI) is indicated due to the focal postictal deficit (Todd''s paralysis) and prolonged seizure, which raise concern for structural abnormality, focal encephalitis (HSV), or complicated CNS infection. Neither study alone is sufficient. Why Other Options Are Wrong: • A (Reassure and discharge): Inappropriate for complex febrile seizure with concerning features. • B (EEG only): Does not address acute infectious or structural concerns. • D (LP only): Misses potential structural pathology or focal encephalitis. • E (Imaging only): Misses potential CNS infection. High-Yield Takeaway: Complex febrile seizures (prolonged, multiple, or focal features) require both lumbar puncture and neuroimaging, unlike simple febrile seizures which typically need neither. SURGERY', NULL, 'internal', 'active'),
  ('B4_inguinal-hernia-watchful-waiting', 'inguinal-hernia-watchful-waiting', 'Batch4', 'Surgery', 'A 78-year-old man with well-controlled hypertension and COPD (FEV1 55% predicted) is found to have a reducible right inguinal hernia on routine physical exam. He has no symptoms—no pain, discomfort, or bulge awareness—and the hernia was discovered incidentally. He has a normal BMI and remains active with daily walks. He has no history of hernia complications.

What is the most appropriate management?', '[{"label":"A","text":"Elective open hernia repair with mesh"},{"label":"B","text":"Elective laparoscopic hernia repair"},{"label":"C","text":"Watchful waiting with surgery if symptoms develop"},{"label":"D","text":"Truss fitting to prevent incarceration"},{"label":"E","text":"Urgent surgical referral due to incarceration risk"}]'::jsonb, 'C', 'Watchful waiting is an acceptable management strategy for asymptomatic or minimally symptomatic inguinal hernias, particularly in older patients or those with significant comorbidities. The WART trial (Watchful Waiting vs Repair Trial) demonstrated that in men with minimally symptomatic inguinal hernias, observation was safe, with low rates of hernia-related emergencies (1-2% per year) and crossover to surgery (about 20-25% at 2-4 years, usually for developing symptoms). For this elderly patient with COPD who has no symptoms, the surgical risk may outweigh the benefit of prophylactic repair. Surgery becomes indicated when symptoms develop. Why Other Options Are Wrong: • A, B (Elective repair): Not mandatory for asymptomatic inguinal hernia; watchful waiting is appropriate. • D (Truss): Trusses are rarely recommended; they don''t prevent incarceration and may cause complications. • E (Urgent referral): No urgency for an asymptomatic, reducible hernia without signs of complications. High-Yield Takeaway: Asymptomatic inguinal hernia in an elderly patient with comorbidities can be managed with watchful waiting; elective repair is not mandatory and is offered when symptoms develop.', NULL, 'internal', 'active'),
  ('B4_cholecystectomy-timing-post-pancreatitis', 'cholecystectomy-timing-post-pancreatitis', 'Batch4', 'Surgery', 'A 48-year-old woman is hospitalized with mild acute gallstone pancreatitis (Ranson score 1, no organ failure, CT shows interstitial edematous pancreatitis). By hospital day 3, her abdominal pain has resolved, she is tolerating a regular diet, and labs show lipase 180 U/L (down from 1,800 U/L), WBC 7,500/μL, and normal liver enzymes. Right upper quadrant ultrasound shows multiple gallstones with a normal common bile duct.

What is the most appropriate timing for cholecystectomy?', '[{"label":"A","text":"After 6 weeks to allow inflammation to resolve"},{"label":"B","text":"During this hospitalization before discharge"},{"label":"C","text":"Schedule electively within 2-4 weeks after discharge"},{"label":"D","text":"Only if recurrent pancreatitis occurs"},{"label":"E","text":"Perform ERCP with sphincterotomy instead of cholecystectomy"}]'::jsonb, 'B', 'For mild gallstone pancreatitis without necrosis or other complications, cholecystectomy should be performed during the index hospitalization (same- admission cholecystectomy) once the patient has clinically recovered. This approach reduces the risk of recurrent biliary events, including recurrent pancreatitis (which occurs in 25-30% of patients within 6 weeks if cholecystectomy is delayed). Waiting 6 weeks was previously standard but has been shown to result in preventable recurrent events. Same-admission cholecystectomy is safe once pain resolves, diet is tolerated, and inflammatory markers are improving. Why Other Options Are Wrong: • A (After 6 weeks): Outdated; significantly increases recurrent biliary event risk. • C (2-4 weeks after discharge): Still delays intervention with unnecessary risk of interval recurrence. • D (Only if recurrence): Reactive approach leads to preventable recurrent pancreatitis and its complications. • E (ERCP with sphincterotomy): Does not eliminate gallbladder as stone source; reserved for common bile duct stones or patients unfit for surgery. High-Yield Takeaway: Cholecystectomy for mild gallstone pancreatitis should be performed during the same hospitalization once the patient has clinically recovered, not delayed for weeks.', NULL, 'internal', 'active'),
  ('B4_appendicitis-interval-appendectomy-skip', 'appendicitis-interval-appendectomy-skip', 'Batch4', 'Surgery', 'A 35-year-old man was treated 8 weeks ago for uncomplicated acute appendicitis managed non-operatively with IV antibiotics due to his preference to avoid surgery. CT at that time showed a non-perforated appendix without abscess. He completed a 7-day antibiotic course with complete resolution of symptoms. Follow-up CT shows resolution of inflammation with a normal-appearing appendix. He remains asymptomatic.

What is the most appropriate management?', '[{"label":"A","text":"Proceed with interval appendectomy within the next 4 weeks"},{"label":"B","text":"Perform colonoscopy before deciding on surgery"},{"label":"C","text":"Interval appendectomy is not required; continue observation"},{"label":"D","text":"Obtain MRI of the abdomen before interval appendectomy"},{"label":"E","text":"Interval appendectomy only if symptoms recur"}]'::jsonb, 'E', 'The management of uncomplicated appendicitis has evolved. Non-operative management with antibiotics is successful in 70-80% of patients, and of those, approximately 30-40% will have recurrence within 5 years. The traditional approach of interval appendectomy for all patients has been questioned. Current evidence suggests that routine interval appendectomy is not mandatory after successful non-operative treatment of uncomplicated appendicitis. A reasonable approach is to offer appendectomy for recurrence. For patients over 40, colonoscopy or imaging follow-up to exclude malignancy masquerading as appendicitis is recommended, but for this 35-year-old with resolved imaging, observation with surgery reserved for recurrence is appropriate. Why Other Options Are Wrong: • A (Interval appendectomy in 4 weeks): Not required for uncomplicated appendicitis treated non-operatively. • B (Colonoscopy first): Typically recommended for patients >40 years to exclude neoplasm; not mandatory for this 35-year-old. • C (Continue observation without offering surgery for recurrence): Subtly incorrect; observation is appropriate, but surgery should be offered if symptoms recur. • D (MRI): No indication; CT has already shown resolution. High-Yield Takeaway: After successful non-operative treatment of uncomplicated appendicitis, interval appendectomy is not mandatory; surgery is reserved for recurrence. BATCH 4 — QUESTION GENERATION COMPLETE Total questions generated: 33 Format: NBME-style clinical vignettes with single best answer Coverage: All 33 locked Batch 4 concepts', NULL, 'internal', 'active'),
  ('B5_Q1_1', 'incidental-pe-observation-criteria', 'Batch5', '', 'A 58-year-old woman undergoes CT chest for lung cancer staging. Imaging reveals a subsegmental pulmonary embolism in a peripheral branch of the right lower lobe. She is asymptomatic with normal vital signs, oxygen saturation 98% on room air, and no leg swelling. Her cancer is limited to a 1.5 cm nodule without lymph node involvement.

What is the most appropriate next step?', '[{"label":"A","text":"Start therapeutic anticoagulation with apixaban"},{"label":"B","text":"Obtain lower extremity duplex ultrasound"},{"label":"C","text":"Place inferior vena cava filter"},{"label":"D","text":"Repeat CT pulmonary angiography in 48 hours"},{"label":"E","text":"Clinical surveillance without anticoagulation"}]'::jsonb, 'E', 'Incidental subsegmental PE in asymptomatic patients—particularly those with isolated peripheral clots and no concomitant DVT—represents a gray zone where anticoagulation may cause more harm than benefit. The 2019 ASH guidelines acknowledge that subsegmental PE without proximal DVT in low-risk, asymptomatic patients may be observed. This patient has no symptoms, stable vitals, adequate oxygenation, and limited-stage cancer. The bleeding risk of anticoagulation may outweigh benefit. Surveillance with close follow-up is reasonable.', NULL, 'internal', 'active'),
  ('B5_Q1_2', 'incidental-pe-observation-criteria', 'Batch5', '', 'A 72-year-old man with COPD undergoes CT angiography for evaluation of a thoracic aortic aneurysm. An incidental filling defect is noted in a subsegmental artery of the left lower lobe. He denies dyspnea, chest pain, or leg swelling. Vital signs: BP 128/76, HR 72, RR 14, SpO2 95% on room air. Lower extremity ultrasound shows no DVT.

Which factor most supports observation rather than anticoagulation?', '[{"label":"A","text":"History of COPD"},{"label":"B","text":"Subsegmental location without DVT"},{"label":"C","text":"Age greater than 70"},{"label":"D","text":"Thoracic aortic aneurysm"},{"label":"E","text":"SpO2 of 95%"}]'::jsonb, 'B', 'The key determinant for observing incidental PE is the combination of subsegmental location AND absence of proximal DVT. When clot burden is minimal and there is no evidence of propagation from the deep venous system, the clinical significance is uncertain. Guidelines suggest that in asymptomatic patients without DVT, the risk-benefit ratio of anticoagulation shifts toward observation. COPD, age, and baseline SpO2 are not the primary factors driving this decision.', NULL, 'internal', 'active'),
  ('B5_Q2_1', 'watchful-waiting-prostate-cancer', 'Batch5', '', 'A 68-year-old man is diagnosed with prostate adenocarcinoma after biopsy for elevated PSA (5.2 ng/mL). Gleason score is 3+3=6, clinical stage T1c, and MRI shows a single lesion in the peripheral zone with no extracapsular extension. He has no urinary symptoms and ECOG performance status 0. Life expectancy is estimated at 15+ years.

What is the most appropriate management approach?', '[{"label":"A","text":"Radical prostatectomy"},{"label":"B","text":"External beam radiation therapy"},{"label":"C","text":"Active surveillance with serial PSA and repeat biopsy"},{"label":"D","text":"Androgen deprivation therapy"},{"label":"E","text":"Watchful waiting with palliative intent"}]'::jsonb, 'C', 'Gleason 3+3=6 (Grade Group 1) prostate cancer has extremely low metastatic potential. For men with low-risk, localized disease and life expectancy >10 years, active surveillance is the preferred strategy per AUA/ASTRO guidelines. This involves serial PSA monitoring (every 6 months), repeat biopsy (every 1-2 years), and intervention only if disease reclassifies. Radical treatment exposes patients to unnecessary risks of incontinence and erectile dysfunction. Watchful waiting (answer E) differs—it implies no curative intent and is reserved for limited life expectancy.', NULL, 'internal', 'active'),
  ('B5_Q2_2', 'watchful-waiting-prostate-cancer', 'Batch5', '', 'A 74-year-old man with Gleason 3+3=6 prostate cancer on active surveillance has had stable PSA (4.8 → 5.1 ng/mL over 2 years). Repeat biopsy shows Gleason 3+4=7 in 2 of 12 cores with <10% tumor involvement per core. MRI shows no extracapsular extension.

Which finding would most warrant transition to definitive treatment?', '[{"label":"A","text":"PSA increase from 4.8 to 5.1 ng/mL"},{"label":"B","text":"Gleason pattern 4 on repeat biopsy"},{"label":"C","text":"Patient age of 74 years"},{"label":"D","text":"2 of 12 cores positive"},{"label":"E","text":"<10% tumor involvement per core"}]'::jsonb, 'B', 'The appearance of Gleason pattern 4 (upgrading to Grade Group 2) represents disease reclassification, which is the trigger to consider definitive therapy. Pattern 4 indicates more aggressive biology with increased metastatic potential. While some men with limited Gleason 3+4 may still qualify for continued surveillance, the presence of pattern 4 shifts the risk-benefit calculation. Minor PSA fluctuations, low-volume disease, and age alone do not mandate treatment.', NULL, 'internal', 'active'),
  ('B5_Q3_1', 'benign-pvc-no-ablation', 'Batch5', '', 'A 34-year-old woman presents with palpitations. Holter monitor shows 8,000 PVCs over 24 hours (8% burden), all monomorphic with LBBB morphology suggesting right ventricular outflow tract origin. Echocardiogram shows normal LV function (EF 62%) and no structural abnormalities. She describes the palpitations as "annoying but not disabling."

What is the most appropriate management?', '[{"label":"A","text":"Catheter ablation of the PVC focus"},{"label":"B","text":"Amiodarone for rhythm suppression"},{"label":"C","text":"Reassurance and lifestyle modification"},{"label":"D","text":"Implantable cardioverter-defibrillator"},{"label":"E","text":"Flecainide for PVC suppression"}]'::jsonb, 'C', 'Monomorphic PVCs from the RVOT in a structurally normal heart are typically benign. PVC burden <10-15% with preserved EF does not require intervention. The patient''s symptoms are tolerable, and there is no evidence of PVC- induced cardiomyopathy. Reassurance, caffeine reduction, and stress management are first-line. Ablation is reserved for high burden (>15-20%) with LV dysfunction or severely symptomatic patients refractory to conservative measures. Antiarrhythmics carry proarrhythmic risk without clear benefit here.', NULL, 'internal', 'active'),
  ('B5_Q3_2', 'benign-pvc-no-ablation', 'Batch5', '', 'A 52-year-old man with frequent PVCs undergoes serial echocardiography. Initial EF was 60%; repeat study 6 months later shows EF 48%. PVC burden on Holter is 22%. He now reports dyspnea on exertion.

Which factor most supports proceeding with catheter ablation?', '[{"label":"A","text":"PVC burden >20%"},{"label":"B","text":"Decline in EF from 60% to 48%"},{"label":"C","text":"New dyspnea on exertion"},{"label":"D","text":"All of the above together indicate PVC-induced cardiomyopathy"},{"label":"E","text":"Monomorphic PVC morphology"}]'::jsonb, 'D', 'The combination of high PVC burden (>15-20%), declining EF, and new heart failure symptoms defines PVC-induced cardiomyopathy—a reversible condition if the ectopic focus is eliminated. Each factor alone is insufficient: some patients tolerate high burden without LV dysfunction; EF decline may have other causes; dyspnea is nonspecific. The constellation together makes the diagnosis and supports ablation, which can restore normal EF. Monomorphic morphology simply indicates a single focus amenable to ablation.', NULL, 'internal', 'active'),
  ('B5_Q4_1', 'small-kidney-stone-expectant', 'Batch5', '', 'A 42-year-old man presents with acute left flank pain. Non-contrast CT shows a 3 mm stone in the left proximal ureter with mild hydronephrosis. Pain is controlled with ketorolac. Creatinine is 0.9 mg/dL, and he is afebrile with no signs of infection.

What is the most appropriate management?', '[{"label":"A","text":"Emergent ureteroscopy"},{"label":"B","text":"Extracorporeal shock wave lithotripsy"},{"label":"C","text":"Ureteral stent placement"},{"label":"D","text":"Medical expulsive therapy and observation"},{"label":"E","text":"Percutaneous nephrostomy"}]'::jsonb, 'D', 'Stones ≤5 mm have >90% spontaneous passage rate. This patient has a 3 mm stone, controlled pain, no infection, and preserved renal function. Medical expulsive therapy (alpha-blocker such as tamsulosin) may facilitate passage. Observation with adequate hydration and pain control is appropriate. Urgent intervention is reserved for: stones >10 mm, uncontrolled pain, infection/sepsis, AKI, or solitary kidney with obstruction. Proceeding directly to ureteroscopy or lithotripsy would be overtreatment.', NULL, 'internal', 'active'),
  ('B5_Q4_2', 'small-kidney-stone-expectant', 'Batch5', '', 'A 38-year-old woman is found to have a 4 mm non-obstructing lower pole renal calculus on CT performed for unrelated abdominal pain. She is asymptomatic and has no history of kidney stones. Urinalysis is normal.

What is the most appropriate recommendation?', '[{"label":"A","text":"24-hour urine metabolic evaluation"},{"label":"B","text":"Extracorporeal shock wave lithotripsy"},{"label":"C","text":"Observation without routine follow-up imaging"},{"label":"D","text":"Ureteroscopic stone removal"},{"label":"E","text":"Annual CT surveillance"}]'::jsonb, 'C', 'Asymptomatic, small (<5 mm), non-obstructing renal stones in patients without prior stone history can be observed without intervention or routine surveillance imaging. Most will never cause symptoms. The radiation exposure and cost of annual CT are not justified. Metabolic workup is typically reserved for recurrent stone formers or larger stones. Intervention is unnecessary for an incidental finding that poses minimal risk.', NULL, 'internal', 'active'),
  ('B5_Q5_1', 'stable-carotid-stenosis-medical-only', 'Batch5', '', 'A 71-year-old man with hypertension and hyperlipidemia is found to have an asymptomatic 55% right carotid stenosis on duplex ultrasound performed for a carotid bruit. He has never had a stroke or TIA. He takes lisinopril, atorvastatin 80 mg, and aspirin 81 mg daily. BP today is 126/74.

What is the most appropriate management?', '[{"label":"A","text":"Carotid endarterectomy"},{"label":"B","text":"Carotid artery stenting"},{"label":"C","text":"Continue current medical therapy without intervention"},{"label":"D","text":"Add clopidogrel for dual antiplatelet therapy"},{"label":"E","text":"Increase aspirin to 325 mg daily"}]'::jsonb, 'C', 'Asymptomatic carotid stenosis <60-70% does not meet threshold for intervention. Even at higher grades (60-79%), the benefit of carotid endarterectomy (CEA) in asymptomatic patients is marginal with modern medical therapy. The CREST-2 trial is investigating whether intensive medical therapy alone is sufficient. This patient is on optimal medical management (high-intensity statin, aspirin, BP control). Adding clopidogrel or escalating aspirin dose has no proven benefit and increases bleeding risk. Observation with continued medical optimization is appropriate.', NULL, 'internal', 'active'),
  ('B5_Q5_2', 'stable-carotid-stenosis-medical-only', 'Batch5', '', 'A 68-year-old woman with asymptomatic 72% left carotid stenosis asks about surgery. She has well-controlled diabetes, hypertension, and takes rosuvastatin 40 mg daily. Her estimated surgical risk (stroke/death) at your institution is 4%.

Which statement best describes the rationale for recommending medical management over CEA?', '[{"label":"A","text":"Her stenosis is below the intervention threshold"},{"label":"B","text":"Surgical risk exceeds expected benefit in asymptomatic stenosis"},{"label":"C","text":"She should wait until she develops symptoms"},{"label":"D","text":"Carotid stenting is preferred over CEA in diabetics"},{"label":"E","text":"Statins eliminate the need for any intervention"}]'::jsonb, 'B', 'For asymptomatic carotid stenosis, CEA benefit is modest (ARR ~1%/year for stroke). Guidelines recommend intervention only if perioperative risk is <3%. At 4% institutional risk, expected surgical harm exceeds benefit. Modern medical therapy (high-intensity statins, antiplatelets, BP/glucose control) has improved outcomes for asymptomatic stenosis, narrowing the gap with surgical intervention. Waiting for symptoms is not advisable—symptomatic stenosis carries higher stroke risk. The decision hinges on balancing procedural risk against annual stroke risk reduction.', NULL, 'internal', 'active'),
  ('B5_Q6_1', 'aortic-aneurysm-surveillance-threshold', 'Batch5', '', 'A 65-year-old man undergoes abdominal ultrasound for unrelated symptoms, revealing a 4.2 cm infrarenal abdominal aortic aneurysm. He is asymptomatic, normotensive, and a former smoker. He has no family history of aneurysm rupture.

What is the most appropriate management?', '[{"label":"A","text":"Immediate referral for endovascular repair"},{"label":"B","text":"Open surgical repair within 30 days"},{"label":"C","text":"CT angiography with surgical planning"},{"label":"D","text":"Repeat ultrasound in 12 months"},{"label":"E","text":"Repeat ultrasound in 6 months"}]'::jsonb, 'D', 'AAA repair is indicated when diameter reaches 5.5 cm in men (5.0 cm in women) or growth exceeds 0.5 cm in 6 months. At 4.2 cm, the annual rupture risk is <1%. Surveillance intervals are size-dependent: 3.0-3.9 cm = every 3 years; 4.0-4.9 cm = every 12 months; 5.0-5.4 cm = every 6 months. This patient appropriately receives annual surveillance. Operating on a 4.2 cm aneurysm would expose him to procedural risk (1-2% mortality for elective repair) without proportionate benefit.', NULL, 'internal', 'active'),
  ('B5_Q6_2', 'aortic-aneurysm-surveillance-threshold', 'Batch5', '', 'A 70-year-old woman has a known 4.8 cm AAA, increased from 4.5 cm one year ago. She is asymptomatic. Her surgical risk is considered average.

What is the most appropriate recommendation?', '[{"label":"A","text":"Elective repair given growth rate"},{"label":"B","text":"Continue annual surveillance"},{"label":"C","text":"Repeat imaging in 6 months"},{"label":"D","text":"Emergency vascular surgery consultation"},{"label":"E","text":"MRA in 3 months"}]'::jsonb, 'C', 'AAA growth of 0.3 cm/year is typical and does not mandate intervention. However, as aneurysm size approaches the threshold (5.0 cm for women, 5.5 cm for men), surveillance intervals should shorten. At 4.8 cm in a woman, she is near the 5.0 cm threshold, warranting 6-month follow-up to detect accelerated growth. If the next study shows ≥5.0 cm or >0.5 cm growth in 6 months, repair should be offered. Annual surveillance would be insufficient given proximity to threshold.', NULL, 'internal', 'active'),
  ('B5_Q7_1', 'low-risk-syncope-discharge-criteria', 'Batch5', '', 'A 28-year-old woman presents to the ED after fainting while standing in line at a concert. She recalls feeling warm and nauseated before losing consciousness briefly. She did not have convulsive activity or incontinence. On exam, she is fully alert with BP 118/72, HR 68, and normal cardiac and neurologic examinations. ECG shows normal sinus rhythm, normal intervals, and no concerning morphology.

What is the most appropriate disposition?', '[{"label":"A","text":"Admit for telemetry monitoring"},{"label":"B","text":"Discharge with outpatient Holter monitor"},{"label":"C","text":"Discharge with reassurance and return precautions"},{"label":"D","text":"Echocardiography before discharge"},{"label":"E","text":"Electrophysiology consultation"}]'::jsonb, 'C', 'This presentation is classic vasovagal syncope: prodrome (warmth, nausea), situational trigger (prolonged standing, hot environment), rapid recovery, and no red flags. The San Francisco Syncope Rule and Canadian Syncope Risk Score identify this as low-risk. Young patients with typical vasovagal features, normal ECG, and normal vital signs do not require admission, telemetry, or extensive workup. Reassurance with advice on prodrome recognition, hydration, and counter- pressure maneuvers is appropriate. Outpatient follow-up with PCP is reasonable.', NULL, 'internal', 'active'),
  ('B5_Q7_2', 'low-risk-syncope-discharge-criteria', 'Batch5', '', 'A 72-year-old man presents after syncope while sitting at dinner. He lost consciousness without warning and woke up on the floor. He has hypertension and takes amlodipine. BP is 142/88, HR 76, and he appears well. ECG shows sinus rhythm with a PR interval of 220 ms and left anterior fascicular block.

What is the most appropriate next step?', '[{"label":"A","text":"Discharge with outpatient loop recorder"},{"label":"B","text":"Admit for cardiac monitoring"},{"label":"C","text":"Reassurance and discharge"},{"label":"D","text":"Carotid sinus massage"},{"label":"E","text":"CT head before discharge"}]'::jsonb, 'B', 'This patient has multiple high-risk features: older age, syncope without prodrome (sudden LOC), syncope while seated (not orthostatic), and conduction abnormalities on ECG (prolonged PR + LAFB suggesting bifascicular block with risk of progression to complete heart block). Bifascicular block with unexplained syncope carries significant risk for bradyarrhythmic events. Admission for telemetry and possible electrophysiology evaluation is warranted. Discharging this patient—even with outpatient monitoring—risks missing high-grade AV block. Update Todos Generate questions for concepts 1-7 Generating questions for concepts 8-14 Generate questions for concepts 15-21', NULL, 'internal', 'active'),
  ('B5_Q8_1', 'antibiotic-stewardship-viral-uri', 'Batch5', '', 'A 35-year-old woman presents with 4 days of nasal congestion, clear rhinorrhea, sore throat, and mild cough. She has low- grade fever (100.2°F). Exam shows clear nasal discharge, mildly erythematous pharynx without exudate, and clear lungs. She requests antibiotics because she "can''t miss work."

What is the most appropriate management?', '[{"label":"A","text":"Amoxicillin for 5 days"},{"label":"B","text":"Azithromycin for 3 days"},{"label":"C","text":"Amoxicillin-clavulanate for 7 days"},{"label":"D","text":"Symptomatic treatment with reassurance"},{"label":"E","text":"Rapid strep test and treat if positive"}]'::jsonb, 'D', 'This presentation—nasal symptoms, clear rhinorrhea, sore throat without exudate, and cough—is consistent with viral upper respiratory infection. Antibiotics provide no benefit for viral URI and contribute to resistance, adverse effects, and unnecessary cost. Guidelines recommend against antibiotics for uncomplicated URI regardless of symptom duration <10 days. Symptomatic care (decongestants, NSAIDs, hydration) and reassurance about expected 7-10 day course is appropriate. Rapid strep testing is low-yield without tonsillar exudate, fever >101°F, or anterior cervical lymphadenopathy.', NULL, 'internal', 'active'),
  ('B5_Q8_2', 'antibiotic-stewardship-viral-uri', 'Batch5', '', 'A 42-year-old man presents with nasal congestion and facial pressure for 6 days. He has green nasal discharge. He is afebrile with mild maxillary tenderness. He is otherwise well and has no immunocompromise.

What is the most appropriate recommendation?', '[{"label":"A","text":"Amoxicillin-clavulanate for acute bacterial sinusitis"},{"label":"B","text":"CT sinus to confirm bacterial infection"},{"label":"C","text":"Continued symptomatic treatment with re-evaluation if worsening"},{"label":"D","text":"Azithromycin for atypical pathogen coverage"},{"label":"E","text":"Intranasal corticosteroids alone"}]'::jsonb, 'C', 'Purulent (green/yellow) nasal discharge does NOT indicate bacterial infection—it reflects neutrophil activity common in viral illness. Acute bacterial rhinosinusitis is diagnosed clinically when symptoms persist ≥10 days without improvement, or with "double-worsening" (improvement then deterioration), or severe onset (fever ≥102°F with purulent discharge for 3-4 days). At 6 days, this patient has uncomplicated viral rhinosinusitis. Antibiotics are not indicated. Continued symptomatic care with saline irrigation and analgesics is appropriate. CT imaging is not needed for uncomplicated cases.', NULL, 'internal', 'active'),
  ('B5_Q9_1', 'chest-pain-low-risk-outpatient-workup', 'Batch5', '', 'A 38-year-old woman presents to the ED with sharp, left-sided chest pain that worsens with deep breathing and position changes. She has no cardiac risk factors. Vital signs are normal. ECG shows normal sinus rhythm without ST changes. Troponin is negative at 0 and 3 hours. HEART score is 1.

What is the most appropriate disposition?', '[{"label":"A","text":"Admit for serial troponins and telemetry"},{"label":"B","text":"Stress testing before discharge"},{"label":"C","text":"CT coronary angiography before discharge"},{"label":"D","text":"Discharge with PCP follow-up"},{"label":"E","text":"Cardiology consultation"}]'::jsonb, 'D', 'HEART score ≤3 indicates low risk (<2% 30-day MACE). This patient has pleuritic, positional chest pain—features atypical for ACS—plus negative troponins and normal ECG. The HEART Pathway validates early discharge without stress testing for low-risk patients. Further cardiac workup (stress test, CTA) in a low-risk patient with non-cardiac features has poor yield and may generate false positives leading to invasive testing. Discharge with PCP follow-up for consideration of musculoskeletal or pleuritic etiologies is appropriate.', NULL, 'internal', 'active'),
  ('B5_Q9_2', 'chest-pain-low-risk-outpatient-workup', 'Batch5', '', 'A 52-year-old man with hypertension and obesity presents with exertional substernal chest pressure that resolves with rest. In the ED, he is pain-free. ECG is normal. Troponin is negative at 0 and 3 hours. HEART score is 4.

What is the most appropriate next step?', '[{"label":"A","text":"Discharge with outpatient stress test within 72 hours"},{"label":"B","text":"Inpatient stress test before discharge"},{"label":"C","text":"Admit for observation and serial troponins"},{"label":"D","text":"CT coronary angiography"},{"label":"E","text":"Discharge with cardiology follow-up in 2 weeks"}]'::jsonb, 'A', 'HEART score 4-6 represents intermediate risk (~12-16% 30-day MACE). This patient has typical anginal symptoms but negative initial workup. Guidelines support either inpatient stress testing OR expedited outpatient testing within 72 hours for intermediate-risk patients who are clinically stable with reliable follow-up. Immediate discharge without any stress testing (answer E) misses the intermediate-risk classification. Admitting all intermediate-risk patients is resource-intensive; outpatient accelerated pathways are validated. The key is ensuring prompt testing access.', NULL, 'internal', 'active'),
  ('B5_Q10_1', 'asymptomatic-gallstones-no-surgery', 'Batch5', '', 'A 55-year-old woman undergoes abdominal ultrasound for elevated liver enzymes, revealing three gallstones (largest 1.2 cm) with normal gallbladder wall thickness and no biliary dilation. Liver enzymes normalize on repeat testing. She has never had abdominal pain, and the stones were incidentally discovered.

What is the most appropriate management?', '[{"label":"A","text":"Elective laparoscopic cholecystectomy"},{"label":"B","text":"Ursodiol for gallstone dissolution"},{"label":"C","text":"MRCP to evaluate for choledocholithiasis"},{"label":"D","text":"Observation without intervention"},{"label":"E","text":"ERCP with sphincterotomy"}]'::jsonb, 'D', 'Asymptomatic gallstones are common (10-15% of adults) and the majority never cause symptoms. Prophylactic cholecystectomy for incidental stones is not recommended—the surgical risk exceeds the low likelihood (~1-2%/year) of developing symptoms. Ursodiol is only effective for small cholesterol stones and is not indicated for asymptomatic stones. MRCP/ERCP are not warranted without clinical concern for CBD stones. Observation with patient education about biliary colic symptoms (postprandial RUQ pain, especially after fatty meals) is appropriate.', NULL, 'internal', 'active'),
  ('B5_Q10_2', 'asymptomatic-gallstones-no-surgery', 'Batch5', '', 'A 48-year-old man with asymptomatic gallstones discovered 2 years ago presents after one episode of postprandial right upper quadrant pain lasting 45 minutes that resolved spontaneously. He is currently pain-free. Ultrasound shows stones without gallbladder wall thickening or pericholecystic fluid.

What is the most appropriate recommendation?', '[{"label":"A","text":"Continue observation"},{"label":"B","text":"Elective cholecystectomy"},{"label":"C","text":"Admit for IV antibiotics"},{"label":"D","text":"HIDA scan"},{"label":"E","text":"Low-fat diet alone"}]'::jsonb, 'B', 'Once gallstones become symptomatic (biliary colic), the risk of recurrent episodes and complications (cholecystitis, pancreatitis, choledocholithiasis) increases substantially. Unlike asymptomatic stones, symptomatic gallstones warrant elective cholecystectomy. This patient had a classic biliary colic episode—postprandial pain lasting <6 hours that resolved. He does not have acute cholecystitis (no fever, wall thickening, or ongoing symptoms), so admission is unnecessary. Dietary modification alone does not prevent recurrence or complications.', NULL, 'internal', 'active'),
  ('B5_Q11_1', 'mild-diverticulosis-no-antibiotics', 'Batch5', '', 'A 58-year-old man presents with left lower quadrant pain for 2 days. CT shows sigmoid diverticulosis with mild pericolic fat stranding but no abscess, perforation, or obstruction. He is afebrile, tolerating oral intake, and has normal WBC. He has no immunocompromise.

What is the most appropriate management?', '[{"label":"A","text":"Admit for IV antibiotics"},{"label":"B","text":"Outpatient oral antibiotics for 7-10 days"},{"label":"C","text":"Supportive care without antibiotics"},{"label":"D","text":"Surgical consultation for sigmoid resection"},{"label":"E","text":"Colonoscopy during this admission"}]'::jsonb, 'C', 'Multiple RCTs (AVOD, DIABOLO) demonstrate that uncomplicated diverticulitis in immunocompetent patients can be managed without antibiotics. Uncomplicated = no abscess, fistula, obstruction, or perforation. This patient has mild CT findings, no systemic illness, and can tolerate oral intake. Supportive care (clear liquids advancing to regular diet, analgesia) is sufficient. Antibiotics should be reserved for complicated disease, immunocompromise, or clinical deterioration. Colonoscopy should be performed 6-8 weeks after resolution to exclude malignancy, not during acute inflammation.', NULL, 'internal', 'active'),
  ('B5_Q11_2', 'mild-diverticulosis-no-antibiotics', 'Batch5', '', 'A 64-year-old woman with diabetes presents with LLQ pain, fever (101.5°F), and WBC 14,500. CT shows diverticulitis with a 2.5 cm pericolic abscess.

What is the most appropriate management?', '[{"label":"A","text":"Outpatient oral antibiotics"},{"label":"B","text":"Admit for IV antibiotics and possible percutaneous drainage"},{"label":"C","text":"Supportive care without antibiotics"},{"label":"D","text":"Emergent sigmoid colectomy"},{"label":"E","text":"Colonoscopy to rule out malignancy"}]'::jsonb, 'B', 'This patient has complicated diverticulitis (abscess) plus systemic signs (fever, leukocytosis) and diabetes (relative immunocompromise). This requires IV antibiotics and likely percutaneous drainage for abscesses >3 cm (2.5 cm is borderline—may resolve with antibiotics alone or require drainage if not improving). The no-antibiotic approach applies only to uncomplicated disease in immunocompetent patients. Emergent surgery is reserved for perforation with peritonitis, not contained abscess. Colonoscopy is deferred until inflammation resolves.', NULL, 'internal', 'active'),
  ('B5_Q12_1', 'pre-diabetes-lifestyle-before-metformin', 'Batch5', '', 'A 45-year-old woman with BMI 31 has fasting glucose of 112 mg/dL and HbA1c of 5.9% on annual screening. She has no other cardiovascular risk factors. She exercises occasionally and has a diet high in processed foods.

What is the most appropriate initial intervention?', '[{"label":"A","text":"Metformin 500 mg twice daily"},{"label":"B","text":"Intensive lifestyle modification program"},{"label":"C","text":"GLP-1 receptor agonist"},{"label":"D","text":"SGLT2 inhibitor"},{"label":"E","text":"Repeat testing in 1 year without intervention"}]'::jsonb, 'B', 'This patient has prediabetes (FG 100-125 or A1c 5.7-6.4%). The Diabetes Prevention Program demonstrated that intensive lifestyle intervention (7% weight loss goal, 150 min/week moderate activity) reduces diabetes incidence by 58%—superior to metformin (31% reduction). ADA guidelines recommend lifestyle modification as first-line for prediabetes. Metformin is an option for high-risk patients (BMI ≥35, age <60, prior GDM, rising A1c) but is second-line to lifestyle. This patient''s risk profile supports starting with lifestyle intervention before pharmacotherapy.', NULL, 'internal', 'active'),
  ('B5_Q12_2', 'pre-diabetes-lifestyle-before-metformin', 'Batch5', '', 'A 52-year-old man with BMI 38, prediabetes (A1c 6.3%), and family history of T2DM in both parents has been unable to lose weight despite 6 months of dietary counseling. He has tried structured exercise programs without success.

What is the most appropriate next step?', '[{"label":"A","text":"Continue lifestyle counseling alone"},{"label":"B","text":"Add metformin"},{"label":"C","text":"Refer for bariatric surgery"},{"label":"D","text":"Start empagliflozin"},{"label":"E","text":"Accept prediabetes as a stable condition"}]'::jsonb, 'B', 'After lifestyle intervention fails or in high-risk prediabetics (BMI ≥35, age <60, history of GDM, strong family history), metformin is appropriate per ADA guidelines. This patient has multiple high-risk features: severe obesity, A1c at upper prediabetic range, and bilateral parental diabetes history. Metformin modestly reduces progression to diabetes. While bariatric surgery is highly effective, it is typically reserved for BMI ≥40 or ≥35 with comorbidities—and metformin should be tried first. SGLT2 inhibitors are not FDA-approved for prediabetes prevention.', NULL, 'internal', 'active'),
  ('B5_Q13_1', 'grade1-varicocele-observation', 'Batch5', '', 'A 17-year-old male is noted to have a left-sided varicocele during a sports physical. It is palpable only during Valsalva (Grade I). Both testes are symmetric in size. He is asymptomatic and has no interest in fertility evaluation at this time.

What is the most appropriate management?', '[{"label":"A","text":"Surgical varicocelectomy"},{"label":"B","text":"Scrotal ultrasound with Doppler"},{"label":"C","text":"Semen analysis"},{"label":"D","text":"Annual observation with testicular size measurement"},{"label":"E","text":"Interventional radiology embolization"}]'::jsonb, 'D', 'Grade I varicoceles (palpable only with Valsalva) in adolescents are common and usually benign. Intervention is indicated for: testicular hypotrophy (>20% size differential or >2 mL volume difference), pain, or abnormal semen analysis in adults. This patient has symmetric testes and no symptoms. Annual monitoring to detect testicular growth arrest is appropriate. Semen analysis is not routinely performed in adolescents. Treatment for asymptomatic, low-grade varicoceles without hypotrophy constitutes overtreatment.', NULL, 'internal', 'active'),
  ('B5_Q13_2', 'grade1-varicocele-observation', 'Batch5', '', 'A 24-year-old man presents for infertility evaluation after 1 year of unprotected intercourse. Exam reveals a Grade II left varicocele. Semen analysis shows oligoasthenospermia (count 8 million/mL, 25% motility). Right testis is normal size; left is slightly smaller.

What is the most appropriate recommendation?', '[{"label":"A","text":"Observation and repeat semen analysis in 6 months"},{"label":"B","text":"Surgical varicocelectomy"},{"label":"C","text":"Intrauterine insemination without surgical correction"},{"label":"D","text":"Clomiphene citrate"},{"label":"E","text":"Reassurance that varicocele is unrelated to infertility"}]'::jsonb, 'B', 'Varicocelectomy is indicated in men with clinical varicocele + abnormal semen parameters + infertility (when female partner is normal or has treatable causes). This patient meets all criteria. Repair improves semen parameters in 60-70% of men and pregnancy rates increase. Observation would delay treatment for a correctable cause. The combination of palpable varicocele, ipsilateral testicular hypotrophy, and abnormal semen analysis strongly supports surgical intervention as the next step.', NULL, 'internal', 'active'),
  ('B5_Q14_1', 'benign-liver-hemangioma-no-imaging', 'Batch5', '', 'A 42-year-old woman undergoes abdominal ultrasound for dyspepsia, which reveals a 2.5 cm hyperechoic lesion in the right hepatic lobe with characteristic features of hemangioma. She has no liver disease risk factors, normal liver enzymes, and no malignancy history.

What is the most appropriate next step?', '[{"label":"A","text":"MRI liver with contrast to confirm diagnosis"},{"label":"B","text":"CT abdomen with contrast"},{"label":"C","text":"Percutaneous liver biopsy"},{"label":"D","text":"Reassurance with no further imaging"},{"label":"E","text":"Repeat ultrasound in 6 months"}]'::jsonb, 'D', 'Hepatic hemangiomas are the most common benign liver tumors. When ultrasound shows classic features (well-defined, hyperechoic, homogeneous lesion) in a patient without malignancy history or liver disease, no further imaging is required. Hemangiomas do not undergo malignant transformation and rarely cause symptoms unless very large (>10 cm). Confirmatory MRI is unnecessary for typical-appearing lesions. Biopsy is contraindicated due to bleeding risk. Surveillance imaging adds cost and anxiety without changing management.', NULL, 'internal', 'active'),
  ('B5_Q14_2', 'benign-liver-hemangioma-no-imaging', 'Batch5', '', 'A 55-year-old man with history of colon cancer treated 3 years ago has a 3 cm liver lesion found on surveillance CT. The lesion shows peripheral nodular enhancement with centripetal fill-in—classic for hemangioma.

What is the most appropriate next step?', '[{"label":"A","text":"No further workup needed"},{"label":"B","text":"MRI liver with hepatobiliary contrast"},{"label":"C","text":"PET-CT"},{"label":"D","text":"Percutaneous biopsy"},{"label":"E","text":"Surgical resection"}]'::jsonb, 'B', 'In patients with prior malignancy, even classic-appearing hemangiomas warrant confirmatory imaging because hepatic metastases can occasionally mimic hemangiomas. MRI with hepatobiliary contrast (gadoxetate) has high specificity for distinguishing hemangioma from metastases. This differs from the prior question because cancer history changes the pretest probability of malignancy. If MRI confirms hemangioma, no further workup is needed. PET-CT and biopsy are not first-line for a lesion that appears benign radiographically. Update Todos Generate questions for concepts 1-7 Generate questions for concepts 8-14 Generating questions for concepts 15-21', NULL, 'internal', 'active'),
  ('B5_Q15_1', 'simple-renal-cyst-no-followup', 'Batch5', '', 'A 60-year-old man has an incidental 3 cm left renal cyst found on CT for kidney stone evaluation. The cyst is homogeneous, water-attenuation, with a thin wall and no septations, calcifications, or enhancement (Bosniak I).

What is the most appropriate recommendation?', '[{"label":"A","text":"MRI for further characterization"},{"label":"B","text":"Percutaneous aspiration and cytology"},{"label":"C","text":"Repeat CT in 6 months"},{"label":"D","text":"No follow-up imaging required"},{"label":"E","text":"Urologic referral for cyst decortication"}]'::jsonb, 'D', 'Bosniak I cysts are simple cysts with essentially 0% malignancy risk. They have thin walls, no septations, no calcification, and do not enhance. No follow-up is needed—these are benign findings that do not warrant surveillance. Imaging or intervention would constitute unnecessary healthcare utilization. The Bosniak classification guides management: I and II require no follow-up; IIF requires surveillance; III and IV require surgical evaluation.', NULL, 'internal', 'active'),
  ('B5_Q15_2', 'simple-renal-cyst-no-followup', 'Batch5', '', 'A 58-year-old woman has a 4 cm renal cyst with a single thin septation and minimal wall thickening but no measurable enhancement on CT (Bosniak II).

What is the most appropriate management?', '[{"label":"A","text":"No follow-up imaging required"},{"label":"B","text":"Follow-up CT in 6-12 months"},{"label":"C","text":"MRI with contrast"},{"label":"D","text":"Surgical excision"},{"label":"E","text":"Percutaneous biopsy"}]'::jsonb, 'A', 'Bosniak II cysts have minimal complexity (thin septations, fine calcification, or hyperdense non-enhancing fluid) but remain benign with <5% malignancy risk. Like Bosniak I, these do not require routine surveillance. Bosniak IIF ("F" for follow-up) is the category that requires imaging surveillance due to increased septations or thickening that cannot be confidently characterized. This lesion''s characteristics (single thin septation, no enhancement) are confidently Bosniak II.', NULL, 'internal', 'active'),
  ('B5_Q16_1', 'low-grade-cervical-dysplasia-observe', 'Batch5', '', 'A 28-year-old woman has LSIL (low-grade squamous intraepithelial lesion) on Pap smear. HPV co-testing is positive for HPV 16. She has no prior abnormal Paps. Colposcopy shows CIN 1 on biopsy.

What is the most appropriate management?', '[{"label":"A","text":"Immediate LEEP excision"},{"label":"B","text":"Repeat Pap and HPV co-testing in 12 months"},{"label":"C","text":"Cryotherapy"},{"label":"D","text":"Cone biopsy"},{"label":"E","text":"Hysterectomy"}]'::jsonb, 'B', 'CIN 1 represents low-grade dysplasia with 60-90% spontaneous regression rates, especially in young women. ASCCP guidelines recommend observation with repeat testing in 12 months rather than treatment, even when HPV 16/18 positive. Treatment (LEEP, cryotherapy) carries risks of cervical insufficiency and preterm birth in future pregnancies. CIN 1 is not precancer—CIN 2/3 is. Only persistent CIN 1 (>2 years) may warrant treatment. Immediate excision is overtreatment.', NULL, 'internal', 'active'),
  ('B5_Q16_2', 'low-grade-cervical-dysplasia-observe', 'Batch5', '', 'A 45-year-old woman has CIN 1 that has persisted for 2.5 years on surveillance. She has completed childbearing. Colposcopy remains consistent with CIN 1 without higher-grade lesions.

What is the most appropriate management?', '[{"label":"A","text":"Continue observation"},{"label":"B","text":"LEEP excision"},{"label":"C","text":"Total hysterectomy"},{"label":"D","text":"Repeat colposcopy in 6 months"},{"label":"E","text":"HPV vaccination"}]'::jsonb, 'B', 'While CIN 1 usually regresses, persistence beyond 2 years is an indication for treatment per ASCCP guidelines. This patient has had CIN 1 for 2.5 years, meeting the threshold for intervention. LEEP excision is appropriate, especially since she has completed childbearing (eliminating concern for cervical insufficiency). Continued observation beyond 2 years is not recommended. Hysterectomy is overtreatment for CIN 1. HPV vaccination may prevent new infections but does not treat existing dysplasia.', NULL, 'internal', 'active'),
  ('B5_Q17_1', 'deprescribing-ppi-long-term', 'Batch5', '', 'A 72-year-old man has been taking omeprazole 20 mg daily for 6 years for "acid reflux." He has no history of Barrett''s esophagus, erosive esophagitis, or peptic ulcer disease. His original symptoms resolved years ago. Recent labs show mildly low magnesium (1.6 mg/dL).

What is the most appropriate recommendation?', '[{"label":"A","text":"Continue omeprazole indefinitely"},{"label":"B","text":"Switch to H2 blocker for better safety profile"},{"label":"C","text":"Trial PPI discontinuation with PRN antacids"},{"label":"D","text":"Double PPI dose to ensure acid suppression"},{"label":"E","text":"Add magnesium supplement and continue PPI"}]'::jsonb, 'C', 'Long-term PPI use without clear indication (Barrett''s, severe erosive esophagitis, recurrent PUD, Zollinger-Ellison) should prompt deprescribing attempt. Risks of chronic PPI include hypomagnesemia (as seen here), C. difficile infection, pneumonia, B12 deficiency, and possible fracture risk. Most patients can successfully taper/stop PPIs with step-down approach: full dose → half dose → H2 blocker → PRN antacids. The hypomagnesemia further supports discontinuation rather than supplementation.', NULL, 'internal', 'active'),
  ('B5_Q17_2', 'deprescribing-ppi-long-term', 'Batch5', '', 'A 65-year-old woman with Barrett''s esophagus (confirmed on prior EGD with intestinal metaplasia) asks if she can stop her PPI since she no longer has heartburn.

What is the most appropriate recommendation?', '[{"label":"A","text":"Discontinue PPI since symptoms resolved"},{"label":"B","text":"Continue PPI indefinitely"},{"label":"C","text":"Switch to PRN PPI use"},{"label":"D","text":"Stop PPI and repeat EGD in 6 months"},{"label":"E","text":"Replace PPI with H2 blocker"}]'::jsonb, 'B', 'Barrett''s esophagus is an indication for lifelong PPI therapy regardless of symptoms. PPIs reduce acid exposure, which may slow progression to dysplasia and adenocarcinoma (though this is based on observational data). Symptomatic improvement does not indicate mucosal healing or reduced cancer risk. Patients with Barrett''s should continue PPI indefinitely and undergo surveillance endoscopy per guidelines. This differs from uncomplicated GERD where deprescribing is appropriate.', NULL, 'internal', 'active'),
  ('B5_Q18_1', 'statin-discontinuation-elderly-frail', 'Batch5', '', 'An 89-year-old woman with advanced dementia, residing in a nursing home, and dependent for all ADLs takes atorvastatin 40 mg for primary prevention. She has no history of cardiovascular disease. Her life expectancy is estimated at <2 years.

What is the most appropriate recommendation regarding statin therapy?', '[{"label":"A","text":"Continue statin for cardiovascular protection"},{"label":"B","text":"Increase to high-intensity statin"},{"label":"C","text":"Discontinue statin"},{"label":"D","text":"Switch to rosuvastatin for better efficacy"},{"label":"E","text":"Add ezetimibe for additional LDL lowering"}]'::jsonb, 'C', 'Statins for primary prevention in patients with limited life expectancy (<2-3 years) have minimal benefit and may cause harm (myopathy, drug interactions, pill burden). Statins require years to demonstrate cardiovascular benefit; time-to- benefit exceeds this patient''s life expectancy. Deprescribing guidelines recommend discontinuing primary prevention statins in frail elderly with limited life expectancy. This aligns with goals of comfort-focused care. Secondary prevention is different—even in advanced age, statins after MI/stroke may have faster benefit.', NULL, 'internal', 'active'),
  ('B5_Q18_2', 'statin-discontinuation-elderly-frail', 'Batch5', '', 'A 78-year-old man with prior MI 5 years ago, currently stable, develops statin-associated muscle symptoms on atorvastatin. He has tried rosuvastatin and pravastatin with similar symptoms. He has mild cognitive impairment.

What is the most appropriate next step?', '[{"label":"A","text":"Discontinue all statin therapy"},{"label":"B","text":"Trial every-other-day rosuvastatin"},{"label":"C","text":"Add coenzyme Q10 and continue atorvastatin"},{"label":"D","text":"Reassure that muscle symptoms are unrelated to statin"},{"label":"E","text":"Switch to fibrate therapy"}]'::jsonb, 'B', 'For secondary prevention (prior MI), some statin therapy is better than none. Before abandoning statins, alternative dosing strategies should be attempted: intermittent dosing (rosuvastatin or atorvastatin every other day or twice weekly) leverages long half-life while reducing muscle symptoms. Studies show intermittent dosing achieves meaningful LDL reduction with improved tolerability. Complete discontinuation sacrifices secondary prevention benefit. CoQ10 has inconsistent evidence. His cognitive impairment doesn''t preclude statin benefit if life expectancy is reasonable.', NULL, 'internal', 'active'),
  ('B5_Q19_1', 'stopping-osteoporosis-drug-holiday', 'Batch5', '', 'A 68-year-old woman has taken alendronate for 5 years for osteoporosis. Her T-score has improved from -2.8 to -2.2. She has not had fractures. She is concerned about long-term bisphosphonate risks.

What is the most appropriate recommendation?', '[{"label":"A","text":"Continue alendronate indefinitely"},{"label":"B","text":"Discontinue alendronate for a drug holiday"},{"label":"C","text":"Switch to denosumab"},{"label":"D","text":"Add teriparatide"},{"label":"E","text":"Repeat DXA in 1 year before deciding"}]'::jsonb, 'B', 'After 5 years of oral bisphosphonate with good response and no fractures, a drug holiday is appropriate to reduce risk of atypical femoral fractures and osteonecrosis of the jaw. The FLEX trial showed that patients with T-score > -2.5 after 5 years of alendronate can safely discontinue for 3-5 years. Bisphosphonates have prolonged skeletal retention, providing residual benefit during the holiday. Monitor with DXA every 2-3 years; resume if significant bone loss or fracture occurs.', NULL, 'internal', 'active'),
  ('B5_Q19_2', 'stopping-osteoporosis-drug-holiday', 'Batch5', '', 'A 75-year-old woman with T-score -3.2 at spine and prior vertebral compression fracture has taken alendronate for 5 years. She asks about a drug holiday.

What is the most appropriate recommendation?', '[{"label":"A","text":"Bisphosphonate holiday is appropriate after 5 years"},{"label":"B","text":"Continue bisphosphonate therapy"},{"label":"C","text":"Switch to drug holiday but add calcium/vitamin D"},{"label":"D","text":"Stop bisphosphonate and switch to raloxifene"},{"label":"E","text":"Drug holiday with repeat DXA in 6 months"}]'::jsonb, 'B', 'Drug holidays are NOT appropriate for all patients after 5 years. High-risk patients—T-score ≤ -2.5 at femoral neck, history of fracture, or high FRAX score—should continue bisphosphonate therapy. This patient has very low bone density (-3.2) AND prior vertebral fracture, placing her at high fracture risk. The benefit of continued therapy outweighs the low absolute risk of atypical fracture. Drug holidays are for lower-risk patients who have responded well to treatment.', NULL, 'internal', 'active'),
  ('B5_Q20_1', 'incidental-thyroid-nodule-stop-surveillance', 'Batch5', '', 'A 50-year-old woman with a 1.2 cm thyroid nodule has had 3 annual ultrasounds showing no interval growth and stable benign features (spongiform appearance, no microcalcifications). Initial FNA was benign (Bethesda II).

What is the most appropriate recommendation?', '[{"label":"A","text":"Continue annual ultrasound surveillance"},{"label":"B","text":"Repeat FNA"},{"label":"C","text":"Discontinue surveillance"},{"label":"D","text":"Surgical thyroidectomy"},{"label":"E","text":"Radiofrequency ablation"}]'::jsonb, 'C', 'ATA guidelines recommend that benign thyroid nodules (Bethesda II on FNA) with no sonographic growth over 2+ years can have surveillance discontinued. The false-negative rate for benign FNA is <3%, and stability further supports benignity. Continued indefinite imaging adds cost, patient anxiety, and radiation exposure without meaningful yield. This patient has demonstrated stability over 3 years with benign cytology—surveillance can stop.', NULL, 'internal', 'active'),
  ('B5_Q20_2', 'incidental-thyroid-nodule-stop-surveillance', 'Batch5', '', 'A 45-year-old man has a 2.5 cm thyroid nodule with suspicious ultrasound features (taller-than-wide, irregular margins). FNA showed atypia of undetermined significance (Bethesda III). Repeat FNA again shows AUS.

What is the most appropriate next step?', '[{"label":"A","text":"Discontinue surveillance"},{"label":"B","text":"Diagnostic thyroid lobectomy"},{"label":"C","text":"Repeat ultrasound in 12 months"},{"label":"D","text":"Third FNA"},{"label":"E","text":"Radioactive iodine ablation"}]'::jsonb, 'B', 'Bethesda III (AUS/FLUS) on repeat FNA with suspicious ultrasound features carries ~15-30% malignancy risk. Options include molecular testing or diagnostic surgery. With persistently indeterminate cytology and concerning sonographic features, surgical excision (lobectomy) is appropriate for definitive diagnosis. Continued surveillance or repeat FNA would further delay diagnosis of potential malignancy. This contrasts with the prior question where benign cytology and imaging allowed surveillance cessation.', NULL, 'internal', 'active'),
  ('B5_Q21_1', 'adrenal-incidentaloma-stop-followup', 'Batch5', '', 'A 58-year-old woman had a 1.5 cm left adrenal adenoma discovered on CT 4 years ago. Annual imaging has shown no growth. Biochemical workup (dexamethasone suppression, plasma metanephrines, aldosterone-renin ratio) has been normal for 4 consecutive years.

What is the most appropriate recommendation?', '[{"label":"A","text":"Continue annual CT surveillance"},{"label":"B","text":"Continue annual biochemical surveillance"},{"label":"C","text":"Discontinue both imaging and biochemical surveillance"},{"label":"D","text":"Surgical adrenalectomy"},{"label":"E","text":"MRI instead of CT for future imaging"}]'::jsonb, 'C', 'Current guidelines (ACR, Endocrine Society) support discontinuing surveillance of adrenal incidentalomas after 4 years of stability. Adenomas that are small (<4 cm), imaging-stable, and biochemically inactive have negligible risk of growth or functional conversion with extended follow-up. Continued imaging adds radiation exposure and cost without benefit. This patient has completed appropriate surveillance duration (4 years of stability) and can be discharged from follow-up.', NULL, 'internal', 'active'),
  ('B5_Q21_2', 'adrenal-incidentaloma-stop-followup', 'Batch5', '', 'A 62-year-old man has a 3.8 cm adrenal mass discovered incidentally. CT shows homogeneous low attenuation (<10 HU) consistent with lipid-rich adenoma. Biochemical evaluation is normal.

What is the most appropriate management?', '[{"label":"A","text":"Surgical adrenalectomy"},{"label":"B","text":"Repeat imaging in 6-12 months"},{"label":"C","text":"Discontinue surveillance—benign imaging features"},{"label":"D","text":"PET-CT"},{"label":"E","text":"Adrenal biopsy"}]'::jsonb, 'B', 'While imaging features (<10 HU attenuation) strongly suggest benign lipid-rich adenoma, initial surveillance is still recommended for masses ≥3-4 cm. Size increases risk of malignancy and functional conversion. Guidelines recommend repeat imaging at 6-12 months initially, with extended intervals if stable. This differs from smaller adenomas that may require less intensive surveillance. The low HU makes malignancy unlikely, so PET and biopsy are unnecessary if the lesion remains stable. Surgery is reserved for growth, functional activity, or suspicious imaging. Update Todos Generate questions for concepts 1-7 Generate questions for concepts 8-14 Generate questions for concepts 15-21 BATCH 5 GENERATION COMPLETE Summary Concept # Concept ID Questions 1 incidental-pe-observation-criteria Q1.1, Q1.2 2 watchful-waiting-prostate-cancer Q2.1, Q2.2 Concept # Concept ID Questions 3 benign-pvc-no-ablation Q3.1, Q3.2 4 small-kidney-stone-expectant Q4.1, Q4.2 5 stable-carotid-stenosis-medical-only Q5.1, Q5.2 6 aortic-aneurysm-surveillance-threshold Q6.1, Q6.2 7 low-risk-syncope-discharge-criteria Q7.1, Q7.2 8 antibiotic-stewardship-viral-uri Q8.1, Q8.2 9 chest-pain-low-risk-outpatient-workup Q9.1, Q9.2 10 asymptomatic-gallstones-no-surgery Q10.1, Q10.2 11 mild-diverticulosis-no-antibiotics Q11.1, Q11.2 12 pre-diabetes-lifestyle-before-metformin Q12.1, Q12.2 13 grade1-varicocele-observation Q13.1, Q13.2 14 benign-liver-hemangioma-no-imaging Q14.1, Q14.2 15 simple-renal-cyst-no-followup Q15.1, Q15.2 16 low-grade-cervical-dysplasia-observe Q16.1, Q16.2 17 deprescribing-ppi-long-term Q17.1, Q17.2 18 statin-discontinuation-elderly-frail Q18.1, Q18.2 19 stopping-osteoporosis-drug-holiday Q19.1, Q19.2 20 incidental-thyroid-nodule-stop-surveillance Q20.1, Q20.2 21 adrenal-incidentaloma-stop-followup Q21.1, Q21.2 Total: 42 questions across 21 concepts Each concept includes: • One question testing the "when NOT to intervene" decision • One question testing the boundary/exception where intervention IS warranted Ready for review or export to QBank format.', NULL, 'internal', 'active'),
  ('B6_Q01', 'anchoring-on-initial-diagnosis-despite-new-data', 'Batch6', 'Internal Medicine', 'A 58-year-old man presents to the emergency department with acute-onset chest pain radiating to his left arm. Initial ECG shows ST elevations in leads V1-V4, and troponin I is elevated at 2.4 ng/mL. He is diagnosed with STEMI and taken for emergent cardiac catheterization, which reveals clean coronary arteries. Post-procedure, he develops hypotension (BP 82/50 mmHg), muffled heart sounds, and jugular venous distension. A repeat ECG now shows low voltage and electrical alternans. The cardiology fellow suggests increasing the heparin drip and adding a second antiplatelet agent.

What is the most appropriate next step in management?', '[{"label":"A","text":"Increase heparin infusion rate"},{"label":"B","text":"Administer IV nitroprusside"},{"label":"C","text":"Perform emergent pericardiocentesis"},{"label":"D","text":"Order repeat coronary angiography"}]'::jsonb, 'C', 'This patient initially presented with findings suggestive of STEMI but had clean coronaries on catheterization. The new triad of hypotension, muffled heart sounds, and JVD (Beck''s triad), combined with electrical alternans on ECG, indicates cardiac tamponade—likely from aortic dissection that was missed due to anchoring on the initial STEMI diagnosis. The cognitive error here is failing to revise the diagnosis when new data (clean coronaries, hemodynamic instability, Beck''s triad) contradicts the initial impression. Emergent pericardiocentesis is life-saving. Why the Wrong Answer is Tempting: The fellow''s suggestion to increase anticoagulation (Choice A) follows logically from the original STEMI framework. Repeating angiography (Choice D) assumes the original diagnosis was correct but incomplete. These choices appeal to those who remain anchored to the initial diagnosis despite clear evidence of a different pathology. NBME Trap Callout: When catheterization doesn''t match clinical presentation, STOP—reconsider the diagnosis entirely. Clean coronaries + hemodynamic collapse = think aortic dissection with tamponade.', NULL, 'internal', 'active'),
  ('B6_Q02', 'ordering-ct-before-ultrasound-in-biliary-disease', 'Batch6', 'Internal Medicine', 'A 45-year-old obese woman presents with 6 hours of severe right upper quadrant pain, nausea, and vomiting after eating fried chicken. Temperature is 37.2°C, blood pressure 138/85 mmHg, and pulse 92/min. Physical examination reveals tenderness in the right upper quadrant with a positive Murphy sign. Laboratory studies show WBC 11,200/μL, AST 52 U/L, ALT 48 U/L, alkaline phosphatase 95 U/L, and total bilirubin 1.1 mg/dL. The intern orders a CT scan of the abdomen with contrast.

Which of the following is the most appropriate imaging study for this patient?', '[{"label":"A","text":"CT abdomen with IV contrast"},{"label":"B","text":"Right upper quadrant ultrasound"},{"label":"C","text":"MRCP"},{"label":"D","text":"HIDA scan"}]'::jsonb, 'B', 'This patient has a classic presentation for acute cholecystitis (postprandial RUQ pain, Murphy sign, mild leukocytosis). The first-line imaging modality is right upper quadrant ultrasound, which can visualize gallstones, gallbladder wall thickening, pericholecystic fluid, and sonographic Murphy sign with high sensitivity and no radiation. The cognitive error is over-ordering advanced imaging when a cheaper, faster, radiation-free bedside test is diagnostic. CT is less sensitive for gallstones and delays diagnosis. Why the Wrong Answer is Tempting: CT (Choice A) feels more "thorough" and is often reflexively ordered in abdominal pain. HIDA scan (Choice D) is useful for acalculous cholecystitis or when ultrasound is equivocal—not as first-line. MRCP (Choice C) is reserved for suspected choledocholithiasis, which the normal bilirubin and alkaline phosphatase argue against. NBME Trap Callout: In biliary disease, ultrasound comes first. CT is not more accurate for gallstones and adds radiation, cost, and delay.', NULL, 'internal', 'active'),
  ('B6_Q03', 'treating-asymptomatic-bacteriuria-in-elderly', 'Batch6', 'Internal Medicine', 'An 82-year-old woman is brought from her nursing home for evaluation of increased confusion over 2 days. She has a history of dementia, hypertension, and recurrent UTIs. Temperature is 36.8°C, blood pressure 128/76 mmHg, and pulse 78/min. She is oriented to person only but is at her baseline mental status per nursing home records. Physical examination reveals no costovertebral angle tenderness, suprapubic tenderness, or dysuria on Foley catheter irrigation. Urinalysis shows 50+ WBC, positive leukocyte esterase, positive nitrites, and many bacteria. Urine culture is pending. The resident requests approval to start ciprofloxacin.

What is the most appropriate next step in management?', '[{"label":"A","text":"Start ciprofloxacin 500 mg twice daily for 7 days"},{"label":"B","text":"Start ceftriaxone 1 g IV daily and admit"},{"label":"C","text":"Obtain blood cultures and start broad-spectrum antibiotics"},{"label":"D","text":"Remove the Foley catheter and observe"}]'::jsonb, 'D', 'This patient has asymptomatic bacteriuria, not a urinary tract infection. She is afebrile, hemodynamically stable, has no urinary symptoms, and her confusion is at baseline. Pyuria and bacteriuria are nearly universal in catheterized elderly patients and do not mandate treatment without symptoms. The cognitive error is treating the lab result rather than the patient. Removing the catheter (if no longer needed) and observation is appropriate. Unnecessary antibiotics promote resistance and cause harm (C. difficile, drug reactions). Why the Wrong Answer is Tempting: The urinalysis looks "dirty" with WBCs, nitrites, and bacteria—this reflexively triggers the UTI treatment algorithm. Altered mental status in the elderly is often blamed on UTI, but without new symptoms or fever, this is attribution error. NBME Trap Callout: Never treat asymptomatic bacteriuria in non-pregnant adults. Pyuria + bacteria + no symptoms = colonization, not infection.', NULL, 'internal', 'active'),
  ('B6_Q04', 'antibiotic-escalation-before-culture-results', 'Batch6', 'Internal Medicine', 'A 64-year-old man with COPD is hospitalized for community-acquired pneumonia and started on ceftriaxone and azithromycin. On hospital day 2, he remains febrile (38.4°C) but reports feeling slightly better. Oxygen saturation is 94% on 2L nasal cannula (improved from 89% on room air at admission). Blood pressure is 132/78 mmHg. Sputum and blood cultures from admission are pending. The night resident suggests changing antibiotics to piperacillin-tazobactam and vancomycin because the patient "isn''t responding."

What is the most appropriate next step in management?', '[{"label":"A","text":"Escalate to piperacillin-tazobactam and vancomycin"},{"label":"B","text":"Continue current antibiotics and await culture results"},{"label":"C","text":"Obtain CT chest to evaluate for abscess or empyema"},{"label":"D","text":"Add levofloxacin for double coverage of atypicals"}]'::jsonb, 'B', 'This patient is showing clinical improvement (better oxygenation, subjective improvement) despite persistent low-grade fever on day 2. Fever can persist for 48-72 hours after appropriate antibiotic initiation—this is expected, not failure. The cognitive error is premature antibiotic escalation before allowing time for response or obtaining microbiologic data. Broadening coverage reflexively increases resistance pressure, adverse effects, and costs without evidence of treatment failure. Why the Wrong Answer is Tempting: Persistent fever triggers anxiety that "we''re missing something" or "coverage isn''t broad enough." Escalating to broad-spectrum agents (Choice A) feels proactive. However, clinical trajectory matters more than temperature alone at 48 hours. NBME Trap Callout: Day 2-3 fever with improving clinical status is NOT antibiotic failure. Wait for cultures before escalating.', NULL, 'internal', 'active'),
  ('B6_Q05', 'confusing-acute-management-with-chronic-optimization', 'Batch6', 'Internal Medicine', 'A 71-year-old man with heart failure with reduced ejection fraction (EF 30%) presents to the emergency department with worsening dyspnea over 3 days. He has 2+ bilateral lower extremity edema, jugular venous distension to 12 cm, and bibasilar crackles. Blood pressure is 88/62 mmHg, and pulse is 102/min. He is started on IV furosemide with good urine output. The ED physician plans to add carvedilol because the patient "isn''t on a beta-blocker despite class I indication."

Which of the following is the most appropriate response to this plan?', '[{"label":"A","text":"Agree and start carvedilol 3.125 mg twice daily"},{"label":"B","text":"Recommend starting carvedilol after discharge when euvolemic"},{"label":"C","text":"Suggest metoprolol succinate instead of carvedilol"},{"label":"D","text":"Add digoxin for rate control before beta-blocker"}]'::jsonb, 'B', 'While beta-blockers are guideline-directed medical therapy for HFrEF, they should never be initiated during acute decompensation. This patient is hypotensive and volume-overloaded—starting a negative inotrope now could precipitate cardiogenic shock. The cognitive error is confusing chronic optimization therapy with acute stabilization needs. Beta-blockers should be started or uptitrated only after the patient is euvolemic, stable, and ideally as an outpatient or before discharge. Why the Wrong Answer is Tempting: Beta-blockers have mortality benefit in HFrEF—this is hammered into trainees. The reflexive application of "missing guideline-directed therapy" during hospitalization overlooks that timing matters as much as drug choice. NBME Trap Callout: Never start beta-blockers in acute decompensated heart failure. Stabilize first, optimize later.', NULL, 'internal', 'active'),
  ('B6_Q06', 'repeating-negative-workup-instead-of-observation', 'Batch6', 'Internal Medicine', 'A 34-year-old woman presents with 3 weeks of fatigue and intermittent palpitations. She denies chest pain, syncope, or dyspnea. She drinks 4-5 cups of coffee daily and has been under significant work stress. Physical examination is unremarkable with regular heart rate of 76/min. ECG shows normal sinus rhythm. TSH, CBC, and comprehensive metabolic panel are normal. 24-hour Holter monitor shows occasional PACs, no sustained arrhythmias. She returns 2 weeks later still feeling palpitations. The attending suggests repeating the Holter monitor and adding an echocardiogram.

What is the most appropriate next step in management?', '[{"label":"A","text":"Repeat 24-hour Holter monitor"},{"label":"B","text":"Order transthoracic echocardiogram"},{"label":"C","text":"Reassurance and lifestyle modification counseling"},{"label":"D","text":"Start metoprolol for symptom control"}]'::jsonb, 'C', 'This young, healthy patient with benign palpitations (isolated PACs, normal ECG, normal labs, no red flags) has completed an appropriate workup. Repeating the same negative tests will not provide new information and reinforces illness anxiety. The cognitive error is over-testing when observation and reassurance are indicated. Excessive caffeine and stress are the likely culprits. Counseling on reducing caffeine and stress management is the appropriate intervention. Why the Wrong Answer is Tempting: Repeating tests (A, B) feels thorough and patient-centered. An echocardiogram seems "harmless." However, low-yield testing reinforces somatization, delays reassurance, and wastes resources. Beta-blockers (D) medicalize a benign condition unnecessarily. NBME Trap Callout: A negative workup doesn''t need repeating. Reassurance IS management.', NULL, 'internal', 'active'),
  ('B6_Q07', 'mistaking-next-best-step-for-most-accurate-test', 'Batch6', 'Internal Medicine', 'A 52-year-old man presents with progressive dysphagia to solids over 4 months and 15- pound unintentional weight loss. He has a 30-pack-year smoking history. Physical examination reveals a thin, anxious man with no palpable lymphadenopathy. The medical student presents the case and recommends CT chest/abdomen/pelvis as the next step "because it''s the most sensitive for staging esophageal cancer."

What is the most appropriate next step in management?', '[{"label":"A","text":"CT chest/abdomen/pelvis with contrast"},{"label":"B","text":"Upper endoscopy with biopsy"},{"label":"C","text":"Barium swallow study"},{"label":"D","text":"PET-CT for staging"}]'::jsonb, 'B', 'This patient has alarm symptoms (progressive dysphagia, weight loss, smoking history) concerning for esophageal malignancy. While CT and PET-CT are used for staging confirmed cancer, the next best step is tissue diagnosis via upper endoscopy with biopsy. The cognitive error is selecting the "most accurate" test for a later stage of workup rather than the immediate next step. You cannot stage a cancer you haven''t diagnosed. Endoscopy allows visualization AND biopsy in one procedure. Why the Wrong Answer is Tempting: CT and PET sound more advanced and comprehensive. Students often conflate "most accurate" with "next best step." Staging workup is premature without histopathologic confirmation. NBME Trap Callout: "Next best step" means the immediate action, not the ultimate diagnostic pathway. Tissue diagnosis precedes staging.', NULL, 'internal', 'active'),
  ('B6_Q08', 'missing-medication-reconciliation-as-cause', 'Batch6', 'Internal Medicine', 'A 78-year-old man presents with 1 week of fatigue, dizziness, and near-syncope. He has hypertension, type 2 diabetes, and benign prostatic hyperplasia. Medications include lisinopril 20 mg daily, metformin 1000 mg twice daily, and tamsulosin 0.4 mg at bedtime. He was recently started on a new medication by his urologist for urinary symptoms. Blood pressure is 98/58 mmHg sitting, with a drop to 82/50 mmHg upon standing. Pulse increases from 72 to 94/min on standing. The intern orders a tilt table test and cardiology consult.

What is the most appropriate next step in management?', '[{"label":"A","text":"Tilt table testing"},{"label":"B","text":"Echocardiogram"},{"label":"C","text":"Medication review and adjustment"},{"label":"D","text":"24-hour ambulatory blood pressure monitoring"}]'::jsonb, 'C', 'This patient has classic orthostatic hypotension (≥20 mmHg systolic drop with symptoms) that developed after a new medication was added. Alpha-blockers like tamsulosin commonly cause orthostatic hypotension, especially when combined with other antihypertensives (lisinopril). The cognitive error is overlooking iatrogenic causes when new symptoms follow medication changes. A thorough medication reconciliation identifying the temporal relationship would reveal the culprit. Expensive cardiac workup is unnecessary. Why the Wrong Answer is Tempting: Dizziness and near-syncope in an elderly man triggers reflexive cardiac workup (echo, tilt table). These tests are appropriate when medication causes are excluded—but medication review should always come first for new symptoms after prescription changes. NBME Trap Callout: New symptom after new medication = medication side effect until proven otherwise. Check the med list first.', NULL, 'internal', 'active'),
  ('B6_Q09', 'treating-lab-value-not-patient', 'Batch6', 'Internal Medicine', 'A 45-year-old woman is admitted for elective cholecystectomy. Preoperative labs reveal serum sodium of 128 mEq/L. She is asymptomatic, alert, and oriented. Blood pressure is 122/78 mmHg. She takes hydrochlorothiazide for hypertension. Serum osmolality is 270 mOsm/kg, and urine osmolality is 450 mOsm/kg. The surgical team requests that medicine "correct the sodium" before proceeding to the operating room, suggesting 3% hypertonic saline infusion.

What is the most appropriate next step in management?', '[{"label":"A","text":"Administer 3% hypertonic saline"},{"label":"B","text":"Hold hydrochlorothiazide and reassess sodium in 24-48 hours"},{"label":"C","text":"Cancel surgery indefinitely until sodium normalizes"},{"label":"D","text":"Fluid restrict to 1 liter per day"}]'::jsonb, 'B', 'This patient has chronic, asymptomatic, mild hyponatremia likely secondary to thiazide diuretics. Hypertonic saline is indicated only for severe symptomatic hyponatremia (seizures, obtundation)—using it here risks osmotic demyelination syndrome. The cognitive error is treating a lab value rather than the patient''s clinical status. Holding the thiazide and allowing gentle self-correction is appropriate. Mild chronic hyponatremia (>125 mEq/L) in an asymptomatic patient does not preclude surgery. Why the Wrong Answer is Tempting: Abnormal labs before surgery create anxiety. "Correcting" the number feels prudent. However, aggressive correction of chronic hyponatremia is dangerous, and the lab abnormality alone doesn''t warrant intervention in an asymptomatic patient. NBME Trap Callout: Asymptomatic + chronic + mild = no urgent correction needed. Treat the patient, not the number.', NULL, 'internal', 'active'),
  ('B6_Q10', 'premature-closure-in-chest-pain-workup', 'Batch6', 'Internal Medicine', 'A 48-year-old man presents with substernal chest pressure for 2 hours, radiating to his left arm, with associated diaphoresis. He has hypertension and smokes 1 pack per day. ECG shows no ST changes. Initial troponin I is negative (<0.01 ng/mL). The physician tells the patient his "heart tests are negative" and prepares discharge paperwork with a diagnosis of musculoskeletal chest pain, instructing follow-up with his primary care physician.

What is the most appropriate next step in management?', '[{"label":"A","text":"Discharge with outpatient stress test in 1 week"},{"label":"B","text":"Admit for serial troponins and observation"},{"label":"C","text":"Obtain CT coronary angiography before discharge"},{"label":"D","text":"Administer GI cocktail and reassess"}]'::jsonb, 'B', 'This patient has multiple risk factors and a classic ACS presentation. A single negative troponin does NOT rule out myocardial infarction—troponins may take 4-6 hours to rise after ischemia onset. The cognitive error is premature closure, accepting a negative initial test as definitive despite high pretest probability. Serial troponins (typically at 0 and 3-6 hours) are required. Discharging this patient risks missed NSTEMI and death. Why the Wrong Answer is Tempting: A negative troponin provides false reassurance. Combined with a non-diagnostic ECG, it''s tempting to conclude "no MI." However, ruling out ACS requires serial markers, not a snapshot. NBME Trap Callout: One negative troponin at presentation does NOT rule out MI. High-risk chest pain requires serial biomarkers. Update Todos Generate Internal Medicine questions (10 concepts) Generating Surgery questions Generate Pediatrics questions (5 concepts) Generate OB/GYN questions (4 concepts) Generate Psychiatry questions (4 concepts) Generate Neurology questions (4 concepts) Generate Emergency Medicine questions (4 concepts) Generate Pulm/Critical Care questions (3 concepts) Generate Nephrology questions (2 concepts) SURGERY', NULL, 'internal', 'active'),
  ('B6_Q11', 'ordering-imaging-before-surgical-consultation', 'Batch6', 'Surgery', 'A 67-year-old man presents to the emergency department with sudden-onset severe abdominal pain for 3 hours. He has a history of atrial fibrillation and is not on anticoagulation. Temperature is 37.6°C, blood pressure is 92/58 mmHg, pulse is 112/min and irregularly irregular. Abdomen is diffusely tender but notably soft—the pain appears out of proportion to physical findings. Lactate is 6.2 mmol/L. The ED physician orders a CT angiogram of the abdomen and tells the surgical resident, "I''ll call you when I have the imaging results."

What is the most appropriate next step in management?', '[{"label":"A","text":"Await CT angiography results before surgical consultation"},{"label":"B","text":"Immediate surgical consultation concurrent with imaging"},{"label":"C","text":"Start IV heparin before imaging"},{"label":"D","text":"Obtain plain abdominal X-ray first"}]'::jsonb, 'B', 'This patient has classic findings of acute mesenteric ischemia: atrial fibrillation (embolic source), pain out of proportion to exam, elevated lactate, and hemodynamic instability. This is a surgical emergency. The cognitive error is delaying surgical involvement for confirmatory imaging when clinical suspicion is high. Surgery should be consulted immediately—they need time to prepare while imaging is obtained. Waiting for CT results before calling surgery wastes critical time in a condition where bowel viability deteriorates by the hour. Why the Wrong Answer is Tempting: Physicians are trained to have "all the data" before consulting specialists to avoid appearing unprepared. However, in surgical emergencies, parallel processing (imaging + surgical notification) saves lives. The CT confirms diagnosis but shouldn''t delay mobilization. NBME Trap Callout: Suspected surgical emergency = call surgery NOW, not after imaging confirms it. Time is bowel.', NULL, 'internal', 'active'),
  ('B6_Q12', 'choosing-elective-repair-timing-incorrectly', 'Batch6', 'Surgery', 'A 72-year-old man with a known 5.8 cm infrarenal abdominal aortic aneurysm presents for routine follow-up. He is asymptomatic. CT angiography from 6 months ago showed the aneurysm measured 5.3 cm. Current imaging shows expansion to 5.8 cm. He has well-controlled hypertension and quit smoking 10 years ago. Surgical risk assessment estimates 2% perioperative mortality. The patient asks if he can "wait another year" since he feels fine and wants to attend his granddaughter''s wedding in 8 months.

What is the most appropriate recommendation?', '[{"label":"A","text":"Agree to delay repair for 1 year with close surveillance"},{"label":"B","text":"Recommend elective repair within the next few weeks"},{"label":"C","text":"Refer for emergent repair today"},{"label":"D","text":"Repeat imaging in 3 months before deciding"}]'::jsonb, 'B', 'AAA ≥5.5 cm (or expansion >0.5 cm in 6 months) meets criteria for elective surgical repair in acceptable-risk patients. This patient has both: size threshold AND rapid expansion. The cognitive error is misidentifying urgency level—this isn''t emergent (no rupture), but delaying elective repair significantly increases rupture risk. The annual rupture risk for 5.5-6 cm AAA is approximately 10%. Waiting a year is not appropriate; repair should be scheduled soon. Why the Wrong Answer is Tempting: The patient is asymptomatic and has a reasonable request (family event). Emergent repair (C) isn''t indicated without rupture. But "elective" doesn''t mean "optional"—it means "planned, non-emergent." Deferring past threshold invites catastrophe. NBME Trap Callout: "Elective" surgery can still be urgent. AAA ≥5.5 cm = repair soon, not "whenever convenient."', NULL, 'internal', 'active'),
  ('B6_Q13', 'intervening-on-stable-incidental-findings', 'Batch6', 'Surgery', 'A 55-year-old woman undergoes CT abdomen/pelvis for evaluation of kidney stones. The scan reveals a 2 cm simple hepatic cyst in the right lobe, an incidental finding. She is asymptomatic from the cyst. Liver function tests are normal. The radiologist notes: "Simple cyst, benign features, no follow-up needed." The surgeon on call is consulted and recommends laparoscopic cyst fenestration "to prevent future complications."

What is the most appropriate management of the hepatic cyst?', '[{"label":"A","text":"Laparoscopic cyst fenestration"},{"label":"B","text":"CT-guided aspiration with sclerotherapy"},{"label":"C","text":"MRI with hepatobiliary contrast for further characterization"},{"label":"D","text":"No intervention; reassurance"}]'::jsonb, 'D', 'Simple hepatic cysts are extremely common, benign, and virtually never require intervention unless symptomatic (pain from mass effect) or complicated (hemorrhage, infection, rupture). This 2 cm cyst has benign imaging features and causes no symptoms. The cognitive error is operating on incidental findings that warrant observation. Surgery exposes the patient to anesthetic risk, complications, and recovery time for a lesion that will almost certainly never cause problems. Why the Wrong Answer is Tempting: Once something is "found," there''s pressure to "do something." Surgeons may default to intervention. Aspiration (B) seems less invasive but is unnecessary for a simple cyst and risks infection/recurrence. The radiologist already gave the answer: no follow-up needed. NBME Trap Callout: Incidental simple cyst = leave it alone. Not every finding needs an intervention.', NULL, 'internal', 'active'),
  ('B6_Q14', 'missing-non-operative-management-window', 'Batch6', 'Surgery', 'A 28-year-old man presents with right lower quadrant pain for 18 hours, fever (38.6°C), and anorexia. CT abdomen shows a dilated appendix (12 mm) with periappendiceal fat stranding but no abscess or free perforation. WBC is 14,500/μL. He is hemodynamically stable. The surgical resident books the OR for emergent appendectomy. The attending asks if any alternatives were considered.

What is the most appropriate initial management?', '[{"label":"A","text":"Emergent open appendectomy"},{"label":"B","text":"Emergent laparoscopic appendectomy"},{"label":"C","text":"IV antibiotics with interval appendectomy if needed"},{"label":"D","text":"CT-guided drainage"}]'::jsonb, 'B', 'Wait—this is actually appropriate surgical management. This patient has uncomplicated acute appendicitis with no abscess or phlegmon. Laparoscopic appendectomy remains the standard of care for uncomplicated appendicitis in most patients. The cognitive error in this question setup would be assuming antibiotics-first management is universally preferred, but the NOTABLE trial and others show surgery remains superior for most patients. The attending''s question is a teaching moment, not an indication to change the plan. Actually, let me revise this question to better fit the concept: Question 14 (REVISED) Concept ID: missing-non-operative-management-window Vignette: A 32-year-old woman presents with 5 days of right lower quadrant pain and low-grade fever. CT abdomen shows a periappendiceal phlegmon (4 cm inflammatory mass) without drainable abscess. She is hemodynamically stable, tolerating oral intake, and her pain is controlled with oral analgesics. WBC is 12,800/μL. The surgical resident schedules emergent appendectomy. Question Stem: What is the most appropriate initial management? Answer Choices: A) Emergent laparoscopic appendectomy B) Emergent open appendectomy with right hemicolectomy C) IV antibiotics with interval appendectomy in 6-8 weeks D) CT-guided drainage followed by immediate surgery E) Oral antibiotics and outpatient follow-up only Correct Answer: C Explanation: This patient has complicated appendicitis with phlegmon (no drainable abscess) and is clinically stable. In this scenario, immediate surgery is associated with higher complication rates (abscess, bowel injury, need for ileocecal resection) because tissue planes are obliterated by inflammation. The cognitive error is defaulting to surgery when conservative management is first-line. Initial IV antibiotics allow inflammation to resolve; interval appendectomy can be performed in 6-8 weeks with lower morbidity. Why the Wrong Answer is Tempting: "Appendicitis = appendectomy" is drilled into trainees. Emergent surgery feels decisive. However, phlegmon without drainable collection is a specific scenario where non- operative management produces better outcomes. NBME Trap Callout: Appendicitis with phlegmon (no abscess) = antibiotics first, surgery later. Don''t operate into inflammation.', NULL, 'internal', 'active'),
  ('B6_Q15', 'ct-before-clinical-exam-in-trauma', 'Batch6', 'Surgery', 'A 24-year-old man is brought to the trauma bay after a high-speed motorcycle collision. On arrival, he is moaning, with blood pooling beneath him. Primary survey: Airway is intact with cervical spine immobilization. Breathing reveals decreased breath sounds on the left. Blood pressure is 72/40 mmHg, pulse 132/min and thready. The trauma team leader states, "Let''s get him to CT for a full trauma pan-scan to see what we''re dealing with."

What is the most appropriate next step in management?', '[{"label":"A","text":"CT head, C-spine, chest, abdomen, and pelvis"},{"label":"B","text":"Left chest tube placement and massive transfusion protocol"},{"label":"C","text":"Portable chest X-ray before any intervention"},{"label":"D","text":"FAST examination before leaving trauma bay"}]'::jsonb, 'B', 'This patient is in hemorrhagic shock with clinical evidence of hemothorax (decreased breath sounds, hypotension after chest trauma). The cognitive error is prioritizing imaging over resuscitation in an unstable patient. Unstable trauma patients should NEVER go to CT—they die in the scanner. Immediate interventions (chest tube for likely hemothorax, massive transfusion) take priority. FAST and portable films can occur in the trauma bay, but this patient needs a chest tube now based on clinical exam. Why the Wrong Answer is Tempting: "Pan-scan" provides comprehensive information and is standard for stable trauma patients. The fear of missing injuries drives imaging-first thinking. However, hemodynamically unstable patients need intervention, not diagnosis confirmation. The clinical exam (decreased breath sounds + shock + mechanism) is sufficient. NBME Trap Callout: Unstable trauma patient + clear indication = treat, don''t scan. CT is for STABLE patients only. Update Todos Generate Internal Medicine questions (10 concepts) Generate Surgery questions (5 concepts) Generating Pediatrics questions Generate OB/GYN questions (4 concepts) Generate Psychiatry questions (4 concepts) Generate Neurology questions (4 concepts) Generate Emergency Medicine questions (4 concepts) Generate Pulm/Critical Care questions (3 concepts) Generate Nephrology questions (2 concepts) PEDIATRICS', NULL, 'internal', 'active'),
  ('B6_Q16', 'treating-viral-syndrome-with-antibiotics', 'Batch6', 'Pediatrics', 'A 4-year-old boy is brought by his mother for 3 days of rhinorrhea, cough, and low- grade fever (38.2°C). He is drinking fluids, playful in the exam room, and attends daycare. Physical examination reveals clear rhinorrhea, mild pharyngeal erythema without exudate, and bilaterally clear lungs. Tympanic membranes are normal. The mother requests antibiotics because "last time this turned into an ear infection" and she doesn''t want to miss work. She appears anxious and says, "I just want to be proactive."

What is the most appropriate management?', '[{"label":"A","text":"Prescribe amoxicillin to prevent bacterial superinfection"},{"label":"B","text":"Prescribe azithromycin because it has anti-inflammatory properties"},{"label":"C","text":"Symptomatic care and reassurance with return precautions"},{"label":"D","text":"Obtain rapid strep test before deciding"}]'::jsonb, 'C', 'This child has an uncomplicated viral upper respiratory infection (URI). No findings suggest bacterial infection (no purulent nasal discharge >10 days, no ear findings, no tonsillar exudate, no lung consolidation). The cognitive error is prescribing antibiotics for a viral syndrome under parental pressure or to "prevent" complications. Antibiotics do not prevent bacterial superinfection after viral URI, and inappropriate prescribing drives resistance and adverse effects (rash, diarrhea, C. diff). Why the Wrong Answer is Tempting: Parental pressure is real—the mother is anxious, cites past experience, and wants to avoid missed work. Prescribing feels like "doing something" helpful. Azithromycin (B) sounds reasonable due to its "anti-inflammatory" reputation, but this is not an indication for use. NBME Trap Callout: Viral URI = no antibiotics, regardless of parental request. Antibiotics don''t prevent complications and cause harm.', NULL, 'internal', 'active'),
  ('B6_Q17', 'over-investigating-benign-murmur', 'Batch6', 'Pediatrics', 'A 6-year-old girl presents for a well-child visit. She is asymptomatic, meets all developmental milestones, and is active in soccer. On cardiac examination, you detect a grade 2/6 vibratory, musical systolic murmur at the left lower sternal border that disappears when she lies down. There is no radiation, thrill, or click. Pulses are normal. The rest of the examination is unremarkable. The mother is concerned because "heart problems run in the family" and requests an echocardiogram.

What is the most appropriate next step?', '[{"label":"A","text":"Order transthoracic echocardiogram"},{"label":"B","text":"Refer to pediatric cardiology for evaluation"},{"label":"C","text":"Obtain ECG and chest X-ray"},{"label":"D","text":"Reassurance that this is a normal finding"}]'::jsonb, 'D', 'This child has a Still''s murmur, the most common innocent murmur of childhood. Characteristic features: vibratory/musical quality, grade 1-3, left lower sternal border, changes with position, no radiation, no symptoms, normal exam otherwise. The cognitive error is over-investigating an innocent murmur because of parental anxiety or vague family history. Echocardiography for classic innocent murmurs is low-yield, costly, and may generate incidental findings requiring further workup. Why the Wrong Answer is Tempting: "Family history of heart problems" raises concern. An echo seems harmless and definitive. However, pattern recognition of innocent murmurs is a core pediatric skill—if the murmur has all classic benign features, testing adds no value. NBME Trap Callout: Still''s murmur (vibratory, musical, changes with position) = innocent. Reassure, don''t echo.', NULL, 'internal', 'active'),
  ('B6_Q18', 'missing-developmental-milestone-red-flags', 'Batch6', 'Pediatrics', 'An 18-month-old boy is brought for a well-child visit. The mother reports he says only "mama" and "dada" but doesn''t use other words or point to request objects. He doesn''t respond consistently to his name, makes poor eye contact, and prefers to play alone, lining up his toy cars repetitively. He walks well and feeds himself. The mother says her older son "was a late talker too" and asks for reassurance. The pediatrician documents "likely normal variant" and schedules routine 2-year follow-up.

What is the most appropriate next step in management?', '[{"label":"A","text":"Reassure and schedule routine 2-year well-child visit"},{"label":"B","text":"Recheck in 3 months for language reassessment"},{"label":"C","text":"Refer for formal developmental evaluation and early intervention"},{"label":"D","text":"Order hearing test only"}]'::jsonb, 'C', 'This child has multiple red flags for autism spectrum disorder: limited vocabulary for age (<6 words at 18 months is concerning), failure to point, poor response to name, limited eye contact, preference for solitary play, and repetitive behaviors. The cognitive error is false reassurance when developmental red flags are present. Early intervention improves outcomes in ASD—waiting for the child to "catch up" delays critical therapies. Referral for formal evaluation should not be delayed. Why the Wrong Answer is Tempting: "Late talker" in an older sibling provides a narrative that normalizes delay. Parents seeking reassurance create pressure to agree. Isolated speech delay might warrant watching, but multiple social-communication red flags require action now. NBME Trap Callout: Multiple developmental red flags ≠ "wait and see." Refer for evaluation at the first visit with concern.', NULL, 'internal', 'active'),
  ('B6_Q19', 'adult-dosing-extrapolation-error', 'Batch6', 'Pediatrics', 'A 7-year-old girl (weight 25 kg) presents with acute otitis media. She has no drug allergies. The physician prescribes amoxicillin 500 mg twice daily for 10 days, the same dose he commonly prescribes for adults with similar infections. The pharmacist calls to clarify the dose.

What is the most appropriate response to the pharmacist?', '[{"label":"A","text":"Confirm the dose as written"},{"label":"B","text":"Change to amoxicillin 875 mg twice daily for better coverage"},{"label":"C","text":"Change to amoxicillin 1000-1125 mg twice daily (80-90 mg/kg/day)"},{"label":"D","text":"Change to azithromycin to avoid dosing confusion"}]'::jsonb, 'C', 'The recommended dose for amoxicillin in acute otitis media is 80-90 mg/kg/day (high- dose) to overcome resistant S. pneumoniae. For a 25 kg child, this equals 2000-2250 mg/day, or approximately 1000-1125 mg twice daily. The prescribed 500 mg twice daily (1000 mg/day = 40 mg/kg/day) is significantly underdosed. The cognitive error is extrapolating adult doses without using pediatric weight-based calculations. Subtherapeutic dosing leads to treatment failure and resistance. Why the Wrong Answer is Tempting: 500 mg BID is a familiar adult dose that "seems reasonable." The original prescription isn''t obviously wrong to someone unfamiliar with pediatric dosing. Changing to azithromycin (D) avoids the dosing issue but uses a less effective antibiotic for AOM. NBME Trap Callout: Pediatric dosing = weight-based calculation, not adult dose adaptation. Always calculate mg/kg.', NULL, 'internal', 'active'),
  ('B6_Q20', 'fever-phobia-driven-intervention', 'Batch6', 'Pediatrics', 'A 2-year-old previously healthy girl is brought to the ED for fever of 39.2°C (102.6°F) for 1 day. She has mild rhinorrhea. She is alert, interactive, drinking fluids, and playing with toys in the exam room. Physical examination reveals no source of bacterial infection— ears are clear, throat is mildly erythematous without exudate, lungs are clear, and abdomen is benign. The mother is very anxious, stating "fevers this high cause brain damage" and demands a full septic workup including blood cultures, lumbar puncture, and IV antibiotics.

What is the most appropriate management?', '[{"label":"A","text":"Obtain CBC, blood culture, urinalysis, and administer ceftriaxone IV"},{"label":"B","text":"Perform lumbar puncture to rule out meningitis"},{"label":"C","text":"Antipyretics, reassurance, and return precautions"},{"label":"D","text":"Admit for observation due to parental concern"}]'::jsonb, 'C', 'This is a well-appearing febrile toddler with clear viral symptoms and no concerning findings on examination. Fever itself, even "high" fever, does not cause brain damage and does not mandate invasive workup in a well-appearing, vaccinated child. The cognitive error is fever phobia–driven over-investigation—allowing parental anxiety to dictate medical decision-making beyond what clinical assessment warrants. The child needs antipyretics, reassurance, and education about fever. Why the Wrong Answer is Tempting: Parental distress is palpable. "Missing meningitis" is a fear. Invasive workup feels thorough and defensive. However, clinical appearance is the most important predictor of serious bacterial infection in febrile children. Well-appearing = low risk. NBME Trap Callout: Well-appearing + vaccinated + no focal source = reassurance, not septic workup. Clinical appearance trumps fever height. Update Todos Generate Internal Medicine questions (10 concepts) Generate Surgery questions (5 concepts) Generate Pediatrics questions (5 concepts) Generating OB/GYN questions Generate Psychiatry questions (4 concepts) Generate Neurology questions (4 concepts) Generate Emergency Medicine questions (4 concepts) Generate Pulm/Critical Care questions (3 concepts) Generate Nephrology questions (2 concepts) OBSTETRICS & GYNECOLOGY', NULL, 'internal', 'active'),
  ('B6_Q21', 'immediate-cesarean-for-non-reassuring-tracing', 'Batch6', 'Obstetrics & Gynecology', 'A 28-year-old G1P0 at 39 weeks gestation is in active labor at 6 cm dilation. Continuous fetal monitoring shows moderate variability with accelerations, but over the past 15 minutes, repetitive late decelerations have appeared with contractions. The fetal heart rate baseline is 145 bpm. The mother is lying supine with an oxygen mask. The obstetric resident prepares to call for emergent cesarean section due to "fetal distress."

What is the most appropriate next step in management?', '[{"label":"A","text":"Proceed with emergent cesarean delivery"},{"label":"B","text":"Initiate intrauterine resuscitation measures"},{"label":"C","text":"Perform immediate amniotomy to assess for meconium"},{"label":"D","text":"Start oxytocin augmentation to expedite delivery"}]'::jsonb, 'B', 'Late decelerations indicate uteroplacental insufficiency, but this Category II tracing warrants intrauterine resuscitation before operative intervention. Measures include: repositioning (left lateral decubitus), IV fluid bolus, discontinuing oxytocin if running, and supplemental oxygen. The cognitive error is jumping to cesarean delivery without attempting resuscitation for a non-terminal tracing. Many Category II tracings improve with conservative measures. Why the Wrong Answer is Tempting: "Late decelerations" triggers alarm—this is a high-stakes finding. The reflex to deliver immediately feels protective of the fetus. However, emergent cesarean without resuscitation attempts exposes mother to surgical risk unnecessarily when conservative measures might resolve the concerning pattern. NBME Trap Callout: Category II tracing with late decels = intrauterine resuscitation first. Cesarean is for persistent distress despite intervention.', NULL, 'internal', 'active'),
  ('B6_Q22', 'delaying-delivery-in-severe-preeclampsia', 'Batch6', 'Obstetrics & Gynecology', 'A 31-year-old G2P1 at 34 weeks gestation presents with headache and blurred vision. Blood pressure is 168/110 mmHg on two readings 15 minutes apart. Urinalysis shows 3+ protein. Labs reveal platelets 98,000/μL, AST 156 U/L, ALT 142 U/L, and creatinine 1.4 mg/dL. She received magnesium sulfate and IV labetalol. The attending suggests continuing expectant management with betamethasone and delivery at 37 weeks "to optimize fetal lung maturity."

What is the most appropriate management?', '[{"label":"A","text":"Continue expectant management until 37 weeks"},{"label":"B","text":"Administer betamethasone and deliver after 48 hours"},{"label":"C","text":"Immediate delivery after magnesium sulfate loading"},{"label":"D","text":"Increase labetalol and recheck labs in 24 hours"}]'::jsonb, 'C', 'This patient has severe preeclampsia with HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) and severe features (severe hypertension, neurologic symptoms, renal dysfunction). This mandates delivery regardless of gestational age after maternal stabilization. The cognitive error is continuing expectant management when delivery is indicated—waiting for steroids or term exposes mother to seizure, stroke, liver rupture, and death. At 34 weeks, neonatal outcomes are good; maternal risk of delay is unacceptable. Why the Wrong Answer is Tempting: "Fetal lung maturity" and "reaching 37 weeks" are appealing goals. Betamethasone benefit is real, but HELLP can deteriorate within hours. Expectant management is only for preeclampsia without severe features. NBME Trap Callout: Severe preeclampsia with HELLP = deliver now. Don''t wait for steroids when maternal life is at risk.', NULL, 'internal', 'active'),
  ('B6_Q23', 'ordering-hsg-before-semen-analysis', 'Batch6', 'Obstetrics & Gynecology', 'A 32-year-old woman and her 34-year-old husband present for infertility evaluation after 14 months of unprotected intercourse without conception. Her menstrual cycles are regular (28-30 days), and she has no significant medical history. The gynecologist orders hysterosalpingography (HSG) and ovarian reserve testing for the woman. When asked about evaluating the husband, the physician states, "We''ll get to him if her workup is negative."

What is the most appropriate approach to this couple''s evaluation?', '[{"label":"A","text":"Complete female workup first, then evaluate male if negative"},{"label":"B","text":"Perform HSG before semen analysis to rule out tubal factor"},{"label":"C","text":"Semen analysis concurrent with initial female evaluation"},{"label":"D","text":"Empiric clomiphene citrate trial before any testing"}]'::jsonb, 'C', 'Male factor contributes to approximately 40-50% of infertility cases, and semen analysis is non-invasive, inexpensive, and informative. The cognitive error is prioritizing invasive female testing before simple male evaluation. HSG involves radiation, contrast, and procedural discomfort—it should not be performed before a semen analysis has ruled out male factor. Both partners should be evaluated simultaneously from the start. Why the Wrong Answer is Tempting: The woman is present in the gynecologist''s office; it''s natural to focus on her. HSG evaluates tubal patency (common cause). However, ordering invasive female tests before a simple male test wastes resources and delays diagnosis if male factor is the primary issue. NBME Trap Callout: Infertility workup = semen analysis FIRST or concurrent. Don''t scope her before testing him.', NULL, 'internal', 'active'),
  ('B6_Q24', 'misinterpreting-physiologic-pregnancy-changes', 'Batch6', 'Obstetrics & Gynecology', 'A 26-year-old G1P0 at 20 weeks gestation presents for routine prenatal visit. She feels well with no complaints. Vital signs show blood pressure 100/60 mmHg (baseline 118/72 mmHg pre-pregnancy) and heart rate 95/min. Laboratory results show hemoglobin 10.8 g/dL and hematocrit 33%. The resident is concerned about "hypotension and anemia" and recommends workup for adrenal insufficiency and orders iron studies with possible transfusion evaluation.

What is the most appropriate next step?', '[{"label":"A","text":"ACTH stimulation test for adrenal insufficiency"},{"label":"B","text":"Iron studies and reticulocyte count"},{"label":"C","text":"Reassurance that these findings are normal in pregnancy"},{"label":"D","text":"Echocardiogram for cardiac evaluation"}]'::jsonb, 'C', 'All of these findings represent normal physiologic changes of pregnancy. Blood pressure decreases in the second trimester (nadir around 20-24 weeks) due to decreased systemic vascular resistance. Hemoglobin falls due to plasma volume expansion exceeding RBC mass expansion (dilutional "anemia of pregnancy"). The cognitive error is pathologizing normal gestational changes—ordering workups for expected findings wastes resources and causes patient anxiety. Why the Wrong Answer is Tempting: BP drop of ~18 mmHg systolic looks concerning out of context. Hemoglobin 10.8 g/dL would trigger anemia workup in non-pregnant patients. The numbers appear abnormal if you don''t know pregnancy physiology. NBME Trap Callout: Know pregnancy physiology: BP nadirs at 20 weeks, Hgb drops to ~10.5-11 g/dL in second trimester. Don''t work up normal findings. Update Todos Generate Internal Medicine questions (10 concepts) Generate Surgery questions (5 concepts) Generate Pediatrics questions (5 concepts) Generate OB/GYN questions (4 concepts) Generating Psychiatry questions Generate Neurology questions (4 concepts) Generate Emergency Medicine questions (4 concepts) Generate Pulm/Critical Care questions (3 concepts) Generate Nephrology questions (2 concepts) PSYCHIATRY', NULL, 'internal', 'active'),
  ('B6_Q25', 'starting-antidepressant-in-undiagnosed-bipolar', 'Batch6', 'Psychiatry', 'A 24-year-old woman presents with 3 weeks of depressed mood, anhedonia, hypersomnia, and poor concentration. She has no prior psychiatric history and denies suicidal ideation. On further questioning, she mentions that she had a "really productive period" 6 months ago when she slept only 4 hours per night, started three business ventures, spent $15,000 on "investments," and felt she had special insights about the stock market. She currently has no manic symptoms. The physician diagnoses major depressive disorder and prescribes sertraline.

What is the most important consideration before starting this medication?', '[{"label":"A","text":"Obtain baseline liver function tests"},{"label":"B","text":"Evaluate for prior manic or hypomanic episodes"},{"label":"C","text":"Check thyroid function to rule out hypothyroidism"},{"label":"D","text":"Warn about sexual side effects"}]'::jsonb, 'B', 'This patient''s history describes a prior manic episode (decreased need for sleep, grandiosity, excessive spending, increased goal-directed activity). This changes the diagnosis from major depressive disorder to bipolar disorder. Starting an SSRI in bipolar depression without a mood stabilizer can precipitate mania/hypomania or rapid cycling. The cognitive error is initiating antidepressant therapy without screening for bipolar disorder. Always ask about past manic symptoms before starting antidepressants. Why the Wrong Answer is Tempting: She currently presents with classic depression. Sertraline is first-line for MDD. The prior "productive period" could be dismissed as just a good phase rather than recognized as mania. But the key details (decreased sleep need, grandiosity, reckless spending) are red flags. NBME Trap Callout: Before any antidepressant: ask about prior mania/hypomania. SSRI in bipolar = potential disaster.', NULL, 'internal', 'active'),
  ('B6_Q26', 'ordering-imaging-for-primary-psychiatric-presentation', 'Batch6', 'Psychiatry', 'A 22-year-old man is brought to the emergency department by his roommate for bizarre behavior over 2 weeks. He believes the government is monitoring him through his phone and that news anchors are sending him coded messages. He has not slept well and appears paranoid. He has no medical history, takes no medications, and urine drug screen is negative. Vital signs and physical examination are unremarkable, and he is neurologically intact. The ED physician orders CT head and MRI brain "to rule out organic causes."

What is the most appropriate use of neuroimaging in this patient?', '[{"label":"A","text":"CT head is mandatory before psychiatric diagnosis"},{"label":"B","text":"MRI brain with contrast to rule out tumor"},{"label":"C","text":"Imaging is not routinely indicated in this presentation"},{"label":"D","text":"PET scan to evaluate for early neurodegenerative disease"}]'::jsonb, 'C', 'This patient has a classic presentation of new-onset psychosis (paranoid delusions, ideas of reference) with no features suggesting organic etiology: no focal neurological findings, no altered mental status fluctuation, no medical comorbidities, normal vitals, negative drug screen. The cognitive error is over-ordering imaging for a primary psychiatric presentation when clinical features are clearly psychiatric. Guidelines do not recommend routine neuroimaging for first-episode psychosis without atypical features. Why the Wrong Answer is Tempting: "Rule out organic cause" sounds thorough and defensive. New psychosis in a young person raises fear of "missing something." However, imaging has very low yield in classic psychiatric presentations without red flags (age >50, focal findings, clouded consciousness, new headache, seizure). NBME Trap Callout: First-episode psychosis with classic features and normal neuro exam = no routine imaging. Clinical context guides workup.', NULL, 'internal', 'active'),
  ('B6_Q27', 'discharging-after-passive-suicidal-ideation-denial', 'Batch6', 'Psychiatry', 'A 35-year-old man is brought to the ED after his wife found a note suggesting he was planning to end his life. He has a history of depression and a prior suicide attempt 2 years ago (medication overdose). On evaluation, he denies current suicidal ideation, states he wrote the note "weeks ago" when he felt bad, and insists he wants to go home. He is calm and cooperative, denies access to lethal means, and reports he has a therapy appointment next week. The ED physician documents "patient denies SI, contracts for safety" and prepares for discharge.

What is the most appropriate next step in management?', '[{"label":"A","text":"Discharge with outpatient therapy follow-up as planned"},{"label":"B","text":"Discharge with crisis line information and safety plan"},{"label":"C","text":"Psychiatric consultation for comprehensive risk assessment"},{"label":"D","text":"Voluntary inpatient admission with patient agreement"}]'::jsonb, 'C', 'This patient has multiple high-risk factors: prior suicide attempt, evidence of recent suicidal planning (the note), and current denial which may represent minimization rather than resolution. "Contracting for safety" is not evidence-based and does not reduce risk. The cognitive error is discharging based on denial alone after recent evidence of suicidal intent. A comprehensive psychiatric risk assessment is essential before any disposition decision. Why the Wrong Answer is Tempting: The patient is calm, cooperative, and denying SI—this feels reassuring. He has outpatient follow-up. "Contracting for safety" feels like a safeguard. However, recent suicidal planning + prior attempt = high risk regardless of current verbal denial. NBME Trap Callout: Recent suicide note + prior attempt = high risk despite denial. Denial after planning behavior requires thorough evaluation, not discharge.', NULL, 'internal', 'active'),
  ('B6_Q28', 'benzodiazepine-first-line-for-chronic-anxiety', 'Batch6', 'Psychiatry', 'A 42-year-old woman presents with 8 months of excessive worry about work, finances, and family health. She reports difficulty relaxing, muscle tension, and trouble falling asleep. She has no panic attacks. She tried "meditation apps" without benefit and is requesting medication. She has no substance use history. The physician prescribes alprazolam 0.5 mg three times daily for generalized anxiety disorder.

What would have been a more appropriate first-line pharmacologic treatment?', '[{"label":"A","text":"Alprazolam 0.5 mg three times daily"},{"label":"B","text":"Lorazepam 1 mg twice daily"},{"label":"C","text":"Sertraline 50 mg daily"},{"label":"D","text":"Clonazepam 0.5 mg at bedtime"}]'::jsonb, 'C', 'First-line pharmacotherapy for generalized anxiety disorder (GAD) includes SSRIs (sertraline, escitalopram), SNRIs (venlafaxine, duloxetine), or buspirone. Benzodiazepines are second-line due to dependence risk, tolerance, rebound anxiety, and cognitive effects with long-term use. The cognitive error is starting a dependence-risk medication as first-line therapy for a chronic condition. SSRIs address both anxiety and common comorbid depression with better long-term outcomes. Why the Wrong Answer is Tempting: Benzodiazepines work fast—the patient will feel better quickly, creating immediate positive feedback. Alprazolam is familiar and commonly prescribed. The patient wants relief now, and SSRIs take weeks to work. However, starting with a benzodiazepine creates dependence that complicates future management. NBME Trap Callout: GAD is chronic → first-line = SSRI/SNRI/buspirone. Benzodiazepines are short-term adjuncts at best, not maintenance therapy. Update Todos Generate Internal Medicine questions (10 concepts) Generate Surgery questions (5 concepts) Generate Pediatrics questions (5 concepts) Generate OB/GYN questions (4 concepts) Generate Psychiatry questions (4 concepts) Generating Neurology questions Generate Emergency Medicine questions (4 concepts) Generate Pulm/Critical Care questions (3 concepts) Generate Nephrology questions (2 concepts) NEUROLOGY', NULL, 'internal', 'active'),
  ('B6_Q29', 'head-ct-before-lp-in-meningitis-without-indication', 'Batch6', 'Neurology', 'A 19-year-old college student presents with 12 hours of severe headache, fever (39.4°C), neck stiffness, and photophobia. He has no significant medical history. Vital signs show blood pressure 128/78 mmHg, pulse 110/min. On examination, he is drowsy but arousable and follows commands. Kernig and Brudzinski signs are positive. There are no focal neurological deficits, papilledema is absent, and he has no seizures. The resident orders CT head before lumbar puncture "to rule out increased ICP."

What is the most appropriate next step in management?', '[{"label":"A","text":"CT head followed by lumbar puncture"},{"label":"B","text":"Immediate lumbar puncture followed by antibiotics"},{"label":"C","text":"Empiric antibiotics, CT head, then lumbar puncture"},{"label":"D","text":"Empiric antibiotics and lumbar puncture, defer CT"}]'::jsonb, 'D', 'This patient has classic bacterial meningitis presentation with no contraindications to immediate lumbar puncture. The IDSA guidelines specify that CT before LP is only needed if the patient has: immunocompromised state, history of CNS disease, new- onset seizure, papilledema, altered consciousness, or focal neurologic deficit. This patient has NONE of these—he is drowsy but follows commands and has no focal findings. The cognitive error is delaying LP for CT when no indication for imaging exists. Every hour of antibiotic delay increases mortality. Why the Wrong Answer is Tempting: "Rule out mass/herniation before LP" is taught broadly and feels safe. However, unnecessary CT delays diagnosis and treatment. Choice C (antibiotics, then CT, then LP) seems like a compromise but still delays LP unnecessarily. NBME Trap Callout: CT before LP is NOT universal. Know the specific indications. No focal deficits + no papilledema + no seizure = proceed directly to LP.', NULL, 'internal', 'active'),
  ('B6_Q30', 'ordering-eeg-for-single-provoked-seizure', 'Batch6', 'Neurology', 'A 28-year-old man with no prior seizure history presents after a witnessed generalized tonic-clonic seizure lasting 2 minutes. He had been drinking heavily at a party the night before and stopped abruptly this morning. He has no history of epilepsy or head trauma. His last drink was approximately 14 hours ago. Examination shows mild tremor, tachycardia (108/min), and diaphoresis. Blood glucose is 95 mg/dL. CT head is normal. The neurology resident orders an EEG and recommends starting levetiracetam.

What is the most appropriate next step in management?', '[{"label":"A","text":"Start levetiracetam and obtain EEG"},{"label":"B","text":"Obtain EEG before starting anticonvulsants"},{"label":"C","text":"Treat alcohol withdrawal, no antiepileptic needed"},{"label":"D","text":"MRI brain with epilepsy protocol"}]'::jsonb, 'C', 'This is a provoked seizure due to alcohol withdrawal (timing 12-48 hours after last drink, autonomic signs, recent heavy use with abrupt cessation). Provoked seizures with an identified and correctable trigger do not require antiepileptic drugs or EEG—they require treatment of the underlying cause. The cognitive error is over-investigating when the trigger is identified and resolved. Benzodiazepines for alcohol withdrawal are the appropriate treatment. Long-term AEDs are not indicated. Why the Wrong Answer is Tempting: Any seizure prompts reflexive consideration of epilepsy workup. EEG and AEDs feel like "standard" management. However, treating a withdrawal seizure with levetiracetam misses the point—the pathophysiology is GABA/glutamate imbalance from alcohol cessation, not an epileptic focus. NBME Trap Callout: Provoked seizure with clear trigger = treat the cause, not epilepsy. Alcohol withdrawal seizures don''t need AEDs.', NULL, 'internal', 'active'),
  ('B6_Q31', 'tpa-hesitation-within-window', 'Batch6', 'Neurology', 'A 68-year-old man presents 2.5 hours after sudden onset of right-sided weakness and slurred speech. CT head shows no hemorrhage. NIHSS score is 14 (moderate-to-severe stroke). Blood pressure is 178/95 mmHg. He takes aspirin daily for coronary artery disease. He had upper GI bleeding 8 months ago, which resolved with PPI therapy. The stroke team is hesitant to give alteplase because of "bleeding history."

What is the most appropriate next step in management?', '[{"label":"A","text":"Withhold alteplase due to prior GI bleeding"},{"label":"B","text":"Administer alteplase within the treatment window"},{"label":"C","text":"Perform CT angiography before thrombolytic decision"},{"label":"D","text":"Obtain gastroenterology consultation before alteplase"}]'::jsonb, 'B', 'GI bleeding more than 21 days ago is NOT a contraindication to IV alteplase. Absolute contraindications include: active internal bleeding, recent intracranial surgery/trauma/hemorrhage, bleeding diathesis, and severe uncontrolled hypertension. This patient''s remote GI bleed (8 months ago, resolved) is at most a relative consideration, and with an NIHSS of 14 and clear benefit, treatment should not be withheld. The cognitive error is misinterpreting relative contraindication as absolute and depriving the patient of a beneficial treatment. Why the Wrong Answer is Tempting: "History of GI bleeding" sounds like a bleeding risk. The team''s hesitation feels cautious. However, withholding thrombolytics from an eligible patient causes measurable harm (disability, death). Know the actual contraindications. NBME Trap Callout: Remote GI bleeding (>21 days) is NOT a contraindication to tPA. Know the actual exclusions—don''t withhold beneficial therapy due to overcaution.', NULL, 'internal', 'active'),
  ('B6_Q32', 'treating-imaging-finding-not-clinical-syndrome', 'Batch6', 'Neurology', 'A 52-year-old woman undergoes MRI brain for evaluation of chronic headaches. The scan reveals a 4 mm unruptured intracranial aneurysm in the anterior communicating artery. Her headaches are described as bilateral, pressure-like, occurring 3-4 times weekly, and present for 10 years without change in character. Physical examination is normal. The neurosurgeon recommends endovascular coiling "before it ruptures."

What is the most appropriate management of this aneurysm?', '[{"label":"A","text":"Endovascular coiling"},{"label":"B","text":"Surgical clipping"},{"label":"C","text":"Serial imaging surveillance"},{"label":"D","text":"Urgent angiography for procedural planning"}]'::jsonb, 'C', 'Small (<7 mm) unruptured aneurysms in the anterior circulation have a very low annual rupture risk (<0.5%). This patient''s chronic tension-type headaches are unrelated to the incidental aneurysm (unchanged character over 10 years). The cognitive error is treating an imaging finding rather than a clinical syndrome. Intervention carries procedural risk (1-2% morbidity/mortality) that may exceed the natural history risk. Serial surveillance with imaging is appropriate for small, asymptomatic aneurysms. Why the Wrong Answer is Tempting: "Aneurysm" sounds dangerous. The neurosurgeon is a specialist recommending treatment. "Preventing rupture" seems obviously good. However, risk-benefit calculation shows that for small, low-risk aneurysms, observation outperforms intervention. NBME Trap Callout: Small incidental aneurysm + asymptomatic = observe, don''t intervene. Procedural risk may exceed natural history risk. Update Todos Generate Internal Medicine questions (10 concepts) Generate Surgery questions (5 concepts) Generate Pediatrics questions (5 concepts) Generate OB/GYN questions (4 concepts) Generate Psychiatry questions (4 concepts) Generate Neurology questions (4 concepts) Generating Emergency Medicine questions Generate Pulm/Critical Care questions (3 concepts) Generate Nephrology questions (2 concepts) EMERGENCY MEDICINE', NULL, 'internal', 'active'),
  ('B6_Q33', 'fluids-before-pressors-dogma-in-septic-shock', 'Batch6', 'Emergency Medicine', 'A 72-year-old man with diabetes presents with fever, confusion, and hypotension. Blood pressure is 74/42 mmHg, pulse 118/min, temperature 39.2°C, and lactate is 6.8 mmol/L. Urine is cloudy, and WBC is 24,000/μL. He is diagnosed with septic shock secondary to urosepsis. The ED physician starts a 30 mL/kg crystalloid bolus (approximately 2.1 L for his 70 kg weight) and plans to reassess "after fluids are complete" before considering vasopressors.

What modification to this resuscitation strategy is most appropriate?', '[{"label":"A","text":"Complete the full 30 mL/kg before adding vasopressors"},{"label":"B","text":"Start vasopressors early, concurrent with fluid resuscitation"},{"label":"C","text":"Limit fluids to 20 mL/kg due to age and diabetes"},{"label":"D","text":"Use albumin instead of crystalloid for better hemodynamic response"}]'::jsonb, 'B', 'While the Surviving Sepsis Campaign recommends 30 mL/kg crystalloid as initial resuscitation, current evidence supports early vasopressor initiation in severe shock rather than sequential fluid-then-pressors approach. Waiting to complete all fluids before starting vasopressors in a patient with MAP ~53 mmHg delays restoration of perfusion pressure. The cognitive error is rigid adherence to "fluids first" dogma when profound hypotension warrants earlier pressor support. Why the Wrong Answer is Tempting: "30 mL/kg first, then reassess" is protocol-driven and widely taught. The fear of "pressors on an empty tank" suggests fluids must be complete first. However, excessive fluid without vasopressors in refractory hypotension leads to fluid overload and delayed perfusion. NBME Trap Callout: Septic shock with severe hypotension = early vasopressors. Don''t wait until fluids are "complete" to start norepinephrine.', NULL, 'internal', 'active'),
  ('B6_Q34', 'serial-troponins-delaying-intervention', 'Batch6', 'Emergency Medicine', 'A 61-year-old man with hypertension and diabetes presents with 45 minutes of crushing chest pain radiating to his jaw and left arm. He is diaphoretic and nauseated. ECG shows 3 mm ST elevations in leads II, III, and aVF. Blood pressure is 142/88 mmHg, and pulse is 62/min. Initial troponin I returns negative (<0.01 ng/mL). The emergency physician orders serial troponins at 0 and 3 hours "to confirm MI before activating the cath lab."

What is the most appropriate next step in management?', '[{"label":"A","text":"Wait for 3-hour troponin before cath lab activation"},{"label":"B","text":"Obtain echocardiogram to assess wall motion abnormalities"},{"label":"C","text":"Activate cath lab for emergent PCI"},{"label":"D","text":"Administer thrombolytics if cath lab delay exceeds 120 minutes"}]'::jsonb, 'C', 'This patient has STEMI based on characteristic symptoms plus diagnostic ST elevations in a coronary distribution (inferior leads). The diagnosis of STEMI is clinical + ECG—it does NOT require troponin elevation. Troponins may be negative early (<4-6 hours) because they take time to rise. The cognitive error is waiting for biomarker confirmation when the clinical picture demands immediate action. Door-to-balloon time targets require immediate cath lab activation. Why the Wrong Answer is Tempting: Negative troponin is reassuring. "Confirming" with serial biomarkers seems thorough. However, in STEMI, every minute of delay increases myocardial death and worsens outcomes. The ECG is the diagnostic standard. NBME Trap Callout: STEMI diagnosis = symptoms + ECG. Negative initial troponin does NOT change management. Activate the cath lab immediately.', NULL, 'internal', 'active'),
  ('B6_Q35', 'negative-initial-workup-equals-discharge', 'Batch6', 'Emergency Medicine', 'A 58-year-old woman presents with 2 hours of substernal chest pressure that resolved spontaneously. She has hypertension and family history of MI in her father at age 52. ECG shows nonspecific T-wave flattening. Initial troponin I is 0.02 ng/mL (normal <0.04 ng/mL). Chest X-ray is normal. The physician tells her the "initial workup is negative" and prepares discharge paperwork with outpatient stress test next week.

What is the most appropriate next step in management?', '[{"label":"A","text":"Discharge with outpatient stress test in 5-7 days"},{"label":"B","text":"Discharge with next-day cardiology follow-up"},{"label":"C","text":"Admit for serial troponins and observation"},{"label":"D","text":"Administer GI cocktail and discharge if pain-free"}]'::jsonb, 'C', 'This patient has intermediate pretest probability for ACS: cardiac risk factors, concerning symptoms, and a troponin that, while below the threshold, is at the upper range of normal (0.02, with cutoff 0.04). A single "normal" troponin does not exclude ACS—serial markers are required. The cognitive error is premature discharge based on a negative initial snapshot when clinical suspicion warrants further observation. Ruling out ACS requires time-based troponin assessment. Why the Wrong Answer is Tempting: "ECG non-diagnostic, troponin normal, chest X-ray normal" sounds like a complete negative workup. The symptoms resolved. Outpatient follow-up seems reasonable. However, ACS rule-out requires serial biomarkers (typically 0 and 3-6 hours minimum). NBME Trap Callout: One negative troponin ≠ ruled out. Intermediate-risk chest pain requires serial biomarkers before safe discharge.', NULL, 'internal', 'active'),
  ('B6_Q36', 'pain-control-withheld-pending-diagnosis', 'Batch6', 'Emergency Medicine', 'A 32-year-old man presents with 6 hours of severe right lower quadrant abdominal pain, rated 9/10. He is writhing on the stretcher, tachycardic (pulse 112/min), and diaphoretic. Examination reveals focal RLQ tenderness with voluntary guarding. CT abdomen is ordered. The patient begs for pain medication. The physician states, "I can''t give you anything until surgery evaluates you—pain medication will mask your exam."

What is the most appropriate next step in management?', '[{"label":"A","text":"Withhold analgesia until surgical consultation"},{"label":"B","text":"Administer IV morphine for pain control"},{"label":"C","text":"Administer oral acetaminophen as a non-masking alternative"},{"label":"D","text":"Offer distraction techniques and reassurance"}]'::jsonb, 'B', 'The outdated dogma of withholding analgesia to avoid "masking" physical exam findings has been definitively refuted by multiple studies. Appropriate analgesia does NOT increase diagnostic errors, delay surgery, or obscure peritoneal signs. The cognitive error is causing unnecessary suffering based on a disproven concern. Pain control is ethical, improves patient cooperation with exam, and does not compromise surgical decision-making. Why the Wrong Answer is Tempting: "Don''t give pain meds until surgery sees them" is still taught in some settings. The fear of masking appendicitis or missing peritonitis persists. However, evidence shows that untreated pain is harmful and that treated patients can still be properly assessed. NBME Trap Callout: Pain medication does NOT mask peritoneal signs. Treat pain—it''s ethical and evidence- based. Update Todos Generate Internal Medicine questions (10 concepts) Generate Surgery questions (5 concepts) Generate Pediatrics questions (5 concepts) Generate OB/GYN questions (4 concepts) Generate Psychiatry questions (4 concepts) Generate Neurology questions (4 concepts) Generate Emergency Medicine questions (4 concepts) Generating Pulm/Critical Care questions Generate Nephrology questions (2 concepts) PULMONOLOGY / CRITICAL CARE', NULL, 'internal', 'active'),
  ('B6_Q37', 'intubation-delay-for-abg-confirmation', 'Batch6', 'Pulmonology / Critical Care', 'A 68-year-old man with COPD presents with severe respiratory distress after 3 days of worsening dyspnea during an exacerbation. He is using accessory muscles, has tripod positioning, and can speak only 1-2 words between breaths. Respiratory rate is 36/min, SpO2 84% on 6L nasal cannula. He appears exhausted. The resident orders an arterial blood gas "to confirm respiratory failure before intubating."

What is the most appropriate next step in management?', '[{"label":"A","text":"Obtain ABG and await results before intubation"},{"label":"B","text":"Increase supplemental oxygen to 15L non-rebreather"},{"label":"C","text":"Trial of BiPAP before considering intubation"},{"label":"D","text":"Proceed with endotracheal intubation"}]'::jsonb, 'D', 'This patient has clinical respiratory failure: severe accessory muscle use, inability to speak, exhaustion, hypoxemia despite supplemental oxygen, and impending respiratory arrest. The diagnosis of respiratory failure is CLINICAL—waiting for ABG confirmation wastes precious time when the patient is decompensating. The cognitive error is waiting for laboratory confirmation when clinical picture is unambiguous. Intubate based on clinical assessment, not numbers. Why the Wrong Answer is Tempting: ABG "confirms" respiratory failure with pH and CO2 values. It feels objective and documented. BiPAP (C) is appropriate for earlier-stage COPD exacerbation, but this patient is beyond that—exhaustion and minimal speech suggest imminent arrest. Waiting for data delays life-saving intervention. NBME Trap Callout: Clinical respiratory failure = intubate. Don''t wait for ABG when the patient is crashing in front of you.', NULL, 'internal', 'active'),
  ('B6_Q38', 'weaning-protocol-override-by-subjective-concern', 'Batch6', 'Pulmonology / Critical Care', 'A 55-year-old woman was intubated 3 days ago for severe pneumonia. She has improved significantly: afebrile, WBC normalizing, FiO2 weaned to 0.30, PEEP 5 cm H2O. She passes a spontaneous breathing trial (SBT): respiratory rate 18/min, tidal volume 450 mL, SpO2 97%, no distress for 30 minutes. She follows commands and has adequate cough. The RASS score is 0, and she has minimal secretions. The attending physician says, "She just looks weak to me—let''s give her another day on the vent to get stronger."

What is the most appropriate next step in management?', '[{"label":"A","text":"Continue mechanical ventilation for another 24-48 hours"},{"label":"B","text":"Increase pressure support and retry SBT tomorrow"},{"label":"C","text":"Extubate the patient"},{"label":"D","text":"Obtain NIF and RSBI before extubation decision"}]'::jsonb, 'C', 'This patient meets ALL criteria for extubation: resolution of underlying condition, adequate oxygenation on minimal settings, passed SBT, follows commands, good cough, minimal secretions. Subjective impressions like "she looks weak" are not evidence-based criteria for continued ventilation. The cognitive error is prolonging mechanical ventilation based on subjective concern despite objective readiness. Each additional day of ventilation increases VAP risk, delirium, and ICU length of stay. Why the Wrong Answer is Tempting: The attending is experienced; "clinical gestalt" carries weight. "One more day to get stronger" seems cautious. However, prolonged ventilation causes harm. Protocol-based weaning outperforms subjective assessment. NBME Trap Callout: Passed SBT + meets extubation criteria = extubate. Don''t override protocols with gut feelings.', NULL, 'internal', 'active'),
  ('B6_Q39', 'oxygen-titration-error-in-copd', 'Batch6', 'Pulmonology / Critical Care', 'A 71-year-old man with severe COPD (FEV1 28% predicted) presents with acute exacerbation. He is dyspneic and confused. Respiratory rate is 28/min, SpO2 82% on room air. ABG shows pH 7.28, PaCO2 72 mmHg, PaO2 48 mmHg. The ED nurse places him on 15L non-rebreather mask to "get his oxygen up." Thirty minutes later, he becomes more somnolent. Repeat ABG shows pH 7.22, PaCO2 92 mmHg, PaO2 112 mmHg.

What error occurred in this patient''s oxygen management?', '[{"label":"A","text":"Oxygen should have been withheld due to COPD"},{"label":"B","text":"High-flow oxygen suppressed hypoxic respiratory drive"},{"label":"C","text":"Non-rebreather caused CO2 rebreathing"},{"label":"D","text":"COPD patients require higher oxygen targets"}]'::jsonb, 'B', 'This patient has chronic CO2 retention (COPD with baseline hypercapnia). In these patients, the respiratory drive is predominantly driven by hypoxemia, not CO2. Administering high-flow oxygen eliminated the hypoxic drive, causing hypoventilation, worsening hypercapnia, and CO2 narcosis. The cognitive error is oxygen titration error in a COPD patient—targeting normal SpO2 (>95%) instead of appropriate target (88-92%). Controlled oxygen delivery (Venturi mask or titrated nasal cannula) is required. Why the Wrong Answer is Tempting: "Hypoxemia is dangerous—get the oxygen up" is instinctual. High-flow oxygen seems safe. However, in CO2 retainers, the hyperoxia-induced hypoventilation can be fatal. Target SpO2 88-92% in COPD. NBME Trap Callout: COPD + CO2 retention = target SpO2 88-92%. High-flow oxygen can kill by suppressing respiratory drive. Update Todos Generate Internal Medicine questions (10 concepts) Generate Surgery questions (5 concepts) Generate Pediatrics questions (5 concepts) Generate OB/GYN questions (4 concepts) Generate Psychiatry questions (4 concepts) Generate Neurology questions (4 concepts) Generate Emergency Medicine questions (4 concepts) Generate Pulm/Critical Care questions (3 concepts) Generating Nephrology questions NEPHROLOGY', NULL, 'internal', 'active'),
  ('B6_Q40', 'creatinine-rise-stopping-ace-inhibitor-prematurely', 'Batch6', 'Nephrology', 'A 62-year-old man with type 2 diabetes and hypertension is started on lisinopril 10 mg daily for new diagnosis of diabetic nephropathy (creatinine 1.4 mg/dL, urine albumin-to- creatinine ratio 350 mg/g). One week later, repeat labs show creatinine increased to 1.7 mg/dL. Potassium is 5.1 mEq/L. Blood pressure is well controlled at 128/76 mmHg. The physician discontinues lisinopril due to "worsening kidney function."

What would have been the most appropriate response to this laboratory finding?', '[{"label":"A","text":"Discontinue lisinopril immediately"},{"label":"B","text":"Continue lisinopril; this creatinine rise is expected and acceptable"},{"label":"C","text":"Switch to amlodipine for blood pressure control"},{"label":"D","text":"Reduce lisinopril dose by 50%"}]'::jsonb, 'B', 'ACE inhibitors cause an expected, hemodynamically-mediated rise in creatinine due to efferent arteriolar dilation—this is NOT nephrotoxicity. A rise of up to 30% from baseline is acceptable and should be tolerated because ACE inhibitors provide long- term renoprotection in diabetic nephropathy. This patient''s creatinine rose ~21% (1.4 to 1.7), which is within acceptable range. The cognitive error is discontinuing a renoprotective agent for an expected physiologic effect. Why the Wrong Answer is Tempting: Rising creatinine looks like kidney injury. "First, do no harm" suggests stopping the apparent offender. However, stopping ACE inhibitors in this situation deprives the patient of a drug with proven benefit for slowing diabetic nephropathy progression. NBME Trap Callout: Creatinine rise up to 30% on ACE/ARB = expected and acceptable. Don''t stop renoprotective therapy for this.', NULL, 'internal', 'active'),
  ('B6_Q41', 'fluid-restriction-in-hypovolemic-hyponatremia', 'Batch6', 'Nephrology', 'A 78-year-old woman with heart failure presents after 3 days of diarrhea and poor oral intake. She is lethargic and has dry mucous membranes, decreased skin turgor, and flat neck veins. Blood pressure is 92/58 mmHg, and pulse is 108/min. Serum sodium is 126 mEq/L, BUN 42 mg/dL, and creatinine 1.8 mg/dL (baseline 1.0). Urine sodium is <10 mEq/L. The resident orders fluid restriction to 1 liter per day "for hyponatremia."

What is the most appropriate next step in management?', '[{"label":"A","text":"Fluid restriction to 1 L/day"},{"label":"B","text":"3% hypertonic saline infusion"},{"label":"C","text":"Isotonic saline infusion"},{"label":"D","text":"Tolvaptan administration"}]'::jsonb, 'C', 'This patient has hypovolemic hyponatremia (diarrhea, poor intake, hypotension, tachycardia, dry membranes, low urine sodium indicating renal sodium conservation). Fluid RESTRICTION is for euvolemic (SIADH) or hypervolemic hyponatremia—not hypovolemia. The cognitive error is applying the wrong treatment protocol based on sodium value alone without assessing volume status. Treatment for hypovolemic hyponatremia is volume resuscitation with isotonic saline, which will suppress ADH and allow free water excretion. Why the Wrong Answer is Tempting: "Hyponatremia = fluid restrict" is a commonly memorized reflex. However, volume status determines treatment. In hypovolemia, restriction worsens hypotension and perpetuates ADH release. Giving saline corrects both volume AND sodium. NBME Trap Callout: Hyponatremia treatment depends on VOLUME STATUS. Hypovolemic = give saline. Euvolemic (SIADH) = restrict fluids. Update Todos Generate Internal Medicine questions (10 concepts) Generate Surgery questions (5 concepts) Generate Pediatrics questions (5 concepts) Generate OB/GYN questions (4 concepts) Generate Psychiatry questions (4 concepts) Generate Neurology questions (4 concepts) Generate Emergency Medicine questions (4 concepts) Generate Pulm/Critical Care questions (3 concepts) Generate Nephrology questions (2 concepts) BATCH 6 — GENERATION COMPLETE Summary System Questions Generated Concept IDs Covered Internal Medicine 10 Q1–Q10 Surgery 5 Q11–Q15 Pediatrics 5 Q16–Q20 OB/GYN 4 Q21–Q24 Psychiatry 4 Q25–Q28 Neurology 4 Q29–Q32 Emergency Medicine 4 Q33–Q36 Pulm/Critical Care 3 Q37–Q39 Nephrology 2 Q40–Q41 TOTAL 41 — Cognitive Errors Covered 1. Anchoring on initial diagnosis despite new data 2. Over-ordering advanced imaging when first-line test is indicated 3. Treating asymptomatic bacteriuria 4. Premature antibiotic escalation 5. Confusing acute vs chronic management 6. Repeating negative workup instead of observation 7. Mistaking "next best step" for "most accurate test" 8. Missing medication as cause of new symptoms 9. Treating lab value, not patient 10. Premature closure in workup 11. Delaying surgical consultation for imaging 12. Misidentifying surgical urgency 13. Intervening on stable incidental findings 14. Missing non-operative management window 15. CT before clinical exam in unstable trauma 16. Treating viral syndrome with antibiotics 17. Over-investigating benign murmur 18. Missing developmental red flags 19. Adult dosing extrapolation to pediatrics 20. Fever phobia–driven intervention 21. Cesarean without intrauterine resuscitation 22. Delaying delivery in severe preeclampsia 23. Invasive female workup before semen analysis 24. Pathologizing physiologic pregnancy changes 25. SSRI in undiagnosed bipolar 26. Excessive imaging for primary psychiatric presentation 27. Discharge after suicide denial despite planning 28. Benzodiazepine first-line for chronic anxiety 29. CT before LP without indication 30. EEG/AED for provoked seizure 31. tPA hesitation for relative contraindication 32. Treating incidental imaging finding 33. Rigid fluids-before-pressors adherence 34. Waiting for troponin in STEMI 35. Discharging after one negative test 36. Withholding analgesia pending diagnosis 37. ABG before clinical intubation 38. Override of weaning protocol by subjective concern 39. Oxygen titration error in COPD 40. Stopping ACE-I for expected creatinine rise 41. Fluid restriction in hypovolemic hyponatremia Batch 6 is ready for review and integration into TribeWellMD.', NULL, 'internal', 'active')
ON CONFLICT (question_id) DO UPDATE SET
  concept_id = EXCLUDED.concept_id,
  batch = EXCLUDED.batch,
  system = EXCLUDED.system,
  stem = EXCLUDED.stem,
  options = EXCLUDED.options,
  correct_answer = EXCLUDED.correct_answer,
  explanation = EXCLUDED.explanation,
  cognitive_error = EXCLUDED.cognitive_error,
  updated_at = now();

-- Verify import
SELECT batch, COUNT(*) as count FROM questions GROUP BY batch ORDER BY batch;
